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Abstract 
In response to rising tuberculosis notification rates in England, the tuberculosis strain 
typing service (TB-STS) was introduced in 2010. This complex intervention involves 
MIRU-VNTR (mycobacterial interspersed repetitive unit-variable number tandem 
repeats) typing of isolates from all tuberculosis patients for the prospective 
identification, reporting and investigation of strain typing clusters. A mixed-methods 
prospective evaluation was conducted, assessing the Structures, Processes, Outputs, 
Outcomes and Context of the TB-STS.  
Structures were described and cost of the service estimated. Processes were explored 
using cross-sectional surveys, and semi-structured interviews assessed user 
experience. Outputs included the impact of the TB-STS on detection of false-positive 
Mycobacterium tuberculosis diagnoses, and its effect on contact tracing yield, 
diagnostic delay and cluster growth. These findings informed the estimation of the 
outcomes: a deterministic mathematical model to estimate the effectiveness of the 
TB-STS over 20 years and a cost-effectiveness analysis.  
The TB-STS cost approximately £1m per year. Between the initial and follow-up 
surveys, knowledge of strain typing increased, perceived usefulness did not change, 
and time spent investigating tuberculosis transmission increased. Interviews 
identified broader benefits such as improved contact tracing and the research 
potential of a strain typing dataset. Between 2010 and 2012, 17,168 isolates were 
typed. The TB-STS detected 17 additional false-positive diagnoses and had no 
significant effect on contact tracing yield, diagnostic delay or cluster growth. 
Mathematical modelling suggested the TB-STS would not reduce tuberculosis 
incidence in the white UK-born population. However, in the non-white UK-born and 
non-UK-born populations, moderate reductions in tuberculosis incidence could be 
observed if detection of latent infection increases from 3%-13%/year or diagnostic 
delay decreases by one week. The TB-STS was not predicted to be cost-effective 
(£95,62/QALY).  
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The TB-STS in its current form was not effective or cost-effective; however, broader 
benefits justify its continuation. Recommendations are made for the TB-STS, future 
typing services and their evaluation. 
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Outline of thesis  
This thesis contains a number of studies that contribute to the evaluation of the 
tuberculosis (TB) strain typing service (TB-STS) in England.  
Chapter 1 presents the background to the thesis. An overview is provided of the 
epidemiology and natural history of TB, TB control and TB strain typing. Existing 
strain typing services are described and the TB-STS in England is briefly introduced. 
Potential frameworks for the evaluation of the TB-STS are discussed. Finally, the 
aims and objectives of this thesis are presented.  
Chapter 2 systematically reviews the literature to investigate the biases associated 
with interpreting the proportion of clustering estimated by strain typing data using 
MIRU-VNTR.  
Chapter 3 details the methods used to address the objectives of the thesis.  
Chapter 4 describes the Structures of the TB-STS. 
Chapter 5 assesses the Processes within the TB-STS. The results of an initial and 
follow-up cross sectional survey of health protection and clinic staff are presented to 
describe the implementation and perception of the TB-STS amongst service 
providers and users. The user experience of the TB-STS is further explored using 
semi-structured interviews. 
Chapter 6 describes the Outputs of the TB-STS, including false positive TB isolation 
detected by the TB-STS, cluster investigation activity and outcomes, and the impact 
of cluster investigations on contact tracing, diagnostic delay, the rate of cluster 
growth.  
Chapter 7 presents the Outcomes of the TB-STS. It describes the results of the 
transmission model used to assess the effectiveness of the TB-STS and the cost-
effectiveness model used to evaluate the cost-effectiveness of the TB-STS. 
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Chapter 8 contextualises the findings of this thesis. Findings are summarised and a 
discussion of the thesis follows, including the strengths and limitations of the 
evaluation, the interpretation of the findings and the relevance of the wider context 
and broader benefits. In this chapter recommendations are made for the TB-STS and 
future strain typing policy, as well as suggestions for molecular typing services in 
general and future evaluations of complex public health interventions. 
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them at different time points, to describe the TB-STS in detail. 
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cluster monitoring database and contributed to the design of the cluster outcome 
reporting form. I designed and conducted the false positive TB detection surveys, 
after which I cleaned, analysed and interpreted the data. I was involved in the 
initiation of the contact tracing yield, diagnostic delay and rate of cluster growth 
studies, leading the discussions around them. I cleaned and merged the datasets for 
the studies. I conducted the analysis and interpreted the data for the contact tracing 
yield and diagnostic delay studies. I conducted the exploratory analysis for the rate of 
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cluster growth study, was involved in the design and interpretation of the main 
analysis, which was conducted by Ted Cohen and Leonid Chindelevitch. I was 
involved in the discussions about the structure of the transmission model and the 
parameter development, and conducted analyses for certain parameters. I was 
involved in the discussions around the design and structure of the cost-effectiveness 
model, I collected the cost data, conducted analyses to define certain parameters and 
cross-checked the sensitivity analysis. I was involved in the discussion of how the 
transmission model would input into the cost-effectiveness model and was involved 
in the interpretation of the model outputs.  
I drafted the recommendations of the evaluation and was part of the discussion with 
the expert steering group to finalise them. I wrote the discussion to this thesis. 
Positionality 
Unless otherwise stated, the research in the thesis was carried out by the author – 
Jessica Mears – who studied Public Health (MSc) at the London School of Hygiene 
and Tropical Medicine and Experimental Psychology (BSc) at the University of 
Oxford. The evaluator had the key generic public health skills and thinking to be able 
to bring the comprehensive evaluation of a complex intervention together into a 
coherent thesis. Given the range of skills required for such an evaluation, input from 
highly specialised professionals was necessary, for example, mathematical modeling, 
economics and clinical expertise were all needed for individual components of the 
work.    
Originally employed by PHE as the TB-STS Evaluation Scientist, the position was 
converted to a PhD studentship after the first six months. The initial time at PHE was 
useful in developing relationships between those working in the TB-STS, having 
access to internal documentation, and understanding the service. The change in role 
from PHE scientist to PhD student enabled the positioning of the evaluation to move 
outside of PHE and into UCL.  
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The motivation to conduct this research was based on the decision that interventions 
and the allocation of public funds should be evidence based, and because the author 
and steering group (Box 1) had genuine equipoise; the available evidence did not 
suggest whether the TB-STS was going to be a cost-effective intervention or not. 
Having been recently appointed to the role at PHE and quickly moving to UCL, 
minimised potential  conflicts of interest. 
An external, independent, multi-disciplinary evaluation steering group was set up, 
consisting of a TB nurse, chest physician, Consultant in Communicable Diseases 
(based in an HPU), TB program directors, epidemiologists, public health specialists, 
microbiologist, mathematical modellers, and a health economist. The names, 
disciplines and affiliations of the steering group are listed below. The evaluation 
steering group acted as an advisory group for the evaluation of the TB-STS, and for 
two specific elements, the transmission dynamic and cost-effectiveness modelling, 
undertaking the analysis. They were also used to check concepts, proposed 
methodologies, and the interpretation of qualitative and quantitative analyses, and 
ensure the findings of the evaluation remained independent. The main outputs of the 
steering group were the evaluation interim report (December 2011) and final 
evaluation report presented to PHE (March 2013), which included the 
recommendations for the TB-STS. Members of the evaluation steering group were 
co-authors on the peer-reviewed publications, led by the candidate, subject to their 
contribution to the papers. All three PhD supervisors were members of the evaluation 
steering group. 
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Chapter 1. Introduction 
This chapter sets the scene for the thesis. An overview is provided of the global 
burden of tuberculosis (TB), the epidemiology of TB in the UK, the natural history of 
TB, TB control and strain typing. The public health applications of strain typing are 
outlined, existing evaluations of strain typing services and potential evaluation 
frameworks are described. Finally, the aims and objectives of the thesis are 
presented. This chapter provides the background to the studies in this thesis and the 
literature presented here is referred to throughout the thesis. 
__ 
1.1 Tuberculosis (TB) 
Global burden of TB 
TB is a global disease, with an estimated 9 million cases in 2013 of which 1.5 
million people died.
1
 TB is the second leading cause of death from an infectious 
disease worldwide, after human immunodeficiency virus (HIV). TB mortality is 
unnecessarily high given that most deaths are preventable if people can access the 
healthcare required for diagnosis and treatment. Since TB was declared as a global 
public health emergency by the World Health Organization (WHO) in 1993, the TB 
mortality rate and incidence rate have been decreasing, but remain high with between 
and within regional variation (Figure 2). 
The TB incidence rate in the WHO European Region was estimated to be 39.4 per 
100,000 in 2012, with an estimated 353,000 new cases.
2
 This represents about 4% of 
the global burden of incident TB. 68,423 TB cases were notified in the European 
Region in 2012 (Figure 3). Of these, 27% (n=18,358) were of foreign origin (Figure 
4). In the UK, the proportion of TB cases notified in 2013 that were foreign born was 
72.5% (5518/288).
3
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Figure 1 – WHO estimates of TB incidence rates, 2013 
 
Source: Global Tuberculosis Report, World Health Organization 20141 
 
Figure 2 – Global trends in estimated rates of TB incidence and mortality 
 
Left: Global trends in estimated overall TB incidence rate (green) and estimated incidence rate of HIV-positive 
TB (red). Right: Trends in estimated TB mortality rates 1990–2013 and forecast TB mortality rates 2014–2015. 
The horizontal dashed line represents the Stop TB Partnership targets of a 50% reduction in mortality rates by 
2015 compared with 1990. Shaded areas represent uncertainty bands. Mortality excludes TB deaths among HIV-
positive people. 
Source: Global Tuberculosis Report, World Health Organization 20141 
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Figure 3 – TB notification rates per 100 000 population, European Region, 2012 
 
Source: European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis 
surveillance and monitoring in Europe 2014. 
 
Figure 4 – Percentages of notified TB cases of foreign origin among all TB cases, European 
Region, 2012 
Sour
ce: European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis 
surveillance and monitoring in Europe 2014. 
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Epidemiology of TB in the United Kingdom (UK) 
TB has re-emerged as a serious public health problem in the UK over the last two 
decades with case notifications reaching 9000 in 2011, a rate of 14.1 per 100,000.
4
 
There has been a slight decrease in the numbers of TB cases in the last two years, 
with 7892 cases notified in 2013, a rate of 12.3 per 100,000.
3
 Approximately half of 
which were pulmonary (52% of cases with known site of disease). 
Figure 5 – TB case reports and rates in the UK, 2004-2013  
Source: Enhance Tuberculosis Surveillance (ETS), Enhanced Surveillance of Mycobacterial 
Infections (ESMI), Office for National Statistics (ONS)
3 
England accounted for 92.4% (7290/7892) of the cases in the UK in 2013 with a rate 
of 13.5 per 100,000, the highest proportion of which were in London (rate of 35.5 per 
100,000). 59.2% of cases in England were culture confirmed and 71.3% of cases 
with pulmonary TB were culture confirmed.
3
 
A majority of cases were male (58% in 2013), and most were aged between 15 and 
44 years old (with a rate of 24.4 per 100,000 in this age group in 2013) (Figure 6).
3
 
Rates of TB were significantly higher in non-UK born cases compared to UK born 
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cases (70 per 100,000 compared to 4 per 100,000) (Figure 6). TB incidence rates are 
highest in those aged 75 and older in the UK born population, whereas in the non-
UK born population the highest rates are in those aged 25 to 29 (rates of 6.6 and 94.3 
per 100,000, respectively). In the last few years, the most common countries of 
origin of non-UK born cases are India, Pakistan and Somalia (30%, 20% and 5%, 
respectively in 2013).
3
 
Figure 6 – TB case reports and rates by age group and place of birth, UK, 2013 
Source: Enhance Tuberculosis Surveillance (ETS), Enhanced Surveillance of Mycobacterial Infections 
(ESMI),Labour Force Survey (LFS) 
Data as at: May 2014. Prepared by: TB Section, Centre for Infectious Disease Surveillance and Control, Public 
Health England    
 
In 2013, 7% of cases in the UK had a previous diagnosis of TB.
3
 Resistance to at 
least one first line antibiotic was identified in 7.8% of all cases, and 1.6% were 
multi-drug resistant (MDR; resistant to at least isoniazid and rifampicin).
3
 These 
rates have been relatively stable over the last decade, with a slight increase between 
2008 and 2011.  
Approximately 10% of TB cases have at least one social risk factor for TB: current 
or history of problem drug misuse, alcohol misuse, homelessness or imprisonment.
3
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Natural history of TB 
TB is caused by Mycobacterium tuberculosis complex. After inhaling aerosolised 
droplets of M. tuberculosis from a person with infectious TB, approximately 30% of 
people become infected.
5
 In the remainder, the infection is cleared, which is likely 
due to host factors (such as the host’s immune response which may eradicate the 
organism) or characteristics of the pathogen (such as the virulence of the strain).  A 
simplified interpretation of the natural history of TB is illustrated in Figure 7.   
Figure 7 – Natural history of TB  
 
A person who is infected with M. tuberculosis may clear the infection and recover 
(follow the blue arrows in Figure 7), may become latently infected (black arrow), or 
develop active disease (red arrow). When an individual is infected with M. 
tuberculosis and the bacilli are in a dormant state, this is known as latent tuberculosis 
infection (LTBI), whereby the patient will show no clinical signs of TB.
6
 This latent 
period can last a lifetime or the infection may reactivate to become active disease at 
any point, known as endogenous reactivation.  Risk factors for reactivation include 
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age and a suppressed immune system.
7
 The variable duration of latent infection of M. 
tuberculosis makes it difficult to identify transmission pathways and implement 
targeted control programmes. 
Most immune competent individuals will not develop TB disease over their lifetime. 
The lifetime risk of progressing to active disease is 5-10%. It is highest shortly after 
infection (80% in the first two years) and decreases subsequently. The risk of 
developing disease is much higher for those who are immunocompromised, 
especially those with HIV, who have a 5-10% annual risk of progressing to active 
TB.
6
  
People who are latently infected, or people who have recovered from a previous TB 
infection can be reinfected with the same or different strain of M. tuberculosis. This 
is known as exogenous infection, or reinfection. The variability between the time of 
infection and disease makes differentiating between endogenous and exogenous TB 
difficult, as there could be many years between infection from the index case and 
disease in the secondary case.
8
 Molecular typing can be used as a tool to differentiate 
between relapse and reinfection (see section 1.3.2, page 21).
9
 
Following treatment for active TB, an individual may clear the infection and recover, 
the treatment may fail and the individual may continue to have active disease, the 
individual may relapse at a later stage and develop recurrent TB. As disease does not 
infer immunity, the individual remains at risk for reinfection and subsequent disease.     
1.2 TB control 
The aims of TB control are to provide care to the infected individual that will reduce 
morbidity and mortality, and ensure the best possible prognosis, and prevent or 
reduce transmission in households and the community. Given what is known about 
the natural history of TB, identifying people who have recently been infected and 
treating them with chemoprophylaxis is a key intervention to prevent progression to 
active disease and the subsequent potential onward transmission. The main methods 
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for TB control are through case finding (active and passive), treatment of cases and 
infected contacts, and vaccination with BCG.  
Case finding 
Active case finding is the active search for new cases of TB or LTBI, as opposed to 
passive case finding which relies on symptomatic cases presenting to the healthcare 
system. Cases of active TB are identified and treated, thereby preventing onward 
transmission, and people with LTBI are identified and treated prophylactically to 
prevent progression to disease.  
The two most common forms of active case finding are contact tracing and screening 
(which is usually targeted to high risk groups, such as migrant entry screening and 
screening of hard to reach populations).
10,11
 Contact tracing forms the basis of a 
traditional public health response to a case of TB in order to identify others who 
might have been infected, i.e. if there has been any onward transmission and in some 
instances to identify the source case, and to target individuals at high risk of TB 
infection or disease.
12
 Contact tracing is based on the ‘stone in the pond’ principle,13 
whereby the close contacts of a TB patient are identified and invited to be screened 
(Figure 8). If a route of transmission has been identified and the need for further 
investigation is required, this process is then extended to a wider circle of contacts.  
Figure 8 – The ‘stone in the pond’ principle for TB contact tracing 
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Once contacts have been identified through contact tracing, they are screened for TB. 
Screening involves testing for active TB or LTBI. Active TB is suspected based on 
symptoms and/or chest x-ray if the disease is pulmonary. In brief, laboratory 
diagnosis is confirmed by microscopy, culture or histopathology on specimens such 
as sputum, bronchial washings, cerebrospinal fluid or lymph nodes. Because of the 
high mycolic acid content of the mycobacterial cell wall, acid-fast bacilli can be 
stained and detected from a sputum sample using an arylmethane staining and acid-
based de-colouring technique (such as the Ziehl-Neelsen stain). Diagnosis can also 
be confirmed using in vitro culture (Lowenstein-Jensen is the most commonly used 
egg-based formulation) or liquid culture (such as BACTEC Mycobacterium Growth 
Indicator Tube (MGIT) 960). Due to the long division time of M.tuberculosis (16 to 
18 hours in optimal conditions), it may take two to four weeks to become culture 
positive.
14
 More rapid diagnostic tests such as nucleic acid amplification tests are 
also available, but are expensive and do not replace the need for culture. The host’s 
basic inflammatory response to infection with M.tuberculosis is the formulation of 
tuberculoid granulomata, which is diagnostic on histology.  
Screening for LTBI can be done with a Tuberculin Skin Test (TST) or an interferon 
gamma release assay (IGRA) test. Contact tracing focuses on contacts from the 
household and non-household (such as the workplace and leisure settings). These 
two contact types are most easily explored through the traditional patient interview. 
However, assessing casual contacts, whom the patient may have never formally met 
before, poses a problem for traditional contact tracing as the patient is unlikely to 
name these people as their contacts.  
Contact tracing is not restricted to TB incidents, but is used as an infection control 
strategy in response to other infectious diseases such as HIV, other sexually 
transmitted infections (STIs) and pandemic influenza. It is relatively easy to establish 
which contacts have been exposed to an STI because the contact required for 
transmission is easily defined. On the other hand, influenza is so infectious and has a 
short infectious period that contacts that have been exposed to the virus can be 
defined very inclusively – as anyone that one has spoken to in the last three days, for 
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example.
15
 TB, on the other hand, can have a very long and variable incubation 
period and the infectiousness is relatively low. This makes defining a contact more 
difficult and the development of transmission models for TB challenging.   
Indicators for the effectiveness of active case finding include the yield of active TB 
and LTBI identified through contact tracing, known as contact tracing yield, and the 
delay between the onset of symptoms and start of treatment, known as diagnostic 
delay. Contact tracing yield and diagnostic delay are described in turn.  
Contact tracing yield 
Contact tracing yield is defined as the proportion of contacts of an index case who 
have LTBI or have active TB disease. Fox et al (2013) conducted a review of the 
prevalence of LTBI and active TB, and the annual incidence of TB among contacts 
of patients with TB in low, medium, and high-income countries.
16
 From high-income 
countries, they included 92 studies reporting the yield of LTBI (79,511 individuals 
with LTBI after screening 284,505 contacts; 28.1%, CI 24.3 to 32.4, I
2
=99.5) and 87 
studies reporting the yield of active TB (5058 active cases identified from 308,048 
contacts; 1.4%, CI 1.1 to 1.8, I
2
=98.7). Interpreting the results of a meta-analysis 
such as this is challenging due to the heterogeneity of the studies included. For 
example, this review included studies of different transmission risk groups (such as 
HIV-positive and drug-resistant TB patients). In addition, the definition of a contact 
varied largely between studies, with some only including ‘close contacts’, or 
‘household contacts’, or ‘casual contacts’, and or contacts from congregate settings.  
Another literature review, assessing the contact tracing yield amongst migrant and 
foreign-born index cases, included 70 studies and estimated the yield of LTBI to be 
31.9% (IQR 16.9-36.9) and active disease to be 0.4 (IQR 0.0-2.2).
17
 
To gather studies more relevant to the TB epidemiology and TB control programme 
in England, the references from Fox et al’s systematic review were examined16 and a 
search of PubMed was conducted to identify more recently published articles from 
low TB incidence countries. The following search terms were used: “tuberculosis” 
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and “contact screening” or “contact tracing” or “contact investigation”. The 
identified articles are summarised in Table 1. There were four relevant studies from 
the UK, presenting data from Birmingham, Blackburn, London and South 
Glamorgan, spanning from 1982 to 2010. The contact tracing yield ranged from 
3.0% to 7.9% for LTBI identified and 0.7% to 2.9% for active TB found. Other 
studies identified in the search were from France, Italy, the Netherlands and the 
USA. 
The mean number of contacts identified and screened per index case was highest in 
the Netherlands (27.7 and 23.7, respectively for LTBI and active TB)
18
 and lowest in 
Turin, Italy (4.3 and 4.0, respectively).
19
 The highest yield of LTBI was in Maryland, 
USA (41% of those screened had LTBI) and the highest yield of active TB was in the 
Tower Hamlets in London (3.8% of contacts of pulmonary TB index cases screened 
had active TB)
20
.
21
 Yield of LTBI and active disease in the studies summarised in 
Table 1 ranged from 3% to 41% and 0.2% to 3.8%, respectively. 
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Table 1 – Summary of identified literature on contact tracing yield in low TB incidence countries 
Author Country Study location Study period Index 
casesa 
Contacts (mean 
per index case) 
Contacts screened 
(coverageb) 
LTBI 
screening testj 
LTBI (%) 
 
Active TB 
(%) 
          
Ansari22 UK South Glamorgan 1992-94 103 732 (7.0) 707 (96.6) H/X 21 (3.0)d 7 (1.0) 
Ormerod23 UK Blackburn 1982-90 649 . 7017 TST . 50 (0.7) 
Saunders24 UK Birmingham 1990-2010 7365 46158 (6.3) 42613 (92.3) TST/IGRA 1687 (4.0) 778 (1.8) 
Saunders24 UK Birmingham 1990-2010 5056c,i 35095 (6.9) 31852 (90.8) TST/IGRA 2220 (7.0) 718 (2.3) 
Underwood21 UK Tower Hamlets 1997-99 227 . 646 TST/X 51 (7.9) 18 (2.8) 
Underwood21 UK Tower Hamlets 1997-99 144c,i . 419 TST/X 29 (6.9) 16 (3.8) 
          
Aissa25 France Paris 2004-05 325 2009 (6.2) 1575 (78.4) TST/X 410 (26.0) 15 (1.0) 
          
Borraccino19 Italy Turin 2001-08 1099 4759 (4.3) 4441 (93.3) TST 1287 (29.0) 22 (0.5) 
          
Mulder18 NL NL 2006-07 642 17124 (27.7) 10391 (60.7) TST/IGRA 841 (8.1) . 
Mulder18 NL NL 2006-07 642 17124 (27.7) 15202 (88.8) TST/IGRA . 91 (0.6) 
Sloot26 NL Amsterdam 2008-11 235c 3743 (15.9) 2337 (62.4) TST/X/IGRA 254 (10.9) . 
Sloot27 NL Amsterdam 2002-11 610c 9332 (15.3) 4774 (51.2) TST/X/IGRA 739 (15.5) . 
          
Behr28 USA San Francisco 1991-96 1525c,g . 11211 TST/X 3976 (35.5) 109 (1.0) 
Davidow29 USA 5 TB programmes 1996 42h 724 (17.2) 494 (68.2) TST 144 (29.1) 1 (0.2) 
Golub20 USA Maryland 2000-01 124 . 703  TST 288 (41.0) 16 (2.3) 
Jereb30 USA 29 states 1999 9199 67585 (7.3) 56100 (83.0) .k 13083 (23.3) 561 (1.0) 
Marks31 USA 11 TB programmes 1996-97 1080c,e . 6225f  TST 1725 (27.7) 134 (2.2) 
Moran-Mendoza32 USA British Columbia 1990-2000 3485 42593 (12.2) 33146 (77.8) TST . 228 (0.7) 
Reichler33 USA 5 health departments 1996 349c 3824 (11.0) 2095 (54.8) TST 655 (31.3) 24 (1.1) 
Sprinson34 USA California 1999-2000 2032 17774 (8.7) 15582 (87.7) .k 4609 (29.6) 111 (0.7) 
NL The Netherlands 
a all TB, unless otherwise indicated; b coverage is the proportion of contacts identified that were actually screened (contacts screened/contacts identified*100); c pulmonary TB 
d given chemoprophylaxis; e smear positive; f close contacts (does not include casual contacts); g paediatric TB; h cases in a workplace setting; i sub-analysis of pulmonary TB cases; j H Heaf test; 
X Chest x-ray; TST Tuberculin skin test; IGRA Interferon Gamma Release Assay; k the screening test was not reported by Jereb et al or Sprinson et al, but based on information in the article it 
can be inferred that TSTs were used
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Diagnostic delay 
Reducing diagnostic delay, the delay between onset of symptoms and diagnosis or 
treatment, is an important feature of a TB control service. During this time, when a 
symptomatic TB case is undiagnosed, they are at risk of transmitting the infection 
within the community and progressing to more severe disease. An effective TB 
control programme will provide early diagnosis and initiation of treatment, to 
improve the prognosis for the individual as well as preventing onward transmission. 
Diagnostic delay is used as a measure of the quality of a TB control programme. The 
total delay can be divided into patient delay (time between onset of symptoms and 
contact with the health service) and healthcare delay (time between contact with the 
health service and diagnosis or treatment).
35–37
  
Although diagnostic delay can be useful, it is inherently biased as it relies on the 
patient’s subjective assessment of the symptoms and their recall for when the 
symptoms started. Treatment start date is a more objective variable to estimate the 
end point of the diagnostic delay, but it is not recorded reliably in the UK 
surveillance dataset. Instead, the notification date is a more complete variable, but it 
may be subject to time lags as the administrative task of entering new cases onto the 
surveillance database may not be completed prospectively, but done retrospectively 
on a regular basis (e.g. monthly or quarterly). As a result, it is difficult to compare 
diagnostic delay across different countries as the data collection and notification 
biases will vary. In addition, there may be cultural differences in the subjective 
assessment of when symptoms, such as a cough, first started.  
A brief review of the literature was conducted to explore the diagnostic delay 
experienced in the UK. PubMed was searched using the search terms (tuberculosis) 
and (“diagnostic delay” or “treatment delay” or “delayed diagnosis” or “delayed 
treatment”) and (UK or England or London). Ten papers were identified that reported 
a measure of delayed diagnosis of TB patients in the UK. One additional report was 
identified from the grey literature.
3
 Five studies were retrospective cohort studies, 
five studies were cross-sectional studies based on surveillance data, and one used 
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national surveillance data. Two systematic reviews containing three studies 
conducted in the UK were identified,
37,38
 all three of which had already been 
identified by this search. Table 2 summarises the studies identified by this search.  
The median diagnostic delay reported across the nine studies ranged from 37 days
39
 
to 126 days.
40
 Excluding the studies that only included children
39
 and women whose 
symptoms started during pregnancy,
41
 the shortest diagnostic delay reported was 49 
days.
42,43
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Table 2 – Summary of literature on diagnostic delay in the UK 
Author Study period Study location Study 
population
a
 
Number of cases Definition of 
diagnostic delay
b
 
Median (IQR) 
diagnostic delay (days) 
Abubakar
39
 1999 - 2006 England and Wales 
b
 Children 3563  treatment 37 (13-89) 
Craig
44
 
c
 Jan 1999 - Aug 2002 Royal Free TB clinic  120 treatment . 
French
45
 2000-2005 England  40779 either 67 (30-131) 
Lewis
40
  Jan 1996 - Oct 1997 Newham Chest Clinic  93 treatment 126 (4-1533) 
Llewelyn
41
 Dec 1995 - May 1998 Northwick Park Hospital  Pregnant women 13  diagnosis 49 (14-210)
 d
 
Paynter
46
 April 2001 - March 2002 North Middlesex University 
Hospital 
 72 treatment 78 (39-159) 
Public Health 
England
3
 
2013 UK  3009 treatment 72 (36-132) 
Rodger
42
 1998 - 2000 London  1355 treatment 49 (14-103) 
Saldana
35
 2007 Thames Valley  273 treatment 73 (65-89) 
Sultan
47
 Jan 2005 - Oct 2010 West Midlands  4840 treatment 81.5 (40-154) 
Wares
43
 1991-1996 Blackburn Royal Infirmary  43 diagnosis 49 (28-91) 
a The study population was all TB cases unless otherwise stated 
b Definition of diagnostic delay was the time between onset of symptoms and: the start of treatment (treatment), the date of diagnosis (diagnosis), or whichever was available (either) 
c Craig et al did not report the median total diagnostic delay. Instead, they reported separately the time between symptom onset and first presentation to primary care (46 (55%) < 3 months, 29 
(35%) > 3 months) and time from first presentation to primary care to start of anti-TB treatment (62 (75%) ≤ 8 weeks, 21 (25%) > 8 weeks) 
d The median and range are reported here (IQR was not reported in the paper)  
 
16 
 
TB Treatment 
The standard treatment for active TB consists of six months of isoniazid and 
rifampicin supplemented in the first two months with pyrazinamide and 
ethambutol.
48
 Any resistance to these first line drugs will be treated with a different 
combination of drugs, usually excluding the drug to which the organism is resistant, 
for up to 18 months. Multi-drug resistant tuberculosis (MDR-TB) (resistant to at least 
rifampicin and isoniazid) is treated with a combination of first and second line drugs. 
Second line drugs are divided into six main classes: aminoglycosides, polypeptides, 
fluoroquinolones, thioamides, cycloserine, and para-aminosalicylic acid.  Four to six 
drugs from separate classes to which the organism is susceptible are selected to treat 
MDR-TB. Treatment is tailored to suit the characteristics of the patient and can last 
up to two years. 
Prophylactic treatment for LTBI consists of either six months of isoniazid or three 
months of rifampicin and isoniazid. If a person has been in contact with a drug 
resistant case of TB, they may be treated prophylactically with six months of 
rifampicin. In the UK, prophylactic treatment is recommended for those aged 35 and 
below (because of increasing risk of hepatotoxicity with age), those HIV positive 
(any age), or healthcare workers (any age).
48
 
BCG vaccination 
The bacillus Calmette–Guérin (BCG) vaccine, a live vaccine derived from an isolate 
of Mycobacterium bovis, was first developed in the 1920s. The efficacy of the 
vaccine varies worldwide, but is most effective for TB meningitis.
49
 This might be 
because BCG does not protect against disease when it is given to people who are 
already infected or who have been sensitised to environmental mycobacteria. Unlike 
the recently developed IGRA test, the tuberculin skin test cannot distinguish a 
positive response caused by M. tuberculosis infection from that caused by BCG 
vaccination or non-tuberculous mycobacterial infection.  
Since 2005, the UK’s vaccination strategy has been to target those at highest risk of 
exposure to TB:
48
  
17 
 
 People who have been in close contact with someone with pulmonary TB, 
who had a negative Mantoux test, have not been vaccinated before, and are 
aged 35 years or younger 
 All infants (0-12 months) living in areas where TB incidence is at least 40 per 
100,000 or with a parent or grandparent born in a country where TB 
incidence is at least 40 per 100,000 
 Children who were not vaccinated as babies and are at high risk of TB 
 People coming to live in the UK from areas where TB is widespread, if they 
have a negative Mantoux test result, have not been vaccinated before, and are 
aged 35 years or younger 
1.3 Strain typing 
The complex natural history of TB has left classical epidemiology with many 
unanswered questions including how to differentiate between recent transmission and 
reactivated previous infection; and to determine whether recurrent TB is due to 
relapse (endogenous) or re-infection (exogenous). Furthermore, there are unanswered 
questions about differences in the epidemiology of different lineages of TB, and the 
molecular evolution of M. tuberculosis.
8,50–52
 Molecular epidemiology – “the use of 
molecular-typing methods for infectious agents in the study of the distribution, 
dynamics, and determinants of health and disease in human populations”53 – has 
started to address these questions. In combination with classic epidemiology, 
differentiating M. tuberculosis isolates by strain type can improve our knowledge 
and understanding of the natural history of TB and TB transmission.  
1.3.1 Strain typing methods 
In the last decade the three main methods commonly used to distinguish between 
different strains of M. tuberculosis are insertion sequence IS6110 restriction 
fragment length polymorphism (RFLP),
54
 spacer oligonucleotide typing 
(spoligotyping)
55
 and mycobacterial interspersed repetitive unit-variable number 
tandem repeats (MIRU-VNTR).
56
 These methods are based on sequences of DNA 
that are found interspersed throughout the bacterial genome or at specific locations 
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on the genome.
8
 More recently, whole genome sequencing (WGS) examines 
variation across most (~90%) of the bacterial genome at the nucleic acid level.
50,57
  
The most appropriate method to detect recent transmission in a population will 
depend on whether the method can discriminate between strains that are not linked 
epidemiologically, whether the ‘molecular clock’ of the biomarker is slow enough to 
identify cases in the same chain of recent transmission and the genetic diversity of M. 
tuberculosis in the population.
8
 A reliable molecular strain typing technique will be 
stable, rapid, reproducible, highly discriminative, easy to perform and interpret, and 
applicable to clinical material/samples.
50,58
 
IS6110 RFLP 
Until recently the most widely used molecular typing method, considered the gold 
standard technique, was IS6110 RFLP typing. IS6110 is an insertion sequence found 
in varying locations and copy numbers in the M. tuberculosis genome. The 
polymorphisms that arise from the different locations and copy numbers of the 
IS6110 allow M. tuberculosis to be grouped into different lineages. The standardised 
method for IS6110 RFLP typing results in a different banding pattern for each strain 
which can be compared using comparison algorithms
54
 such as those incorporated 
into the Bionumerics software.
59
 
IS6110 RFLP does not meet all the criteria for a good molecular typing tool for 
TB:
8,60,61
 
 The process is laborious with a slow turnaround time (requiring several 
weeks to culture enough DNA); 
 A proportion of M. tuberculosis isolates contain no or very few copies of 
IS6110 insertions (low copy number (LCN)) so they cannot be distinguished 
using this technique (five or fewer are not discriminatory)
62
, requiring a 
second typing method; and 
 The interpretation and comparison of the banding patterns relies on the 
subjective opinion of the researcher.  
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Spoligotyping 
Spoligotyping is used in combination with other typing methods to provide a highly 
discriminatory typing system.
63,64
 This method is based on the presence or absence of 
43 unique, non-repetitive DNA ‘spacer’ sequences in a distinct chromosomal region, 
known as the Direct Repeat region, that are interspersed with 36-bp repetitive 
sequences (direct repeats).
55
 The result is binary data based on the presence or 
absence of spacer sequences, which can be compared between strains. Spoligotyping 
can accurately discriminate between strains with a low copy number of IS6110 and 
can easily detect lineages that are characterised by spacer deletions (such as Beijing 
strains which have 34 spacer deletions).
62,65
  
The advantages of spoligotyping are that results are reproducible, easy to interpret 
and easily compared, and the procedure is rapid and requires small amounts of DNA. 
Disadvantages are that it has a lower discriminatory power compared to the other 
methods described here, and is subject to convergent evolution (whereby 
phylogenetically unrelated strains have the same spoligotyping patterns because of 
the irreversible deletion of spacer sequences).
66
 
MIRU-VNTR 
MIRU-VNTR typing is based on genetic elements found in the M. tuberculosis 
chromosome termed mycobacterial interspersed repetitive units (MIRU).
56
 Supply et 
al described 41 MIRU-VNTR in the M. tuberculosis genome.
67
 Each locus contains 
multiple copies of a repeated sequence; the variation in the number of copies at each 
site provides the basis for a unique identifier. Copy number is established by PCR 
amplification of the loci using primers specifically designed for the flanking region 
of each of the loci. The copy number can be expressed as a digit so that the copy 
numbers of all the loci typed can be recorded as a string of digits. The amplified loci 
are then analysed using computer software packages such as Bionumerics
59
 or 
GeneScan
68
 to build dendrograms for comparison.  
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Figure 9 – The principle of MIRU-VNTR typing of M. tuberculosis.  
 
The size of each locus is measured using PCR amplification designed for the flanking region of each locus 
(indicated by the red arrows). Because the size of a unit is known, the number of repetitive units can be inferred 
by the size of the PCR product. As this is done for 24 loci, the strain type is presented as a 24-digit long 
numerical code. 
Source: Borgdorff and van Soolingen, Clinical Microbiology and Infection, Volume 19, Issue 10, pages 889-901, 
4 JUN 2013 DOI: 10.1111/1469-0691.12253 
 
Evidence suggests that the discriminatory power of 24 MIRU-VNTR is slightly 
lower than IS6110 RFLP,
69,70
 but is more discriminatory for low IS6110 copy 
strains.
71
 Used in combination with spoligotyping, the discriminatory power of 24 
MIRU-VNTR is comparable to IS6110 RFLP in low and high TB incidence 
settings.
72,73
  
Advantages of the MIRU-VNTR strain typing include the ease with which the 
numerical strain type can be interpreted and compared, the speed at which typing can 
be conducted, and the high throughput nature of the method. Disadvantages of 
MIRU-VNTR typing is that not all loci can be successfully amplified for every strain 
and that the ‘molecular clock’ of the biomarker is unclear. Early estimates suggested 
that the mutation rate of VNTR loci was extremely slow,
74
 whereas more recent 
estimates are much higher,
75
 resulting in some (unresolved) debate about whether 
recent transmission could be underestimated using this typing method.
76,77
  
Whole Genome Sequencing (WGS) 
The M. tuberculosis sequence was published in 1998
57
 and since then sequencing 
methods have become more efficient and cost-effective. WGS identifies the whole 
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genome sequence from which Single Nucleotide Polymorphisms (SNPs), variations 
in single nucleotides arising from mutations on the genome, can be identified. 
Analysis of SNPs allows M. tuberculosis to be classified into strains based on SNP 
differences. SNP analysis shows how closely linked individuals are in time, and 
because backward mutations are rare, the direction of transmission can also be 
determined.
50,78–80
 There is growing support for WGS to be used to detect chains of 
recent transmission and discriminate between reactivation and reinfection of TB.
81,82
 
WGS has the highest discriminatory power for distinguishing between strains as it is 
based on the analysis of the genome at approximately 70% of nucleotide positions.
57
 
The ‘molecular clock’ of WGS SNP analysis is currently uncertain. There is some 
evidence that it is stable and the rate of change is rarely more than 5 SNPs in a three 
year period
78
, whereas others have shown that the mutation rate to be more 
variable.
82,83
 Studies have suggested that where MIRU-VNTR typing has clustered 
patients, WGS has divided these clusters, and where MIRU-VNTR typing has 
differentiated patients, WGS has found they are genetically linked.
78,81
  
WGS is a useful instrument for understanding TB transmission and natural history, 
but its feasibility as a routine tool for public health is still being explored.
78
 The cost 
of the technique and complexity of the bionformatic analysis needed are currently 
barriers to its wider use, requiring specialist software and highly skilled staff for data 
analysis and interpretation. It is expected that the cost will decrease over the next few 
years
50,84
 and pipelines for analysis are being developed.
85
 
1.3.2 Public health applications of strain typing 
TB strain typing can be used for the following, each of which is discussed in more 
detail below: 
 To estimate TB transmission;  
 To prove or disprove suspected transmission; 
 To identify risk factors for recent transmission; 
 To interrupt transmission through targeted contact tracing;  
 To distinguish between reactivation and reinfection; and 
22 
 
 To identify incidents of false positive TB isolation. 
Estimating transmission 
Strain typing can distinguish between clustered cases and unique cases. Clustered 
cases – cases with indistinguishable strains of M. tuberculosis – can be used to 
estimate the amount of recent transmission occurring in a population by assuming 
that one case in each cluster is the source case and the rest are part of a subsequent 
chain of transmission.
86
 Estimates of recent transmission provide a useful measure to 
evaluate the success of TB control programmes as you would expect recent 
transmission to decrease following a successful intervention.
87–89
 Strain typing can 
also help identify and investigate outbreaks or chains of ongoing transmission.
86,90,91
 
This occurs where cases that are not epidemiologically linked through contact 
tracing, are clustered by strain type. Strain typing can also be used to disprove 
epidemiological links between cases where transmission is thought to have occurred 
when strains are indistinguishable.
28
  
Potential biases in the interpretation of TB strain typing need to be considered (this 
topic is reviewed systematically in Chapter 2 (page 31)). There is a difference 
between the number of patients that are linked epidemiologically through contact 
tracing and the number of patients in molecular clusters defined by strain typing, 
making it unclear what the true rate of recent transmission is. Studies in the United 
States have found low concordance between epidemiological links between patients 
and molecular clusters.
28,86
 This could represent the underestimation of transmission 
identified through contact tracing, or the overestimation of recent transmission 
identified by strain typing. An alternative explanation is that it may be impossible to 
establish transmission through interviews with patients.
92
 The disparity between 
epidemiological information and molecular information illustrates the importance of 
combining the two sources of information to inform TB control activities. 
There is evidence to suggest that rates of clustering by IS6110 RFLP are influenced 
by the diversity of strains in the population, TB incidence, study design and 
characteristics of the population.
93
 No studies have examined whether the same 
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biases occur with MIRU-VNTR. This is addressed in detail by the systematic review 
in Chapter 2.
94
 
Proving or disproving suspected transmission 
Strain typing can be used to prove or disprove suspected transmission identified 
through contact tracing or a suspected outbreak. If two cases have an epidemiological 
link (e.g. if they are colleagues), then indistinguishable strain types provide further 
evidence for transmission. If a case is suspected of being part of a larger outbreak, a 
distinguishable (not matching) strain type will disprove their involvement in the 
outbreak. 
This tool is more useful in settings with a low TB incidence. This is because in high 
TB incidence settings where the proportion of clustering is very high, direct links 
between patients confirming suspected transmission are only found in a small 
proportion of instances. For example, in a gold-mining community in South Africa, 
in most instances miners with the same IS6110 RFLP strain of TB did not share the 
same room, so transmission was not occurring in the dormitories as had been 
expected.
95
 In these circumstances contact tracing becomes a rudimentary method to 
screen the population and cases are identified, not because of recent transmission 
from the index case, but because they have acquired TB within the population more 
broadly.
28
 In low incidence areas, however, strain typing can more reliably be used to 
identify or prove suspected transmission. 
Risk factors for recent transmission 
Strain typing has enabled epidemiologists to identify risk factors for recent 
transmission, based on their risk factors for being in a molecular cluster. This makes 
it possible to target high risk groups with ad hoc TB control interventions. Fok et al 
conducted a systematic review of molecular epidemiological studies using IS6110 
RFLP typing to investigate risk factors for clustering.
96
 Thirty-six studies from 17 
different countries of low, medium and high TB incidence identified male sex, young 
adults, native (vs. foreign-born), urban residence (vs. rural), alcohol and drug abuse, 
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homeless, exposure in crowded settings (including prisons), and pulmonary TB as 
risk factors for clustering.  
Interrupting transmission 
Cluster investigations are the extended contact tracing and investigation activity 
surrounding a molecular cluster of patients. They can be used to: identify 
epidemiological links between clustered cases; identify non-traditional transmission 
settings (such as bars and churches);
97
 identify unsuspected outbreaks;
98–101
 or help to 
target contact tracing investigations based on the characteristics of the first two cases 
in a cluster.
102,103
 
Conversely, strain typing can be used to evaluate contact tracing and its 
effectiveness. For example, strain typing has identified cases that were missed by 
traditional contact tracing, such as contacts that were from outside of the household 
or close contact group, or hard to reach groups (such as the homeless or drug 
users).
89,104
 In addition, strain typing has disproved suspected transmission, showing 
that a proportion of TB in household contacts have different strains of TB, ruling out 
household transmission.
28,105
 
Relapse and reinfection 
Recurrent TB may be caused by relapse or exogenous reinfection. Differentiating 
between relapse and reinfection is important for TB case management and control 
strategies.
81,106–108
 Where historical isolates from previous TB episodes are available 
it is possible to distinguish between relapse and reinfection in a patient, based on the 
assumption that reinfection is likely to result from M. tuberculosis with a strain type 
that is different from the previous infection (whereas relapse will be the same strain). 
Identifying reinfection is important as it shows that cases in high burden settings are 
arising from new infections rather than reactivation.
109
 Reinfection is demonstrated 
by evidence of mixed infections where one patient is infected with more than one 
strain of M. tuberculosis.
110,111
 The inference that M. tuberculosis infection does not 
result in sufficient acquired immunity against repeat infection has important 
implications for TB control. Rates of relapse and reinfection vary across different 
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countries, increasing with higher TB incidence and density of active disease,
112
 and 
also across different subgroups. Patients with HIV are at increased risk of recurrent 
TB because of an increased risk of reinfection.
9,106,113
 
False positive TB isolation 
Strain typing can also be used to identify and confirm false positive M. tuberculosis 
isolates. Though not directly related to TB epidemiology, this is important for quality 
control and TB programming. False positive isolation may be the result of 
contamination, mislabelling or mishandling of clinical samples.
114
 A false positive 
diagnosis of TB can cause physical and emotional distress to the patient and their 
contacts as a result of the TB treatment and the contact tracing and screening that 
will be carried out around the index case, all of which will have costs. In addition, 
false positive TB diagnosis may delay the diagnosis of the patient’s true condition, 
which has important cost and health implications.
115
 When multiple isolates are 
processed in the laboratory within a certain time period have the same strain type, 
possible false positive isolation can be investigated. It has been suggested that this 
should apply to isolates processed within seven days,
116
 though the optimum time 
period will vary depending on the caseload of the laboratory. The adoption of MIRU-
VNTR typing should help to improve the speed at which false positive TB diagnoses 
are detected.
117
 
Rates of reported false positive isolation range from 0.1% to 65.9%,
118
 but these 
estimates include studies initiated because of a suspicion that false positive isolation 
was occurring. It is, therefore, not surprising that the rates identified in these were 
higher. Population based studies with a sample size greater than 500 have a much 
smaller range of lower estimates (between 0.1% and 3%). Using IS6110 RFLP 
typing the rate of cross-contamination in London has previously been estimated to be 
between 0.54% and 0.93% (depending on whether you include possible incidents of 
cross contamination or not),
118
 which is lower than the rates observed in the USA 
(Jasmer et al observed 2% in California;
119
 Braden et al observed 3.5% in 
Arkansas
120
; and Frieden 3% in NYC).
121
 There is no UK-wide estimation of the rate 
of false positive TB isolation detected by MIRU-VNTR typing. 
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1.3.3 National TB strain typing services 
Universal strain typing services are currently operating in the Kingdom of Denmark 
(Denmark, Greenland, Iceland and the Faroe Islands), the Netherlands, USA, 
Norway and Slovenia. The services are summarised in Table 3.  
The first national strain typing service was initiated in the Netherlands in 1990, based 
on IS6110 RFLP typing of all TB isolates. Since 1995, the national cluster nurse 
routinely reports new cases in a cluster to the nurses whose patients are in the cluster. 
Standardised questionnaires about possible epidemiological links between the cases 
in the cluster are completed by additional information gathering and collaboration 
between the nurses. These questionnaires are returned to the national cluster nurse 
and are linked to the national TB surveillance database. This process is summarised 
in Figure 10. In the Dutch service there is no threshold for cluster investigation; all 
clusters are investigated. This approach seems to be manageable for TB nurses in the 
Netherlands (personal communication with Marushka Sabek, the national cluster 
nurse, 30
th
 September 2010), where the burden of TB is much lower than in England 
– the number of cases in the Netherlands was 958 in 2012 (5.7 per 100,000), 122 
compared to 8751 in England (13.9/100,000).
123
 
Figure 10 – Flow of information in the strain typing service in the Netherlands 
Based on personal communication with Marushka Sabek, the national cluster nurse, and Dick van Soolingen, 
head of the Mycobacterium Reference Laboratory  (meetings in Rotterdam and Bilthoven in October 2010) 
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Table 3 – Summary of national TB strain typing services  
Country Typing method, year 
started 
Reporting Software  Cluster investigation Key 
publications 
Denmark IS6110 RFLP, 1992 
24 MIRU-VNTR, 2009 
Routinely reported to the hospital department 
managing the patient with other laboratory results. 
Report to surveillance authorities when requested 
No. Strain typing linked 
manually to clinical and 
epidemiological data 
Ad hoc investigations initiated 
by the authorities in the five 
Danish regions 
124–126 
The 
Netherlands 
IS6110, 1990  
24 MIRU-VNTR, 2008 
To national cluster nurse and municipal health service Cluster forms are attached to 
each patient in the web-based 
surveillance system. 
All clusters 100,105,127–129 
Norway IS6110, 1994 
+ Spoligotyping, 1999 
24 MIRU-VNTR, 2012 
Routinely reported to the laboratory that sent the 
MTB isolate and to the Department of Infectious 
Disease Epidemiology at the Norway Institute of 
Public Health. If transmission is suspected the public 
health doctor in charge is contacted.  
Results are recorded in the 
national TB register along 
with the other information 
about each TB case 
Clusters that fulfil the following 
criteria are investigated: ≥3 
cases, diagnosed within 2 years, 
born in Norway or different 
countries of birth, and lived at 
least 6 months in Norway. Any 
cluster with children or MDR 
130–132 
Sloveniaa IS6110 RFLP, 2000 
+ Spoligotyping, 2003 
24 MIRU-VNTR, 2009 
. . . 133,134 
USA 12 MIRU-VNTR, 2004  
24 MIRU-VNTR, 2009 
Strain types are submitted, maintained and accessed 
via the TB Genotyping Information Management 
System (TB-GIMS). Alerts about cluster priority are 
automatically generated  
TB Genotyping Information 
Management System (TB-
GIMS), 2010 
Low, medium and high alert 
clusters based on expected 
geospatial concentrations of a 
strain in a specific county 
88,135–137 
      
aThe reference laboratory in Slovenia was contacted via email to gather more information about their service, but no response was received. 
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The USA was the first country to start using MIRU-VNTR strain typing. In this 
setting, the strain typing information is reported through the Tuberculosis 
Genotyping Information Management System (TB-GIMS), a purpose-built software 
to collate and report information about strain typing and detect outbreaks. The 
outbreak detection is based on identifying greater than expected numbers of a single 
strain in one geographical area (county), compared with the national distribution of 
that strain, and sending alerts indicating low, medium or high risk of recent 
transmission. These alerts can help TB programs to identify outbreaks and prioritise 
strain typing clusters for cluster investigation. The National TB Genotyping Service 
is centred around the TB-GIMs which is accessed by the laboratories to upload the 
strain typing data, by the state public health teams to monitor and analyse the data, 
and by local TB programs to access data on individual cases or clusters. State and 
local TB programs work together to use the strain typing information for TB control 
and cluster investigations. A comprehensive guide to the application of strain typing 
to TB prevention and control was published to inform all TB program staff.
138
  
1.3.4 The TB strain typing service in England 
Following the steady rise of TB rates in the UK, the Chief Medical Officer published 
a TB Action Plan in 2004 that identified key control measures including the need for 
a national strain typing service as a component of TB control.
139
 Three main 
requirements were identified for the implementation of a typing service:  
1. Standardised laboratory methods to appropriately differentiate M. 
tuberculosis isolates;  
2. The establishment of a central database containing both typing and 
epidemiological data; and  
3. Operational guidelines on the public health use of molecular typing data.140  
Prior to January 2010, strain typing was used on an ad hoc basis in all parts of 
England, apart from the West Midlands where 15 loci MIRU-VNTR had been 
carried out universally since 2003.
91,141–143
 This meant that a 15 MIRU-VNTR strain 
type could be requested from the laboratories where the addition of patient strain 
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types would contribute greatly to public health decision making. Strain typing was 
used to identify outbreaks or disprove suspected transmission between cases.
91,99
 For 
example, if two cases of TB were diagnosed in a school, the strain types would be 
requested to establish whether there had been transmission within the school or not. 
This would help to decide whether a large screening programme should be conducted 
in the school.  
The TB Strain Typing Service (TB-STS) was launched in January 2010. It was 
initiated as a three-year project, running from October 2009 to December 2012. A 
prospective evaluation was commissioned by Public Health England (PHE) at the 
start of the service in order to inform PHE’s strain typing strategy, i.e. whether the 
TB-STS should continue after the project period, and if so, how?  
The TB-STS was based on prospective typing of Mycobacterium tuberculosis using 
24 loci MIRU-VNTR. The results would be linked to existing national 
epidemiological and laboratory datasets, and reported in real time to front line teams. 
It was hypothesised that prospective universal strain typing and analysis of clusters 
could be used in real time to inform public health action. 
The TB-STS was designed to support and strengthen the national TB control 
programme through the following aims (Figure 11):
140
 
 To provide universal prospective strain typing of every first M. tuberculosis 
isolate from all TB patients in England with MIRU-VNTR typing; 
 To generate the information needed to stop further transmission; 
 To contribute towards contact investigations in real time; and  
 To detect or confirm false positive cultures, thereby preventing the 
consequences of incorrect diagnoses due to laboratory contamination or error. 
If the TB-STS were not implemented, then the following would be expected: 
 Transmission will continue undetected for strain type clustered cases that are 
not identified as epidemiologically linked through traditional contact tracing; 
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 Where transmission is suspected public health action will be taken 
unnecessarily unless an ad hoc strain typing request is made; and 
 False positive TB isolates will not be detected and patients with false positive 
TB will receive unnecessary treatment. 
31 
 
Figure 11 – The aims 
of the TB-STS  
Shaded boxes are the five 
components of the TB-
STS.  
Dotted lined boxes are 
indirect outputs of the 
cluster investigations that 
were hypothesised to 
interrupt transmission. 
Dashed lined boxes 
could not be adequately 
captured for this 
evaluation.  
*Confirmed (or possible) 
epidemiological links 
identified  
STM strain typing 
module (software to 
integrate strain typing 
with epidemiological and 
clinical data) 
CT contact tracing 
DD diagnostic delay 
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1.4 Evaluating strain typing as a tool for TB control 
Evaluations explore whether interventions and policies do what they intend to do, 
and what impact they have. This is necessary because interventions are costly, funds 
are limited and for every intervention implemented, there is an opportunity cost – 
what alternative interventions could have been implemented with the same 
resources? Evaluations, therefore, enable decision-makers to set priorities. There is 
also the possibility that interventions may have unexpected, adverse effects. 
Evaluations can be useful for the design of future interventions and policies. There 
are five main evaluation paradigms: experimentalist, pragmatist, constructivist, 
pluralist and realist. These approaches are briefly summarised here. 
Experimental evaluation is based on the experimental research design whereby an 
intervention is introduced into one of two groups that are matched (either by 
randomisation or matching on potential confounders) and the groups are measured 
before and after the intervention.
144
 This relies on a theory of causation that removes 
all other possible causative agents so that there is just one possible causal link; the 
intervention. This approach is not easily applied to interventions that exist in the real 
world and introduces the ‘black box’ problem, whereby it only produces a 
description of the outputs, rather than explaining why some does or doesn’t work. 
Pragmatist evaluation calls for evaluations to be useful to those that they are intended 
for; they are utilisation-focussed. There are four features of a pragmatic evaluation: 
utility, feasibility, propriety and accuracy.
145
 This focus raises the problem of the 
policy-maker or the funder having too much influence over the evaluation, removing 
the equipoise and the objectivity. This approach also led the way for a text-book 
approach to evaluation, with a prescriptive step-by-step method.
146,147
 
Constructivist evaluation turns the focus away from the outputs of an intervention 
and the policy makers, towards the processes and meaning – engaging all possible 
stakeholders to establish why or why not an intervention works.
148
 This paradigm 
falls short because it does not allow for the objective assessment of an intervention or 
the asymmetry of power across the stakeholders. 
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Pluralist evaluation is an attempt to combine the experimental, the pragmatist and the 
constructivist paradigms. One form of this is the comprehensive evaluation, which 
ash three main activities:
149
  
1. Analysis of the intervention design 
2. Monitoring of the program implementation 
3. Assessing program utility. 
This approach is criticised for trying to encompass too much; being too broad and 
requiring too many resources to conduct properly.
150
  
The final paradigm summarised here attempts to make the pluralist approach more 
realistic and applicable to the real world. Realist evaluation is based on a generative 
model of causation: that an action is causal only if its outcome is triggered by a 
mechanism acting in context (outcome=mechanism+context).
150
  Pawson and Tilley 
(1997) argue that an evaluation should demonstrate if the program works, what it is 
about the program that works for whom and in what conditions. The realist 
evaluation is based on Wallace’s (1971) wheel of science and argues for an 
evaluation cycle that includes:
151
  
 Theories (based outcome=mechanism+context);  
 Hypotheses (that hypothesise what might work for whom and in what 
circumstances);  
 Observations (multi-method data collection and analysis of the mechanisms, 
context and outcomes); and 
 Program specification (what works for whom and in what circumstances). 
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Figure 12 – Realist evaluation cycle 
Adapted from: Pawson and Tilley (1997) p.85 
150
   
 
Existing evaluations of TB strain typing services 
TB surveillance is carried out in most countries to varying degrees of scope and 
quality.
1
 However, molecular surveillance is a relatively new and expensive form of 
surveillance currently reserved for richer countries with lower TB burdens, and for 
research purposes. Therefore, molecular surveillance for TB occurs in very few 
countries; in 2014 the only countries with a universal molecular surveillance system 
for TB were the Netherlands,
100,127
 the USA,
64,136
 Denmark,
124,152
 Norway
130,132
 and 
Slovenia.
133,134
 The public health value of such surveillance systems has been 
demonstrated through the retrospective evaluation of strain typing data.
87,102,116,127
 A 
universal service in England was anticipated to add value to the TB control 
strategy.
153
 
Evaluations of existing strain typing services have focussed on single elements of the 
service such as the discrimination of the typing method,
69
 effectiveness of cluster 
investigations,
97,152
 and the ability to identify cross contamination.
117
 No evaluation 
35 
 
to date has looked at the entirety of the service and analysed its complexity, taking 
into account the resources and infrastructure, the processes involved, the multiple 
outputs and the long term outcomes. 
Complex interventions 
A national strain typing service is a complex intervention. Complex interventions are 
often defined as interventions with several interacting components.
154
 The MRC’s 
definition of a complex intervention includes: 
 Number of, and interactions between, components within the experimental 
and control interventions 
 Number and difficulty of behaviours required by those delivering or receiving 
the intervention 
 Number of groups or organisational levels targeted by the intervention 
 Number and variability of outcomes 
 Degree of flexibility or tailoring of the intervention permitted 
Complex interventions present difficult problems for evaluators due to the nature of 
their complexity – the design and delivery of the intervention is complex; the effect 
of the local context on the interventions is variable; and the length and complexity of 
the pathway between the intervention and its outcomes may be difficult to unwrap. In 
addition, there are practical difficulties in applying experimental research methods to 
service evaluation. A strain typing service is a complex intervention because it has 
many different parts that are organised and delivered by different groups (such as 
laboratories, public health teams, clinical teams); these groups accept and implement 
the service differently in different settings and across different parts of the country; 
and the causal chains between a strain typing service and its potential outcomes are 
complicated and difficult to capture.  
To increase the number and improve the quality of evaluations, frameworks for 
evaluating complex interventions have been developed. The MRC published a 
‘Framework for the Development and Evaluation of RCTs for Complex 
Interventions to Improve Health’ in 2000.155 In 2006 they published an update based 
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on the experience collected by the scientific community, the need to include non-
experimental research methods and to make it applicable to interventions outside of 
the health service.
154
 The overall framework covers the development and piloting of 
an intervention, the evaluation and dissemination of findings. The evaluation 
framework has three main components: assessing effectiveness, process evaluation 
and assessing cost-effectiveness. It is acknowledged that an experimental research 
design is not always possible in the evaluation of a complex intervention, instead 
quasi-experimental or observational studies may be adequate alternatives. The 
framework advocates for a good theoretical understanding of the intervention in 
order to identify appropriate outcome measures, and suggests the use of surrogate 
outcomes measures. 
The MRC evaluation framework has been criticised by ‘realists’ for not including an 
explanation of the mechanisms of change that might link the intervention with the 
outcomes and not examining how the intervention might interact with the context. 
Realist evaluation is based on a generative model of causation: that an action is 
causal only if its outcome is triggered by a mechanism acting in context 
(outcome=mechanism+context).
150
 Pawson and Tilley (1997) argue that an 
evaluation should demonstrate if the programme works, what it is about the 
programme that works for whom and under what conditions.  
Whilst the MRC framework advocates for the development of the intervention to be 
based on theory, it does not include the role of a theory in the evaluation process, 
which is crucial to other theory-driven frameworks.
156,157
 Theory-driven frameworks 
are based on the thesis that understanding the theory underlying an intervention is 
necessary for understanding whether it works and how it works. Theory of Change is 
one such framework in which a hypothesised theory of how the intervention affects 
change is developed with stakeholders and can be tested empirically.
158
 The 
advantages of Theory of Change is that it can better represent the complexity of an 
intervention as it makes explicit the causal pathways, but does not impose a structure, 
allowing for interactions, feedback loops and multiple pathways. Compared to the 
MRC Framework, disadvantages of Theory of Change is that there are multiple, 
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prescriptive steps that need to be followed which may not be appropriate for the 
evaluation context and it does not include a framework for the dissemination of 
results.
159,160
 
These frameworks incorporate the processes involved in the development of the 
intervention as well as its evaluation. There is an assumption that the evaluation team 
have been a part of the intervention design team and that the design, implementation 
and evaluation of the intervention is (or can be) an iterative process. In situations 
where this is not the case, and the evaluation is either retrospective, or as an add-on 
to the implementation of the intervention, these frameworks may not be the most 
appropriate choice. 
Donabedian’s formative framework for evaluating the quality of medical care161 
provides a framework around which an evaluation can be designed, without 
prescribing any particular steps, nor assuming that the evaluators are involved in the 
design of the intervention from its initiation. The framework divides a service up by 
its Structures, Processes, Outputs and Outcomes. ‘Structures’ refers to the resources 
and inputs of the service; ‘Processes’ refers to the activity of the resources and the 
processes involved in the service; ‘Outputs’ refers to the products of the service; and 
‘Outcomes’ refers to changes resulting from such outputs. An advantage of this 
framework is that it ensures that the whole of the service is considered in the 
evaluation, rather than just focussing on the Outcomes of the service and ignoring the 
Structures and Processes that produce those outcomes. In effect, by evaluating the 
Processes one is attempting to avoid so-called Type III errors – where one ends up 
evaluating an intervention that is not implemented properly.
162
  Process evaluation 
can provide the insight and context necessary to interpret the outputs of a service, 
help to explain differences between the observed and expected outcomes, and 
identify ways of intervening to improve the service.
154
 Subsequently, this enables the 
researchers to develop constructive recommendations based on the Structures and 
Processes of the service – elements of the service that can be directly influenced – as 
recommended in other evaluation guidelines.
154
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Evaluation frameworks tend to agree in many ways: the evaluation design should 
take into account who the evaluation is for and what kind of decisions it might 
influence; hypotheses about how the intervention will affect change should be made 
explicit; the appropriate methods available (of which there are likely to be multiple) 
should be used to understand if the intervention works, how it works, and in what 
contexts.  
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1.5 Aims and Objectives of this thesis  
1.5.1 Aim 
The aim of this thesis is to evaluate the TB-STS in England. 
1.5.2 Objectives 
The objectives of this thesis are: 
1. To systematically review the literature to examine the effect of study design 
and setting on the estimation of the proportion of TB clustering by MIRU-
VNTR strain typing 
2. To describe the Structures of the TB-STS 
3. To evaluate the Processes of the TB-STS 
a. To assess the implementation and perceptions of the TB-STS 
b. To explore the user experience of the TB-STS 
4. To evaluate the Outputs of the TB-STS 
a. To describe the laboratory outputs of the TB-STS, including 
estimating the proportion of false positive TB isolation identified by 
the TB-STS 
b. To quantify the public health outputs of the TB-STS 
5. To evaluate the Outcomes of the TB-STS 
a. To investigate the effectiveness of the TB-STS 
b. To assess the cost-effectiveness of the TB-STS 
6. To contextualise the findings of the evaluation 
a. To discuss the strengths and limitations of the evaluation 
b. To make recommendations for future typing services and evaluations 
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Chapter 2. Effect of study design and setting 
on TB clustering estimates using MIRU-VNTR: 
A systematic review 
One of the main applications of strain typing is to monitor clustering rates as an 
estimate of recent transmission over time (described on page 21). Published reviews 
have identified factors that might influence or bias clustering by IS6110 RFLP.
93,96
 
No study has repeated this analysis using more up-to-date typing methods, which is 
important for understanding the epidemiology of TB and to shape the application of 
molecular typing to improve TB control. In this chapter, the available literature 
reporting clustering using MIRU-VNTR typing was reviewed systematically to 
examine if the biases that occur using RFLP typing are also relevant for studies 
using MIRU-VNTR.  
__ 
Studies using IS6110 RFLP data show that the proportion of clustering observed can 
be affected by 1) study design (affecting the proportion of eligible cases that are 
included in the study); 2) features of the typing method (such as the ability to type 
isolates with low copy numbers); and 3) study setting (such as characteristics of the 
study population). For example, the proportion of clustering increases when the 
fraction of the total data sampled increases
96,163,164
 and when study duration 
increases.
109
  
MIRU-VNTR strain typing is increasingly being adopted worldwide,
64,100,127,134,152
 
yet unlike IS6110 RFLP, the evidence for the interpretation of the findings such as 
the impact of study design and setting on clustering have not been reviewed. 
Although the two typing methods have been shown to have a similar discriminatory 
value, the markers evolve independently and at different rates, resulting in a 
difference in clustering between the two methods.
165
 This suggests that there could 
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be differences in the way study design, typing method and setting affects clustering 
by the two methods. A systematic review was conducted to assess the evidence for 
the impact of study design and setting on the interpretation of TB transmission using 
clustering derived from MIRU-VNTR strain typing – as has been shown using 
IS6110 RFLP typing.   
2.1 Methods 
Five electronic databases were searched (EMBASE, ISI Web of Science, CINHAL, 
Scopus and Medline (Ovid)) up to 20
th
 October 2014. The search strategy combined 
the following terms with Boolean operators: Tuberculosis, strain typing, and 
transmission (Appendix 1). The search was limited to studies using the standard 
MIRU-VNTR method,
166
 in humans only, and in English.  
All titles and abstracts from each of the searches were examined. The full text of 
each paper was obtained and reviewed if the study reported MIRU-VNTR strain 
typing of M. tuberculosis complex isolates with at least 15 of the standardised 24 loci 
(ETR A, B, C, D, E; MIRU 2, 10, 16, 20, 23, 24, 26, 27, 39, 40; VNTR 424, 1955, 
2163b, 2347, 2401, 3171, 3690, 4052, 4156).
56,70,166
 
Studies using fewer than 15 loci were not included because the level of 
discrimination is inadequate for epidemiological use (n=121).
166
 Studies that used 
loci different to the standardised 15 and 24 set were not included in the analysis in 
order to reduce the heterogeneity between studies (n=19). All publication types were 
included in this first screen to ensure that no relevant data were missed.  
Reviews, letters, editorials, outbreaks or case reports (n=103) were excluded in the 
second screen. Studies that used incomplete sampling (e.g. studies using subsets of 
populations such as multidrug-resistant patients) (n=47) and studies that had a 
sample size of less than 50 (n=4) were also excluded.  
A reviewer (Jessica Mears) extracted the following data items from all included 
studies using a form developed in Excel (Microsoft 2010): publication details (year, 
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authors, study country), study details (study duration, loci typed, secondary typing 
method, study population, whether participant consent was required (a characteristic 
of the study design that was used as proxy for sampling fraction, assuming that 
where consent was required the sampling fraction was low)), the number of clustered 
and unique isolates, and the covariates of interest: the maximum size of clusters; the 
proportion of clusters containing two cases; the proportion of the population that was 
culture positive; the proportion of culture positive isolates typed; risk factors for 
clustering; and the Hunter Gaston Discriminatory Index (HGDI)).
167
 Ibrahim 
Abubakar extracted data from 10% (n=3) of the included papers for external validity, 
disagreements were discussed and a consensus agreed upon. 
The main outcome measure – the proportion of TB isolates clustered by MIRU-
VNTR strain typing – was calculated as the number of clustered isolates/number of 
clustered+unique isolates. Where there were uncertainties the two reviewers 
consulted each other. 
Authors were contacted if TB incidence rate was not reported. Where no response 
was received WHO country estimates of TB incidence for the study year were 
used.
168
 As so few studies reported the proportion coinfected with TB/HIV, these 
estimates for the study country were taken from an EU-wide survey and WHO 
country profiles.
169,170
 Due to poor recording of the sampling fraction (the number of 
isolates typed/the total number of culture positive TB cases diagnosed during the 
study period (n=19)), whether the study required the consent of participants (yes/no) 
was included as a proxy for (low/high) sampling fraction. The risk of bias within 
each study was assessed using the STROME-ID checklist.
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Data were analysed in Stata version 12 (StataCorp. 2011. Stata Statistical Software: 
Release 12. College Station, TX: StataCorp LP.). Where studies reported data from 
more than one set of loci, the method with the highest discriminatory value was 
included (i.e. MIRU-VNTR 24 would be chosen over MIRU-VNTR 15, and MIRU-
VNTR 15 plus Spoligotyping would be chosen over MIRU-VNTR 15 alone) (n=8). 
This review was not concerned with summary measures of clustering, but factors that 
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influenced clustering; therefore articles must have included at least one of the 
covariates. Continuous variables were transformed where the distribution was 
skewed. The proportion clustered was transformed using the Freeman Tukey 
transformation.
171
 Study heterogeneity was assessed using a forest plot and the chi
2
 
test of heterogeneity. Univariable meta-regression analyses were carried out to 
determine the effect of the study design covariates on the proportion of clustered 
isolates. All covariates in the analysis were hypothesised to influence the proportion 
clustered a priori.  
Sensitivity analyses were conducted to see the effect of removing studies reporting 
0% clustering, with only extra-pulmonary TB cases, only M.bovis cases, studies 
using the ‘old 12’ MIRU loci as part of their 15 loci, and studies assessed as having a 
high likelihood of bias (STROME-ID score less than 20).  
2.2 Results 
The search identified 7274 references resulting in 27 studies (25 journal articles and 
2 conference abstracts) included after deduplication and title/abstract/full text 
screening (Figure 13). The study setting and design characteristics of the included 
studies are shown in Table 4.  
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Figure 13 – Results of systematic search, screening and data extraction 
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Table 4 – The study setting and design characteristics of the included articles 
Ref Study setting Study design 
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172 New South Wales, Australia 6.7 0.2 0.0 63.7 . . 36 1128 . . m24 N no 32 low 20.1 
173 Tabriz and Orumieh, Azarbaijan 26.0 . 5.2 87.0 5 81.8 12 156 . 94.5 m15 O no 28 low 32.7 
72 Brussels-Capital Region, Belgium 35.2 5.1 10.8 . 23 64.2 24 530 86.1 87.9 m24 N no 32 low 29.6 
174 Brussels-Capital Region, Belgium 35.2 5.1 . 100 . . 39 802 81.8 84.7 m24s N no 25 low 28.8 
175 Ontario, Canada  4.8 0.4 . . 18 58.8 65 2016 . . m24s N no 31 low 23.1 
176 Changping District, Beijing, China . 0.3 . 100 0 . 30 318 31.5 94.6 m24 N no 19 high 0.0 
177 Croatia 19.0 0.1 . . 45 48.3 36 1587 . . m15 N no 19 high 62.8 
178 Amhara region, Northwest Ethiopia . 24.0 17.6 100 13 . 5 244 . . m24 N yes 26 low 45.1 
179 Finland 5.0 0.0 . . 20 . 48 1048 75.4 99.4 m15s . no 29 low 33.9 
73 Hamburg, Germany 12.7 . . . . 45.5 12 154 78.2 91.1 m24s N no 34 low 22.1 
180 Schleswig-Holstein, Germany 3.2 0.1 . . 22 44.4 48 277 . . m24s N no 16 high 27.1 
181 South West Ireland 15.3 3.3 . 82.7 12 . 36 171 79.5 96.1 m24s N no 36 low 27.5 
182 South Tawara, Kiribati 370.0 . 4.1 100 25 55.6 24 73 45.4 98.6 m24s N yes 24 low 75.3 
69 Netherlands 6.5 0.2 . . . 57.2 60 3978 . 100.1 m24 N no 30 low 46.7 
183 Kharkiv, Russia 94.0 3.8 63.3 100 10 50.0 3 98 . 100 m15 O yes 19 high 31.6 
184 Eastern province, Saudi Arabia 4.0 . . 73.1 24 19.0 24 522 . . m24s N no 23 low 40.2 
185 Singapore 40.5 1.2 . . 21 48.0 24 1128 82.0 34.5 m24s N no 30 low 30.8 
133 Slovenia 10.6 0.0 . . 6 . 12 196 94.4 97.5 m24s N no 31 low 36.2 
186 Almeria, Spain 26.0 6.0 . . 8 . 27 281 . 81.9 m15 N no 18 high 43.1 
187 Sweden 4.8 0.1 . . 10 . 36 406 . . m24s N no 22 low 21.2 
188 Mubende, Uganda . 86.0 31.1 87.8 11 70.0 6 67 21.5 90.5 m15s N yes 25 low 35.8 
189 East Lancashire, UK 18.3 8.2 . . 13 58.3 102 332 48.5 69.9 m15 O no 23 low 42.8 
190 UK . 8.2 . 42.3 12 50.0 48 102 90.7 87.2 m15 O no 32 low 30.4 
191 London, UK 44.9 8.2 . . . . 9 964 36.0 100 m24 N no . . 37.0 
192 Midlands, UK 15.0 8.2 . . . . 48 4207 58.3 100 m15 O no . . 61.2 
193 Odessa and Nikolaev, Ukraine 80.4 3.9 34.2 100 . . 4 225 . . m15 O yesg 23 low 60.4 
194 Hanoi, Vietnam 146.0 10.0 0.0 100 . . 20 465 92.7 91.9 m15s N yes 31 low 55.3 
Footnotes overleaf
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a Estimates from of the prevalence of TB/HIV co-infection in the study country 169,170  
b 15=15 MIRU-VNTR loci (made up of the ‘old 12’ or ‘new 12’ defined in the footnote below), 24=24 MIRU-VNTR loci (ETR A, B, C, D, E; MIRU 2, 10, 16, 20, 23, 24, 26, 27, 39, 40; VNTR 
424, 1955, 2163b, 2347, 2401, 3171, 3690, 4052, 4156), S=with Spoligotyping  
c O= old 12 MIRU loci (MIRU 2, 4, 10, 16, 20, 23, 24, 26, 27,30, 31, 39, 40), N=new 12 MIRU loci (MIRU 10, 16, 26, 31, 40 + Mtub 04, 21, 39 + ETR A C + QUB 11b, 26)  
d S-ID STROME-ID scores; individual studies score one for each element of checklist they had addressed  
e Risk of bias was assessed using the STROME-ID checklist. Studies scoring <20 were categorised as have a high risk of bias.  
f The proportion of clustering was calculated as the number of clustered isolates/number of clustered + unique isolates  
g 11.3% did not consent to being part of the study. The other studies that required consent for isolates to be typed did not report the refusal rate 
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Studies were published between 2007 and 2014. The number of studies reporting 
each variable of interest is shown in Table 5. The clustering reported varied from 0% 
176
 to 62.8%.
177
 In all studies, clustered isolates were defined as having identical 
strain types based on the MIRU-VNTR loci typed, with or without Spoligotyping. 17 
studies included isolates from newly diagnosed TB cases, three studies reported 
including isolates from new and chronic cases of TB, and seven did not report this 
information. In addition, ten studies did not include repeat isolates from the same 
patient, one study included a repeat isolate from one patient, and the remaining 17 
did not report whether repeat isolates were included or not. Furthermore, four studies 
included isolates with missing loci in the cluster analysis, whereas four excluded 
isolates with missing loci, and the remaining 20 did not report how they dealt with 
missing loci.  
Table 5 – The number of studies that reported the variables of interest 
 
Reported Missing 
Study setting 
  
TB incidence 8 19 
TB/HIV co-infection 5 22 
Previous TB treatment 9 18 
Proportion pulmonary TB 14 13 
Maximum cluster size 19 8 
% clusters with 2 cases 14 13 
 
  
Study design 
  
Study duration  27 0 
Study size 27 0 
% population that is culture positive 15 12 
% culture positive typed 19 8 
24 loci (compared to 15) 27 0 
Repeat isolates 12 15 
Missing loci 8 19 
Double alleles 1 26 
Consent required 6a 21 
Epidemiological information 6 21 
a Only one study reported the consent rate 
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A forest plot shows the spread of clustering reported by number of loci and 
additional typing method (Figure 14). Significant heterogeneity was identified 
between the studies (p<0.001), suggesting that a meta-regression would be an 
appropriate analysis. 
Figure 14 – Forest plot showing the proportion of clustering reported in each study by the 
number of MIRU-VNTR loci typed 
The number of loci typed is categorised into 15 loci (m15), 15 loci with Spoligotyping (m15s), 24 loci (m24) and 
24 loci with Spoligotyping (m24s). The study reference is shown in the right hand column. 
 
The univariable meta-regression shows evidence for the proportion of clustering to 
decrease as the number of MIRU-VNTR loci typed increased from 15 to 24 (p=0.04; 
Table 6), accounting for 14% of the between study variation, and to increase when 
the study participants consented to being included in the study (p=0.03), accounting 
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for 14% of the between study variation. The proportion of clustering increased as the 
TB incidence in the population increased (p=0.007, Adj R
2
 = 26.7). There was also 
evidence for the proportion of clustering to increase as the maximum cluster size 
increased (p=0.001), accounting for 48% of between study variation.  There was no 
evidence of the other study design or study setting variables significantly influencing 
the proportion clustered. Though non-significant (p>0.05), the TB/HIV coinfection 
rate in the population explained 2% of the between study variation. Too few studies 
included information on the proportion of clusters containing two cases, proportion 
of the study sample with previous TB or with pulmonary TB, so these could not be 
included in the analysis (Table 5). 
Table 6 – Univariable metaregression showing the coefficients for change in the proportion of 
clustering and the percentage of between-study variation explained by variables describing the 
study design and setting 
 n Coefficient a CI p Adj R2 b 
Study setting      
TB incidence 23 0.14 0.04-0.24 0.007 26.74 
TB/HIV co-infection 23 0.04 -0.03-0.11 0.246 2.00 
Maximum cluster size 19 0.20 0.09-0.30 0.001 48.20 
      
Study design      
Study duration  27 -0.02 -0.09-0.06 0.677 -3.37 
% population that is culture positive 15 0.34 -1.23-1.96 0.661 -5.92 
% culture positive typed 19 0.22 -1.08-1.52 0.725 -5.41 
Study size 27 0.03 -0.11-0.16 0.702 -3.31 
24 loci (compared to 15) 27 -0.30 -0.59--0.01 0.04 13.58 
Consent required 27 0.38 0.04-0.72 0.029 14.41 
a Coefficients for the change in the proportion of clustering for each covariate. E.g. for a one unit increase in 
maximum cluster size, the proportion of clustering increases by 0.2. 
b The proportion of between-study variation explained by the univariate meta-regression. 
Sensitivity analyses to examine the effect of excluding studies reporting 0% 
clustering,
176
 only M.bovis cases,
190
 studies using the ‘old 12’ MIRU 
loci,
173,183,189,190,192,193
 and studies assessed as having a high risk of 
bias,
176,177,180,186,195
 did not generally change the results. The proportion of culture 
positive TB in the population remained insignificant but explained 2.6% of the 
between study variation when excluding 0% clustering (p=0.278 and Adj R
2
=2.62). 
Similarly, the proportion of culture positive TB in the population remained 
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insignificant but explained 2.6% of the between study variation when excluding 
studies with the highest risk of bias (p=0.278 and Adj R
2
=2.62). The number of loci 
typed became non-significant, but explained 9.6% and 10.5% of the between study 
variation when excluding studies using the ‘old 12’ loci and the highest risk of bias, 
respectively (p=0.106, Adj R
2
=9.63; p=0.111, Adj R
2
=10.51, respectively). 
2.3 Discussion 
This review identified 27 studies that met the inclusion criteria. The findings show 
that the interpretation of studies using MIRU-VNTR to estimate clustering is subject 
to bias relating to study design and setting; however, there were insufficient data 
available to fully explore this impact.  
As expected, the proportion of clustering decreased with a greater number of MIRU-
VNTR loci typed, with increasing TB incidence and with increasing maximum 
cluster size. Requiring consent to type patient isolates increased the proportion of 
clustering, which is not expected, given that the sampling fraction would be lower in 
these studies.  
The other study design variables included in this analysis, such as study duration, did 
not significantly influence the proportion of isolates that were clustered, contrary to 
previous findings 
93
. This is likely to be because of a lack of good quality evidence: 
of the 27 studies that met the inclusion criteria for the review, none reported all the 
variables of interest, reducing the power of the analysis and precluding multivariable 
meta-regression (Table 5). Importantly, key details of cluster analyses were not 
reported consistently across the studies, such as whether repeat isolates from the 
same patients were included, or typing profiles with missing loci were included, 
introducing new, unmeasured biases. In addition, the range of the variables may have 
been too limited to show any impact on clustering estimates. For example, the 
proportion of culture positive isolates typed ranged from 34.5% to 100%, with 17 of 
the 19 studies reporting this variable from 81.9% to 100%. Furthermore, most of the 
studies (17/27=63%) were from low TB burden settings and therefore may be 
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reflecting the rate at which imported cases have matching strain types by chance, 
rather than rates of recent transmission. 
The sensitivity analysis suggested that, when excluding the studies with the greatest 
risk of bias, the culture-positivity in the population might explain a small amount of 
the between study variation. This is consistent with estimates of the influence of 
sampling on the proportion of clustering using IS6110 RFLP typing.
196
 In the 
sensitivity analysis excluding studies that used the ‘old 12’ loci, the effect of the 
number of loci typed becomes non-significant. This is likely because studies using 
the ‘old 12’ accounted for six out of ten studies reporting 15 loci, reducing the 
number of studies and the power of the model. 
This study is a timely evaluation of the impact of study design on estimates of TB 
clustering using MIRU-VNTR strain typing because it has been incorporated into 
national typing services globally.
64,197
 The findings are relevant where strain typing 
is used to evaluate TB control systems across different settings because the 
proportion of clustering is influenced by the number of loci typed, the TB incidence 
and the maximum cluster size. Given that strain typing methods are advancing 
beyond MIRU-VNTR typing and that the application of whole genome sequencing to 
TB control and public health strategies has been demonstrated,
78,79,198,199
 it is 
important that the biases in the analysis of such methods are explored and compared. 
Understanding how to design and compare research studies for public health will 
greatly improve the benefit gained from newer technologies.  
The strength of this meta-analysis was limited by (a lack of) detail reported by the 
included studies. This review has highlighted the need for better quality reporting in 
primary studies to enable future reviews to be more robust. Recently published 
standards for reporting of molecular epidemiology for infectious diseases should 
improve the quality of reporting.
53
 This review is further limited by our inability to 
access 58 of the title/abstract screened articles for full text screening. 
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The use of TB strain typing as a public health tool in TB control programmes is 
increasing globally. This review has identified a lack of good quality studies that can 
contribute to our understanding in interpreting the molecular typing of TB. It has also 
shown that the proportion of clustering derived from MIRU-VTNR typing is 
influenced by the number of loci typed, whether consent is required to type isolates, 
TB incidence in the study setting, and the maximum cluster size, highlighting these 
as important considerations in the design and interpretation of future studies.  
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Chapter 3. Methods 
This chapter describes the methods employed in this evaluation. I begin by briefly 
describing the evaluation framework adopted. The methods used to address each 
component of the framework are then presented in turn. A mixed methods approach 
was employed, including quantitative and qualitative approaches, using both 
primary data collection and secondary data analysis.  
As a guide to the reader, an icon is shown in the top right-hand corner of the title 
page of this and each subsequent chapter. This is based on the evaluation framework 
(see below and Figure 16  for an explanation) and will highlight which evaluation 
component is being addressed by each chapter. 
__ 
 
3.1 Evaluation framework 
The Donabedian framework
161
 was chosen as the evaluation framework for this 
thesis for a number of reasons. Firstly, taking into account the design and 
implementation of the TB-STS (i.e. national intervention with a national rollout 
implementation plan), the role of the evaluator (i.e. external and independent, and not 
involved at the design stage of the intervention), the Donabedian framework is the 
most appropriate approach as it does not assume the evaluator has influence on the 
initial design of the intervention and, therefore, an integrated evaluation design (as 
the MRC framework intuits)
160
. Secondly, the framework takes into account the 
totality of the TB-STS and, because it does not include step-by-step instructions or a 
specific methodology for applying the framework (such as Theory of Change),
157
 it is 
suitably flexible and pragmatic in order that the evaluation could be conducted 
within the constraints of the available data and resources. Thirdly, the Donabedian 
framework is simpler compared to other approaches outlined above. The application 
of a relatively simple framework to a complex intervention created scope for the 
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framework to be adapted for the specific evaluation (see below) and the inclusion of 
choice elements from other evaluation frameworks (e.g. the use of a causal diagram 
to illustrate the aims of the TB-STS – Figure 17 – is an approach advocated by 
Theory of Change).
157
 Counter to this, the alternative, more complex evaluation 
frameworks do not lend themselves so well to adaptation (such as the inclusion of 
useful elements from different frameworks). 
As explained above, the Donabedian framework
161
 was chosen in order to take into 
account the totality of the TB-STS, to have the flexibility to conduct the evaluation 
within the constraints of the available data and resources, and to apply a relatively 
simple framework to a complex intervention. This framework has been adapted to 
take into account the context across the Structures, Processes, Outputs and Outcomes 
(Figure 15). As described previously, ‘Structures’ refers to the resources and inputs 
of the TB-STS such as the creation of service-specific roles; ‘Processes’ refers to the 
activity of the resources and the processes involved in the TB-STS such as the 
laboratory processes and reporting; ‘Outputs’ refers to the products of the TB-STS 
activities such as cluster investigations; and ‘Outcomes’ refers to changes resulting 
from the Outputs such as a change in TB transmission. ‘Context’ refers to the need to 
take into account the political, economic and technological context in order that the 
findings be interpreted appropriately and in a way that is relevant to the policy 
decision-makers (as advocated by realist evaluation theory).
200
  
The evaluation consists of the following components (Figure 16): a descriptive 
component (Structures); cross-sectional surveys of user-perspectives and a 
qualitative component involving semi-structured interviews with Health Protection 
Units (HPUs) (Processes); a description of the laboratory outputs and an 
investigation into false positive TB isolation (laboratory Outputs); an exploration of 
the outcomes of cluster investigations (public health Outputs); a transmission model 
and a cost-effectiveness model (Outcomes). The Context is considered in the 
discussion (Chapter 8). These methods are detailed in the remainder of this chapter. 
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An overview of the evaluation of the TB-STS, including the framework and methods 
used, is shown in Figure 16. The timeline for the implementation of the TB-STS and 
the data collection timeline for each of the evaluation components are shown in 
Figure 17.  
Figure 15 – The evaluation framework used here is an adaptation of the Donabedian framework 
that divides an intervention into the Structures, Processes, Outputs and Outcomes 
This is an adaptation of the Donabedian framework in which the intervention is divided into Structures, 
Processes, Outputs and Outcomes. In addition, the Context is considered across the intervention. 
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Figure 16 – The evaluation model of the TB-STS  
 
The Structures, Processes, 
Outputs and Outcomes of 
the TB-STS are shown in 
the white boxes with 
coloured outlines. To their 
right, the methods used to 
describe, measure or 
estimate these elements are 
shown in coloured boxes. 
Dotted lined boxes are 
indirect outputs of the 
cluster investigations that 
were hypothesised to 
interrupt transmission. 
 
STM Strain typing module 
is the software system for 
the integration of strain 
typing data with 
epidemiological and clinical 
data; STPB Strain Typing 
Project Board were the PHE 
board responsible for the 
implementation of the TB-
STS 
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Figure 17 – Evaluation data collection in the context of the implementation of the TB-STS 
 
STM strain typing module; FP false positive TB isolation; CT contact tracing yield; NCL North Central London; DD diagnostic delay; CG cluster growth; KPuPr knowledge, perceived 
usefulness and practices; UE user experience
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3.2 Describing the TB-STS 
To describe the TB-STS – how it is structured and how it functions – the following 
activities were carried out:  
 a search was conducted of the PHE website to find published documents and 
web pages;  
 the PHE intranet was searched for documents produced internally;  
 meetings were attended and minutes read from the TB Strain Typing Project 
Board; and 
 discussions/interviews with members of the TB Strain Typing Project Board 
and the PHE Finance team were conducted by email, telephone and face-to-
face over the course of the evaluation.  
3.3 Initial and follow-up cross-sectional surveys 
The successful implementation of the TB-STS depends not only on laboratory 
scientists to type the isolates, but also on public health staff to use the cluster reports 
to inform their decisions, and clinical staff to gather additional information about the 
clustered patients. Consequently, the engagement of public health and clinical staff 
with the service is likely to have a direct impact on its implementation and 
subsequent impact.  
The technology acceptance model is a theory for how people will come to accept and 
use a new technology.
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 It suggests that one’s perception of usefulness and ease of 
use will influence one’s attitude towards the technology, which will influence their 
behavioural intention, and subsequently whether they actually adopt the technology. 
The technology acceptance model is used here because it suggests that someone’s 
perceived usefulness of a technology can influence their intention to use it, regardless 
of their attitude towards it. For example, if the TB-STS is perceived to be useful, it 
may be used, even if people don’t like the service.  If one assumes that perceived 
ease of use of strain typing is influenced by an individual’s knowledge, then the 
theory can be illustrated as shown in Figure 18.  
59 
 
Figure 18 – The technology acceptance model, as modified for application to the TB-STS 
 
An initial and follow-up web survey of public health and clinical staff working in TB 
control was carried out to establish the extent to which the TB-STS had been 
implemented by measuring the effect of the service on changes in knowledge, 
perceived usefulness and uptake, assessing the impact of the service implementation 
on workload, and measuring changes in contact tracing yield over time. The results 
of this two-part survey were used to guide the semi-structured interviews described 
below, and helped to develop parameters for the cost-effectiveness analyses. 
Objectives of the initial and follow-up surveys: 
1. Knowledge: To assess changes in the awareness of the TB-STS and 
knowledge of strain typing 
2. Perceived usefulness: To explore changes in perceived usefulness of the TB-
STS 
3. Practices: To investigate the practices associated with the TB-STS and 
capture any changes over time in 
a. Laboratory turnaround times 
b. The extent to which the TB-STS has been implemented 
c. How strain typing is used and its impact on TB control  
d. TB-associated workload 
4. Estimate the yield of contacts with TB disease or LTBI identified through 
contact tracing, and capture any changes over time (for these methods see 
page 75). 
5. General comments: To collect and explore any further comments that survey 
respondents wanted to share with the researcher 
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3.3.1 Study Design 
An initial survey was conducted in November 2010 prior to the release of the 
Handbook, using a web-based survey questionnaire (www.objectplanet.com/opinio). 
A follow-up survey was conducted in March 2012, following the completion of the 
public health training (see ‘training’ on page 98). Figure 17 (page 57) shows the 
timing of the surveys in relation to the implementation of the TB-STS.  
For these surveys, it was assumed that prior to the Handbook publication in 
December 2010, the TB-STS would not have had an impact on clinical staff and 
health protection professionals and their work in TB control, and therefore the 
situation could be compared to the ad hoc service provided prior to the TB-STS (see 
page 56). Put simply, the publication of the Handbook marked the initiation of the 
TB-STS for public health application.  
The target population were all public health staff, chest/respiratory physicians and 
TB nurses working in TB control in England at the time of both surveys. Questions 
were asked about the knowledge (awareness of the service, training, resources and 
self-reported knowledge), perceived usefulness of the service, and practice (if and 
how strain typing is accessed and used, and its associated workload). In addition, 
nurses were asked about five recent index cases and their contacts to estimate the 
number of contacts with TB disease and LTBI identified through contact tracing 
(termed contact tracing yield). This is explained in more detail in the methods for 
contact tracing yield (page 73). There was an option for open-ended responses at the 
end of the survey for any general comments. The survey was piloted with a nurse, a 
physician and a public health specialist to ensure that the questions were clear and 
interpreted appropriately. All questions and possible responses are available in 
Appendix 2 and published.
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For most of the survey, individual respondents were of interest (e.g. their personal 
knowledge and opinions of strain typing for TB control and any change in workload 
following the introduction of the TB-STS), rather than the opinion of a TB clinic, TB 
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service or HPU. A sample size of 100 was calculated to provide adequate statistical 
power (80%) to detect a proportion change from 90% to 99% for key implementation 
questions. The initial survey was emailed to all users of the TB notification system 
(Enhanced Tuberculosis Surveillance; ETS),
203
 and to staff responsible for TB 
control in HPUs who were asked to pass it on to their local TB teams. Therefore, the 
sampling frame could not be enumerated. The follow-up survey was emailed to 
respondents to the initial survey.  
3.3.2 Analysis 
Participants that responded to both surveys were included in the statistical analysis. 
Responses from people working at national, regional or PCT-level (including cluster 
investigators) and people working in Wales were excluded because the survey 
questions were tailored to people working in HPUs and clinics (not in regional and 
national offices), PCTs were reorganised in 2012 and did not exist at the time of the 
follow-up survey and Wales was not part of the TB-STS. These people received the 
survey because they were registered ETS users. 
HPU was used as a proxy for geographical area on which TB incidence rates were 
based because it was (correctly) anticipated that the geographic jurisdiction would 
remain following the creation of Public Health England in April 2013, ensuring it 
would be a comparable unit at the follow-up survey. The TB incidence of the HPU 
area in which respondents worked was used as a unit of analysis throughout the 
survey (defined as low, medium and high incidence based on an annual notification 
rate of <10/100,000 population, 10 to 19/100,000 and ≥20/100,000 respectively). TB 
incidence categories were defined based on the mean TB incidence rate in England 
and Wales during 2007-2009 (14.95 per 100,000 population). Mean TB incidence 
was calculated using the mid-year population estimates from 2008.
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The knowledge, perceived usefulness and practices of public health and clinical staff 
working on TB control were compared across the initial and follow-up surveys by 
calculating and comparing medians and inter-quartile ranges (IQR), and means and 
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standard deviations (SD), and using two-sample t-tests, chi
2
 tests, Wilcoxon rank 
sum tests, and logistic regression, where appropriate. Calculations excluded item 
non-responses. Analyses were conducted overall, by professional category and the 
TB incidence of the HPU area in which respondents worked (low, medium and high 
incidence defined above). Statistical analyses were considered significant at the 95% 
level (p≤0.05). The characteristics of non-responders and responders were compared 
using logistic regression for binary or ordered variables where appropriate. 
Knowledge 
To explore the awareness and knowledge public health and clinical staff had about 
strain typing and its uses, responses to questions across the two surveys regarding 
whether respondents had heard of the TB-STS, had access to strain typing data, had 
received any training, or had access to resources or tools to help them interpret and 
use strain typing data were compared. They were then asked to rate their knowledge 
of how to interpret the MIRU-VNTR data on a scale of one to five, one representing 
no knowledge and five representing excellent knowledge. These questions attempted 
to establish the extent to which the TB-STS training strategy had been implemented 
and whether professionals working in TB felt well-equipped to use strain typing.  
Perceived usefulness 
Survey respondents were asked to rate how useful they found the strain typing 
information: very useful, quite useful, not very useful or useless.  
Practices 
Practices (a): Laboratory turnaround times 
One of the key elements for an efficient service is the time it takes for the strain 
typing result to reach the local public health teams. Nurses and physicians were 
asked “how many weeks after a sample is sent to the lab do you receive the 
individual strain type?” Health protection staff were asked “do you usually access/get 
hold of strain typing data before or after you have finished contact tracing?” It was 
not possible to compare the distribution of responses and mean number of weeks 
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reported across the two surveys because none of the respondents included in the 
panel data responded to the question in the initial survey. Therefore, given the item 
non-response, the follow-up data alone are presented. 
Practices (b): How strain typing is used and its impact on TB control 
The questionnaire explored the way in which clinical and health protection 
professionals used the TB-STS, i.e. their strain typing-related practices. This was an 
opportunity to begin to understand the Processes within the TB-STS, the way strain 
typing data are used and how it impacts the management and control of TB. 
Questions were asked about how strain typing was accessed and used, and whether it 
influenced the TB control activities of the different professional groups.  
Practices (c): TB-related workload 
TB-related workload was measured in order to compare the workload before the 
implementation of the TB-STS and capture any change in workload that might be 
attributed to the TB-STS. Survey respondents were asked a variety of questions to 
capture their workload associated with TB. The questions posed to nurses, physicians 
and health protection staff varied according to their specific roles. Estimated 
workload was used to define the human resource cost of the TB-STS for the cost-
effectiveness model. 
Nurses were asked about their TB caseload including: the number of new active TB 
cases, the number of TB cases that needed contact tracing, the number of contacts 
they had screened in the last month and how many hours this took. Physician TB 
workload was measured by the number of new TB cases started on treatment by the 
physician each month and the frequency of TB incident meetings attended by the 
physician. The workload of health protection staff working in HPUs was estimated 
by the number of cluster investigations in the HPU in the last month and the 
proportion of time spent on cluster investigations. 
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Estimates of contacts screened with active disease and LTBI 
For methods see page 75. 
Free text for general comments  
The follow-up survey provided an opportunity to collect general comments that 
respondents felt were not covered by the set questions. This was achieved by 
including free text space at the end of the questionnaire with the following prompt: 
“If you have any other comments about how you use (or don’t use) strain typing data 
and how useful you find it please write in the box below.” The comments were used 
to inform the development of the semi-structured interviews described below. 
3.3.3 Survey responses 
There were 248 responses to the initial survey, 137 responses to the follow-up survey 
(55% retention), and for 124 there were responses to both the initial and follow-up 
surveys (Figure 19). Respondents to the initial survey who did not respond to the 
follow-up survey were not significantly different to those that responded to both: no 
particular profession, full-time/part-time position or TB incidence was more (or less) 
likely to respond to the follow-up survey, and there was no significant difference 
between the proportion of people who had heard of the TB-STS or had access to 
strain typing at the time of the initial survey (Table 7).  Respondents were from all 
nine regions of England and covered 24 (of 26) HPUs, representing areas of low, 
medium and high TB incidence.  
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Figure 19 – Responses to the initial and follow-up surveys 
 
 
a The email was sent to all users of the Enhanced TB Surveillance database. This included all administrative staff 
as well as well as staff working at national, regional and Primary Care Trust level, which were not relevant to this 
survey.  
b It is not known how many people received the email via through the HPU cascade. 
c This response rate is an underestimation because of the denominator used. 
d Respondents working at national, regional or PCT-level (n=27) and those from Wales (n=9) were excluded from 
this analysis. 
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Table 7 – Characteristics of non-responders and responders to the follow-up surveya 
  
Non-responders to the 
follow-up survey 
Initial & follow-up 
survey responses* 
  
n %b n %b 
Total 
 
121 
 
124 
 Profession HPU 23 19.0 28 22.6 
 
Physician 29 24.0 30 24.2 
 
Nurse 69 57.0 66 53.2 
TB incidencec  Low 50 42.0 56 45.2 
 
Medium 32 26.9 33 26.6 
 
High 37 31.1 35 28.2 
Work time  Full-time 87 77.0 95 79.2 
 
Part-time 26 21.5 25 20.2 
Heard of the TB-STS, initial survey 100 84.7 105 85.4 
Access to strain typing, initial survey 99 81.8 90 72.6 
a Using the information reported in the initial survey 
b There were no significant differences between characteristics of non-responders and responders (logistic 
regression was used to test the association of each characteristic with the outcome non-responder/responder, 
p>0.05) 
c Area where respondents worked is defined as low, medium and high TB incidence defined as <10/100,000, 10-
19/100,000, ≥20/100,000 population, respectively 
 
3.4 Semi-structured interviews 
The initial and follow-up surveys were useful in assessing the implementation of the 
TB-STS, but they did not give much insight into the user experience. Free-text 
comments written in the follow-up survey suggested that to help understand how the 
service was being used and the benefits and barriers to the service, the experiences of 
those using the TB-STS could be further explored.  
Semi-structured interviews were used to understand more about the public health 
component of the TB-STS and the overall value of the TB-STS for health protection.  
Rationale for using semi-structured interviews 
The process undertaken to describe the TB-STS and the initial and follow-up surveys 
identified some areas for more in-depth exploration. The most appropriate approach 
to engage directly with service users and to learn about their different experiences 
with the TB-STS was through semi-structured interviews that could be conducted 
over the phone, at a time convenient to the interviewee.  
Semi-structured interviews provided an opportunity for more in-depth information to 
be gathered (compared to data collected from the survey); the interviewee is able to 
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influence the topic, making the process responsive to the ideas and opinions of the 
respondent and allowing for unanticipated issues to emerge; further questions can be 
asked to understand the perspective of the respondent; and it allows a more natural 
conversation to take place. 
Data collection 
Semi-structured interviews were carried out with the main TB strain typing contact at 
each HPU. The aim of the interviews was to explore the different processes that are 
employed around the country to process, disseminate and act upon strain typing 
information.  
The main TB strain typing contact at each HPU was identified through the national 
and regional CIs. Using the comments from the follow-up surveys, pilot interviews 
were designed and carried out with the TB strain typing leads at two HPUs during 
October 2012 to inform the development of the semi-structured interview guide (Box 
2). The interview topic guide was adapted iteratively throughout the interview 
process, as new topics of interest emerged. The guide included questions on how and 
when cluster reports are received, what the HPU does with the information in the 
cluster report and suggestions for improving the service.  
During November and December 2012 the remaining 24 HPU leads were 
interviewed. Telephone interviews lasted 20-30 minutes. 17 of 24 interviews were 
recorded (no recording devices were available for the other seven for which notes 
were taken during the interviews).  
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Box 2 – Interview guide for interviews with HPU strain typing leads 
 
Analysis 
Transcripts and notes from the semi-structured interviews were analysed using a 
thematic analysis based on the Framework approach.
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 This approach was chosen 
because the analysis can be based on the predefined themes from the initial and 
follow-up surveys, as well as allowing for new themes to emerge from the interview 
data. This approach includes the following steps: familiarisation with the data (i.e. 
reading over the transcripts and notes); developing a thematic framework; coding the 
transcripts according to the framework and revising the framework as more data are 
analysed; once all data were coded, themes and sub-themes were refined and a 
descriptive analysis presented. These steps were followed with a bottom-up 
analytical approach, so that the shape of the analysis could inform the remaining 
interviews. The analysis was conducted using Excel.  
Interview guide for interviews with the HPU strain typing lead: 
1. What is your role in the HPU? Job/profession? 
a. Are you sent cluster reports (from lab and/or cluster investigators)? 
b. How many people receive cluster reports (from lab and/or cluster investigator)? 
2. From whom do you receive cluster reports? Labs? Cluster investigator? 
3. What do you do with a cluster report? Outcome reporting form? 
a. When do you receive it? Is this too early/too late/the right time to be useful to 
you? Who is involved in looking at it? 
b. Does the information within it affect your decision making? What is it most 
useful for? 
c. If you act on it, do you use the strain typing handbook as a guide? Are the 
thresholds appropriate for your area? 
d. What does ‘cluster investigation’ mean to you? What does it involve? Who 
decides when an investigation should be launched (cluster review meetings)? 
e. Who does it involve? Do you use the questionnaires (why not)? 
f. How much time does it take? 
g. What do you do with the information? 
h. How does it affect your decision making (local outbreaks identified? Helped to 
solve a known outbreak?)? 
i. Please give examples of when it did 
ii. Please give examples of when it didn’t 
4. Are there ways you think the service would work better or the strain typing would be 
more useful? 
a. E.g. Would it be better if you used the strain typing when you felt you needed it, 
rather than you being advised by cluster investigators when to investigate?  
b. Are enough resources available to use the strain typing as you would wish? 
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The analysis was carried out alongside the interviews so that themes identified in the 
analysis could inform the remaining interviews. The themes were quality-checked, 
validated and discussed with the PhD supervisors and relevant members of the 
evaluation steering group throughout the analysis. Themes were revised where 
appropriate and additional themes were added when they arose. The interviews that 
had already been analysed were re-visited to examine how the data related to the 
recently added themes. Once all 26 interviews had been coded into themes, more 
detailed sub-themes were identified and charted. The HPUs were grouped into low 
(n=14), medium (n=7) and high (n=5) TB incidence areas for the analysis. 
3.5 False positive TB isolation survey 
False positive isolation may be a result of contamination in the clinic or the 
laboratory, mislabelling or mishandling of clinical samples.
114
 One of the drivers for 
the initiation of the TB-STS was that the service would aid the identification of false 
positive isolation, saving the costs associated with the unnecessary treatment of false 
positive cases. Strain typing can identify (and confirm) suspected false positive TB 
isolates by showing that two or more isolates processed at a similar time in the 
source or reference laboratory have the same strain type. It can also confirm or refute 
a suspected incident of false positive isolation that was identified through another 
channel such as clinical suspicion, by showing that they have indistinguishable or 
different strain types and preventing the investigation of a false positive outbreak.  
Data on suspected false positive isolates were collected from all three reference 
laboratories between October 2010 and 2012 (see Figure 17, page 57) based on their 
individual laboratory false positive isolation protocols. The protocol developed by 
the Birmingham laboratory was shared between the laboratories but not adopted 
formally.
207
 A data collection form was developed and completed quarterly to 
establish the number of isolates typed in the previous quarter, the number suspected 
of being false positive isolates or not because of the strain typing data, and the 
number confirmed to be false positive TB isolation (or not) because of the strain 
typing data (Figure 20).  
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Figure 20 – False positive isolation data collection form sent quarterly to the three reference 
laboratories 
 
Each incident of false positive isolation suspected between October 2010 and 
October 2012 was recorded alongside the outcome of the reference laboratory’s 
communication with the source laboratory. The outcome of the communication was 
categorised as possible, unconfirmed and unlikely cross-contamination. A short 
email questionnaire was designed for each of these outcome categories (Appendix 3). 
Email questionnaires were sent to the source laboratory to establish whether they 
were aware of the incident before they were contacted by the reference laboratories, 
if they carried out an investigation, and if so, the outcome of their investigation and 
its impact on their laboratory protocol. These data were used as a parameter in the 
cost-effectiveness model of the TB-STS. 
3.6 Capturing cluster investigation activity and outputs 
Public health Outputs of the TB-STS include the public health and TB control 
activities carried out, or not carried out, as a result of the strain typing information. A 
measurable output is the number of cluster investigations carried out and the 
outcomes of those investigations. Cluster investigations are described in Chapter 4 
(page 92). The next few paragraphs describe the different data collection strategies 
explored to capture cluster investigation activity and their outcomes: the strain typing 
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module; the cluster monitoring database; cluster outcome reporting forms; and the 
database of national clusters. Personal identifiers were removed for the analysis of 
these data. 
3.6.1 The cluster monitoring database  
The software for collating and reporting the strain typing and epidemiological data 
(the STM) had not been developed in time (see Chapter 4, page 91), therefore a 
cluster monitoring database was developed to collect primary data specifically for 
this evaluation. This enabled CIs to make a record of each cluster that was 
investigated and the outcomes of those investigations (Figure 21). The cluster 
monitoring database collected information on all the clusters that were formally 
investigated at a local (HPU), regional and national level. It recorded the number of 
cases per cluster, the date the cluster started to be investigated, the date it closed, the 
action taken during or as a result of the investigation, and the ETS ID numbers of the 
cases in the cluster (which allows it to be linked to the national dataset). Data were 
input following the receipt of cluster questionnaires from HPUs and any other 
communication with HPUs. The cluster monitoring database enabled CIs to keep a 
record of the investigations they were initiating and was a shared file, accessible by 
all three CIs. The database was developed using Microsoft Access. 
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Figure 21 – Cluster monitoring database: cluster entry form 
 
3.6.2 Cluster outcome reporting forms 
Direct measures of the outcomes of interest from cluster investigations are the 
number of additional epidemiological links identified between clustered patients and 
the number of secondary cases identified as a result of the strain typing information.  
Cluster outcome reporting forms were developed to capture the outcomes of local 
and regional cluster investigations. To report on the activities and outcomes of 
cluster investigations, these forms were completed and sent to the CIs every six 
months until the investigation closed. The information collected on the forms is 
reported and described. 
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3.6.3 Database of national clusters 
The national TB cluster team developed an additional database of national clusters 
that contains more detail. The database records all clusters of two or more patients 
that are from more than one region. It holds information on whether there are any 
epidemiological links between the cases and whether the links were found following 
a cluster investigation. A descriptive analysis was conducted. 
3.7 Indirect measures of the impact of the TB-STS on TB control: 
secondary data analyses 
Due to the restricted cluster investigation activity and outcome data (described 
above), alternative approaches to measure the impact of the TB-STS on TB control 
are presented in the following section. These alternative methods and data sources 
are explored based on the assumption that strain typing will enable targeted cluster 
investigations and as a result one would expect to identify a greater number of LTBI 
and cases of TB disease earlier. It was hypothesised that this would lead to three 
indirect outcomes (see the diagram of the aims of the TB-STS, Figure 11 on page 
31):  
1. An increased yield of LTBI and TB disease identified through contact tracing 
when the index case is in a cluster that is investigated (compared to when the 
index case is in a cluster that is not investigated);  
2. A reduction in the time between symptom onset and diagnosis, termed 
diagnostic delay; and 
3. A change in the rate of cluster growth following a cluster investigation 
(compared to no investigation). 
All data were cleaned in Excel (2010) and Access (2010). 
3.7.1 Contact tracing yield 
Contact tracing yield is the proportion of contacts who have LTBI or active TB 
disease. It was hypothesised that the TB-STS would increase contact tracing yield. If 
a case is in a cluster and the cluster is investigated then one might expect more TB 
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disease and LTBI to be identified, as a result of the additional information about the 
transmission occurring within that cluster. Figure 22 shows how more targeted 
contact tracing (because of the additional information collected in a cluster 
investigation) could produce a higher yield of active TB and LTBI, rather than 
following the traditional stone in the pond principle (Figure 8, page 8). 
Figure 22 – More targeted contact tracing (shown in orange) as a result of the TB-STS might 
lead to a greater contact tracing yield (as compared with approach illustrated with the 
blue/green concentric circles) 
 
To explore this, the outcomes of contact tracing were investigated using two different 
datasets. The first used data collected from nurses in the initial and follow-up survey 
to summarise the number of contacts screened per index case and the outcomes of 
the screening (see page 58 for a description of the surveys, and see below for a 
description of the data collected, and Appendix 3 for the survey questions). The 
second data source combined data from North Central London Sector and Leicester 
TB clinics and was used to analyse the impact of cases being part of a cluster and/or 
part of a cluster that was being investigated on the contact tracing yield (see below). 
Means, medians and proportions are all presented, as contact tracing yield is a key 
parameter for the cost-effectiveness model. Figure 17 (page 57) shows the data 
collection time periods in the wider context of the TB-STS implementation and 
evaluation. 
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Overall estimates of contact tracing activity and yield: survey data 
Using the initial and follow-up survey (page 53), the aim was to estimate the yield of 
contacts with TB disease or LTBI identified through contact tracing, and capture any 
changes over time. 
Nurses were asked to detail up to five recent TB index cases whose contacts had 
been screened. They were asked for the following information for each case: date of 
birth, site of disease (pulmonary or extra-pulmonary), smear test result, culture result, 
when the strain type was available to the nurse, the number of contacts identified, 
and the number of contacts screened. They were also asked to report the number of 
contacts that had active TB disease and the number of contacts that had LTBI.  
Means, medians, standard deviations, inter-quartile ranges or ranges were presented 
and results were compared across the initial and follow-up surveys using the 
Wilcoxon rank sum test. The proportion of contacts screened, with active disease and 
LTBI and the exact confidence intervals based on the Binomial distribution were 
calculated and compared across surveys using the chi
2
 test of significance and the 
Fisher’s exact test of significance where one or more cells has an expected frequency 
of less than five. 
The impact of cluster status and cluster investigations on contact tracing yield: 
clinic data 
Data collected from North Central London (NCL) Sector and Leicester TB Services 
that contained information on the number of contacts screened per patient and the 
outcome of that screening in July 2012 for pulmonary TB cases diagnosed in 2011, 
were used in this analysis. These data were linked to the ETS and the cluster 
database. For each case reported in these areas the number of their contacts that were 
screened was calculated and the outcomes of the screening were summarised (e.g. 
three contacts with LTBI and zero with active disease). The number of contacts 
screened, the number with active disease and the number with LTBI were calculated 
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and compared between cases that were unique (not clustered), clustered and part of a 
cluster investigation, and clustered but not part of a cluster investigation. 
Medians and inter-quartile ranges (IQR) for the contact tracing yield for pulmonary 
index cases are presented by clustering and whether the cluster was investigated. The 
Wilcoxon-rank sum test was used to compare differences between the groups. A 
sensitivity analysis was conducted assuming that index cases with missing contact 
tracing information yielded no cases of active disease or LTBI. This was based on 
the assumption that those with positive results would be more likely to be recorded. 
The proportions of contacts screened, with active disease and LTBI and the exact 
confidence intervals based on the Binomial distribution were calculated and 
compared across unique/clustered and investigated/not investigated clusters using the 
chi
2
 test of significance and the Fisher’s exact test of significance where one or more 
cells had an expected frequency of less than five. 
3.7.2 Diagnostic delay  
Diagnostic delay is the time between symptom onset and case notification. It was 
hypothesised that the diagnostic delay would be reduced following the introduction 
of the TB-STS because cluster investigations would lead to undiagnosed TB cases 
being actively identified earlier. A case-control design was used to compare the 
diagnostic delay observed with cluster investigations and without. Diagnostic delay 
was defined as the number of days between onset of symptoms and the date of 
notification. Date of notification was used instead of date of treatment as it was a 
more complete field.  
Cases were defined as pulmonary TB cases diagnosed in 2011 that were part of a 
cluster that was investigated and were diagnosed after the cluster investigation was 
initiated. There were two comparison (control) groups: a) pulmonary cases diagnosed 
in 2011 that were part of a cluster that was investigated and were diagnosed before 
the cluster investigation was initiated; b) pulmonary TB cases diagnosed in 2011 that 
were part of a cluster that was not investigated.  The first two cases from each cluster 
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were excluded to take into account possible household transmission (as the 
diagnostic delay for these two cases will not be affected by the presence or absence 
of a cluster investigation).  
The analysis included 121 pulmonary cases diagnosed after the cluster was 
investigated, 117 diagnosed before the cluster was investigated and 139 cases that 
were part of clusters that were not investigated at all. The analysis was stratified by 
cases that were UK born and non UK born, and was re-run excluding children under 
the age of 16. Medians and inter-quartile ranges (IQR) were presented and compared 
using the Wilcoxon rank sum test. 
3.7.3 Rate of cluster growth 
The rate at which new cases of TB are added to a cluster indicates the rate of ongoing 
transmission in the community. The relative changes in the size of clusters were 
explored. It was hypothesised that the rate of cluster growth would differ before and 
after a cluster investigation was initiated (Figure 23). Cluster investigation may 
increase apparent rate of cluster growth (as a result of additional cases being 
identified more quickly) or may decrease the rate of cluster growth (if the earlier 
identification of cases limits transmission). In ideal circumstances a cluster 
investigation may transiently increase the rate of cluster growth, later decrease the 
rate and then plateau as transmission is interrupted (Figure 23).  
Figure 23 – Hypothesised rate of cluster growth prior to, and following a cluster investigation 
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It was hypothesised that the rate at which new cases were added to a cluster would 
change following the initiation of a cluster investigation. To visualise the data, using 
a selection of the national TB notification data from 2010 and 2011, the number of 
cases in a cluster was plotted by the number of days before or after the cluster 
investigation was started.  
2010 and 2011 data from the ETS were merged with the cluster monitoring database. 
After cleaning the data and excluding the first case in each of the 113 clusters, there 
remained a total of 949 cases. A univariate linear regression was initially conducted 
and the final set of variables used in the multivariate regression were: sex, UK born, 
age group (treated as an ordinal variable), site of disease, case order (the order in 
which cases were added to the cluster), cases discovered after a cluster investigation 
was started, and cluster level (local, regional and national) and lineage, the latter 
being factor variables. See Appendix 4 for the model equations. 
3.8 Transmission model 
The hypothesised Outcomes of the TB-STS were: 
 The TB transmission prevented through the earlier identification and 
treatment of cases with TB disease and LTBI; 
 The costs saved through interrupting transmission and preventing cases; and  
 The costs saved by identifying and not treating false positive TB patients (see 
Figure 11, page 31).  
A deterministic age-structured model was used to explore the possible reductions in 
TB incidence as a result of the TB-STS over a 20-year period (Figure 24). Details of 
the model are provided in Appendix 5. This extends previous models considering the 
transmission dynamics of M. tuberculosis in England and Wales
112
 and recent work 
on preventive therapy.
208
 The model incorporates contact between individuals and 
rates of immigration and emigration based on Office for National Statistics data.
209
 
For simplicity, the model considers only pulmonary TB and considers three different 
epidemiological scenarios: low, medium and high incidence (notification rates of ~7, 
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~20 and ~120 per 100,000) – comparable to that in the white UK born population 
(with decreasing annual risk of infection (ARI)), non-white UK born (0.1% ARI), 
and the non-UK born (1% ARI). 
In the absence of the TB-STS, the average diagnostic delay is assumed to be 10 
weeks (as estimated for cases that were not in clusters; Table 32, page 155).  The 
effect of a one-week reduction in diagnostic delay due to the TB-STS was explored 
and it was assumed that patients start TB treatment (on average) two weeks after 
diagnosis.  
In the absence of the TB-STS, 3% of all (recently or latently) infected individuals are 
assumed to have been detected each year.  This proportion is unknown, but was 
probably low given the low number of latently-infected contacts per index case (see 
Table 28 page 150 and Appendix 5).  The effect of assuming that it increased to 13% 
after the introduction of the TB-STS was explored. It was assumed that uptake of 
preventive treatment (PT) among those eligible is 95% and that 85% complete the 
course of treatment.
48
 The model parameters can be found in Appendix 5. In 
sensitivity analyses, the effect of pessimistic and optimistic assumptions about 
uptake (30% and 100%, respectively) and completion (50% and 100%, respectively) 
of PT were explored.   
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Figure 24 – General structure 
of the transmission model 
PT, preventive treatment. Coloured 
text and shading is used to reflect 
similar categories of people: yellow 
shading is used for people on PT, 
purple text is used for compartments 
for people with latent infection, 
green text is used for newly infected 
or reinfected people, red is used for 
diseased people and orange, blue 
and pink text is used for detected 
cases, people on treatment and the 
recovered respectively. 
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3.9 The cost-effectiveness model 
The cost-effectiveness model builds on the transmission model by using the 
estimates of effectiveness. It incorporated estimates of contact tracing yield, false 
positive TB isolation and costing collected or estimated as part of this thesis. The aim 
was to estimate the cost-effectiveness of the TB-STS as an addition to the current 
system for TB control in England. The cost-effectiveness analysis is illustrated in 
Figure 25. Further details of the model can be found in Appendix 6. 
The analysis adopted a public sector perspective.  Estimates of the cost of setting up 
and operating the national TB-STS were made based on information from Public 
Health England and the TB Reference Laboratories (see Table 9, page 100). Capital 
costs were annuitized over an assumed ten-year lifetime for equipment.  Costs and 
health effects (in QALYs) were estimated over a 20-year time horizon, and applying 
a 3.5% annual discount rate to both costs and QALYs (as recommended by NICE).
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The estimated impact of the TB-STS on false positive isolation is presented in Table 
20, page 138. For the economic analysis, it was assumed that five cases of 
unnecessary treatment would be avoided per year due to the TB-STS (ten cases per 
annum were tested in the sensitivity analysis). 
The estimated impact of the TB-STS on contact tracing workload was estimated 
from the cross-sectional surveys and is presented in Table 16, page 110. In the 
economic analysis, an opportunity cost for additional time spent by HPU staff on 
cluster investigations was assumed: 4.4% working time equivalent (WTE) for 26 
CCDCs at £99,000pa, costing a total of £113,256 per year (total annual cost of 
£50,000 per year and £500,000 per year tested in the sensitivity analysis).  
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Figure 25 – Structure 
of the cost-
effectiveness analysis 
STS TB Strain typing 
service; FP false positive 
TB isolation; QALY 
quality adjusted life year; 
∆ change 
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The estimated impact of the TB-STS on case finding and contact tracing yield was 
estimated from the contact tracing yield analysis and is presented in Table 29, page 
151. These results were used to calculate an estimate of the number needed to screen 
to diagnose LTBI (number screened/number LTBI identified). The estimate was 
weighted to take into account the number of unique cases, clustered and investigated 
cases, and clustered but not investigated cases. The number of active TB cases per 
index case was estimated, based on expert judgement and the results of the contact 
tracing yield analysis.  
The results of the transmission model provided estimates over the 20-year period for 
each modelled scenario: the number of contacts with LTBI identified, the number of 
contacts starting preventative treatment, the number of people with active TB 
diagnosed and starting treatment, as well as the impact on the number of incident TB 
cases.   
The costs associated with diagnosis and the treatment of latent and active TB were 
estimated based on recommended practice and expert opinion.  The unit costs of 
tests, medications, outpatient contacts and inpatient stays were obtained from 
national sources which estimate the national average units costs to the NHS: 
Department of Health Reference Costs 2010-11 for Tuberculosis Specialist Nurse 
contacts, outpatient consultations (respiratory clinic), and inpatient admissions; 
British National Formulary, Sept 2012 for medications; and personal communication 
from PHE Finance Division for theTB-STS.
211,212
 Patients with TB who drop out 
were likely to be identified and offered treatment again at a later time.  Such repeat 
cases were included in the transmission model estimates of the number of people 
diagnosed per year, and incurred additional costs for diagnosis and treatment in the 
cost-effectiveness analysis.  For simplicity, it was assumed that the cost of diagnosis 
and treatment was the same for new and repeat cases. 
QALYs lost due to TB-related mortality are estimated based on: TB incidence by 
age;
123
  case-fatality rates by age group;
213
 life expectancy (ONS); and mean quality 
of life by age (EQ5D scores) in the general population  (Health Survey for England). 
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The case fatality rates were taken from an analysis of national surveillance data 
linked to mortality data, with capture-recapture methods used to estimate the number 
of unascertained deaths.
213
  In this analysis, case fatality was defined as a death 
within 12 months of the start (or notification) of TB treatment, and where TB was 
mentioned on the death certificate or if treatment outcome monitoring had stated that 
the death was caused by or contributed by TB.  This includes deaths in which TB 
was reported as a contributory factor, as well as deaths directly caused by TB.  
The results are presented in the form of an Incremental Cost-effectiveness Ratio 
(ICER), which is the additional cost per additional QALY gained with the TB-STS.  
The difference in costs and the difference in health effects with/without the TB-STS 
are estimated (Box 3).  Any costs or health impacts incurred under both systems were 
ignored. The ICER was compared with the NICE threshold of £20,000 to £30,000 
per QALY gained to determine whether the TB-STS was cost-effective or not.
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Box 3 – The Incremental Cost Effectiveness Ratio (ICER) for the TB-STS 
 
3.10 Ethical Considerations 
The research conducted for this thesis was classified as a service evaluation by 
University College London Hospital Foundation Trust and therefore specific ethical 
approval was not required. Personal identifiers were removed and data were 
anonymised prior to analyses. Data were stored on the Public Health England secure 
server, in adherence to the requirements for national surveillance data and the 
Caldicott principle. 
3.11 Summary of evaluation methods 
This prospective evaluation was a mixed-methods approach using primary data 
collection and routine data sources. Primary data collection included cross-sectional 
surveys of health protection and clinic staff, semi-structured interviews with health 
ICER = 
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protection staff, surveys of reference and hospital laboratories and the cluster 
monitoring database. A summary of the evaluation methods and how each 
component was used to inform or parameterise other parts of the evaluation is 
illustrated in Figure 26. 
All data were cleaned and analysed using Stata version 12 (StataCorp. 2011. Stata 
Statistical Software: Release 12. College Station, TX: StataCorp LP.) and Microsoft 
Excel (2010), unless stated otherwise. 
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Figure 26 – 
Interaction of the 
evaluation 
components 
Arrows represent the 
flow of data or results 
from one component 
to another. 
All components are 
considered in Context 
of the TB-STS.
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Chapter 4. Structures of the TB-STS 
In this chapter I give an overview of the TB-STS. I describe the components of the 
TB-STS, how it relates to the existing TB control service, and illustrate its 
implementation on a timeline. Finally, the fixed costs of establishing and running the 
TB-STS are presented. 
__ 
The TB-STS was based on prospective typing of Mycobacterium tuberculosis using 
24 loci MIRU-VNTR. It was designed with the intention that strain typing results 
would be linked to existing national epidemiological and laboratory datasets, and 
reported in real time to front line teams. It was hypothesised that prospective 
universal strain typing and analysis of clusters could be used in real time to inform 
public health action (see Figure 11, page 31).  
The TB-STS is composed of five operational workstreams: 1) 24 MIRU-VNTR 
typing and reporting, 2) software development and national reports, 3) public health 
and clinical action, 4) quality assurance, and 5) the evaluation (Figure 27). Each of 
these workstreams is described below. Figure 28 shows the implementation of the 
TB-STS within the first three years, the change from the Health Protection Agency 
(HPA) to PHE, and the evaluation period. A simplified diagram of the existing TB 
service and the addition TB-STS is illustrated in Figure 29.  
Figure 27 – The five workstreams of the TB-STS 
The Evaluation incorporates the remaining four workstreams of the TB-STS 
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Figure 28 – Timeline showing the change from the HPA (orange) to PHE (red), the implementation of the TB-STS (black) and the evaluation period (turquoise) 
 
STM strain typing module 
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Figure 29 – Simplified illustration of the existing TB service and the addition of the TB-STS 
The components above the dotted line were conducted as part of the existing TB service, and everything below 
the dotted line is part of the TB-STS. The TB-STS involves the laboratories, PHE national staff (CIs), HPUs, and 
those working in the clinic setting. These different settings are represented in the different coloured boxes. 
 
4.1 24 MIRU-VNTR typing and reporting 
This workstream is initiated when a sample is taken from a suspected TB patient and 
sent to a local laboratory for culture. Once growth of acid fast bacteria is detected the 
culture is sent to one of the three Mycobacterium reference laboratories (in London, 
Birmingham or Newcastle) for identification. If identified as M. tuberculosis, drug 
susceptibility testing will be set up and the first culture per patient will be selected 
for 24 MIRU-VNTR typing. Subsequent cultures are typed if they are collected more 
than two months after the first. The document HPA Mycobacterium tuberculosis 
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Strain Typing: A guide to data production and distribution provides more detail on 
the typing methods and reporting standards.
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The 24 MIRU-VNTR strain type for each isolate is reported back to the local 
laboratory that submitted the positive culture on the standard report containing 
identification and drug susceptibility results. It is also reported to the local HPU 
where the patient is being treated and loaded onto MycobNET (the laboratory 
database held at PHE) so that it can be matched to the Enhanced Tuberculosis 
Surveillance (ETS) system (the national TB notification system) for surveillance 
purposes. 
Clustering and cluster names are generated using the following algorithm:
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i. A cluster comprises two or more isolates with indistinguishable 24 MIRU-
VNTR strain types. 
ii. For an isolate to be included in a cluster at least 23 loci must have been typed 
successfully, i.e. the strain type must contain at least 23 digits. 
iii. An unequivocal cluster number is given when at least one member of the 
cluster has a full 24 loci strain type. 
iv. Isolates are not included in a cluster if the permitted ≤2 missing loci do not at 
least correspond to all those missing in the most complete member of a cluster. 
v. Where missing loci fail to place an isolate unequivocally within a single 
cluster, typing is repeated. 
vi. Prefix letters indicating the phylogenetic lineage are determined. 
vii. The cluster designation is completed by adding a unique four digit number 
following the letter that indicates the lineage.  
Cluster reports are sent to HPUs on a monthly basis by the London and Birmingham 
laboratories. The reports contain new clusters within the HPU, previously reported 
clusters within the HPU where new cases have been added, and new cases from 
within the HPU that are part of a regional or national cluster. Cluster reports from all 
three laboratories are sent to the Cluster Investigators (CIs). 
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4.2 Software development and national reports 
Cluster nomenclature 
An online cluster naming tool was developed by PHE using the cluster name 
designation algorithm (described on the previous page). This tool acts as a repository 
for cluster names enabling all the laboratories to use the same cluster name for every 
cluster. When a complete 24 loci MIRU-VNTR strain typing profile is submitted, the 
database of strain types with an assigned cluster name is searched. If the submitted 
profile matches an existing cluster, this isolate will be added to that cluster. If the 
submitted profile does not match an existing cluster, a search is conducted of unique 
profiles stored in the database. Where there is a successful match, a new cluster is 
created and a name is assigned to that complete MIRU-VNTR profile. 
When an incomplete 24 loci MIRU-VNTR profile is submitted, the cluster naming 
tool will attempt to provisionally match the submitted profile to any existing clusters 
with identical incomplete profiles, and provisionally assign the associated cluster 
name. If the incomplete profile submitted does not match an existing cluster, unique 
profiles in the database that contain no missing loci will be searched. Where a match 
can be found a new cluster will be created and a name assigned. 
The tool can be found at:  
http://www.hpa-bioinformatics.org.uk/TBCluster/tbhome.php 
Strain typing module (STM) 
The STM is a software module that is integrated into the ETS. The module is 
designed to identify and report strain typing clusters. It enables the collation and 
reporting of the strain typing data with the epidemiological and clinical data stored in 
ETS, thereby identifying strain typing clusters and presenting them with the 
epidemiological information to assist with cluster investigation. Clinical and risk 
factor information relevant to cases in a cluster can then be reviewed. The STM 
contains questionnaires designed to collect additional information on cases that are 
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part of a strain typing cluster, and record information on cluster investigation. In 
addition, the STM can be used to search for cases by cluster name or strain type. 
The development of the STM began at the start of the National Strain Typing Project 
in October 2009 and was due to be released at the end of 2010. However, there were 
severe delays in the development of the software. In September 2012 the STM was 
piloted with the Newcastle laboratory and the areas it serves, and was released in 
November 2013 (Figure 28). This was after the completion of the TB-STS 
evaluation. Prior to this, the essential functions of the STM were carried out by 
interim systems (Table 8). As a result, the impact of the STM was not captured by 
this evaluation.  
Table 8 – Functions of the STM that were carried out by other means 
STM function Function re-created in absence of the STM 
Identify and report strain typing clusters Laboratories do this using Bionumerics software 
and send reports by email and letter to CIs and 
HPUs 
Collating and reporting of strain typing data with 
epidemiological and clinical data from ETS 
CIs do this by hand and create cluster reports by 
hand, which are emailed to HPUs 
Clinical and risk factor information relevant to 
the cases in the cluster can be reviewed 
The CIs collate the information together and 
include it in the cluster report they produce 
Questionnaires designed to collate additional 
information on cases in a cluster  
The CIs post or email questionnaires to the 
relevant HPUs or TB nurses.  
Questionnaires to record information on cluster 
investigation 
Information on cluster investigation activities and 
outcomes are collected using cluster outcome 
reporting forms which are sent from the CIs by 
email or post to HPUs. 
 
4.3 Public health and clinical action 
Strain typing information can be used to guide public health and clinical action.
197
 
Public health action refers to any additional action that is taken in an attempt to 
interrupt TB transmission. It includes outbreak investigation and extended contact 
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screening. The public health action that is generated by the TB-STS is initiated 
through cluster investigations. A cluster investigation is the additional investigation 
carried out around a cluster of TB cases with indistinguishable strain types. Cluster 
investigations are initiated based on criteria set out in the TB Strain Typing Cluster 
Investigation Handbook.
197
 The criteria, or thresholds, for initiating a cluster 
investigation relate to the number of cases in the cluster and the characteristics of the 
cases within the cluster (Box 4). The Handbook was developed as part of the public 
health component of the TB-STS to guide the public health application of strain 
typing in England.  
Box 4 – Thresholds for the initiation of a cluster investigation 
 
Figure 30 and Figure 31 are from the Handbook
197
 and show the flow of information 
and processes that lead to, and constitute a local and national cluster investigation. 
The criteria and thresholds for investigation are shown in the legend for Figure 30 
and Figure 31. Cluster investigations are coordinated by CIs, with local HPUs 
responsible for local cluster investigations and the national cluster team responsible 
for national cluster investigations.  
The reference laboratories send cluster reports to the CIs on a monthly basis. The 
London and Birmingham laboratories also send the cluster reports to the relevant 
Thresholds/criteria for the initiation of a cluster investigation, as defined in the TB Strain Typing Cluster 
Investigation Handbook:190 
1. Where all the cases in the cluster reside within a single HPU, 5 or more persons within 24 months (2 
years), of which 2 occurred in the last 6 months; with TB caused by indistinguishable strains; 
2. Where the cases in the cluster reside across more than one HPU within a single region, 10 or more 
persons within 24 months (2 years), of which 2 occurred in the last 6 months; with TB caused by 
indistinguishable strains; and 
3. Where the cases in the cluster reside across more than one region, 10 or more persons within 24 
months (2 years), of which 2 occurred in the last 6 months; with TB caused by indistinguishable 
strains. 
If the cluster contains any of the risk factors identified as increasing the likelihood of recent transmission, a 
cluster investigation should be considered when the cluster contains fewer cases than stated in the above 
thresholds (see the Legend to Figure 30 and Figure 31, page 95, for a list of the risk factors for recent 
transmission).  
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HPUs. Some HPUs will use the cluster reports sent from the laboratories to inform 
their decision making. For example, HPUs may use the data to confirm or refute 
suspected transmission, but many HPUs will wait to receive cluster reports from the 
CIs as these include recommended actions.  
When the CIs receive the cluster reports they carry out a preliminary strain type 
review. Relevant information about each case is extracted from ETS and, based on 
the size of the cluster and the characteristics of the cases within the cluster, a 
judgement is made about whether a cluster should be investigated further and a 
cluster investigation launched. The summary of the preliminary cluster review and 
any recommended actions are contained in the cluster report that is then distributed 
to the relevant HPUs. 
From this point, HPUs are responsible for investigating the local clusters identified 
for further investigation by collecting more information from the clustered patients to 
try to establish whether there is any evidence for on-going transmission. For national 
clusters it is the national team that directly contacts TB nurses about their patients. 
Where there is evidence of on-going transmission, public health interventions may be 
implemented. Any findings or actions should be reported to the CIs.  
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Figure 30 – A flow chart showing the flow of information and decision making algorithms 
involved in a local cluster investigation 
 
 
 
 
 
 
Legend for Figure 30 and Figure 31 
Source: The TB Strain Typing Cluster Investigation Handbook197 
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Figure 31 – A flow chart showing the flow of information and decision making algorithms 
involved in a national cluster investigation 
 
Source: The TB Strain Typing Cluster Investigation Handbook197 
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Human resources 
The TB-STS created seven new full-time permanent public health positions and one 
short-term position: one national Cluster Investigator (CI); four CIs responsible for 
local and regional clusters; one national strain typing scientist; one national strain 
typing administrator); and one short-term strain typing administrator for ‘the rest of 
England’. To cut costs, two of the local/regional CIs were not appointed, leaving the 
remaining two responsible for clusters in London and the South East, and the rest of 
England. This did not include the resources allocated for the evaluation. No 
additional public health positions were created within HPUs or in the NHS.  
Cluster investigations 
Three different systems have been developed by the CIs to organise and coordinate 
cluster investigations, based on their access to administrative and technical support 
and in lieu of the STM.   
1. The national CI leads on national cluster investigations from the PHE Centre 
for Infectious Disease Surveillance and Control in London, collecting 
information from nurses and HPUs and advising HPUs on further public 
health and clinical action that may be required. The national CI is supported 
by a scientist, an administrator and is line managed by the Head of the TB 
Section.  
2. The CI for London and the South East (SE) sits in the regional office in 
London and sends out cluster reports advising HPUs which clusters should be 
investigated. The CI provides support to the HPUs, who lead the local 
investigations and any further public health and clinical action. Regional 
clusters in London and the SE and some national clusters are coordinated by 
the CI. The CI for London and the SE is supported by the London Regional 
Office and line managed by the London Regional Epidemiologist.  
3. The CI for the rest of England sits in the North East region and collates the 
information for cluster reports before sending them to the relevant HPU with 
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recommended actions. Local cluster investigations are led by the local HPU, 
regional cluster investigations are expected to be led by the HPU with the 
most cases in that cluster, and any national clusters that are being coordinated 
by this CI are left to the HPUs to investigate locally with some demographic 
information about the cases from different HPUs included in the cluster 
report. Neither local nor regional clusters are coordinated by the CI across the 
rest of England. The CI for the rest of England had short-term administrative 
support and is line managed by the TB Lead for the North East. 
Training 
The aim of the training programme was to enable the implementation of the public 
health component of the TB-STS by equipping public health and clinical teams to 
use the strain typing information to inform public health decisions. It involved face-
to-face and online resources aimed at those working in HPUs and relevant NHS staff, 
and was carried out between January 2011 and February 2012. The publication of the 
Handbook
197
 and a Q&A sheet
215
 in December 2010 was the first stage of the 
training strategy for the TB-STS and provided health protection staff with guidance 
on how to understand, interpret and use strain typing for TB control. The rest of the 
training consisted of a workshop at each HPU between January 2011 and February 
2012 facilitated by a CI, and a seminar and webcast at the national Health Protection 
Conference in September 2012.  
4.4 Quality assurance 
Laboratory quality control 
There are three levels of laboratory quality control that have been built into the 
service: internal quality control (IQC), PHE quality assurance (PHEQA), and 
external quality assurance (EQA). The IQC is on-going throughout the year and the 
PHEQA and the EQA are spread out across the year so that a panel is analysed at 
each laboratory every two months.  
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 IQC. Each reference laboratory re-types and analyses a minimum of 1% of all 
cultures processed at the laboratory.  
 PHEQA. Three times a year the National Mycobacterium Reference 
Laboratory in London produces and distributes a panel of 8 DNA samples to 
the reference laboratories. Once returned, the results are collated and shared 
with the participating laboratories. A teleconference is then set up to resolve 
any inconsistencies between the data produced across the three laboratories 
and to suggest remedial actions. 
 EQA. The reference laboratories participate in the National External Quality 
Assessment Service (NEQAS) EQA. Four quality assurance samples are sent 
three times a year. Where the samples contain MTBC, typing data are 
submitted and the results are scored. 
Public health quality control 
The PHE STPB one agreed marker of quality for public health quality control.  
 For at least 80% of clusters that cross the threshold for a cluster investigation, 
a decision about further public health action should be made using strain 
typing information. This should be limited by geographical boundary. 
Clusters are categorised as: 
o Probable or definite chain of transmission identified and actions taken 
to interrupt further transmission; 
o No apparent chain of transmission identified, no further action 
deemed necessary; 
o Investigation inconclusive; 
o To maintain a watching brief;  
o Investigation continuing; or  
o Other.  
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4.5 Cost of the TB-STS 
Using information from the PHE Finance Division and the RMN, it was possible to 
estimate the cost of the TB-STS based on annual activity. The fixed costs of 
establishing and running the TB-STS amount to approximately £1 million per year 
(Table 9).  
Table 9 – Fixed costs of establishing and running the TB-STS 
  Per year  
PHE set up     
Evaluation    £15,753  
a 
Software development   £30,739  
a
 
HPS consultant project work   £8,050  
a
 
London laboratory set-up costs    £63,896  
a
 
Total  £118,438 
a
 
    
HPU     
Cluster Investigators (3 posts)   £184,905   
CCDC time (+4.4% x 26 WTE CCDC)   £113,256  
b 
Total   £298,161   
    
London laboratory 4,297 tests per year   
Consumables £20.02 per test  £86,026   
Overheads -  -   
Staff costs £51.42 per test  £220,952   
Total  £306,978  
    
Birmingham laboratory 1,075 tests per year   
Consumables £65.46 per test  £70,370   
Overheads £9.21 per test  £9,901   
Staff costs £33.50 per test  £36,013   
Total   £116,283   
    
Newcastle laboratory 908 tests per year   
Consumables £70.61 per test  £64,114   
Overheads £19.03 per test  £17,279   
Staff costs £55.95 per test  £50,803   
Total   £132,196  
    
Overall total   £972,056  
a Cost annuitised over 10 years using discount rate of 3.5% per year. 
b CCDC workload estimated from the initial and follow-up surveys (Chapter 5) 
Data source (unless otherwise stated): communication with PHE Finance Division and the RMN 
CCDC Consultant in Communicable Diseases 
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4.6 Discussion of the strengths and limitations of the methods used 
to evaluate the Structures of the TB-STS 
Describing the Structures of the TB-STS helped to identify gaps in the system. For 
example, the delay in the development and release of the STM had a negative impact 
on the performance of the TB-STS. The importance of this impact on the evaluation 
findings are discussed on page 200. 
The methods used to describe the Structure of the service meant that changes to the 
implementation of the service could be identified. For example, the Project Initiation 
Document indicated that the service had funding for four regional CIs, however two 
posts were not filled in order to provide a saving to the HPUs. The process of 
information gathering was important in itself, as it engaged all of the service 
stakeholders, from whom further data were required for the remaining components of 
the evaluation. 
The cost of the TB-STS cannot be compared to other national services as the costing 
of other national services has not been published. However, the set-up costs are 
likely to be determined by the number of reference laboratories being equipped to 
type, and the number of isolates typed per year. 
As with any complex intervention, the TB-STS is not a stable system, so presenting 
an accurate description of the service is difficult. The Structures of the service 
described in this thesis were correct at the end of the evaluation period, in April 
2013, and are representative of the service evaluated. 
Summary of findings 
The TB-STS is based on prospective typing of Mycobacterium tuberculosis using 24 
loci MIRU-VNTR. The results are linked to existing national epidemiological and 
laboratory datasets, and reported in real time to front line teams to inform local TB 
control. The prospective strain typing and real time reporting of results to inform 
public health action is what makes the TB-STS a novel intervention. The service is 
comprised of five components: 24 MIRU-VNTR loci typing and reporting of all first 
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isolates from TB patients, cluster analysis and reporting from laboratories to public 
health staff, public health assessment and decision-making around clusters, 
subsequent cluster investigations, quality assurance (including identifying laboratory 
contamination), and this prospective evaluation. The overall cost of running the TB-
STS is approximately £1 million per year. 
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Chapter 5. Processes in the TB-STS 
In this chapter, I show results from initial and follow-up cross-sectional surveys that 
I undertook to evaluate the Processes involved in the TB-STS. Specifically, the 
surveys assessed the implementation of the TB-STS and the knowledge, perceived 
usefulness and practices of service users. These surveys were designed to capture 
changes over time between the first and third years of the TB-STS. The survey 
methods and response are described on page 53. 
The findings of the surveys identified areas where more detail needed to be captured 
on the user experience of the TB-STS. Semi-structured interviews were used to 
investigate this further and the findings are presented in latter part of this chapter. 
The interview methods are shown on page 66. 
__ 
5.1 Implementation and perception of the TB-STS: Results of the 
initial and follow-up cross-sectional surveys 
The online initial and follow-up questionnaire survey assessed the knowledge, 
perceived usefulness and practices of public health staff, physicians and nurses 
working in TB control in November 2010 and March 2012. The survey methods and 
response are detailed in the Methods chapter (page 53). 
5.1.1 Knowledge 
Between the initial and follow-up surveys there were increases in the proportion of 
respondents who had heard of the TB-STS, had access to strain typing results, had 
received training, and had access to training resources (p<0.001, p=0.004, p=0.003 
and p=0.032, respectively; Table 10). The self-rated knowledge of how to use strain 
typing also increased over time (Figure 32). Nurses reported lower average 
knowledge in both surveys compared to physicians and health protection staff.  
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Table 10 – Knowledge: Awareness to the TB-STS and access to strain typing data and resources 
  
Initial survey Follow-up survey 
   n % n % p-valued 
Heard of the TB-STSa Total 105 85.4 123 99.2 <0.001 
Profession Health protection 28 100 28 100 . 
 Physician 20 66.7 30 100 0.001 
 Nurse 57 86.4 65 98.5 0.015 
TB incidence Low incidence 49 87.5 56 100 0.006 
 Medium incidence 24 72.7 32 97.0 0.010 
 High incidence 32 91.4 35 100 0.077 
Access to strain typing datab Total 90 72.6 108 87.1 0.004 
Profession Health protection 26 92.9 27 96.4 0.553 
 Physician 21 70.0 23 76.7 0.559 
 Nurse 43 65.2 58 87.9 0.002 
TB incidencec Low incidence 38 67.9 47 83.9 0.047 
 Medium incidence 24 72.7 28 84.9 0.228 
 High incidence 28 80.0 33 94.3 0.074 
Access to training (health protection staff) 8 28.6 19 67.9 0.003 
Access to resources (health protection staff) 16 57.1 23 82.1 0.042 
a Have you heard of the TB-STS (apart from in this survey)? (Yes / No); b Do you have access to strain typing 
data? (Yes / No); c HPU-defined area where respondents worked is defined as low, medium and high TB 
incidence defined as <10/100,000, 10-19/100,000, ≥20/100,000 population, respectively; d Chi2 test of 
significance comparing responses from the initial and follow-up surveys 
 
Figure 32 – Knowledge: Self-reported knowledge of strain typing 
Sel
f-reported knowledge about how to use strain typing was scored on a scale of 1 to 5, where 1 represented ‘no 
knowledge’ and 5 represented ‘excellent knowledge’. Dark bars represent responses to the initial survey and light 
bars represent responses to the follow-up survey. 
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There were significant increases in access to all resources listed: the Handbook, 
training workshop, colleagues, and webcast/online training (Table 11). The 
Handbook, written to guide health protection staff (see page 92), was accessed by 
75% of health protection staff, and as one would expect given its target audience, by 
fewer physicians and nurses (7% and 17%, respectively). Similarly, the training 
workshop was attended by 39% of health protection staff, but fewer clinical staff. 
The most widely used resource was speaking to colleagues, which was reported by 
over half of all respondents, and increased significantly between the two surveys in 
health protection staff and nurses. The webcast/online training session was the least 
used resource, with fewer than 10% having taken part in one. The ‘other’ responses 
remained broadly the same across the surveys and included speaking to 
microbiologists (initial n=6, follow-up n=2), speaking to colleagues from PHE (n=1, 
n=3), referring to CDC guidance (n=1, n=1), searching the literature (n=1, n=1), and 
attending a presentation (n=0, n=1). 
Table 11 – Knowledge: Access to resources 
  
Initial survey Follow-up survey 
 
  
n % n % p-valuea 
Handbook 10 8.1 34 27.4 p<0.0001 
 
Health protection 10 35.7 21 75.0 0.003 
 
Physician 0 0.0 2 6.7 0.150 
 
Nurse 0 0.0 11 16.7 0.001 
Training workshop 3 2.4 19 15.3 p<0.0001 
 
Health protection 3 10.7 11 39.3 0.014 
 
Physician 0 0.0 1 3.3 0.313 
 
Nurse 0 0.0 7 10.6 0.007 
Colleagues 43 34.7 66 53.2 0.003 
 
Health protection 12 42.9 21 75.0 0.014 
 
Physician 15 50.0 18 60.0 0.436 
 
Nurse 16 24.2 27 40.9 0.041 
Webcast/online training 0 0.0 11 8.9 0.001 
 
Health protection 0 0.0 5 17.9 0.019 
 
Physician 0 0.0 3 10.0 0.076 
 
Nurse 0 0.0 3 4.5 0.080 
Otherb 
 
10 8.1 8 6.5 
 a Chi2 test for significance comparing responses from the initial and follow-up surveys  
b‘Other’ included speaking to microbiologists (initial n=6, follow-up n=2), speaking to colleagues from the 
Health Protection Agency (n=1, n=3), referring to CDC guidance (n=1, n=1), searching the literature (n=1, n=1), 
attending a presentation (n=0, n=1), and don’t know (n=1, n=0). 
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5.1.2 Perceived usefulness 
Respondents’ opinion of the usefulness of TB strain typing was high amongst all 
respondents and did not change significantly between the surveys (95.7% to 94.7%, 
p=0.667; Table 12). A greater proportion of respondents from low TB incidence 
areas found strain typing useful at the follow-up survey, compared to those working 
in high TB incidence areas (97% compared to 89%, respectively), though this result 
was not statistically significant at the 0.05 level (OR=0.13, 95% CI 0.01-1.13, 
p=0.075). 
Table 12 – Perceived usefulness: Number and proportion of respondents that reported strain 
typing to be useful
a
  
  
Initial survey Follow-up survey 
 
  
Useful Not useful Useful Not useful 
 
  
n %  n % n %  n % pb 
Total respondents that reported 
using strain typing 66 95.7 3 4.3 89 94.7 5 5.3 0.667 
Profession Health protection 22 95.7 1 4.3 24 96.0 1 4.0  
 
Physician 16 100 0 0.0 20 95.2 1 4.8  
 
Nurse 28 93.3 2 6.7 45 93.8 3 6.3  
TB incidence Low 31 100 0 0.0 38 97.4 1 2.6  
 
Medium  16 94.1 1 5.9 26 96.3 1 3.7  
 
High  19 90.5 2 9.5 25 89.3 3 10.7  
a The following question was asked to respondents who reported that they used strain typing data for TB control 
(figure 3): Do you find the strain typing information useful? (Very useful / Quite useful / Not very useful / 
Useless) ‘Very useful’ and ‘Quite useful’ are grouped into ‘useful’, and ‘Not very useful’ is presented as ‘Not 
useful’. No one reported finding the strain typing ‘useless’ in either survey. 
b Chi2 test for significance comparing responses from the initial and follow-up surveys, missing items were 
excluded.  
  
5.1.3 Practices 
Nurses and physicians in the follow-up survey reported a mean/median of 7 (range = 
2-12) weeks from sample collection to the return of the strain typing result from the 
laboratory (Table 13). Twenty-four per cent of health protection staff (6/24; 
missing=3) reported receiving the strain typing data before they completed contact 
tracing. 
There was a significant increase in the number of respondents that reported using 
strain typing between the initial and follow-up surveys (Figure 33). At the follow-up 
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survey, the most common way health protection staff accessed strain typing was 
through CIs and clinic staff through HPU reports (Table 14). There was an increase 
in the number of respondents who reported using strain typing to: identify links 
between cases (65.3% to 78.2%, p=0.02; the most common use); disprove links 
between cases (46.8% to 58.9%, p=0.06); and justify stopping contact tracing (20.2% 
to 30.6%, p=0.06) (the latter two were not significant at the 0.05 level; Table 15).  
Figure 33 – Practices: Respondents that use strain typing for TB controla 
 
Dark bars represent responses to the initial survey and light bars represent responses to the follow-up survey. 
 P-values from Chi2 tests for significance comparing initial and follow-up proportions are shown. 
a How often do you use strain typing data in your case management of outbreak investigation? Never / For few 
cases / For about half of cases / For many cases / For every case. ‘For few cases’, ‘for about half of cases’, ‘for 
many cases’ and ‘for every case’ were grouped to show the proportion of respondents that use strain typing.  
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Table 13 – Practices: The average number of weeks it takes for the strain typing result to be 
returned from the laboratory, as estimated by nurses and physicians at follow-up
a
  
 
Responses to the 
questionb Mean (SD) Median (IQR) Range 
Nurse 21 7.2 (2.2) 7 (6-8) 4-12 
Physician 14 5.7 (2.5) 6.5 (4-8) 2-10 
Total 35 6.6 (2.4) 7 (4-8) 2-12 
a Nurses and physicians who do not have access to strain typing data excluded from this analysis 
Missing items, nurses (n=15) physicians (n=5); b 25 responses were not quantified: “many weeks” (n=1 nurse), 
“variable”  (n=3 – 1 physician, 2 nurses), “don’t routinely receive” (n=7 – 1 physician, 6 nurses), “have never 
received” (n=1 nurse), “don’t know” (n=13 – 11 nurses, 2 physicians). 
 
Table 14 – Practices: How strain typing data are accessed 
  
Initial survey Follow-up survey 
 
  
n % n % pa 
Request for specific cases 43 34.7 34 27.4 0.217 
 
Health protection 16 57.1 13 46.4  
 
Physician 14 46.7 12 40.0  
 
Nurse 13 19.7 9 13.6  
Receive automatically 23 18.5 30 24.2 0.278 
 
Health protection 8 28.6 9 32.1  
 
Physician 7 23.3 7 23.3  
 
Nurse 8 12.1 14 21.2  
Contact labs directly 32 25.8 26 21.0 0.368 
 
Health protection 10 35.7 8 28.6  
 
Physician 7 23.3 12 40.0  
 
Nurse 15 22.7 6 9.1  
Cluster report from lab 30 24.2 31 25.0 0.883 
 
Health protection 12 42.7 15 53.6  
 
Physician 5 16.7 5 16.7  
 
Nurse 13 19.7 11 16.7  
Report from HPU 43 34.7 51 41.1 0.295 
 
Health protection 8 28.6 9 32.1  
 
Physician 6 20.0 10 33.3  
 
Nurse 29 43.9 32 48.5  
TB notification system 17 13.7 14 11.3 0.565 
 
Health protection 5 17.9 7 25.0  
 
Physician 0 0.0 0 0.0  
 
Nurse 12 18.2 7 10.6  
Cluster investigatorb 0 0.0 51 41.1 . 
 
Health protection . . 18 64.3  
 
Physician . . 8 26.7  
 
Nurse . . 25 37.9  
a Chi2 test for significance comparing proportions between the initial and follow-up survey 
b The cluster investigators did not start their roles until January 2011, after the initial survey, so this possible 
answer was only included in the follow-up survey 
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Table 15 – Practice: How strain typing data are useda 
  
Profession Initial survey Follow-up survey 
 
   
n % n % p 
Identify clusters and links between cases 81 65.3 97 78.2 0.024 
  
Health protection 22 78.6 25 89.3  
  
Physician 18 60.0 21 70.0  
  
Nurse 41 62.1 51 77.3  
Disprove clusters and links between cases 58 46.8 73 58.9 0.056 
  
Health protection 21 75.0 24 85.7  
  
Physician 13 43.3 15 50.0  
  
Nurse 24 36.4 34 51.5  
Justify extended contact tracing 51 41.1 60 48.4 0.250 
  
Health protection 16 57.1 19 67.9  
  
Physician 11 36.7 10 33.3  
  
Nurse 24 36.4 31 47.0  
Justify stopping contact tracing 25 20.2 38 30.6 0.058 
  
Health protection 13 46.4 13 46.4  
  
Physician 3 10.0 5 16.7  
  
Nurse 9 13.6 20 30.3  
To provide more information 34 27.4 44 35.5 0.171 
  
Health protection 13 46.4 10 35.7  
  
Physician 5 16.7 6 20.0  
  
Nurse 16 24.2 28 42.4  
a What do you use strain typing for? (multiple selections possible) (Don’t know / Identify clusters and links 
between cases / Disprove clusters and links between cases / Justify extended contact tracing / Justify stopping 
contact tracing / To provide more information / Other (please specify)) 
 
Table 16 shows workload reported by nurses and health protection staff. For the 
nurses, no significant changes in contact tracing workload were reported. Health 
protection staff reported a significant increase in the mean number of 
epidemiologically-initiated investigations over a three month period (mean 0.5 to 2.8, 
p=0.04) and the mean number of these investigations for which strain typing was 
used to provide more information (0.6 to 1.8, p=0.03), but there was no change in the 
number that were influenced by the strain typing (1.2 to 0.4, p=0.17).  There was no 
reported difference in the number of clusters investigated because of strain type 
(though in high incidence areas a large, but non-significant, decrease was reported) 
and the number of strain typing investigations that identified epidemiological links 
between cases remained low (Table 16). Overall, the proportion of time health 
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protection staff spent on cluster investigations increased significantly (from 2.7% to 
7.2%, p=0.04). 
There was no reported change over time in the frequency at which physicians were 
called to incident meetings (a meeting, often multi-disciplinary, held to discuss a TB 
patient, group or cluster of cases that are of particular concern) (p=0.503; most 
reported once every three months or less (65.5% at in the initial survey and 67.9% at 
follow-up) and there was no change in the number of physicians who reported strain 
typing as being relevant to an incident meeting (57.8% to 55.6%, p=0.875) 
Table 16 – Practices: The workload associated with the TB-STS for nurses and health 
protection staff 
  Surveya nb median (IQR) mean (SD) p-valuec 
Nurses        
No. contacts screened in the last 
month 
I 57 21 (11-36) 37.1 (53.5) 
 
F 55 20 (8-40) 33.9 (45.1) 0.37 
No. hours spent on contact 
tracing in the last month 
I 55 8 (4-16) 12.0 (10.8) 
 
F 52 7.5 (3.5-15.5) 16.1 (41.7) 0.24 
% time spent on contact tracing 
I 57 20 (10-30) 24.2 (16.5) 
 
F 54 20 (10-25) 21.7 (17.6) 0.22 
Health protection staff        
Investigations initiated because 
of epidemiological links 
I 23 0 (0-1) 0.5 (0.8) 
 
F 21 1 (0-2) 2.8 (6.1) 0.04 
Strain typing used to provide 
more information in 
epidemiological investigation 
I 22 0 (0-1) 0.6 (1) 
 
F 22 1 (0-2) 1.8 (2.5) 0.03 
Strain typing influences an 
epidemiological investigation 
I 23 0 (0-1) 0.8 (1.1) 
 
F 14 0.5 (0-2) 1.2 (1.6) 0.17 
Investigation initiated because of 
strain typing 
I 23 0 (0-2) 2.2 (6.3) 
 
F 22 0 (0-1) 1.1 (2.3) 0.79 
Epidemiological links identified 
in strain typing cluster 
I 22 0 (0-0) 0.4 (0.8) 
 
F 20 0 (0-0) 0.4 (0.8) 0.52 
% time spent on investigations 
I 23 1 (0-5) 2.7 (3.2) 
 
F 25 5 (0-5) 7.2 (11.1) 0.04 
a Initial (I) and follow-up (F) surveys 
b n is numbers of people who answered the question 
c Paired sample t-test comparing initial and follow-up responses 
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5.2 User experience: Results of the semi-structured interviews 
Free-text comments from the follow-up survey showed that whilst the survey was 
useful in assessing the implementation of the TB-STS, it did not give much insight 
into user experiences of the TB-STS. Semi-structured interviews were carried out 
with the main TB strain typing contact at each HPU. The aim of the interviews was 
to explore the different processes that are employed around the country to process, 
disseminate and act upon strain typing information. The methods for these interviews 
can be found on page 66. 
All 26 HPUs were approached for this study and all of them accepted the interview 
request (two of which were used to pilot the interviews). Five were high TB 
incidence HPUs, seven were medium incidence and the remaining 14 were low 
incidence HPUs.  
The macro themes that were drawn out of the interviews were: 
 The decision-making and information gathering processes involved in the 
TB-STS (process);  
 The value of the TB-STS (value);  
 Examples of how the TB-STS had been used (examples);  
 Issues relating to the TB-STS; and 
 Suggestions for how the TB-STS could be better implemented or used 
(suggestions).  
Figure 34 shows the breakdown of the interviews into themes and sub-themes. These 
themes are now presented in turn. 
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Figure 34 – The themes and sub-themes identified in the semi-structured interviews with health 
protection staff 
 
5.2.1 Variation in the decision-making and information gathering processes 
across HPUs 
The sub-themes of the processes in the TB-STS that emerged from the interviews are 
summarised in Figure 35.  
Figure 35 – Sub-themes of ‘Processes’ 
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Decision-making processes 
The interviews identified variation between the HPUs in the way the strain typing 
information is reviewed and stored, and the gathering of information that constitutes 
a cluster investigation.  
In some areas, the strain typing information was reviewed thoroughly before 
decisions were made about cluster investigations. This process involved the CCDC 
lead, the Handbook, advice from colleagues (often including a TB nurse) and the 
advice of the cluster investigator (CI), and a handful of HPUs had monthly multi-
disciplinary meetings where they discussed clusters.  In contrast to this holistic 
approach, there were many HPUs where they relied more thoroughly on the advice 
of the CI. One HPU reported the involvement of the regional lead, who would review 
the clusters and give them guidance on the next steps. 
“Use professional judgement, Handbook and the advice of the Cluster 
Investigator and other colleagues.” (CCDC, Low TB incidence) 
“We follow the recommendation on the report.” (CCDC, Low TB incidence) 
“We rely on a monthly meeting…we look at cases and clusters and see what 
we should prioritise.” (CCDC, Low TB incidence) 
Because many HPUs followed the advice of the CIs, the thresholds for investigation 
were less relevant to them as they were not taking decisions about whether to 
investigate themselves. One respondent felt the thresholds, in terms of the number of 
cases, were appropriate but that the risk factors for early investigation were not. 
Others found that the thresholds were sometimes appropriate and sometimes 
inappropriate. Specifically, many low TB incidence areas reported investigating 
clusters under the threshold, whereas the high TB incidence areas followed the 
thresholds more closely. Similarly, some people found the Handbook a useful 
reference tool, whereas others did not use it at all as they would just follow the 
advice of the CI. 
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“I don't know if we've paid much attention to the thresholds. They haven't 
necessarily impacted on what we've done because two [cases] in certain 
circumstances might be enough to trigger some action whereas if a cluster of 
four turns to five it might not be a difference.” (CCDC, Low TB incidence) 
“We have the luxury to spend more time to have a quick look if they are 
potentially linked. We have a lower margin to look at it. We work it [the 
threshold] as appropriate in our area.” (Senior Nurse Specialist and 
Regional TB Lead, Low TB incidence) 
“Strict about thresholds and liaise with [the CI]…unless we've already 
picked up some links ourselves through incident management.” (Nurse 
Specialist, High TB incidence) 
“Actually we wait for [the CI]. I don't think we have used the guidelines as 
such.” (CCDC, Medium TB incidence) 
Some of the HPUs that were more involved in the decision-making process had also 
developed a local cluster monitoring database. In these areas, the HPUs mirrored the 
role of the cluster investigator and carried out a preliminary cluster review by linking 
the cluster information to information held locally and on the ETS. This was not a 
widespread activity and tended to be only in low TB incidence areas. 
“Even before we receive the report…we keep an eye on the VNTR and 
within the unit we create a spreadsheet…and then on an ad hoc basis we 
can look at it.” (CCDC, Low TB incidence HPU) 
“[The London laboratory] sends out monthly spreadsheets. I look to see 
what is going on in the area. If there is a new cluster I will look at it, even if 
it is less than the Handbook threshold. I investigate connections between 
people using ETS, HPZone, ask TB nurses. I organise a meeting to see if we 
need to take public health action. The cluster report is generated…and I go 
through the same process.” (Health Protection Nurse and TB Lead, Low TB 
incidence HPU) 
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Information gathering 
There were four main routes of information gathering and TB nurses were critical to 
them all:  
1. Direct contact between the HPU and patients (sometimes through TB nurses);  
2. Delegating the cluster investigation to TB nurses and asking them to liaise 
between themselves; 
3. Through multidisciplinary cluster meetings; and 
4. By changing contact tracing practices.  
The most significant of these was the changing contact tracing practices so that the 
information that may eventually be required for a cluster investigation was collected 
when the patient was first diagnosed. Not many HPUs have attempted this change, 
but many see the value in gathering the information at the earliest possible moment. 
This change in practice came about in response to nurses being asked to complete 
cluster questionnaires after their patients had finished treatment, making it difficult to 
contact them and/or the contact being traumatic for the patient. 
“Some of the TB nurse teams have already incorporated the content of the 
questionnaire into their normal screening process.” (CCDC and Regional TB 
Lead, Medium TB incidence) 
The HPUs that took decisions at monthly meetings would gather some of the 
information at the meeting because the TB nurses, physicians, microbiologist and 
HPU are all present to fill in any information gaps.  
“I circulate it to all my TB nurses so they all have a copy and I forward on to 
others as necessary. I ask them for feedback if there is anything pertinent to 
tell me, otherwise every other month we go through each report cluster by 
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cluster and if there is anything significant we will report it back.” (CCDC, 
Medium TB incidence) 
Where monthly meetings did not take place, communication with the TB nurses 
appeared to be either active or passive. Some HPUs spoke with nurses directly on the 
phone or arranged to go and see them to gather the information, whereas others “just 
pass it on to the TB nurses…and ask the TB nurse to liaise with the other areas”. 
There was a distinction between the willingness of HPUs and nurses to collect the 
information based on whether the TB patient was still on the books or whether they 
had finished their treatment and had been discharged. A strategy adopted by one 
HPU was to “email the nurse if the case if from a while ago and ask them to look at 
their notes to see if anything relevant sticks out…if the case is current I’ll ring 
straight up”.   
“We have done quite a bit of work getting a standardised form for TB nurses 
to use so that they are collecting person, place and time information up 
front. They've adapted the questionnaire but I cannot give you assurance 
that it is being implemented properly. In my area the service doesn't see it 
as a priority. If the patients are still on the books and we think there is a 
cluster growing we'll ask them for details”. (CCDC, Low TB incidence) 
The cluster questionnaire (used as a template to gather more information as part of a 
cluster investigation) was used in some areas and not others. It was deemed useful 
because it provided a framework for gathering more information and some areas had 
developed their own local questionnaire based on the cluster questionnaire provided. 
However, some people talked about the questionnaires being “sent out of the blue”, 
without any further communication or explanation so some nurses “didn’t know what 
to do with them”.   
5.2.2 The value of the TB-STS  
The sub-themes of the value of the TB-STS that emerged from the interviews are 
shown in Figure 36. 
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Figure 36 – Sub-themes of ‘Value’ 
 
The value of the cluster report and cluster investigator 
The cluster reports were valued by some HPUs because they lightened their 
workload by providing them with the summary information that they needed to know 
and recommending actions for certain clusters. This means that the HPUs did not 
have to look too closely at the strain typing reports themselves or monitor the strain 
typing locally. This was valued by HPUs, especially in low TB incidence areas 
where TB was not a high priority. 
“[Cluster reports] recommended local cluster investigations which is very 
helpful because when you’re faced with growing numbers of cases and 
clusters it is useful to know where to focus your attention.” (CCDC, Low TB 
incidence) 
“[The CI] sends cluster reports…saves us the effort of going through the 
[local] database.” (CCDC, Medium TB incidence) 
The additional information held on the cluster reports can lead to more targeted 
investigations by the HPU. It was reported particularly helpful in situations where it 
was difficult to get information from patients as it provided nurses with specific lines 
of inquiry, rather than more general questioning that elicits an equally vague 
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response. On the other hand, one HPU argued that the information stored on the ETS 
was not detailed enough to make a recommendation about whether the cluster should 
be investigated, and that the decisions about clusters should be led locally where the 
local intelligence is held. 
“We found it very useful because I didn't know the other cases associated 
with [the cluster]…so when we get these additional pieces of information it 
helps the TB nurses go back and ask specific questions - especially where 
there are language barriers and problems engaging with the patients.” 
(CCDC, Low TB incidence) 
“Sometimes the summary is useful as we are armed with a few extra 
questions or directions.” (CCDC, High TB incidence) 
Some HPUs were already aware of the cases in a cluster and their epidemiological 
links so the reports did not add any additional information and, therefore, did not 
lead to any public health action. For some it was seen as reassuring when the strain 
typing information confirmed what they already knew, whereas others felt that the 
cluster reports were not valuable. This may be explained by the timeliness that cases 
appear in cluster reports. 
One of the main criticisms of the cluster reports was that they were not timely. Many 
HPUs found that by the time the cluster report arrived they had already completed 
their local investigation and contact screening activities, leaving no opportunity for 
the cluster information to influence public health activity. As a result the cluster 
report did not add anything to local TB control. In fact, some HPUs said that they 
referred to the laboratories directly for individual strain typing information where 
they suspected transmission because it was much quicker than waiting for the cluster 
reports. 
“We do more action even before we receive the cluster report. It’s not too 
late, but definitely not timely to take public health action. We could do with 
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a bit more real-time reporting…then we could do away with our local 
register.” (CCDC, Low TB incidence) 
“By the time we get the report we already know about it and have carried 
out actions. It’s always too late… [the service] is not generating new 
information apart from the typing.” (Senior Health Protection Specialist, 
Medium TB incidence) 
“If we have a feeling about cases then that would be very much in real time 
so you’d then request it and it would be on diagnosis, rather than a year or 
two down the line. We would do that anyway. We quite often request the 
VNTR for a patient and wouldn’t necessarily check the cluster information 
because it is easier and quicker to ask for the VNTR [from the 
laboratories].” (Nurse Specialist, High TB incidence) 
Another criticism of the cluster reports was that they often contained erroneous 
information or cases that were not from that HPU. This created additional, often 
unnecessary, work for the HPU and the TB nurses which wasted time, caused 
confusion, and people lost their confidence in the data. This problem was mainly 
associated with clusters that were both local and national as the information sharing 
systems between the local and national clusters was not very robust. 
“It is a muddle when it is a national cluster - sometimes we are asked about 
patients that aren't even in our area. That has happened a couple of times. 
Not sure how robust the system is that someone in another part of the 
country will be identified as part of a cluster - don't feel very confident about 
that.” (Lead Practitioner Health Protection Nurse, Low TB incidence) 
In general, however, HPUs enjoyed being able to see how the TB in their area fits 
into the wider picture and appreciate learning about regional and national clusters. 
The cluster investigators provided an important advisory role to the HPUs who 
struggled with the increasing workload and helped them to prioritise the clusters 
where an investigation may have led to public health action. 
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“I value the opinions and guidance and expertise and knowledge about - 
they know what is going on and what people are doing in other areas. It is 
useful to have their advice…draw from other experiences.” (Health 
Protection Nurse and TB Lead, Low TB incidence) 
How the strain typing is used 
Strain typing was mainly used to confirm or refute suspected transmission. Where 
suspected transmission was confirmed with strain typing it could be used to justify 
the time and resources then spent on managing complex TB cases, as well as 
justifying the actions taken. The ability to rule out suspected transmission changed 
the way that some HPUs managed their incidents, and the strain typing had become 
part of their decision-making process. However, where transmission was suspected 
in a particularly high risk setting, HPUs would request the strain typing directly from 
the laboratory so that transmission could be confirmed or ruled out quickly. In these 
circumstances the role of the cluster reports was diminished. 
“Useful both in highlighting potentially linked cases we may not have 
thought of and disproving cases that might have been linked. There is a 
definite value in that.” (Senior Nurse Specialist and Regional TB Lead, Low 
TB incidence) 
“Most of the benefits from strain typing has been where we started off 
before all of this - to confirm or refute epidemiological links.” (CCDC, 
Medium TB incidence) 
Only a few HPUs reported using strain typing to identify potential new links between 
cases. This was the more conventional activity around a cluster investigation, 
requiring more time and resources and often resulted in a lot of effort but no newly 
identified links.  
“There is implications for it because it tells us to throw the net wider or to 
stop. Sometimes it makes the work more, and no real outcome, but it does 
help – another reassurance mechanism. Gives us a justification for what 
we're doing.” (CCDC, High TB incidence) 
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The strain typing was reported to be particularly useful for on-going outbreaks as it 
helped to define a case in an outbreak (where the case is culture positive) so one 
could learn early on about new cases and this could influence the contact tracing 
strategy and allow for targeted contact tracing as early as possible.  Where cases 
were reluctant to disclose their contacts, strain typing could help to identify 
relationships with other cases and helped the nurses tailor their interviews with 
patients. 
Some HPUs found the strain typing useful for monitoring and evaluation. Where 
additional cases were identified with the same strain type and they were linked 
epidemiologically to another case in the cluster it suggested that the contact tracing 
was not as thorough as it should have been, or where no more cases were added to 
the strain typing cluster one could be certain that the contact tracing was carried out 
well. One HPU has even used the strain typing to argue for more resources for TB so 
that contact tracing could be carried out more thoroughly. 
Added value 
The ability to see the bigger picture of TB was identified as an added value of the 
TB-STS. HPUs were focussed on their own geographical area and the strain typing 
provided information about how they fit into the national context.  However, 
according to the HPU staff interviewed from areas of low, medium and high TB 
incidence, in terms of public health output the TB-STS had not yet delivered. Many 
people, especially in high TB incidence areas, felt that the TB-STS generated more 
work that led to little benefit.  
“Hasn't added benefits so far, but hasn't highlighted anything we weren't 
already dealing with...Very happy to receive the strain typing - wouldn’t 
want to not receive it.” (CCDC, Medium TB incidence) 
“My gut feeling is that they are perhaps not the most efficient use of scarce 
resources. I haven't seen anything arising out of these investigations that's 
actually made a difference in terms of public health management, and yet 
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there is a lot of traffic of questionnaires being distributed from Colindale to 
TB nurses.” (CCDC, Medium TB incidence) 
“Haven't done anything so far that has led to us being able to target wider 
screening or to feel like we’ve taken a public health action that wouldn't 
already have been taken. We haven't delivered anything on the back of it.” 
(CCDC, High TB incidence) 
The TB-STS added value in other more general ways that strengthened the TB 
service as a whole. It helped to engage TB nurses with the public health aspects of 
TB and developed their relationship with HPUs. On the other hand, the increased 
demand placed on TB nurses to gather additional information and complete more 
forms put pressure on this relationship in some areas. This pressure, however, 
resulted in TB nurses in some areas collecting the data in the cluster questionnaires 
prospectively for each case, rather than retrospectively and this was recognised as a 
main benefit of the service so far. 
“It's a good thing. It's been helpful for us. It's a good way of getting people 
more interested in more work around TB. Doing cluster investigations has 
been a good way also of building up relations with the nurses. They now 
ring us to ask about strain typing. It has improved dialogue.” (CCDC and 
Regional TB Lead, Medium TB incidence) 
Many HPUs saw the potential future value of the TB-STS and acknowledged that the 
service was still new and that, as more data are collected and analysed, more could 
be learned from it.  
Despite the lack of outcomes and drain on resources, people felt that it would be 
regressive to stop strain typing. 
“From a clinical viewpoint the effects are marginal. Would I keep the cluster 
work that's being done? Yes, I probably would. Would I fund it out of my 
budget? Probably not.” (CCDC, Medium TB incidence) 
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“The general strain typing is like a fishing expedition.” (CCDC, Low TB 
incidence) 
5.2.3 Examples of cluster investigations 
Respondents from the HPUs provided examples of many types of cluster 
investigations: where no new epidemiological links were found, where strain typing 
confirmed or refuted suspected transmission and where strain typing identified new 
cases and new links between cases or new settings for transmission and where public 
health actions were required (Table 17). 
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Table 17 – Examples of cluster investigations and the influence of strain typing 
Use of strain typing Example 
No public health outcome 
Low incidence “Last week a hospital microbiologist rang and said there were two cases of TB with the same VNTR number. Two Philippinos…Do they know each other from another setting? You dig for 
more information and find out they are absolutely unconnected to each other. Someone should tell us that it is the predominant strain in the Philippines. Later I find out that one in five people in 
the Philippines have the same VNTR. If I know that this is a common strain then it will help us to say there is no point in throwing in more resources to investigate further. Otherwise we'll be 
doing more and more and we'll end up doing nothing!” 
Medium incidence “We had a cluster about a year ago of 8 patients in predominantly white UK born with socially complex or chaotic lifestyles. That's as specific as we got I terms of epidemiological links and we 
couldn't establish, despite all the work, teleconferences, etc....most of these people are chaotic and that's it!” 
High incidence “Regional cluster going on now. Some of the cases were recently discussed at the cohort review so have had local discussion and identified some links between the cases in SW London. No 
questionnaires were returned. Why? Cases were from one or two years ago - clinics probably ignore they are not currently seeing the person and night hot have time to pull out notes. Once 
you've gone back beyond a year it is hard to ask people to do it.” 
Prove/refute suspected transmission 
Low incidence “Case of TB in a homeless person who was squatting in a garage. Then another case of someone who squatted in the same garage within six months, but they had totally different strains. We 
were about to chase lots of homeless people around!” 
Medium incidence “One particular family in the last 6 years they've had 11 cases of TB, 7 or which were culture confirmed. I didn't know about them because they had different surnames and different addresses 
and didn't have the same strain type. The TB nurse asked me about them and she was worried that they weren't managing the cases properly. But the different strain types showed that there was 
no transmission they could have interrupted.” 
High incidence “There were a few cases in prison. Once we started talking to the case they said they knew where they got it from, but we checked the typing and it was different. We heard of another prison in 
the country who were doing screening and found that they [our case and their case] had links...all had different VNTRs.” 
New link / case / setting / identified outbreak / public health action 
Low incidence “We've just had a second case with strain typing in a factory that we screened two years ago because there was a guy who was very infectious and was undetected for six months. We did 
intensive screening and didn't find anyone else [at the time]. Now we have someone with the same strain type so obviously there was transmission [in the factory] so we'll get the TB service to 
interview a bit more and raise awareness and keep an eye on the place. That's useful. We couldn't get that information from contact screening at the time.” 
Medium incidence “We had a cluster in the Polish homeless people. There were 13 contacts and three of them were cases within six months and a fourth is in hospital. With each case we identify the contacts and 
try to get in touch with all of them. But the second case comes up and it wasn’t identified in the initial contact tracing. [The strain typing] tells us are we finding it out all the contacts.” 
High incidence “Put quite a bit of work into a national cluster – alcoholics. Had incident meetings, went carefully through the questionnaires: was there a common context where we could focus some action? 
We couldn't identify one thing that was shared between them, but there were individual links between some cases. In common was unemployed and alcohol. We did take public health 
interventions by writing to all GPs in [the area] to make them aware of the cluster, raising awareness with local GPs about the on-going outbreak in that group…and alcohol awareness stuff, 
awareness raising too. They were general initiatives based on what we knew about the cluster.” 
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5.2.4 Issues 
HPUs identified many issues and problems with the TB-STS. The sub-themes of the 
issues raised during the interviews were: 
 Communication 
 Process 
 Regional and national clusters (compared to local clusters) 
 Resources 
The time between the date the case was diagnosed and treated and when they 
appeared on the cluster report was identified as an issue. It was noted that you could 
be waiting up to two months before a case was included on a cluster report as the 
reports were sent out every month. This was a problem because if the information 
was not reported in real-time it could not elicit a real-time response. In addition, due 
to the time it may take for the investigation threshold to be reached, cases may be 
included in a cluster report one or two years after they had been discharged. This 
made the additional information gathering difficult. This was recognised as an 
important barrier to data collection.  
“No questionnaires were returned. Why? Cases were from one or two years 
ago - clinics probably ignore they are not currently seeing the person and 
night hot have tie to pull out notes. Once you've gone back beyond a year it 
is hard to ask people to do it. If cases are in the last 12 months then it 
should be easy to pull out notes or remember - if it's real to them, then it's 
more likely.” (CCDC, High TB incidence) 
Communication problems within the TB-STS were identified. One HPU claimed that 
“until a couple of weeks ago I did not know that there was a person who had ‘cluster 
investigator’ in their job title!” and others were struggling to fully understand their 
role and what was expected of them. People had different experiences when 
investigating usual TB incidents compared to cluster investigations.  
“The incidents that we deal with, we get to know them quite well because 
we work closely with the clinics, speak with the patients and liaise with 
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where it is situated. Whereas the clusters feel much further removed. There 
is no reason why the HPU would be involved. It feels more of an academic 
exercise in some ways.” (Nurse Specialist, High TB incidence) 
The main issue identified by all the HPUs was a lack of resources. HPUs described 
the lack of resources allocated to TB services in general and questioned whether the 
TB-STS was a good way to spend money. There was a strong awareness that the 
HPUs were not given any additional resources to investigate clusters and that TB 
nurses and physicians working in the NHS were not allocated any additional 
resources to collect the extra information. This opinion was held across low, medium 
and high TB incidence areas and some HPUs were concerned that the increasing data 
requests would put pressure on their relationships with the TB services.  
“I have some concern on the questionnaire side and the full cluster 
investigation - in the good will of our NHS partners and how much they 
contribute to that. Most of them have been quite enthusiastic because it is 
new, sexy and something to learn, but can see them becoming less wilful. 
There are mutterings about not being commissioned to do them [the 
questionnaires]”. (Senior Nurse Specialist and Regional TB Lead, Low TB 
incidence) 
Some questions and queries were raised by the HPUs. There were many questions 
surrounding the interpretation of strain typing. People weren’t clear on what it meant 
if someone in their HPU was clustered with someone from a different geographical 
area, how missing loci should be interpreted, and when a cluster did not represent 
recent transmission but represented a strain endemic to a certain population. There 
were also questions about the cluster investigation activities, such as how many times 
patients should be approached for information and how often you should contact 
them if you have new information, how the results of a cluster investigation will 
affect case management, how to investigate without breaking patient confidentiality, 
how to find links, what should lead to public health action and how to get feedback 
on national clusters. 
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5.2.5 Suggestions 
The categories of suggestions that were discussed in the interviews were:  
 Efficiency and best use of data 
 Feedback, communication and learning 
 WGS 
Efficiency and best use of the data 
HPUs suggested that reducing the number of clusters requiring additional work 
would help to improve people’s experience of the service. They suggested that 
automating the systems and raising the thresholds would help by allowing people to 
focus on the important clusters, rather than all clusters that appear in their area. In 
addition, some HPUs suggested that a dedicated team to investigate strain typing 
clusters could lead to better public health outcomes. One HPU suggested that local 
engagement could be improved by focussing on the local benefits to clinical and 
public health services.  
“I think the cluster typing has to inform and strengthen the clinical services 
because then once supporting the delivery of the clinical and public health 
programme locally, informing it, you get people engaged, understanding 
clusters, using them, it becomes one of the daily activities. Real time, as 
they're developing and using the information directly with services then it 
becomes relevant to them, rather than just flood people with masses of 
retrospective clusters and risk factors and patient risk factors.” (CCDC, 
Medium TB incidence) 
There was a call for more epidemiological support. Many HPUs had developed a 
local database of strain types but did not have the skills to analyse it and extract 
useful information from the data. 
Feedback, learning and communication 
There was a strong sense that communication, feedback and the ability of the TB-
STS to learn from its outputs was not adequate. Concerning communication, HPUs 
felt there needed to be better data sharing between the local cluster investigators and 
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the national cluster team as it slowed the service down when they only had access to 
part of the cluster information. Some HPUs also felt that it wasn’t clear what they are 
expected to do with the strain typing information. 
Whole genome sequencing (WGS) 
WGS was suggested as a method that would split MIRU-VNTR clusters up, thereby 
reducing the number of clusters that would require investigation. Concerns, however, 
were raised that the MIRU-VNTR TB-STS should be properly implemented and 
integrated into the TB service before introducing a new system. 
“It is important to get our head around how we integrate epidemiological 
and genomic data. For most people on the front line most people are not at 
that point and if we miss this opportunity most people will struggle with 
whole genome sequencing. I certainly think that it potentially has value but 
I'm not sure we've done it [the MIRU-VNTR strain typing service] justice.” 
(CCDC, Medium TB incidence) 
5.3 Discussion of the Processes in the TB-STS 
5.3.1 Strengths and limitations of the methods to evaluate the Processes 
An initial and follow-up cross-sectional survey was chosen because it is a study 
design that could be feasibly conducted, at low cost, in the time-frame available. 
Furthermore, electronic surveys were easily disseminated as everybody in the target 
group had PHE or NHS email addresses. Additionally, as no information was 
available prior to the first survey it was a particularly appealing method to capture 
data about the initial phase of the TB-STS; it was possible to design, pilot and 
disseminate the survey quickly. It was also easy to repeat the survey at the second 
time point to assess any changes that may have taken place between two periods. 
However, the study has a number of limitations, which are discussed below.   
Firstly, the survey was developed after the initiation of the TB-STS so baseline 
information could not be collected.  As a result, we may have underestimated the 
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difference between the surveys. However, the initial survey was conducted before the 
roll-out of any training for the TB-STS and prior to the employment of all national 
staff to coordinate cluster investigations and therefore it seems unlikely that there 
would have been any major changes prior to the first survey. 
Secondly, the target population for the survey consisted of all public health staff, 
physicians and nurses working in TB control in England. It was not possible to 
enumerate the sampling frame because no register of clinical and health protection 
staff working in TB could be identified making it impossible to calculate a response 
rate and any associated potential biases. Response bias may have occurred if only 
those with a vested interest in the TB-STS (either positive or negative) responded to 
the survey; however, given that there was neither overwhelming support nor 
objection to the TB-STS, this is unlikely to have occurred or these responses may 
have cancelled each other out. In addition, the survey may have over-represented 
those with a smaller workload (as people with a greater workload may not have had 
time to respond to the survey); there were more responses from low TB incidence 
areas (45%, 27% and 28% from low, medium and high TB incidence areas) but this 
reflects the distribution of TB across England.    
Thirdly, the 50% retention rate between the surveys is quite low which could bias the 
results if there was a systematic difference between responders and non-responders.  
It is possible that the opinions and experiences of a particular group of people were 
omitted. However, the validity of our results is supported by the fact that non-
responders to the follow-up survey did not differ significantly compared to those that 
responded to both surveys based on profession or burden of TB in their geographical 
area.  
Finally, the survey was not powered to look for differences between professions or 
geographical areas and when testing multiple hypotheses one might find a significant 
result due to chance. Therefore, it is especially important to consider the findings of 
the surveys in the wider context of the evaluation and the other methods used, and 
interpret them accordingly. 
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Interviews were used to explore the TB-STS user experience. This was appropriate 
given that the findings were used in a health services research context to supplement 
the quantitative work conducted around the implementation and perception of the 
TB-STS. They provide useful insights into the use and perceptions of the TB-STS 
from the perspective of the main service user (health protection staff). This was 
useful for understanding the broader findings of the evaluation. Semi-structured 
interviews were chosen as the method of data collection because they provided an 
opportunity for more in-depth information on issues identified through describing the 
service and the initial and follow-up survey, to be gathered and further explored. 
Data from these interviews also inform the interpretation of the thesis findings (see 
discussion, page 191).  
All the people who were approached by the interviewer accepted to participate; the 
interviews were representative of all HPUs. Interviews potentially result in a number 
of biases associated with the interviewee, in this case the strain typing leads in the 
HPUs and their perception of the interviewer. The strain typing leads had very 
different roles depending on the burden of TB in their HPU which may have 
influenced the way they approached the interview: for some, strain typing was a 
large part of their job so they may have been keen to highlight its importance and 
utility to justify their role; for others, strain typing was a small part of their overall 
job so they may have understated its usefulness in order to justify not using it, 
creating more time for other parts of their job.  
The role of the interviewer may also be important. The interviewer presented herself 
as an external evaluation scientist, who had no conflict of interest. However, people 
may have assumed that the interviewer worked for PHE. This may have led to a 
social desirability bias whereby the interviewees say what they think the interviewer 
wants to hear – if the interviewer was perceived to be from PHE, this could have led 
to exaggerated support for the TB-STS. Finally, the interviews were all conducted 
over the telephone, increasing the distance between the interviewer and interviewees, 
and excluding non-verbal cues. Not being able to see who was conducting the 
interview may have helped interviewees to speak openly, or it could have made them 
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feel more guarded as there was less opportunity to build a rapport. Given the service 
delivery nature of the interviews, rather than those covering personal issues, these 
biases are likely to have minimal impact.  
5.3.2 How this relates to other work 
National TB strain typing services have been introduced in other 
countries,
100,133,136,152
 but the knowledge, perceived usefulness and practices of users 
have not been evaluated. However, the impact of strain typing on contact tracing 
activities in the Netherlands has been assessed.
127
 Consistent with that study, no 
change was observed in the workload associated with the TB-STS for nurses and 
physicians, even though strain typing was used by more people at the follow-up 
survey (indicating the roll-out of the service). This may be because it is difficult to 
measure marginal changes in workload associated with a particular service where the 
workforce is already working at full capacity. Health protection staff, however, spent 
a greater proportion of time on cluster investigations. Given that the Handbook had 
not been published and all the cluster investigation coordinators were not in position 
at the time of the initial survey, this is not surprising and suggests that the TB-STS 
had been integrated into the TB control activities of the HPUs. It is not known what 
the opportunity cost of this was; what were health protection staff spending less time 
on in order to spend more time on cluster investigations? 
The median time it takes for the strain type to be received by TB nurses and 
physicians following a specimen collection was seven (IQR 4-8) weeks. This is 
shorter compared to that reported for the USA (8.9 (6.1-12.3) weeks from specimen 
collection to receipt at typing laboratory and 1.4 (0.6-1.3) weeks from receipt at 
laboratory to reporting the result),
216
 but is still too long for real time reporting. The 
time delay experienced in England may explain why 76% of health protection staff 
reported that the strain type is received after contact tracing has already finished.  
Based on evidence from the USA one would expect more possible transmission links 
to be identified when strain typing informs contact tracing.
88,97
 This was not detected 
in the survey despite an increase in the time health protection staff spent on cluster 
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investigations and the number of investigations that used strain typing. This 
discordance between the findings on subjective report of utility and the public health 
outcomes reported could be because the current methods used by public health staff 
to identify epidemiological links may be inappropriate or ineffective, or there may 
have been an increase in suspected (but not established) transmission because of the 
strain typing information.  
The TB-STS relies on HPUs and TB nurses to work together to implement any 
public health action in response to on-going transmission in the community. This 
raises the important issue of whether the TB service has the capacity to act upon the 
information collected through cluster investigations. For the TB-STS to have a public 
health impact and reduce TB transmission, cluster investigations would have to lead 
to the detection of previously unidentified latently infected and active TB. 
5.3.3 Summary of findings  
Initial and follow-up cross-sectional surveys of TB-STS users were conducted to 
assess the implementation of the TB-STS. There was an increase in the number of 
people that used strain typing and knowledge of the TB-STS between the two 
surveys.  A change in perceived usefulness was not evident as the majority of 
respondents found strain typing useful to them at both time points. Nurses and 
physicians waited to receive the strain typing for an average of seven weeks after 
sending the sample to the laboratory and the majority of health protection staff 
received the results after completing contact tracing. With respect to workload 
associated with the TB-STS, there was no change over time in the contact tracing 
activities of nurses or the frequency of incident meetings attended by physicians; 
however the proportion of time health protection staff spent on investigating TB 
transmission increased significantly. Despite strain typing being used to provide 
more information to public health staff at follow-up, there was no increase in 
epidemiological links identified. 
Semi-structured interviews with the strain typing leads in each HPU explore the user 
experience of the TB-STS. They found that some HPUs reviewed the strain typing 
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information thoroughly and others just followed the recommendations of the CI. 
Many low TB incidence areas reported investigating clusters under the threshold, 
whereas many high TB incidence areas followed the thresholds more closely. The 
cluster reports were liked by some HPUs because they summarised the strain typing 
information well; however, some HPUs found that the reports did not add any 
additional information and therefore did not lead to public health action. Many HPUs 
felt that, although there were many uses for the strain typing (such as confirming or 
refuting transmission), the service generated a lot of work but had not yet had a 
public health impact. Despite this, people felt that it would be regressive to stop the 
TB-STS. 
The advantages and disadvantages of the TB-STS identified by HPU strain typing 
leads are presented in Figure 37 and exemplified by the following quote:  
“Would I keep the cluster work that’s being done? Yes, I probably would. 
Would I fund it out of my budget? Probably not.” 
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Figure 37 –The pros and cons of the TB-STS 
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Chapter 6. Outputs 
In this chapter I present the results of a broad investigation into the Outputs of the 
TB-STS by presenting the laboratory Outputs, including the detection of false 
positive TB isolates, followed by the public health Outputs. The false positive TB 
isolation survey methods can be found on page 69.  
Multiple approaches were taken in an attempt to measure the public health Outputs 
of the service. Firstly, I present the available data on cluster investigations and their 
outcomes (methods on page 70). Secondly, the results of alternative investigations 
into the contact tracing yield, diagnostic delay and rate of cluster growth associated 
with cluster investigations (methods from page 73).  The laboratory Outputs and the 
indirect public health Outputs were fundamental in providing parameters for the 
transmission and cost-effectiveness models.  
__ 
6.1 Laboratory Outputs 
The laboratory Outputs of the service include the number of M. tuberculosis isolates 
typed with 24 MIRU-VNTR and the false positive TB isolates identified by the TB-
STS. Table 18 shows the number of isolates typed by the reference laboratories 
between 2010 and 2012 and the number with at least 22 loci. It shows the variation in 
workload across the laboratories. The largest proportion (n=11,069, 64.5%) of 
isolates were typed in the London laboratory, with 3,159 (18.4%) in Birmingham and 
2,940 (17.1%) in Newcastle. The total number of isolates typed between 2010 and 
2012 was 17,168. Of these, 58.7% had complete 24 loci strain types. Between 2010 
and 2012, the proportion of isolates with strain types at least 23 digits long (the 
minimum requirement suggested in the TB-STS data production guide),
214
 was 
84.6%.  
The total number and proportion of clustered cases, the number of clusters, and 
estimates of recent transmission in England between 2010 and 2012 are shown in 
Table 19.  
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Table 18 – The number and proportion of isolates typed in each of the reference laboratories  
Laboratory Year 
Total isolates 
typed 
Complete 24 loci 1 missing locus At least 23 loci 
   
n % n % n % 
London 2010 3429 1689 49.3 1036 30.2 2725 79.5 
 
2011 3921 2319 59.1 1117 28.5 3436 87.6 
 
2012 3719 2239 60.2 1098 29.5 3337 89.7 
         
Birmingham 2010 979 647 66.1 172 17.6 819 83.7 
 
2011 1092 753 69.0 190 17.4 943 86.4 
 
2012 1088 796 73.2 165 15.2 961 88.3 
         
Newcastle 2010 995 557 56.0 224 22.5 781 78.5 
 
2011 969 557 57.5 224 23.1 781 80.6 
 
2012 976 527 54.0 215 22.0 742 76.0 
       
  
Total 2010 5403 2893 53.5 1432 26.5 4325 80.0 
 
2011 5982 3629 60.7 1531 25.6 5160 86.3 
 
2012 5783 3562 61.6 1478 25.6 5040 87.2 
 
2010-2012 17168 10084 58.7 4441 25.9 14525 84.6 
Communication from laboratories January/February 2013 
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Table 19 – Number of clustered cases and clusters in England and by HPUa, 2010-2012 
Geographical area (country, region and HPU) Culture 
confirmed 
cases 
Cases with strain typeb  No. cases clusteredc No. 
clusters 
Estimated proportion of 
cases due to recent 
transmissiond 
No. clusters by size 
  n % n %   2-4 5-9 ≥10 
Englande 14248 11491 80.6 5973 52.0 1371 40 1084 198 89 
           
North of England           
North East 310 223 71.9 46 20.6 17 13 16 1 0 
Cumbria and Lancashire 347 238 68.6 79 33.2 22 24 17 4 1 
Yorkshire and Humber 1080 819 75.8 228 27.8 65 20 53 9 3 
Greater Manchester 890 639 71.8 154 24.1 47 17 41 3 3 
Cheshire and Merseyside 218 171 78.4 26 15.2 11 9 11 0 0 
Midlands and East of England           
East Midlands 747 620 83.0 197 31.8 63 22 53 9 1 
West Midlands 1706 1401 82.1 599 42.7 154 32 129 13 12 
Anglia and Essex 466 376 80.7 81 21.5 33 13 32 1 0 
South Midlands and Hertfordshire 610 486 79.7 122 25.1 41 17 37 3 1 
London 5997 4999 83.4 2286 45.7 593 34 487 69 37 
South of England           
Sussex, Surrey and Kent 613 506 82.5 138 27.3 52 17 47 5 0 
Thames Valley 516 424 82.2 87 20.5 36 12 35 1 0 
Wessex 291 241 82.8 62 25.7 21 17 20 0 1 
Devon, Cornwall and Somerset 152 122 80.3 30 24.6 8 18 7 0 1 
Avon, Gloucester and Wiltshire 305 226 74.1 55 24.3 20 15 19 1 0 
aThese geographical areas are the recently re-defined HPUs, now known as Health Protection Centres; bCulture confirmed cases with a MIRU-VNTR profile with at least 23 complete loci 
cClustered cases are clustered within geographical area; dCalculated using the n-1 method (number of cases-number of clusters/number of clustered+unique cases); eThe number of clusters in 
England is higher than the sum of all HPUs because it includes cluster that span more than one HPU 
Source: Tuberculosis in the UK: Annual Report on Tuberculosis Surveillance in the UK, 2013123
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6.1.1 The TB-STS and false positive TB isolation 
One potential benefit of the TB-STS is earlier identification of the false positive TB 
cases that can result from laboratory contamination.  In addition to the avoidance of 
anxiety for patients and their families, earlier identification of such cases has health 
and financial implications if treatment is avoided or reduced and the true diagnosis is 
missed or delayed. The false positive TB isolation survey methods are on page 69.  
Between June 2010 and June 2012 11,059 TB isolates were typed at the reference 
laboratories (Table 20). There were 70 suspected incidents of false positive TB 
isolation (0·6%), of which 30 (42·9%) were confirmed as false positive, giving a rate 
of false positive TB isolation in England of 0·3% (30/11,059). Seventeen (56·7%) of 
the suspected incidents were not known to the source laboratories, and 8 patients 
were started on unnecessary treatment (Table 20).  
These results were used as a parameter in the cost-effectiveness model (page 81).  
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Table 20 – The number of false positive incidents identified by the reference laboratories and confirmed by the source laboratories between June 2010 and June 
2012. 
 London Birmingham Newcastle Total 
 n % n % n % n % 
Total isolates typed1 7,341  2,023  1,695  11,059  
Total false positive incidents suspected 58 0.79 11 0.54 1 0.06 70 0.632 
         
Incidents confirmed as cross-contamination 26 44.8 3 27.3 1 100 30 42.93 
Incidents confirmed as true TB (i.e. not false positive) 25 43.1 4 36.4 0 0.0 29 41.43 
Information not known 7 12.1 4 36.4 0 0.0 11 15.73 
         
Incidents known about by source laboratories before contact from reference 
laboratory 
10 17.2 3 27.3 . . 13 43.34 
Number of false positive patients started on treatment 8 13.8 0 0.0 . . 8 26.74 
1 reported by each laboratory on the data collection form 
2 proportion of all isolates typed 
3 proportion of all incidents suspected 
4 proportion of confirmed cross-contamination incidents 
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6.2 Public health Outputs 
The direct public health Outputs of the TB-STS are the cluster investigations and 
their outcomes. In addition to this, indirect outcomes of the TB-STS were 
investigated: the contact tracing yield, diagnostic delay and rate of cluster growth 
(see the illustration of the aims of the TB-STS, Figure 11, page 31). Information on 
cluster investigations and their outcomes was designed to be collected, collated and 
stored using the STM. In the absence of the STM, the following data sources were 
used: a cluster monitoring database, cluster outcome reporting form, and a database 
of national clusters (see methods on page 70)  
6.2.1 Direct measures: cluster investigations and their outcomes 
The cluster monitoring database was developed in order that CIs could record the 
characteristics and activities surrounding each investigated cluster and the 
investigation outcomes. Between 2010 and 2012, 188 clusters were recorded in the 
database and 160 of these included a start date for the investigation (Table 21).  
Table 21 – The number of local, regional and national clusters by the year in which a cluster 
investigation was first launched, as reported in the cluster monitoring database  
Cluster type Year in which cluster first became active 
Total in the 
cluster database 
 2010 2011 2012a 2010-2012a 2010-2012ab 
Local 2 32 30 64 69 
Regional 0 7 6 13 15 
National 15 37 31 83 104 
Total 17 76 67 160 188 
aJan 2010-Oct 2012 
bThis column is greater than the previous column due to missing information about the date a cluster is first 
investigated 
 
Cluster size at the point at which an investigation became active ranged from two to 
12 for local clusters and two to 44 for national clusters (Figure 38). Figure 38 shows 
that the threshold of five cases for a local investigation and ten cases for a national 
investigation is often disregarded, either because the cluster contains cases with risk 
factors for transmission, and/or HPUs and national teams are choosing to investigate 
clusters earlier.  There are peaks at two cases, three cases and five cases for local 
investigations and two cases and ten cases for national investigations.  
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Figure 38 – The distribution of cluster size on the date a cluster investigation is initiated, 2010-
2011 
 
The median number of days a cluster investigation remained active (of those 
investigations that had already been closed at the time of the evaluation, n=86) was 
129 days (IQR 50 to 188). The median length of a cluster investigation was longer 
for national clusters compared to local clusters (171 (IQR 60 to 336) and 97 (43 to 
157), respectively). 
Outcomes of cluster investigations 
Cluster outcome reporting forms collected information on the outcomes of local and 
regional cluster investigations carried out by HPUs (i.e. the number of additional 
epidemiological links identified between clustered patients and the number of 
secondary cases identified as a result of the strain typing information). These forms 
were not received by the CIs for all clusters that were investigated. Between the 
publication of the form in the second version of the Handbook in September 2011, 
and February 2013, and 92 cluster investigations were launched (according to the 
cluster monitoring database). The content of the forms are summarised in Table 22 
and Table 23. 
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Table 22 – The cluster outcome reporting form: Information about the actions and outcomes of 
cluster investigations and usefulness of the TB-STS 
 Local Regional National Total 
(%) 
Not 
answered 
Number of clusters 26 6 10 42 . 
Reason for investigation      
Threshold reached 18 2 6 26 (62) 1 
Below threshold, but with risk factors 3 1 0 4 (10) 1 
Actions     . 
Extended contact tracing 7 0 2 9 (21) 14 
Additional contacts found/screened in cluster 5 0 2 7 (17) 35 
New epidemiological links found in cluster 15 2 3 20 (48) 3 
Public health outcomes a     8 
Probable/definite transmission 4 1 2 7 (17) . 
Investigation inconclusive 9 2 2 13 (31) . 
No apparent transmission 5 3 4 12 (29) . 
Investigation on-going 2 0 0 2 (5) . 
Was the strain typing useful? b     15 
Strain typing was useful 11 3 2 16 (38) . 
Strain typing was not useful 6 2 3 11 (26) . 
Numbers presented are numbers of clusters. The denominator for the proportions presented is 42. 
a Only possible to select one option 
b “Was the strain typing information useful to you?” Yes / No 
 
The total number of cluster outcome reporting forms returned to the local/regional 
CIs since 2011 was 42 (9 national clusters, 6 regional clusters and 27 local clusters). 
26 investigations were launched because the threshold was reached and four were 
launched below the threshold because of patient risk factors. Nine investigations lead 
to extended contact investigations and seven investigations screened more contacts, 
identifying LTBI and active TB cases (Table 23). New epidemiological links were 
found in 20 clusters. Strain typing was reported to be useful for 16 clusters (and not 
useful for 11 clusters).  
The contact tracing activity and yield from screening additional contacts as part of a 
cluster investigation was only reported for seven clusters (labelled A to G) (Table 
23).  Across all seven cluster investigations, 1275 further contacts were screened, 23 
(1.8%) were diagnosed with active TB, 125 (9.9%) had LTBI of which 100 (80%) 
were treated with prophylaxis. It is not known how this differs to the contacts 
initially screened in these clusters. The final public health decision for clusters is 
reported in Table 22.  
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Table 23 – Information on the contact screening activity and outcomes reported for the 
additional contacts screened 
Cluster Additional contacts 
screened 
Active cases (%)a LTBI (%)a Prophylaxis given 
(%)b 
A 118 12 (10.2) 21 (17.8) 21 (100) 
B 628 0 (0) 37 (5.9) 37 (100) 
C 157 2 (1.3) 7 (4.5) 5 (71.4) 
D 81 1 (1.2) 23 (28.4) . 
E 6 0 (0) 0 (0) 0 (0) 
F 102 8 (7.8) 24 (23.5) 24 (100) 
G 165 0 (0) 13 (7.9) 13 (100) 
Total 1257 23 (1.8) 125 (9.9) 100 (80.0) 
Information presented in this table was only available for seven clusters (labelled A-G) 
aAs a proportion of the additional contacts screened 
bAs a proportion of LTBI 
a and b These proportions do not include the contacts screened as part of traditional contact tracing that would have 
been conducted prior to the cluster investigation 
 
More details on a greater number of national clusters were input onto the cluster 
monitoring database. Table 24 shows the total number (and proportion) of national 
clusters reported in 2010 and 2011, the number that were recorded as having no 
epidemiological links between the cases, the number that reported some 
epidemiological links between cases and the number where the links were found 
following a cluster investigation. This is broken down by the number of cases in the 
clusters. 369 national clusters were reported onto the cluster monitoring database in 
2010 and 2011. 33 (10.6%) clusters reported to have epidemiological links known 
between some cases and nine (2.4%) clusters reported finding epidemiological links 
following an investigation. 
Table 24 – Number (%) of national cluster investigations where epidemiological links have been 
identified, by the size of the clusters 
Number (%) of national 
clusters 
Number of cases in cluster Total 
 <5 5 to 9 10 to 19 20 to 49 50+  
National clusters 260 63 31 11 4 369 
Clusters without reported 
epidemiological links 
254 (97.7) 54 (85.7) 16 (51.6) 4 (36.4) 1 (25) 329 (89.2) 
Clusters with reported 
epidemiological links 
6 (2.3) 9 (14.3) 13 (41.9) 8 (72.7) 3 (75) 39 (10.6) 
Epidemiological links 
established following a cluster 
investigation 
1 (0.4) 2 (3.2) 2 (6.5) 3 (27.3) 1 (25) 9 (2.4) 
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6.2.2 Indirect measures of the impact of the TB-STS on TB control: Contact 
tracing yield 
It was hypothesised that the TB-STS would help to identify more cases of active 
disease and LTBI through better targeted or extended contact tracing. Contact tracing 
activity was examined using two data sources: information on index cases reported 
by nurses in the initial and follow-up survey, and clinic data from NCL sector and 
Leicester. The methods can be found on page 73.  
6.2.2.1 Overall estimates of contact tracing activity and yield 
Of the 66 nurse respondents to the survey, 30% and 49% completed the questions 
about contact tracing yield in the initial and follow-up surveys respectively, with the 
majority (75%) reporting on five recent index cases. In total, the details of 86 index 
cases were recorded in the initial survey and 141 in the follow-up survey. The 
majority of index cases were from low TB incidence areas (51%), 28% were from 
medium incidence areas and 18% were from high incidence areas, which is 
proportional to the TB incidence across the country. 
For the majority of cases, nurses reported that the strain type for the index cases 
never became available (65% and 58% from the initial and follow-up surveys; Figure 
39). Only 4% of strain typing results in the initial survey and 5% in the follow-up 
survey were available before contact tracing activities had started. When the strain 
typing data were made available to nurses did not change between the two surveys 
(chi
2
=1.34, p=0.72). 
561 contacts were identified by 85 index cases in the initial survey and 1172 contacts 
were identified by 138 index cases in the follow-up survey (missing = 1 from initial 
and 3 from follow-up surveys;  Table 25). The median number of contacts identified 
and screened was between 3 and 4 per index case, and the median number of 
contacts found to have active disease and LTBI was zero across the two surveys. The 
median number of contacts identified by the index case, screened, and found to have 
active TB disease or LTBI did not change significantly over time (p>0.01 for all).  
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Figure 39 – Contact tracing yield: The point at which the strain typing data for individual cases 
was made available to nurses  
 
The proportion of contacts screened and the proportion of contacts with LTBI 
decreased significantly between the two surveys (contacts screened decreased from 
91.4% to 86.9%, p=0.005; contacts with LTBI decreased from 12.1% to 8.4%, 
p=0.023; Table 26). The proportion of contacts with active disease did not change 
significantly between the surveys (2.1% and 1.8%, p=0.610). 
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Table 25 –The mean (standard deviation), median (inter-quartile range) and range of the number of contacts identified, screened, with active TB disease and with 
LTBI: responses from the initial and follow-up cross-sectional surveys.  
   Initial survey (n=86) Follow-up survey (n=141)  
  Index case site of 
disease 
Number 
of index 
cases 
Total 
contacts 
Mean (SD) Median 
(IQR) 
Range Number 
of index 
cases 
Total 
contacts 
Mean (SD) Median 
(IQR) 
Range p-value 
Contacts identified by the index case            
 Total  85 561 6.6 (10.4) 3 (2-7) 0-64 138 1172 8.5 (22.2) 4 (2-7) 0-200 0.300 
  Pulmonary 55 471 8.6 (12.4) 4 (2-10) 0-64 88 1027 11.7 (27.3) 5 (3-9) 0-200 0.288 
  Extra-pulmonary 30 90 3 (2.7) 2 (1-5) 0-10 50 145 2.9 (2.0) 3 (2-4) 0-10 0.662 
Contacts screened            
 Total  83 513 6.2 (10.2) 3 (1-6) 0-64 134 1018 7.6 (18.2) 3.5 (2-7) 0-150 0.609 
  Pulmonary 55 432 7.9 (12.1) 3 (2-9) 0-64 87 904 10.4 (22.1) 5 (3-9) 0-150 0.315 
  Extra-pulmonary 28 81 2.9 (2.6) 2 (1-4) 0-10 47 114 2.4 (1.9) 3 (1-4) 0-7 0.665 
Contacts with active disease            
 Total  83 11 0.1 (0.7) 0 (0-0) 0-5 131 18 0.1 (0.5) 0 (0-0) 0-4 0.333 
  Pulmonary 55 11 0.2 (0.9) 0 (0-0) 0-5 85 16 0.2 (0.6) 0 (0-0) 0-4 0.531 
  Extra-pulmonary 28 0 0 (0) 0 (0-0) 0-0 46 2 0.0 (0.2) 0 (0-0) 0-1 0.267 
Contacts with LTBI            
 Total  83 62 0.7 (1.9) 0 (0-1) 0-13 130 86 0.6 (1.5) 0 (0-1) 0-10 0.977 
  Pulmonary 55 59 1.1 (2.2) 0 (0-1) 0-13 84 78 0.9 (1.8) 0 (0-1) 0-10 0.933 
  Extra-pulmonary 28 3 0.1 (0.3) 0 (0-0) 0-1 46 8 0.2 (0.5) 0 (0-0) 0-2 0.909 
ap-value from the Wilcoxon rank sum test 
Results are reported by site of disease of the index case. 
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Table 26 –The proportion (CI)a of contacts screened, with active disease and LTBI: responses 
from the initial and follow-up cross-sectional surveys.  
 
Initial survey 
% (CI)  
Follow-up survey 
% (CI) p-valueb 
% (CI) of identified contacts screened 
  
All index cases 91.4 (88.8-93.6) 86.9 (84.8-88.7) 0.005 
Index case pulmonary TB 91.7 (88.9-94.0) 88.0 (85.9-89.9) 0.032 
Index case extra-pulmonary TB 90.0 (81.9-95.3) 78.6 (71.0-85.0) 0.024 
% (CI) of contacts screened with active TB 
 
All index cases 2.1 (1.1-3.8) 1.8 (1.1-2.8) 0.610 
Index case pulmonary TB 2.5 (1.3-4.5) 1.8 (1.0-2.9) 0.346 
Index case extra-pulmonary TB 0.0 (0.0-4.5) 1.8 (0.2-6.2) 0.512c 
% (CI) of contacts screened with LTBI 
 
All index cases 12.1 (9.4-15.2) 8.4 (6.8-10.3) 0.023 
Index case pulmonary TB 13.7 (10.6-17.3) 8.6 (6.9-10.7) 0.005 
Index case extra-pulmonary TB 3.7 (0.8-10.4) 7.0 (3.1-13.4) 0.367c 
aExact confidence intervals calculated based on the binomial distribution 
bChi2 test for significance 
cFisher’s exact test for significance 
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6.2.2.2           The impact of clustering and cluster investigations on 
contact tracing yield 
In 2011, for NCL sector and Leicester TB clinics, there were 220 pulmonary TB 
cases with unique strain types and 97 clustered pulmonary TB cases who had 
information on their traced contacts. Of the clustered cases, 29 were in a cluster that 
had been investigated and 68 were in a cluster that was not investigated. 
The characteristics of cases in clusters that were investigated versus clusters that 
were not investigated were broadly similar (Table 27). There were some exceptions: 
the proportion of cases with any drug resistance was higher in clusters that were not 
investigated, though non-significant (3.0% versus 14.5%, p=0.081), and recent 
incarceration in prison was significantly higher in clusters that were not investigated 
(6.1% versus 13.0%, p=0.018).   
There was a greater proportion of non-UK born cases (compared to UK born) in 
clustered cases (investigated or not), consistent with national surveillance data.
3
 A 
significantly larger proportion of cases in a cluster that was investigated were UK 
born compared to cases in a cluster that was not investigated (39.4% versus 23.3%, 
p=0.020).  
The median number of contacts screened, with active TB and LTBI was significantly 
greater in clustered compared to unique cases (Table 29).  No difference was 
observed between cases that were part of a cluster that was investigated compared to 
not investigated (p>0·1 for all).  
A sensitivity analysis was conducted to assess the impact of missing data. The 
analysis assumed that index cases with missing contact tracing information yielded 
no (zero) cases of active disease or LTBI.  The results showed that the comparison of 
median yields in unique and clustered cases remained the same, but were no longer 
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significant (p=0.06 for active cases and p>0.1 for LTBI) (Table 30).  Median yields 
were broadly similar for cases in clusters investigated or not (p>0.1 for both). 
The estimated proportions of contacts screened in clustered cases that were 
investigated or not investigated that had active disease and LTBI were high as all 
missing data were excluded from the analysis (2.4% and 5.1% of contacts in 
clustered cases that were investigated or not investigated, respectively, were 
diagnosed with active TB, and 22.1% and 27.8% with LTBI) (Table 29). Under these 
assumptions, the contact tracing yield was greater in cases that were in clusters that 
were not investigated, compared to those investigated, but these findings were not 
significant (p>0.1).  
A more realistic estimation of the proportion of contacts screened with active disease 
and LTBI is shown in the sensitivity analysis, in which 1.6% and 3.0% of contacts 
had active TB and 16.8% and 20.5% of contacts found had LTBI in clustered cases 
that were investigated or not investigated, respectively. Under these assumptions, 
there was no significant difference between the contact tracing yield in clusters that 
were investigated versus not investigated (p>0.1) (Table 30). The assumptions in the 
sensitivity analysis mean that the denominator was total contacts screened in the 
dataset, rather than contacts of index cases for which information was available.  
The mean number of contacts screened per LTBI found is shown in Table 28, taking 
into account the proportion of cases that had a unique strain type, in a cluster that 
was investigated or in a cluster that was not investigated. These estimates were used 
to parameterise the cost-effectiveness model (page 175). 
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Table 27 – Characteristics of cases in clusters that were investigated versus cases in clusters that 
were not investigated.  
Characteristics of cases Clustered investigated (%) Clustered not investigated (%) 
Total 33 69 
Smear positive 14 (42.4) 28 (40.6) 
Drug resistant 1 (3.0) 10 (14.5) 
<16 years old 2 (6.1) 1 (1.4) 
Homeless 1 (3.0) 1 (1.4) 
Prison 2 (6.1) 9 (13.0) * 
Drug/alcohol abuse 4 (12.1) 7 (10.1) 
Previous TB treatment 0 (0) 2 (2.9) 
UK born 13 (39.4) 16 (23.2) * 
HIV status and history of severe mental health were not available. Characteristics of clusters such as size when 
cluster investigated, presence of a child, and cluster level (local/regional/national) were not available. 
* Chi2 test using ‘diagnosed after cluster investigated’ as the reference category, p-value<0.05 
 
Table 28 – The mean number of contacts screened per LTBI found, weighted by whether the 
strain type was unique, clustered and investigated, or clustered and not investigated 
   Mean number of contacts per 
index case screened 
  
 n (%)  Screened Active 
TB 
LTBI  Contacts screened 
per LTBI found 
Not clustered 220 (38)  4.36 0.11 0.93  4.68 
Clustered investigated 29 (5)  6.59 0.21 1.68  3.91 
Clustered not investigated 68 (12)  5.44 0.33 1.90  2.86 
Total 317  2.6 0.1 0.7  3.97 
Sensitivity analysis: missing=0        
Not clustered 227 (39)  4.22 0.06 0.65  6.48 
Clustered investigated 33 (6)  5.79 0.09 0.97  5.97 
Clustered not investigated 69 (12)  5.36 0.16 1.10  4.87 
Total 329  2.6 0.0 0.4  5.94 
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Table 29 – Contact tracing yield for index cases by clustering and whether the cluster was investigated: NCL and Leicester clinic data. 
 
Unique cases Total clustered 
cases 
p-valuea Cases in a cluster that 
was investigated 
Cases that were in a cluster 
that was not investigated 
p-valueb 
Contacts screened 
Index cases (n) 220 97  
29 68 
 
Contacts screened  (n) 959 561  
191 370 
 
Median screened (IQR) 3 (1-5) 4 (2-7) 0·008
c 4 (2-9) 4 (2-6) 0.474c 
Contacts with active disease 
Index cases with information available (n) 131 47  
14 33 
 
Contacts screened (n) 593 341  125 216  
Contacts with active disease (n) 14 14  
3 11 
 
% (CI) contacts screened with active TBde 2.4 (1.3-3.9) 4.1 (2.3-6.8) 0.132
f 2.4 (0.5-6.9) 5.1 (2.6-8.9) 0.271g 
Median active (IQR) 0 (0-0) 0 (0-0) 0·011
c 0 (0-0) 0 (0-0) 0.896c 
Contacts with LTBI 
Index cases with information available (n) 159 59  
19 40 
 
Contacts screened (n) 761 410  145 265  
Contacts with LTBI (n) 148 108  
32 76 
 
% (CI) contacts screened with LTBIde 19.4 (16.7-22.4) 26.3 (22.1-30.9) 0.006
f 22.1 (15.6-29.7) 27.8 (23.3-34.5) 0.146f 
Median latent(IQR) 0 (0-1) 1 (0-2) 0·016
c 1 (0-2) 1 (0-2) 0.330c 
a Comparing unique cases with clustered cases;  
b Comparing cases in a cluster that was investigated with case that were in a cluster that was not investigated  
c Wilcoxon rank sum test  
d Exact confidence intervals calculated based on the binomial distribution 
e Number with active disease \ number of contacts screened *100 
f Chi2 test of significance 
g Fisher’s exact test of significance 
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Table 30 – Sensitivity analysis. Contact tracing yield for index cases by clustering and whether the cluster was investigated, assuming that index cases with missing 
contact tracing information yielded no cases of active disease or LTBI: NCL and Leicester clinic data 
 Unique cases Total clustered 
cases 
p-valuea Cases in a cluster that 
was investigated 
Cases that were in a cluster that 
was not investigated 
p-valueb 
Contacts screened 
     Index cases (n) 227 102  
33 69 
 
Contacts screened  (n) 959 561  
191 370 
 
Median screened (IQR) 3 (1-5) 4 (1-7) 0.02 c 4 (1-8) 4 (2-6) 0.872
 c 
Contacts with active disease     
Index cases with information available (n) 227 102  
33 69 
 
Contacts screened (n) 959 561  191 370  
Contacts with active disease (n) 14 14  
3 11 
 
% (CI) contacts screened with active TBde 1.5 (0.8-2.4) 2.5 (1.4-4.2) 0.147f 1.6 (0.3-4.5) 3.0 (1.5-5.3) 0.401
g 
Median active (IQR) 0 (0-0) 0 (0-0) 0.059 c 0 (0-0) 0 (0-0) 0.819
 c 
Contacts with LTBI     
Index cases with information available (n) 227 102  
33 69 
 
Contacts screened (n) 959 561  191 370  
Contacts with LTBI (n) 148 108  
32 76 
 
% (CI) contacts screened with LTBIde 15.4 (13.2-17.9) 19.3 (16.1-22.8) 0.055 f 16.8 (11.8-22.8) 20.5 (16.5, 25.0) 0.288
 f 
Median latent (IQR) 0 (0-1) 0 (0-1) 0.418 c 0 (0-2) 0 (0-1) 0.436
 c 
a Comparing unique cases with clustered cases 
b Comparing cases in a cluster that was investigated with case that were in a cluster that was not investigated  
c Wilcoxon rank sum test  
d Exact confidence intervals calculated based on the binomial distribution 
e Number with active disease \ number of contacts screened *100 
f Chi2 test of significance 
g Fisher’s exact test of significance 
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6.2.3 Indirect measures of the impact of the TB-STS on TB control: Diagnostic 
delay 
An additional mechanism that the TB-STS may help to interrupt TB transmission is 
through the earlier diagnosis of TB disease, preventing further transmission in the 
community. The earlier diagnosis may be possible if an investigation of a cluster 
leads to more targeted screening and public health action. This could lead to the 
identification of contacts or people exposed to TB who have TB disease but may not 
have sought care until later, thereby reducing diagnostic delay. The methods for this 
case-control study can be found on page 76. 
There were 526 clustered cases of pulmonary TB in England in 2011, after removing 
the first and second cases within each cluster to take into account possible household 
transmission. 208 were in a cluster that was not investigated and 318 were in a 
cluster that was investigated. Information on diagnostic delay was available for 139 
and 238 cases, respectively (Table 32).  
The characteristics of cases in clusters that were not investigated, cases that were 
diagnosed before the cluster was investigated and cases diagnosed after the cluster 
was investigated were broadly similar (Table 31). There were, however, some 
differences. There was a higher (non-significant) proportion of smear positive cases 
in clusters that were investigated compared to cases in a cluster that were not 
investigated (61.5% or 60.3% versus 55.4%, respectively, p>0.05) – this is not 
surprising as smear positivity is a risk factor for transmission. There was a 
significantly higher proportion of drug resistant cases in clusters that were not 
investigated (22.3% versus 7.4%, p>0.05), similar to the population from NCL and 
Leicester (Table 27, page 150). 
The median diagnostic delay was not significantly different in cases that were in a 
cluster that was not investigated (n=139; 62 days) or diagnosed before a cluster 
investigation was launched (n=117; 85 days), compared to those diagnosed after the 
start of the cluster investigation (n=121; 77 days). The results did not change when 
stratifying by UK born (n=293), non UK born (n=328) and excluding cases under the 
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age of 16 (n=12) (Table 33). As previously observed, UK born cases had a longer 
diagnostic delay compared to the non-UK born cases.
35
 
A sensitivity analysis was conducted to see the effect of using date of notification 
instead of date of treatment to define diagnostic delay, but this did not change the 
results. 
Table 31 – Characteristics of cases in clusters that were not investigated, cases that were 
diagnosed before the cluster was investigated, cases diagnosed after the cluster was investigated. 
  Cluster investigated 
Characteristics 
of cases 
Cluster not 
investigated (%) 
Diagnosed before cluster 
investigated (%) 
Diagnosed after cluster 
investigated (%) 
Total 139 117 121 
Smear positive 77 (55.4) 72 (61.5)  73 (60.3) 
Drug resistant 31 (22.3) 
a
 10 (8.5) 9(7.4) 
<16 years old 7 (5.0) 6 (5.1) 4 (3.3) 
Homeless 13 (9.4) 12 (10.3) 14 (11.6) 
Prison 20 (14.4) 13 (11.1) 15 (12.4) 
Drug/alcohol 
abuse 9 (6.5) 5 (4.3) 6 (5.0) 
Previous TB 9 (6.5) 14 (12.0) 6 (5.0) 
UK born 85 (61.2) 74 (63.2) 82 (67.8) 
HIV status and history of severe mental health were not available. Characteristics of clusters such as size when 
cluster investigated, presence of a child, and cluster level (local/regional/national) were not available. 
a Chi2 test using ‘diagnosed after cluster investigated’ as the reference category, p-value<0.05 
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Table 32 – The diagnostic delay for clustered pulmonary cases from 2011, based on whether 
they were in a cluster that was investigated, and whether they were diagnosed before or after 
the investigation was launched 
 Cases that were in a 
cluster that was not 
investigated 
Cases in a cluster that was investigated 
 Diagnosed before the 
investigation was launched 
Diagnosed after the 
investigation was launched 
Number of clusters 120 58 38 
Number of cases 139 117 121 
Mean (SD) (days) 113.2 (117.9) 140.8 (271.9) 113.5 (128.7) 
Median (IQR) (days) 62 (32-127) 86 (47-155) 77 (41-157) 
p valuea 0.1567 0.4257 ref 
ap-value for the Wilcoxon rank sum test  
 
 
 
Table 33 – The diagnostic delay for UK born, non-UK born, and cases over the age of 16 who 
are clustered pulmonary TB cases from 2011, by cluster investigation and whether they were 
diagnosed before or after the investigation was launched. 
 
Cases that were in a 
cluster that was not 
investigated 
Cases in a cluster that was investigated 
  
Diagnosed before the 
investigation was 
launched 
Diagnosed after the 
investigation was 
launched 
UK born 
   
Number of clusters 38 48 28 
Number of cases 54 56 66 
Mean (SD)  120.2 (85.4) 135.1 (226.2) 110.3 (93.1) 
Median (IQR)  109 (55-168) 76 (42.5-144.5) 81.5 (42-162) 
p valuea 0.3278 0.6962 ref 
Non-UK born    
Number of clusters 27 81 24 
Number of cases 59 71 51 
Mean (SD)  161.6 (374.2) 104.8 (143.9) 124.8 (166.4) 
Median (IQR)  69 (43-133) 60 (31-122) 80(45-161) 
p valuea 0.7146 0.1411 ref 
≥16 years    
Number of clusters 118 58 38 
Number of cases 137 114 117 
Mean (SD)  113.2 (179.1) 144.1 (274.8) 116.2 (130.0) 
Median (IQR)  62 (32-125) 92 (51-155) 80 (42-161) 
p valuea 0.0868 0.4200 ref 
ap-value for the Wilcoxon rank sum test  
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6.2.4 Indirect measures of the impact of the TB-STS on TB control: Rate of 
cluster growth 
The relative change in the size of clusters was explored. It was hypothesised that the 
rate of cluster growth would differ before and after a cluster investigation was 
initiated. Cluster investigation may increase apparent rate of cluster growth (as a 
result of additional cases being identified more quickly) or may decrease the rate of 
cluster growth (if the earlier identification of cases limits transmission). In an ideal 
circumstance a cluster investigation may transiently increase the rate of cluster 
growth and then later decrease the rate. The methods for this study are on page 77. 
Figure 40 shows examples of cluster growth over time and the size of clusters at the 
point they are investigated. The local clusters shown here are not representative as 
they do not include any clusters that are investigated with just two cases (as this isn’t 
well visualised as a line graph). Figure 38 (page 141) shows the distribution of 
clusters sizes at the point they are investigated, giving an overview of the size of 
clusters when they are investigated. 
Figure 40 – Examples of the rate at which TB cases were added to national and local clusters 
during 2010 and 2011. The figure shows the rate of cluster growth in relation to the cluster 
investigation. 
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The univariate analysis identified cluster type (local, regional and national), case 
order and whether diagnosed before or after the cluster investigation as potential 
factors associated with the rate of cluster growth. The multivariable linear regression 
had significant (p<0.01) coefficients for the intercept, the cluster level being national 
(i.e. additional cases accruing in 'national' clusters are added more quickly compared 
with cases occurring in local clusters), and the case order (i.e. each subsequent case 
in a cluster arrives sooner than the previous ones, possibly reflecting the fact that as 
clusters spread there are more infectious TB cases so more opportunities for 
transmission and thus the intervals between subsequent cases are expected to 
decrease, or that intervals between cases are more likely to represent differences in 
variability in incubation period rather than intergenerational time as clusters grow). 
No other variables were significant (Table 34).  
Table 34 – Regression analysis investigating the impact of cluster type (local, regional, national), 
case order and whether diagnosed before or after the cluster investigation on the rate of cluster 
growth 
  Coefficient 95% CI p-value 
Cluster type Local ref   
 Regional -4.9  -29.9, 20.0 0.698 
 National -46.0  -60.7, -31.3 <0.001 
Case order  -1.1  -1.5, -0.7 <0.001 
Diagnosed after investigation 0.0  -11.3, 11.3 0.997 
Intercept 99.4 65.5, 133.2 <0.001 
  
6.3 Discussion 
6.3.1 Strengths and limitations of the methods used to evaluate the Outputs of 
the TB-STS 
Laboratory Outputs 
The false positive TB isolation survey was designed to observe how frequently the 
reference laboratories queried isolates for potential cross-contamination based on the 
strain typing information, and to establish how many of these queries had not been 
previously identified. It did not attempt to measure the cross-contamination rates 
within TB laboratories in England. This was important to ensure cooperation from 
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the laboratories who might not have shared their data so freely if the service they 
provide was being evaluated. As a result, the findings can only be interpreted in the 
context of the TB-STS, and cannot be used to assess the quality of TB laboratory 
services in general.  
The two-step process of collecting information from the reference laboratories and 
then following up with the source laboratories was necessary because although the 
reference laboratories would write to the source laboratories to alert them of a 
possible cross-contamination event, they would not follow up with them to find out 
the outcome of their query. In fact, the reference laboratories had heard back from 
source laboratories in 19 incidents out of 70 (27%). The follow-up survey to source 
laboratories was an appropriate method of data collection (compared to a telephone 
survey) as it gave the recipient time to find out the result of an investigation before 
responding. However, due to the survey method, very few questions could be posed, 
so the information collected was limited.  Source laboratories may have wished to 
appear well-informed and therefore responded that they were already aware of the 
false positive diagnosis when they were not. This would have biased the survey 
results, underestimating the impact of the TB-STS at detecting these incidents. 
Future evaluations should conduct an audit to find out the outcomes of each incident, 
especially the eight patients who were unnecessarily started on treatment (Table 20). 
Public health Outputs 
Cluster investigation activities and outcomes 
The delay in the development of the STM until after the evaluation period severely 
limited the data collection around cluster investigations. Interim reporting systems 
were established in order to capture some of this activity. These were designed with 
stakeholders to ensure their utility (for the service to be monitored as well as for the 
evaluation) and usability. There were, however, many limitations to these systems so 
they could not be used to parameterise the transmission and cost-effectiveness 
models.  
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The cluster monitoring database was not linked to the routine laboratory, clinical and 
epidemiological data, and it required CIs to manually input each case that was part of 
a cluster. As a result, the database had lots of missing fields and was not regularly 
updated. The cluster monitoring database focussed on whether epidemiological links 
between clustered cases were identified. However, this was retrospective and was 
only relevant if it had an impact on subsequent public health action. The database 
should have collected information on the actions taken because of the strain typing 
information and the resulting outcomes of these actions.  
In addition to justifying further investigation, the TB-STS could be used to disprove 
transmission between cases where transmission had been suspected. For example, the 
diagnosis of TB disease in multiple students attending the same college within a few 
weeks of each other may suggest on-going transmission at the college. If the strain 
types are distinguishable, there is no evidence for transmission between the students. 
In this scenario, the strain typing results will have prevented a large investigation and 
screening programme around the students and the college. Data on the activity 
avoided as a result of the TB-STS was not collected (Figure 11, page 31). Capturing 
activities that do not happen is challenging. This problem was addressed by using the 
cross-sectional survey and semi-structured interviews to gather examples of where 
strain typing has been used to disprove suspected transmission. Although these 
insights captured through qualitative methods cannot tell us the frequency of this 
event, they can be used to demonstrate whether these events occur at all.  
Refuting possible transmission was one of the main uses of the strain typing 
information that was reported in the initial and follow-up survey. In addition, this 
was one of the sub-themes identified in the semi-structured interviews with HPUs. 
See Table 17 (page 124) for examples of refuting possible transmission between 
cases.  Recall bias may play an important role here as people may remember 
incidents where the strain typing results prevented public health action more clearly 
than where strain typing did not add anything to a particular incident. Alternatively, 
it may work in the other direction where people are less likely to remember where 
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they did not take action, compared to where the strain typing led to further public 
health action. 
Contact tracing yield 
Strengths and limitations of the initial and follow-up survey design are discussed in 
Chapter 4 (page 128). The specific questions around contact tracing are discussed 
here. To minimise the potential recall bias that might occur when asking nurses about 
the details of patients, they were asked to record the details of five recent cases for 
whom contact tracing had been completed. However, it is possible that they reported 
the five most memorable recent cases (e.g. with unusual outcomes), the details of 
which they could remember most easily.  To try to avoid this, they were prompted to 
get their case notes before completing the contact tracing questions.  
The significant decrease in the proportion of contacts screened and with LTBI is 
surprising given that the TB-STS aims to help target contact tracing more effectively. 
The decrease in the proportion of contacts screened may be because there was an 
increase in the number of contacts identified between the two surveys (though this 
was not significant). Alternatively, the TB-STS may have encouraged people to 
prioritise clustered cases, so that the contacts of other cases are not screened. 
However, this would not explain why the yield of LTBI decreased as well – under 
these circumstances you would expect them to increase, unless patients that had 
infected fewer of their contacts were being prioritised. Regardless, these results reject 
the hypothesis that the TB-STS will increase contact tracing yield. 
The data used to investigate the impact of cluster investigations on contact tracing 
yield were from two study sites in England: the North Central London Sector and 
Leicester. This was a convenience sample based on which TB services routinely 
collected the relevant data. The outcomes of contact investigations were not collected 
on the central notification system. Whilst this sample covers two TB services in 
different regions of England, it is not a representative sample as both settings have a 
high TB incidence (Leicester City 57/100,000 in 2011 and NCL 34/100,000 in 
2011).
4,217
 There may be a self-selection bias whereby the sites that collect data on 
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their contact tracing activities might therefore, due to an increased interest in the 
metric, provide a more effective contact tracing service compared to sites that do not 
collect these data. If this were the case, then the impact of the TB-STS may have 
been harder to observe due to its marginal effect on an effective contact tracing 
service.  
The analysis only included pulmonary TB cases, which accounts for ~50% of TB 
cases in England, so the impact of the TB-STS on contact tracing for extra-
pulmonary TB cases is not known. Because of the smaller chance of transmission 
from a case of extra-pulmonary TB, contact tracing yield is usually lower in these 
cases,
24
 suggesting that the contact tracing yield estimated in this thesis is 
overestimated. 
The characteristics of cases in clusters that were investigated versus clusters that 
were not investigated were broadly similar. However, the proportion of cases with 
any drug resistance was higher in clusters that were not investigated and recent 
incarceration in prison was significantly higher in clusters that were not investigated. 
This is surprising given that drug resistance or recent incarceration in prison are 
criteria for cluster investigation, but may also reflect incidents where lots is known 
about the epidemiology of TB in these cases before the strain typing results are 
received (for example, once all exposed contacts in a prison are screened following 
diagnosis of the index case, further screening around a secondary case is unlikely). 
This might go some way to explain why the contact tracing yield is slightly higher 
(though not significantly so) in cases that were not investigated compared to those 
investigated. In addition, greater effort may go into contact tracing around a drug 
resistant patient or someone with a history of prison (in line with national 
guidance).
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It is surprising that the contact tracing yield was greater (though not significantly) for 
cases in clusters that were not investigated compared to cases that were in clusters 
that were investigated. This suggests that the screening process was less effective 
with the addition of the TB-STS, possibly due to the selection criteria to actively 
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investigate clusters (this interpretation influenced the recommendations about the 
future of cluster investigations (Box 6, page 204)). On the other hand, this could be 
expected as the greatest contact tracing yield of an infectious index case is likely to 
be found through the initial household contact tracing and any further screening 
associated with a cluster investigation is, by its nature of ‘casting the net wider’, 
going to have a lower return. If this latter hypothesis is true, the benefit of finding 
and treating an undiagnosed case of LTBI or active disease must outweigh the 
additional cost of the less efficient contact tracing as well as the costs of the TB-STS 
for the service to be cost-effective.  
Another explanation for this finding is that some cases would have been diagnosed 
and immediately be part of an ongoing cluster investigation. These cases may have 
been a contact of another case in the cluster, and therefore have fewer contacts to 
trace (as they may have shared some contacts with their index case). Bearing this 
scenario in mind, as more cases are diagnosed through active case finding (e.g. 
cluster investigation), the contact tracing yield may decrease, rather than increase as 
more cases have shared contacts. 
A strength of this analysis, is the link between the clinic data on contact tracing yield 
and the clustering data, enabling the investigation into the impact of cluster 
investigation on contact tracing yield. However, with only one year of data available 
(2011), it is not surprising that no impact was observed.  Data for cases diagnosed in 
2011 were collected up to July 2012, allowing for the time it takes to conduct contact 
tracing and cluster investigations.  
The sensitivity analysis conducted (which assumed that missing data on the number 
of contacts screened with active disease or LTBI were zeros) is more realistic 
because it is unlikely that active cases and LTBI identified through contact tracing 
would not be reported; it is more likely that missing values represent zeros. 
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Diagnostic delay 
Diagnostic delay is a key indicator for the success of a TB programme. Despite this, 
the date of symptom onset necessary to calculate diagnostic delay was only recorded 
in 75% (238/318) of pulmonary TB cases diagnosed in 2011 that were in an 
investigated cluster. Thus the sampling fraction was reduced and a bias potentially 
introduced as those cases with no recorded symptom onset may have had a 
particularly long delay to diagnosis if, for example, they could not remember when 
their symptoms had started.  
The characteristics of cases in clusters that were not investigated, cases that were 
diagnosed before the cluster was investigated and cases diagnosed after the cluster 
was investigated were broadly similar. The higher proportion of drug resistant cases 
in clusters that were not investigated compared to those that were diagnosed after the 
investigated was initiated was, on the one hand, unexpected as drug resistance is a 
criterion for cluster investigation. On the other hand, if a large drug resistance 
outbreak is known about in detail, the identification of an additional case may not 
lead to an investigation.
91
 This was consistent with the data from NCL and Leicester 
used for the investigation of contact tracing yield (though numbers were too small in 
for a significant difference to be detected). One would expect drug resistant cases to 
be identified earlier and have a shorter diagnostic delay because of the increased 
contact tracing effort surround a case with drug resistant TB. Therefore diagnostic 
delay may have been underestimated in the cases that were not in a cluster that was 
investigated. There were no significant differences between cases that were 
diagnosed before or after cluster investigations were initiated. 
This analysis gives a snapshot of the impact of cluster investigations initiated in 2011 
on the diagnostic delay in cases diagnosed during the same year. A strength of this 
analysis is that it compares the diagnostic delay in cases diagnosed before or after a 
cluster investigation, something that has not been done before. It is limited by having 
only one year of data, and may be under powered to detect the observed difference.  
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In this analysis there were three groups: cases diagnosed before a cluster 
investigation, after an investigation and cases in a cluster that was not investigated. 
Ideally, you would want to compare patients with similar characteristics and risk 
profiles who are clustered and investigated, to patients who are clustered and not 
investigated and then randomly assign each cluster to be either investigated or not. 
Or, more specifically, randomly assign each cluster that is recommended for 
investigation following the preliminary cluster review (though this would not be 
ethnically sound as there is evidence that certain patient characteristics are risk 
factors for transmission). The problem with the approach taken here is that those 
cases diagnosed before an investigation might be different to those diagnosed after 
an investigation. And cases in a cluster that is not investigated are likely to be 
different to cases in a cluster that is investigated, as characteristics of cases within a 
cluster are used to determine whether a cluster should be investigated or not. 
However, given that the service was implemented nationally, without the opportunity 
to randomise clusters to be investigated or not, comparing the diagnostic delay before 
and after the initiation of a cluster investigation is an indication of how close the TB 
service is to interrupting transmission (on the assumption that if diagnostic delay 
decreases to zero, transmission has been interrupted). 
Rate of cluster growth 
The multivariate linear regression examining cluster growth is appropriate because it 
takes full advantage of all the available data (i.e. data from the cluster monitoring 
database and the ETS). However, there are some notable limitations, for example it 
may be biased toward the null by potentially “averaging out” the positive (through 
more aggressive case finding) and negative (through limiting transmission 
opportunities from cases detected more rapidly) effects of the cluster investigation on 
cluster growth, and the model excludes the first case in each cluster. 
This analysis was conducted using two years of data, meaning that there was a 
maximum two-year follow-up per cluster, with most clusters having less than two 
years of follow-up (assuming the second case in each cluster was not diagnosed on 
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1
st
 January 2010). This may not have been enough time to observe the change in rate 
of cluster growth after the initiation of a cluster investigation. 
In addition, the date of the start of an investigation may not be very meaningful. The 
start of an investigation is the date the CI assesses the cluster as having met the 
threshold for investigation and launches an investigation by sending the cluster report 
and cluster questionnaires to the relevant HPUs or TB nurses. The date that these 
reports are then acted upon (which is the date from which any impact could be seen) 
is unknown. The time between the launch of the investigation by the CIs and the 
action taken could be very lengthy, rendering the investigation start date arbitrary. 
6.3.2 How this relates to previous studies 
Laboratory outcomes 
A study conducted in London reported a cross-contamination rate of between 0.5% 
and 0.9%, which is higher than the 0.3% reported here. A slightly lower estimate is 
to be expected because the figure reported here is based solely on the incidents 
queried because of the TB-STS, rather than any other information (such as clinical 
suspicion).  One explanation for this is the variation between the laboratories. 
Although a protocol for identifying false positive isolates using strain typing was 
shared between the three laboratories, there was a difference in the number of queries 
raised, with the Newcastle laboratory only querying one incident (0.06%) in a 24-
month period. Excluding Newcastle from the analysis, however, did not change the 
cross-contamination estimate because Newcastle type a small proportion of overall 
isolates. The discrepancy between the laboratories raises questions about how closely 
the protocol is followed and whether the threshold for querying isolates was 
appropriate. In addition to the low rate of cross-contamination, the number of true 
false positive isolates identified per year because of the TB-STS was lower than 
expected.
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The unexpectedly low numbers of false positive TB isolates identified by the TB-
STS may be explained by the timing of the evaluation. Although the TB-STS was not 
166 
 
launched until January 2010, two of the three TB reference laboratories had been 
conducting TB strain typing for research undertaken during the previous decade 
(using IS6110 RFLP, or 12 or 15 MIRU-VNTR). Any major problems with 
laboratory protocol may have already been picked up by the strain typing data and 
changes to the protocol already made. As a result, we may be trying to measure 
something very small. The impact of strain typing on false positives is likely to come 
just after the introduction of strain typing to a population. However, given that the 
identification of false positive TB isolation was one of the justifications for the 
introduction of the TB-STS and was hypothesised to influence the results of the cost-
effectiveness analysis (Figure 11, page 31), our finding of a minimal impact is 
important. 
Cluster investigation activity 
Electronic systems to link strain typing data to surveillance data exist in other 
countries with strain typing services (e.g. TB-GIMS in the USA).
218
 Nationwide 
population studies reporting the cluster investigation activities of the Netherlands and 
the USA suggest that, with the necessary systems in place, these data can be 
collected systematically.
127
 Where comprehensive data collection and reporting 
systems exist, assessing the cluster investigation activity can give useful insight into 
the impact of strain typing on TB control.
127
  
Contact tracing yield 
The estimates of contact tracing yield from the survey population were comparable 
to published UK estimates of the contact tracing yield for pulmonary TB cases 
(Table 35).
21,24
 The contact tracing yield in clustered and unique cases has not been 
previously studied. The estimated number of clustered and unique cases from NCL 
and Leicester were higher than the survey sub-study, those reported in the cluster 
outcome reporting form, and previous studies from the UK (but more consistent with 
studies conducted elsewhere in Europe
26
 or on smear positive pulmonary TB cases in 
the USA
31
 (Table 1, page 12)), but the sensitivity analysis results were closer to the 
survey estimates. The differences might be explained by the high TB incidence in the 
study sites, or the self-selection bias described above (whereby sites that have a 
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stronger contact tracing service may be more likely to have enhanced data 
collection). The survey estimates, on the other hand, may be subject to recall bias in 
addition to being mostly from low TB incidence areas (51% of TB cases from the 
survey estimate were from a low TB incidence HPU, 28% medium incidence and 
18% high incidence). Therefore, the survey estimates are likely to be better 
representative of the contact tracing yield across England, whereas the clinic 
estimates more represent the contact tracing yield in areas with a high burden of TB. 
The cluster outcome reporting form contains important information on the impact of 
cluster investigations on contact tracing yield and provides (weak) evidence that 
yield does not change with a cluster investigation.  
Table 35 – Estimates of contact tracing yield for pulmonary TB cases from the thesis sub-studies 
and other published studies from the UK 
Data source Table (page)   % contacts with 
active TB 
% contacts 
with LTBI 
Cross-sectional survey  Table 26 (p147) Initial 2.5 13.7 
 Follow-up 1.8 8.6 
     
Cluster outcome reporting form Table 22 (p142) Clustered 1.8 9.9 
     
Clinic data from NCL and Leicester    
(missing values excluded) 
Table 29 (p151) Unique  2.4 19.4 
Clustered  4.1 26.3 
     
Clinic data from NCL and Leicester   
(missing values=0) 
Table 30 (p152) Unique  1.5 15.4 
Clustered  2.5 19.3 
     
Saunders, Birmingham 1990-201024   2.3 7 
     
Underwood, Tower Hamlets 1997-
199921 
  3.8 6.9 
Unique=unique strain types 
Clustered=in a strain typing cluster 
All studies include pulmonary TB only 
 
The finding that strain typing is rarely received by nurses is not surprising, given that 
cluster reports are sent to health protection staff in HPUs. What is important, 
however, is that it suggests that cluster information is not received when it could 
influence the contact tracing activities. Rather, it is received after contact tracing has 
already been completed, if at all. This reduces the potential impact of the strain 
typing information as additional information gathering for a cluster investigation will 
always be retrospective. Similarly, reports on the genotyping service in the USA 
found that the median time from specimen collection to the date the strain typing 
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result was linked to the surveillance data was 13.6 weeks (IQR 9.2-19.0),
216
 which is 
presumably after contact tracing around the patient has been completed. In the 
Netherlands, however, contact tracing is standardised and the information required 
for a cluster investigation is collected at the time of contact tracing, rather than 
retrospectively once the strain typing result has been received. This process should 
result in the strain type influencing decisions more rapidly as the necessary 
information about a clustered TB case is already available and nurses are less likely 
to have to re-interview the patient to collect more information. 
Diagnostic delay 
This is the first assessment of the TB-STS and its impact on diagnostic delay. Since 
the presentation of the TB-STS evaluation to PHE in April 2013, diagnostic delay 
has been recognised as an important indicator for a TB service and was reported in 
PHE’s Tuberculosis Annual Report.3 The median diagnostic delay across the UK in 
2013 was 72 days, which lies within the range reported here (62 to 85 days in 
clusters that were not investigated and cases diagnosed before the cluster was 
investigated, respectively). 
It is not surprising that the median diagnostic delay was shorter (62 days) in clusters 
that were not investigated as these are more likely to be smaller clusters of household 
transmission. Though not significant, the median diagnostic delay was eight days 
shorter in cases diagnosed after the initiation of a cluster investigation, compared to 
before, suggesting that the cluster investigation may be identifying cases earlier.  
Rate of cluster growth 
The rate at which new cases of TB are added to a cluster indicates the rate of ongoing 
transmission in the community. The rate of cluster growth has not been explored in 
the UK, but the number and proportion of clusters of various sizes are reported in the 
national surveillance report as an indicator for TB control.
3,123
 The majority of 
clusters remain small; in the UK between 2010 and 2013 the proportion of clusters of 
size two was 46.3% (858/1854) and the median cluster size was three (range 2 to 
166).
3
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Previous studies have not evaluated the impact of cluster investigations on the rate of 
cluster growth. For example, Driver et al
103
 investigated the influence of the 
demographic, clinical, and epidemiological characteristics of the first two cases in a 
cluster in New York City on the rate of cluster growth, and Kik et al
102
 investigated 
the characteristics of the first two cases in a cluster to see if they predicted whether 
the cluster would grow to include five or more cases. The analysis presented here 
suggests that cluster investigations do not have an impact on the rate TB clusters 
grow within two years of the initiation of the cluster investigation. This could be 
because the transmission chain has already been interrupted, suggesting that the 
cluster investigation was either successful, or unnecessary.  
During 2010 and 2011 the average length of a cluster investigation was 129 days 
(n=86, IQR 50-188; see page 140), excluding any ongoing investigations. These 
findings raise questions about how long a TB service can afford to conduct a cluster 
investigation before affecting the rate at which the cluster is growing, and whether 
cluster investigations are being conducted appropriately and in clusters where they 
could have the most impact. 
6.3.3 Summary of findings 
Laboratory Outputs 
The laboratories typed 17,168 M. tuberculosis isolates between 2010 and 2012, 
84.6% of which had at least 23 loci. 
Seventy (0.6%) of the total isolates typed between 2010 and 2012 were suspected as 
false positive TB isolates because of their strain type. Thirty of these (43%) were 
confirmed as cross contamination incidents, of which 17 had not been previously 
identified by the source laboratories.  
Public health Outputs 
Cluster investigation activities and outcomes 
In the absence of the STM, interim databases and data collection forms were 
produced to collect data on cluster investigation activities and their outcomes (Table 
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8, page 92). Cluster investigation activities are summarised across three databases 
and a case management tool. 188 clusters were recorded in the cluster monitoring 
database between 2010 and 2012. Clusters were investigated when they included 
between 2 and 44 cases, and remained open for a median of 129 days (IQR 50-188). 
The median length of cluster investigations is an underestimate because 
investigations that had not yet closed were not included in the estimate. The large 
number of clusters that are investigated when they contain two cases could be 
because the cases are assessed as high risk in terms of transmission (based on the 
criteria in the Handbook), or low incidence areas may investigate clusters earlier due 
to the rarity of the disease and/or availability of resources. (Cluster outcome 
reporting forms were completed and returned for 42 local and regional clusters. New 
epidemiological links were found within 20 clusters, but public health action was 
taken in only three clusters. Strain typing was reported to be useful for 16 clusters 
(and not useful for 11 clusters). Epidemiological links were established following a 
cluster investigation for only 2.4% of national clusters that were reported during 
2010 and 2011. 
Contact tracing yield 
There was no difference in the time point that nurses received strain typing data 
(before, during or after the contact investigation, or never) between the initial and 
follow-up surveys, with the majority of nurses never receiving it. The median contact 
tracing yield did not change between the surveys. The proportion of contacts 
screened and the proportion of contacts with LTBI decreased between the two 
surveys; the proportion of contacts with active disease did not change.  
In NCL and Leicester, the median contact tracing yield was significantly greater in 
clustered cases compared to unique cases. There was no significant difference in 
contact tracing yield between cases that were in clusters that were investigated versus 
clusters that were not investigated. 
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Diagnostic delay 
Compared to clustered cases diagnosed after the start of the cluster investigation, the 
median diagnostic delay was not significantly different in clustered cases that were 
not investigated or cases diagnosed before a cluster investigation was launched. 
Rate of cluster growth 
The null hypothesis that cases arriving after initiation of a cluster investigation are 
associated with a change in the rate new cases are added to a cluster compared to 
cases arriving before the cluster investigation (adjusting for other variables) cannot 
be rejected. Therefore, there is no evidence to suggest that the rate at which clusters 
grow is different before or after a cluster investigation is launched. 
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Chapter 7. Outcomes 
This chapter presents the results of the TB transmission model and the cost-
effectiveness model, developed to estimate the effectiveness and cost-effectiveness of 
the TB-STS. The structure of each model is shown in Figure 24 (page 80) and Figure 
25 (page 82), respectively, and the underlying assumptions for the models are 
described on page 78 and 81, respectively. Further details of the modelling methods 
and results can be found on pages 78 and 81 and in Appendix 5 and Appendix 6. The 
model parameters that were estimated from elsewhere in this thesis are shown in 
Table 36. For my contribution to the transmission model and cost-effectiveness 
model please refer to ‘My role in this thesis’ on page xxiv. 
Briefly, the baseline scenario (S0) without the TB-STS assumes 3% of LTBI are 
detected and a diagnostic delay of 12 weeks. Given that there was no measurable 
impact of the TB-STS on public health Outputs (Chapter 6), all other scenarios 
represent the potential (not realised) impact of the TB-STS. Therefore, the models 
investigate what impact the TB-STS would have to have in order to be effective and 
cost-effective. 
Table 36 – Model parameters estimated from sub-studies in this thesis 
Parameter Study source Page no. 
Cost of the TB-STS Description of Structures 100 
Average  TB-STS associated workload at an HPU Initial and follow-up surveys 103 
False positive TB isolation False positive TB isolation survey 138 
Mean number of contacts screened per index case Contact tracing yield 148 
Average number of LTBI and active disease identified 
per index case 
Contact tracing yield 148 
Average diagnostic delay Diagnostic delay 153 
Impact of the TB-STS on the number of incident TB 
cases 
Transmission model 172 
__ 
7.1 Modelling the effectiveness of the TB-STS 
The model structure is shown in Figure 24, page 80.Three epidemiological scenarios 
were considered in the transmission model, representing the variation in ARI within 
the UK population. For each scenario, the age-specific annual TB incidence, 
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proportion of individuals who have ever been infected, and proportion of new cases 
that have been newly infected or recently re-infected are shown in Figure 41.  
Figure 41 – Characteristics of the epidemiological scenarios considered in the transmission 
model 
 
A. The age-specific annual TB incidence per 100,000 population.   
B. The age-specific proportion of individuals who have ever been infected.   
C. The age-specific proportion of new cases that have been newly infected or reinfected in the previous 5 years 
ARI annual risk of infection 
 
Figure 42 summarizes predictions of the impact of the TB-STS on TB incidence for 
the three epidemiological scenarios considered.  For the white UK population, the 
predicted incidence decreased from four to less than one per 100,000 per year 
between 2005 and 2030 in the absence of additional interventions.  Reducing 
diagnostic delay and/or increasing the proportion of infections that were detected in 
this population because of the TB-STS is predicted to have little impact on TB 
incidence (Figure 42A).  
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For populations with a similar incidence to that of the non-white UK born 
population, increasing the proportion of infections detected from 3% per year to 13% 
is predicted to lead to a small reduction in TB incidence, compared to that in the 
absence of the TB-STS.  For example, for this scenario, 20 years after the 
introduction of the TB-STS, the predicted incidence is 11% less than that in the 
absence of TB-STS (Figure 42B) (ranging between 4% and 12% for pessimistic and 
optimistic assumptions, respectively, relating to uptake and completion of preventive 
treatment), with about one case prevented per 100,000 per year over this period 
(Figure 42B).  Combining an increase in the proportion of infections detected to 13% 
per year with a one week reduction in diagnostic delay is predicted to approximately 
double the reduction in TB incidence, with just over two cases prevented per 100,000 
per year over the period 2010-2030 (Figure 42D).  
Of the scenarios considered, the TB-STS is predicted to lead to the greatest 
reductions in TB incidence in high transmission settings, similar to the non-UK born 
population. For this scenario, 20 years after the introduction of the TB-STS, the 
predicted incidence is about 15% less than that in the absence of TB-STS (Figure 
42C), with about 10 cases prevented per 100,000 per year over this period (Figure 
42C). When an increase in the proportion of infections detected to 13% per year is 
combined with a one week reduction in diagnostic delay, the reduction in TB 
incidence increases to 40% (Figure 42C), with over 30 cases prevented per 100,000 
per year over the period 2010-2030 (Figure 42D). Under this scenario, and broadly 
accounting for the relative proportions of people living in low, medium and high 
incidence areas in the population (based on primary care trust-level data),
204
 we 
would estimate that the TB-STS would prevent approximately 1400 cases in England 
per year (although this does not account for the range in the number of cases 
prevented in a given setting, nor the age distribution, migration rate or HIV 
prevalence in the different populations). 
175 
 
Figure 42 – Predicted impact of the TB-STS   
 
Predicted impact of reducing diagnostic delay from 12 to 11 weeks and increasing the proportion of infections 
that are detected by the TB-STS from 3% to 13%. The number of cases occurring per 100,000 per year in a 
setting in which the tuberculosis incidence is (A) similar to that in the white UK population (declining ARI)), (B) 
similar to that in the non-white UK born population group (ARI=0.1%/year), (C) similar to that in a high 
transmission, non-UK born population group (ARI=1%/year), and (D) shows the average annual number of cases 
prevented per 100,000 population for these scenarios over 20 years after the introduction of the TB-STS. 
 
 
7.2 The cost-effectiveness of the TB-STS 
The structure of the cost-effectiveness model is shown in Figure 25, page 82. Cost of 
the TB-STS and QALY estimates associated with the TB-STS are shown in 
Appendix 6. 
Transmission model outputs 
The results of the transmission model provided estimates for the population of 
England over a 20-year period (2010-2030) assuming a constant risk of infection of 
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0.1% per annum for each modelled scenario of: the number of contacts with LTBI 
identified, the number of contacts starting preventative treatment, the number of 
people with active TB diagnosed and starting treatment, as well as the impact on the 
number of incident TB cases (Table 37). The outputs of the transmission model 
shown in Table 37 were input into the cost-effectiveness model. The baseline (S0) is 
intended to reflect the expected costs and Outcomes of the TB control system in the 
absence of the TB-STS. This is modelled assuming that 3% of previously infected 
individuals are identified per year and that mean diagnostic delay is 12 weeks. A 
further 14 scenarios are considered, that vary the assumptions for the proportion of 
LTBI detected between 3% and 13% and diagnostic delay between 8 and 12 weeks.  
This exercise is intended to assess what impact the TB-STS would have to have in 
order to be cost-effective.  
The cost-effectiveness scenarios of the TB-STS are estimated under the assumptions 
that it: 
a) Increases the proportion of infected cases detected from 3% to 4%, 5%, …, 
13% (S1 to S10) with a constant diagnostic delay of 12 weeks. 
or 
b) Reduces the diagnostic delay from 12 weeks to 11, 10, 9, 8 weeks (S11 to 
S14) with a fixed LTBI of 3%. 
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Table 37 – Summary of transmission model results for baseline (S0) and 14 scenariosa 
Scenario % LTBI 
found 
DDb 
(weeks) 
LTBI 
diagnosed 
LTBI 
starting 
treatment 
New TB 
casesc 
TB cases 
diagnosedc 
TB cases 
starting 
treatment 
S0 3% 12 8,987 8,538 6,672 7,502 6,640 
        
S1 4% 12 11,298 10,733 6,585 7,408 6,556 
S2 5% 12 13,334 12,668 6,502 7,316 6,475 
S3 6% 12 15,131 14,375 6,420 7,227 6,397 
S4 7% 12 16,718 15,882 6,342 7,140 6,321 
S5 8% 12 18,120 17,214 6,265 7,056 6,246 
S6 9% 12 19,361 18,393 6,191 6,974 6,174 
S7 10% 12 20,459 19,436 6,118 6,895 6,104 
S8 11% 12 21,432 20,360 6,048 6,817 6,036 
S9 12% 12 22,295 21,180 5,979 6,742 5,969 
S10 13% 12 23,060 21,907 5,912 6,668 5,904 
S11 3% 11 7,835 7,443 4,964 5,631 4,990 
S12 3% 10 7,011 6,661 3,828 4,379 3,884 
S13 3% 9 6,412 6,091 3,051 3,520 3,125 
S14 3% 8 5,964 5,666 2,504 2,912 2,588 
aMean number of cases per year for population of England (53m) over 20 years, assuming constant ARI of 0.1%. 
bDD Diagnostic delay  
cThe estimated number of cases diagnosed exceeds the number of new cases in each year as there is a pool of 
cases who have previously not been diagnosed or who have defaulted from treatment. 
 
Scenario analysis 
The incremental costs and effects of the TB-STS under each scenario are shown in 
Table 38. Under our base case assumptions, if the TB-STS had increased the 
proportion of LTBI detected from 3% to 4% with no impact on the mean time to 
diagnosis for active cases, it would not be cost-effective.  Although the improvement 
would have prevented an estimated 1,726 cases of TB (over 20 years for the 
population of 53m), saving approximately £3.8m in diagnosis and treatment costs, 
this cost was more than offset by the direct cost of the TB-STS (£14.3m), the 
additional costs of screening contacts (£32.5m) and of prophylactic treatment 
(£22.2m).  The net impact on health expenditure was an estimated increase of 
£65.2m.  This cost increase is associated with a QALY gain of around 682 years of 
healthy life, giving an estimated ICER of £95,628 per QALY gained, which is well 
above the range usually considered to be cost-effective in the NHS (a maximum of 
£30,000 per QALY gained). 
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Estimated cost-effectiveness did improve under the assumption that the TB-STS 
achieved a greater increase in the proportion of LTBI detected.  However, over the 
range tested this improvement was still not sufficient to bring the ICER below the 
£30,000 threshold (scenarios S1 to S10 compared to S0, Table 38).  If the 
introduction of the TB-STS has increased the identification of an additional 10% of 
prevalent LTBI - an additional 281,461 people diagnosed with LTBI over 20 years - 
the estimated cost per QALY gained was £54,539 (scenario S10 compared to S0, 
Table 38). 
In contrast, the results were very sensitive to small reductions in the average time 
from onset of symptoms to the start of treatment for active disease.  A reduction from 
12 weeks to 11 weeks was estimated to yield a large reduction in the number of 
incident TB cases, and hence in the numbers of contacts to be screened and in people 
requiring prophylactic treatment (S11 and S12 compared to S0, Table 38).  There 
was therefore a net saving in healthcare expenditure (almost £85m saved), as well as 
a large health improvement (16,000 QALYs gained).  Bigger reductions in the 
diagnostic delay, would achieve even larger cost savings and health improvements. 
Deterministic sensitivity analysis 
Results under a range of other changes to the model parameters are shown in Table 
39.  Unless stated otherwise, these analyses all relate to the comparison between 
scenarios S1 and S0 (1% increase in the proportion of prevalent LTBI cases 
diagnosed with TB-STS; no difference in diagnostic delay), and with all other 
parameters held constant at the base case values.  
Other than reductions in diagnostic delay, the only changes tested that gave an 
estimated ICER below the usual NICE threshold of £30,000 per QALY related to an 
increase in the QALY loss from TB.  However, in order to achieve this result, quite 
strong assumptions were required about the TB-related mortality and/or morbidity: 
equivalent to an overall mean loss of two full years of healthy life per case (see row 
in Table 39 labelled “TB case fatality”). 
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Table 38 – The incremental costs and effect and the resulting ICERs for the scenarios explored compared to the baseline (S0)a 
Scenario % LTBI 
detected 
DDb Contact 
screening 
£ 
Prophylactic treatment 
£ (QALYs) 
TB diagnosis & treatment 
£ (QALYs) 
Total incremental 
costc 
£ 
Total 
incremental 
effect (QALYs) 
ICERd 
(£ per QALY 
gained) 
S1 4 12 32,539,484 22,240,304 (-27.70) -3,809,472 (707.27) 65,219,944 682 95,628 
S2 5 12 61,643,979 42,132,714 (-52.48) -7,511,038 (1,394.66) 110,515,283 1,345 82,190 
S3 6 12 87,710,528 59,948,754 (-74.68) -11,110,571 (2,063.18) 150,798,339 1,991 75,742 
S4 7 12 111,087,030 75,926,436 (-94.58) -14,613,304 (2,713.84) 186,649,790 2,622 71,194 
S5 8 12 132,081,043 90,275,317 (-112.45) -18,024,077 (3,347.55) 218,581,910 3,238 67,515 
S6 9 12 150,961,412 103,179,853 (-128.53) -21,347,548 (3,965.19) 247,043,344 3,839 64,349 
S7 10 12 167,965,309 114,801,926 (-143.01) -24,587,951 (4,657.47) 272,428,913 4,427 61,539 
S8 11 12 183,301,973 125,284,356 (-156.06) -27,749,123 (5,155.15) 295,086,833 5,002 59,999 
S9 12 12 197,154,669 134,752,505 (-167.86) -30,834,794 (5,728.84) 315,322,008 5,563 56,678 
S10 13 12 209,685,394 143,317,116 (-178.53) -33,848,402 (6,289.25) 333,403,736 6,113 54,539 
S11 3 11 -13,640,543 -9323,117 (11.61) -76,153,948 (16,032.60) -84,867,979 16,047 * 
S12 3 10 -23,552,487 -16,097,775 (20.05) -128,625,846 (26,950.25) -154,026,480 26,973 * 
aBaseline scenario (S0) assumes 3% LTBI detected and 12 weeks diagnostic delay 
bDD Diagnostic delay  
cTotal incremental cost includes the incremental cost of running the TB-STS (£14,298,781) and the costs saved from the identification of false positive TB diagnoses (-£49,153) and the 
associated QALY gain (2.45) 
dICER = Incremental cost of the TB-STS(£) / Incremental effect of the TB-STS (in QALYs). The NICE threshold of cost-effectiveness is £20,000-30,000 per QALY gained 
*The costs saved and the QALYs gained outweigh the additional costs associated with the TB-STS in these scenarios 
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Table 39 – Results of the deterministic sensitivity analysis 
Parameter changed (base 
case value) 
Parameter  
values tested 
Incremental 
cost  
(£) 
Incremental 
effect 
(QALYs) 
ICER  
(£ per 
QALY) 
% LTBI detected +1% with TB-STS (base 
case) 
£65,219,944 682 £95,628 
 +10% with TB-STS £333,403,736 6,113 £54,539 
     
Diagnostic delay -1 week with TB-STS  -£64,867,979 16,047 Dominant 
(no reduction) -4 weeks with TB-STS -£239,774,497 40,078 Dominant 
     
Discount rates 1.5% for QALYs £65,219,944 1,093 £59,682 
(3.5% QALYs, 3.5% costs) 0% for QALYs £65,219,944 1,643 £39,707 
     
Time horizon 15 years £55,453,941 431 £128,807 
(20 years) 10 years £42,475,021 212 £200,212 
     
Cost of software £500,000 £65,622,236 682 £96,218 
(£264,593) £1,000,000 £66,476,695 682 £97,471 
     
Cost to HPUs £50,000 pa £64,289,459 682 £94,234 
(£113,256 pa) £500,000 pa £70,908,886 682 £103,970 
     
False positives 10 cases avoided pa £65,170,792 684 £95,214 
(5 avoiding treatment pa) 100 cases avoided pa £64,286,046 729 £88,233 
     
Utility loss from FP 0.5 for 4 months £65,219,944 692 £94,273 
(basecase 0.1 for 4 months) 0.5 for 12 months £65,121,639 716 £90,909 
     
Contacts screened 
(basecase 4.11) 
2 contacts per LTBI 
diagnosed 
£49,073,148 682 £71,953 
 6 contacts per LTBI 
diagnosed 
£81,858,521 682 £120,025 
     
Adverse effects of CPx 0% £65,219,944 710 £91,896 
(basecase 10%) 100% £65,219,944 433 £150,737 
     
Yield of TB diagnosis 2 per case £66,844,254 682 £98,010 
(5 investigated per case) 10 per case £62,512,761 682 £91,659 
     
TB case fatality 1% all ages £65,219,944 330 £197,537 
(0.3% 0-4 to 17.6% 55+) 10% all ages £65,219,944 2,249 £28,995 
     
TB morbidity 0.05 QALYs lost per case £65,219,944 599 £108,832 
(0.12 QALYs lost per case) 1 QALY lost per case £65,219,944 1,684 £38,732 
     
Cost of prophylaxis £300 per case £51,955,851 682 £77,180 
(£743 per case) £1,000 per case £72,900,343 682 £106,890 
     
Cost of treatment £500 per case £65,854,499 682 £96,559 
(£1,114 per case) £5,000 per case £61,202,523 682 £89,738 
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7.3 Discussion 
7.3.1 Strengths and limitations of the methods used to evaluate the Outcomes 
of the TB-STS 
The transmission model extends previous models considering the transmission 
dynamics of M. tuberculosis.
112,208
 The model takes into account the variation in 
transmission dynamics across age, migration patterns, and the use and effectiveness 
of preventative therapy. It is integrated with the rest of this evaluation, using data 
from the investigations into contact tracing yield and diagnostic delay (Figure 26, 
page 86). In addition, it inputs into the cost-effectiveness model, allowing for the 
effectiveness and cost-effectiveness of the TB-STS to be estimated over a 20-year 
time horizon. Likewise, the cost-effectiveness model is integrated into the rest of the 
evaluation. As well as being directly linked to the transmission model, it derives 
parameters from the cross-sectional surveys, contact tracing yield and diagnostic 
delay analyses, and the false positive isolation survey (Table 36, page 172). 
The outputs of the transmission model suggest that the impact of the TB-STS is 
different across the three epidemiological scenarios, most notably having very little 
impact in the white UK-born population. These differences result from the model 
assumptions; specifically those around the assumptions underlying the scenarios 
considered and PT. Firstly, the assumptions regarding the proportion of LTBI and 
TB in the population across different age groups, and the proportions due to 
reactivation versus recent transmission are important in understanding the 
transmission model outputs (Figure 41). Secondly, no one aged ≥35 years and 95% 
of those aged <35 years who are identified as having been infected are assumed to 
start PT,
219
 with 85% of these completing the full course of treatment. PT is assumed 
to provide 65% protection against disease whilst individuals are taking the 
treatment
220,221
 and the full course of PT is assumed to fully cure the infection so that 
individuals can only develop disease subsequently if they are reinfected.   
Considering these assumptions, the model estimated that the TB-STS would have 
minimal impact in the white UK-born population. This is because the proportion of 
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individuals who have been infected is low (<10%) for those aged <55 years, but 
increases to 50% for those aged ≥55 years (Figure 41B). Therefore the impact of 
identifying an increased proportion of LTBI will not have an impact on TB incidence 
because those being identified would not be eligible for PT. In addition, because the 
predicted TB incidence is highest amongst those aged ≥55 years (Figure 41A), and 
the proportion of disease that is attributable to recent transmission decreases steadily 
with increasing age, reaching <10% for those aged ≥55 years, the impact of reducing 
diagnostic delay in the white UK-born population is smaller compared with that in 
the alternative epidemiological scenarios where the proportion of TB attributable to 
recent transmission is correspondingly greater. Conversely, the non-white UK-born 
and non-UK-born scenarios assume that a greater proportion of LTBI is in those aged 
<35 years (Figure 41B), compared to that for the white UK-born scenario, so can be 
given PT.  This means that, due to a large proportion of TB in these scenarios being 
in younger age groups (Figure 41A), the proportion of TB attributable to recent 
transmission in the overall population is >90%, which, in turn, leads to an increased 
impact of increasing the proportion of LTBI detected and reducing diagnostic delay 
on TB transmission in these populations. 
There are several limitations to the transmission model. An important limitation is 
that there are no data on the percentage of all infections in the population that were 
detected before the introduction of the TB-STS and it is therefore assumed that this 
equalled 3%. Large screening studies may help to calculate this percentage. A further 
limitation is that there are no data on the ARI in the population, which is likely to 
vary between communities and different parts of the country. We have also assumed 
that preventative treatment cures infections. The extent to which this is realistic is 
presently unclear
208
 and, if preventative treatment does not cure infections, we may 
have overestimated the number of cases prevented through detecting a given 
proportion of infections. The model did not include HIV prevalence or drug 
resistance because the prevalence of HIV and drug resistance is relatively low in 
England
3 
and to limit the complexity of the model. 
This analysis failed to demonstrate that the TB-STS is a cost-effective use of 
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resources.  It suggests that it is unlikely that earlier identification of false positive 
cases related to laboratory contamination, or increases in the identification and 
prophylactic treatment of contacts with LTBI could, on their own, justify the cost of 
the system.  It was not possible to conduct a probabilistic sensitivity analysis to 
characterise the overall impact of uncertainty over the parameters and assumptions 
over the transmission model and cost-effectiveness analysis. This is because of time 
and resource restraints and because of the high level of uncertainty around the model 
parameters in the first place.  However, simple deterministic sensitivity analysis 
suggested that the results are, with one major exception, quite robust to plausible 
changes in most parameters.  The key uncertainty relates to the lack of evidence over 
whether the TB-STS is associated with earlier diagnosis and treatment for active 
cases. 
Although the proportion of LTBI detected is not known, the possibility of the TB-
STS increasing this by 1% seems more likely than decreasing the diagnostic delay by 
one week. This is because diagnostic delay is driven by the passive presentation of 
people with TB due to recent transmission and reactivation and those identified 
through active case finding, and the TB-STS can only have an impact on those 
identified through the latter route. The proportion of prevalent LTBI detected 
increases as more people are screened. The non-significant increase in the mean 
number of contacts identified and screened per index case between the initial and 
follow-up surveys (Table 25, page 146) suggests that the TB-STS might increase the 
number of contacts screened, so could plausibly increase the proportion of LTBI 
detected. In addition, if the TB-STS were to improve contact tracing practices (as 
postulated by HPU strain typing leads in the semi-structured interviews), an increase 
in the number of contacts screened would be expected.
222
 
The finding that the service is not cost-effective is consistent with evidence from the 
Birmingham and Bradford areas. The two studies demonstrated the high workload 
associated with cluster investigations.
223,224
 One of the investigations presented did 
not identify any further transmission of TB, but required an estimated 20 hours of 
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work. If a full cost-effectiveness analysis had been conducted in that setting, it seems 
unlikely that it would have been found to be cost-effective. 
7.3.2 Summary of findings 
The mathematical modelling suggested that increasing the proportion of infections 
detected would have little value in reducing TB incidence in the white UK born 
population. However, in the non-white UK born and non-UK born populations, over 
20 years, if detection of LTBI increases from 3% to 13% per year then TB incidence 
would decrease by 11%; reducing diagnostic delay by one week could lead to 25% 
reduction in incidence. 
However, even assuming the TB-STS leads to a small (1%) improvement in the 
contact tracing yield in a medium-incidence population (similar incidence to that of 
the non-white UK born population), the service was not estimated to be cost-
effective over a 20-year period: £95,628 per quality adjusted life year (QALY) if the 
proportion of LTBI detected were to increase from 3% to 4%.  Assuming an increase 
from 3% to 13%, the estimated incremental cost per QALY gained (£54,539) still did 
not reach a level considered to be cost-effective in the UK.  These results were much 
more sensitive to reductions in the diagnostic delay: e.g. if the TB-STS reduced 
diagnostic delay by one week, the system would save £85m and gain over 16,000 
QALYs over 20 years. 
185 
 
Chapter 8. Discussion 
The discussion aims to contextualise the findings of this evaluation. In this chapter I 
summarise and evaluate the main findings presented in this thesis. This chapter 
discusses the strengths and limitations of the research as a whole, outlines 
recommendations for implementing and evaluating a public health intervention on a 
national scale, and suggests directions for future research. The strengths and 
limitations of each sub-study and how the findings relate to previous studies have 
been discussed at the end of each chapter (Structures: page 101; Processes: page 
128; Outputs: page 157; Outcomes: page 181).  
__ 
8.1 Summary of thesis 
The TB-STS involves MIRU-VNTR typing of the first isolate from every TB patient 
for the prospective identification, reporting and investigation of strain typing 
clusters, to be used in real time to inform public health action. 
A mixed-method evaluation of the TB-STS in England was conducted between 
January 2010 and April 2013. Using an adapted Donabedian evaluation framework, 
the Structures were described, the Processes investigated, the Outputs measured, and 
the Outcomes estimated. The Context of the TB-STS is explored here. The methods 
used and the main findings are summarised in Table 40.  
186 
 
Table 40 – Table of objective, study, main findings, publication  
Objective Methods Main findings Page Pub. 
1. To examine the effect of 
study design and setting on 
the estimation of the 
proportion of clustering by 
MIRU-VNTR strain typing 
Systematic review of the literature The number of MIRU-VNTR loci typed, requiring consent to type patient isolates (as a proxy 
for sampling fraction), the TB incidence and the maximum cluster size had a significant 
association with the proportion of clustering. 
40 94 
2. To describe the 
Structures of the TB-STS 
Description of the service based on grey 
literature, and conversations with 
stakeholders/key informants  
The TB-STS is a complex intervention with multiple interacting components, relying on 
different elements of the public health and national health services in England to communicate 
and cooperate. Crucially, the software to link the services together was not completed within 
the evaluation time period. Interviews found people had mixed experiences, but identified 
broader benefits, of the TB-STS. 
87  
3. To evaluate the 
Processes of the TB-STS 
Initial and follow-up cross-sectional 
surveys and semi-structured interviews with 
health protection staff  
The TB-STS had been integrated into the TB services across England by March 2012, but 
perceived usefulness of the service did not change. There was improved reported knowledge of 
strain typing and increased frequency of use. The majority of health protection staff received 
the strain typing after they had completed contact tracing activities and the proportion of time 
spent on investigating TB transmission increased. Interviews explored mixed experiences of 
the TB-STS, but identified broader benefits of the TB-STS such as the overall strengthening of 
information collection for contact tracing and its contribution to a greater understanding of TB 
epidemiology. 
103 202 
4. To evaluate the Outputs 
of the TB-STS 
Analysis of cluster investigations, contact 
tracing yield, diagnostic delay, rate of 
cluster growth, and false positive TB 
isolation. 
Between 2010 and 2012, 17,168 isolates were typed, 84.6% of which had at least 23 completed 
MIRU-VNTR loci. The TB-STS identified 17 additional false positive TB diagnoses. The 
direct outputs and outcomes of cluster investigations were not well captured so could not be 
used to inform the evaluation. Indirect outputs of cluster investigations were explored instead. 
The TB-STS had no significant effect on contact tracing yield, diagnostic delay or the rate of 
cluster growth. 
111 225 
5. To evaluate the 
Outcomes of the TB-STS 
Deterministic TB transmission model and 
cost-effectiveness model 
The mathematical model estimated that the TB-STS would have little value in reducing TB 
incidence in low incidence settings and, of the scenarios explored, the greatest potential impact 
is estimated in high incidence settings if the proportion of LTBI that are detected increases to 
13% and diagnostic delay reduces by one week. The TB-STS was not estimated to be cost-
effective over 20 years (£95,628/QALY). 
172 225 
6. To contextualise the 
findings of this evaluation 
Discussion The TB-STS is not effective or cost-effective, but broader benefits that were not accounted for 
in the modelling justify its continuation. 
185  
Pub. Publication resulting from this thesis
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8.2 The wider context of the TB-STS 
The scientific, economic and technological context of the TB-STS can be considered 
in terms of: 
1. The increase in funding for the application of molecular biology to TB 
epidemiology and public health; 
2. Global economic downturn leading to austerity measures; and 
3. The political will to utilise novel molecular techniques to improve public 
health. 
During the evaluation period, there has been increasing interest in the application of 
molecular biology to epidemiology and public health. In 2009 the UK Clinical 
Research Consortium awarded £5.1m to the Modernising Medical Microbiology 
Consortium in Oxford to investigate the application of WGS to infectious disease 
surveillance and molecular epidemiology – M. tuberculosis was one pathogen of 
interest.
85
 The Oxford Consortium includes the Oxford Biomedical Research Centre, 
Wellcome Trust Sanger Institute in Cambridge and PHE, involving PHE in the 
forefront of molecular epidemiology and infectious disease surveillance. In addition 
two Health Innovation Challenge Fund grants have been awarded by the Wellcome 
Trust to Oxford and Cambridge Universities to translate WGS into routine clinical 
microbiological practice and to develop a world-class system of active 
surveillance.
227
  In 2013, the UK Prime Minister pledged £100 million to the 100k 
Genome Project, which includes the whole genome sequencing of M. tuberculosis.
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This increase in funding for the application of molecular biology to TB epidemiology 
and public health reflects the scientific and funding communities’ interest in the area 
and their incentive to make it work. 
Following an economic downturn at the end of the 2000s, the UK entered a period of 
‘austerity’, whereby spending cuts were applied across the Government and quasi 
autonomous non-governmental organisations (quangos) were dismantled and either 
shut down or moved into Government. The Health Protection Agency was a quango 
and following large budget cuts from 2010 onwards, in April 2013 it became Public 
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Health England, part of the Government’s Department of Health. This had 
implications for the resources made available to the TB-STS and hence impacted on 
its implementation. While new resources were being invested in developing WGS for 
TB, substantial reductions were made to the public health infrastructure. This has 
limited PHE’s ability to utilise and evaluate information generated by the TB-STS 
and more recently WGS, through the investigation of potential outbreaks – one of the 
main justifications for such a service. 
A strong political will to utilise novel molecular techniques to protect and improve 
public health is evident in England. Despite the findings of this evaluation, PHE are 
exploring the use of universal prospective WGS for front-line TB control and are 
piloting such a service in the Midlands (Prof Ibrahim Abubakar, personal 
communication). Although an evaluation of the service is planned, the results will 
not be made publicly available. It is clear that WGS has some advantages over a 
MIRU-VNTR typing service,
50,78,82
 but it is currently more expensive so its cost-
effectiveness is uncertain.  
8.3 Evaluation framework and design 
As a result of the complexity of national public health interventions or policies, many 
are not evaluated. Or, if they are, they do not take into account the entirety of the 
intervention and reasons why or how it might or might not work. Instead, they may 
focus on the easy (or easier) to measure outcomes. This leaves policy makers 
vulnerable to the enthusiasm around new technologies and the idea that because this 
new technology is useful in some settings, it will be useful across the country. It is, 
therefore, commendable that PHE included a prospective evaluation in the 
development of the TB-STS. 
The framework adopted for the evaluation of the TB-STS was an adapted version of 
the Donabedian healthcare evaluation framework,
161
 designed to describe and 
evaluate the entirety of the service. The Donabedian framework is a simple 
evaluation model that divides the service into Structures, Processes, Outputs and 
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Outcomes. This ensures that all aspects of the service are taken into account, from 
the service design, to its day-to-day functioning, to its overall impact. The framework 
prevents the evaluator from focussing on just one element of the service, and makes 
sure that the parts of the service that can be adjusted and changed are included in the 
evaluation. As a result, recommendations have been made to PHE about how to 
improve the service that involve structural and process-driven changes that are easily 
implemented, rather than introducing only output and outcome-related targets (Box 
6, page 204). 
An additional advantage of the Donabedian framework is that it helps to identify how 
to assess each component and how the results of each component might feed into 
another. In this evaluation, the programme cost of the TB-STS was determined from 
the description of the Structures, results of the cross-sectional surveys were used to 
develop the semi-structured interviews and parameterise the cost-effectiveness 
model, the false positive TB isolation results were input into the cost-effectiveness 
model, the analysis of contact tracing yield and diagnostic delay were used in the 
transmission model, which input into the cost-effectiveness model (Figure 26, page 
86). 
The Donabedian model was adapted by including an overarching component which 
acknowledges the context of the TB-STS. This discusses the overarching benefits 
and costs of the TB-STS that may not have been captured by the quantitative 
evaluation methods.  
The evaluation framework applied here also has limitations. For one, some might 
argue that it is too simplistic. There is a wealth of evaluation literature prescribing 
different approaches to evaluation and whilst these can be helpful in challenging a 
researcher to think through their model of evaluation and what questions are being 
asked, the evaluation theories are often more than approaches, but methodologies, 
thereby being prescriptive about how they should be done.  
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This evaluation was commissioned by PHE (then the Health Protection Agency) to 
inform their TB strain typing strategy. Although PHE can be praised for their 
inclusion of the evaluation into the TB-STS structure, the timing of, and budget for 
the evaluation restricted the evaluation design options. In addition, PHE employees 
were helpful and compliant with the data collection conducted for the evaluation and 
the gathering of information about the service, but further involvement of PHE staff 
would not have been appropriate. On the other hand, NHS staff were not required to 
support the evaluation, so any information from them was voluntary. The 
Donabedian framework did not limit the evaluation to a particular methodology and, 
as a result, the design of the evaluation could reflect these constraints. 
Ideally, the evaluation would have been either a clustered trial comparing sites that 
were randomly allocated the TB-STS to those that did not have the TB-STS, or a 
controlled before and after design where the baseline before the service could be 
compared to a time after the service had been implemented.
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 However, due to the 
timing of the evaluation, the national implementation of the service, and the limited 
availability of baseline data, these evaluation designs could not be used. Therefore, a 
mixed-methods approach was used to evaluate this service, including qualitative, 
quantitative, direct and indirect methods. A mixed methods approach, as opposed to 
randomised trial, can be the most appropriate way of evaluating a national 
program.
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This flexible and responsive approach to evaluation is shared by Habicht and 
colleagues
230
 who argue that the evaluation design will depend on who the evaluation 
is for (who the decision-maker is) and what types of decisions will be made as a 
consequence of the evaluation. Their framework is based on two axes that concern 
the indicators of interest (provision, utilisation, coverage or impact of the 
intervention) and the type of inference to be made (adequacy, plausibility or 
probability). In the context of the TB-STS, which was evaluated to inform PHE’s 
strain typing strategy in England, the lack of adequate data have resulted in 
recommendations based on both probability and plausibility.  
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A recent evaluation of an intervention to find and treat hard to reach TB patients in 
London is an example of how a pragmatic evaluation of a complex intervention can 
influence policy.
11
 The ‘find and treat’ evaluation could not be designed as a 
randomised trial. Despite this, the findings of the evaluation were used to influence 
policy on targeted active case finding for TB.
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8.4 Evaluating the Processes 
Evaluating the Processes can provide the insight and context necessary to interpret 
the Outputs of a service (e.g. has the service been implemented properly? Has the 
service been implemented differently in different places?), help to explain 
differences between the observed and expected Outcomes, and identify ways of 
intervening to improve the service.
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 The semi-structured interviews helped to better 
understand how the TB-STS was implemented; how the TB-STS had been 
implemented in different HPUs and how health protection staff used the service. 
Although many limitations of the TB-STS were raised, the interviews also elicited 
support for the service. 
The implementation of the service, supporting the interpretation of the outputs, the 
identification of ways of improving the service, and the broader benefits of the 
service that were identified through the interviews are now discussed in turn. 
Implementation 
Evidence for the successful implementation of the laboratory elements of the TB-
STS (such as the typing of isolates and reporting of strain typing results) can be 
found in the laboratory Outputs (page 135). The implementation of the public health 
component of the TB-STS is more complex, as was identified by evaluating the 
Processes: findings from the surveys and the interviews suggest that some of the 
public health elements of the TB-STS (such as the preliminary cluster reviews and 
the dissemination of cluster reports) were well implemented, but other elements were 
less well implemented (such as the reach of the training provided about the TB-STS 
and support for HPUs to conduct cluster investigations). These findings impact on 
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the way the public health Outputs of the TB-STS were interpreted, and helped to 
identify areas that could be improved within the service. 
The lack of a functioning STM raises concerns of type III error. The failure to 
develop the STM within the evaluation period resulted in insufficient data collection 
and data quality, as well as creating the problem of evaluating a service that is not 
properly implemented. However, whilst there would have been benefits attained with 
the release of the STM in the standardisation of reporting and data access, the extent 
to which a functioning STM would impact on the Outputs of the service and the 
consequent impact on the effectiveness of the service is unknown.  
Taking into account the interim systems that were implemented to perform the 
functions of the STM, such as the cluster reports generated by the laboratories and 
CIs, and the alternative data collection and storage methods developed (see Table 8, 
page 92 for more detail), one cannot conclude that the introduction of the STM 
would have a profound impact on the functioning of the service. In addition, it is not 
clear that the STM would have a significant impact on the diagnostic delay – a key 
driver for the effectiveness of the TB-STS – for the following reasons: 
1. The analysis and reporting of clusters based on the criteria in the strain typing 
Handbook for local and national clusters happened promptly and was sent to 
HPUs and clinics regularly. However, it would have been useful to reconcile 
this information with other data in the surveillance system using the STM, 
improving the timeliness of the cluster reports by removing the need for CIs 
to collate the information. 
2. A major issue identified by the semi-structured interviews with HPUs was 
that by the time isolates were cultured and subsequently typed prospectively, 
most HPUs already knew about the links between cases that they considered 
to be important. Therefore, the strain typing arrived too late not because the 
laboratories were not undertaking the software based analysis promptly due 
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to the lack of the STM, but because the process of getting to the fingerprint 
takes too long. 
3. One area where the STM would have been particularly useful (even if it did 
not inform the investigation of clusters) is in providing the data to 
demonstrate the effect of the TB-STS on the diagnosis of additional cases in 
clusters. Again, for many clusters there was an attempt to collect the 
information that would have gone into STM using paper forms but the 
response rate was very variable. There is no reason why this information 
would be more complete using the STM. 
4. In addition, one can speculate that providing the software is one step, but 
getting people to use it is another step entirely. PHE’s experience of 
developing and launching the ETS tells us that it can be very difficult to get 
people working across PHE and the NHS to adopt a new software system – 
the ETS was introduced in 1999 and had been adopted electronically by the 
entire country by 2010 (personal communication with Dr Laura Anderson 
from PHE, 2010). 
Supporting information to help interpret findings 
The interview findings can be integrated to help better understand and interpret the 
results of the rest of the evaluation. The semi-structured interviews were used to find 
out more about what a cluster investigation involves in each HPU and how strain 
typing influenced decisions. It was identified that HPUs used the strain typing 
differently and received different support from the CIs, thereby helping to explain the 
variation in the implementation of the TB-STS and helping to elucidate the survey 
findings around workload and cluster investigation activities. For example, the 
increasing cluster investigation workload for HPU staff without any increase in the 
number of epidemiological links found between clustered cases may reflect the lack 
of resources available for clinic staff to conduct further contact tracing around an 
historical patient.  Alternatively, this may be because the criteria used to initiate a 
cluster investigation are not appropriate – importantly, the semi-structured interviews 
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identified that HPUs did not adhere to the thresholds stated in the guidelines, but 
adapted them to their local situation to make them more feasible given local case 
load and the resources available.  
The cross-sectional surveys suggested that the strain typing was usually received 
after contact tracing had already been completed. Consistent with this, many 
interviewees commented that the strain typing was often received too late to have an 
impact on their decision-making. In some instances, this was reassuring as the strain 
typing confirmed what was already suspected. However, this was viewed by some as 
frustrating as the strain typing provided no additional contribution to TB control. In 
conclusion, the hypothesis that the TB-STS would contribute towards contact 
investigations in real time was not plausible. 
Identifying ways to improve the service 
Firstly, the surveys identified gaps in the training strategy. Nurses were not included 
in the training strategy, but the surveys found that nurses had the lowest self-rated 
knowledge of strain typing. In addition, interviews identified that some HPUs used 
the strain typing as a way of engaging nurses in TB control, suggesting that, since the 
service relied on nurses to collect more information for cluster investigations, 
including nurses in the training strategy could help improve the functioning of the 
service.  
Secondly, the interviews identified a lack of resource for the public health 
implementation of the TB-STS.  The problem with the design of the TB-STS was 
that it did not account for the input required from TB nurses in a cluster 
investigation, so no resources were allocated to support them. Alongside this, the 
introduction of the TB-STS coincided with the period of austerity in the UK 
following the global economic downturn. As a result, PHE had to make significant 
savings, and the public health side of the intervention was altered by removing two 
permanent CI positions (who had not yet been hired). This resulted in the remaining 
CIs having too great a workload, therefore not being able to support the HPUs 
sufficiently.  
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The perceived lack of resources for the public health component of the TB-STS was 
a key theme from the interviews that was not captured by the other evaluation 
methods. This finding goes some way to explain why there was no measurable 
impact of the cluster investigations – if there were no resources available to 
investigate clusters then the impact of the investigations would be negligible. As the 
economic instability and political context dictate that public funds are coming under 
increasing pressure, additional new resources for the TB-STS are unlikely (unless it 
is shown to be highly cost-effective, which is not the case). Therefore, cluster 
investigations are unlikely to become effective (or cost-effective). 
Thirdly, the interviews provided a platform to collect suggestions for service 
improvement from the HPUs, the main users of the TB-STS. The suggestions were 
helpful in further understanding the current problems with the service, as well as 
assisting with the development of the recommendations for the future of the service. 
For example, HPUs suggested that reducing the number of clusters requiring 
additional investigation might improve their experience of the TB-STS. This 
suggestion, along with the finding that more investigations were being conducted but 
no impact on TB transmission could be detected, led to the development of a 
recommendation that routine cluster investigations should be discontinued (Box 6, 
page 204). 
Broader benefits of the service 
The interviews identified broader benefits of the service that had not been captured 
by the other evaluation studies. For example, the improved data collection by nurses, 
the move towards standardised data collection for contact tracing in some areas, the 
increased engagement of nurses with the public health aspects of TB (as opposed to 
just the clinical aspects), the improved relationships between HPUs and TB nurses, 
and the improved understanding of TB epidemiology in England. In addition, the 
value of the strain typing information for TB research and its ability to contribute to 
our understanding of TB in England and worldwide was acknowledged. 
Interestingly, even though many people had not experienced any benefit of the TB-
STS to public health, or were frustrated by the additional workload associated with it, 
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some people felt that it would be ‘regressive’ to stop the service. This finding has 
important implications for the introduction of other national interventions, especially 
where the effectiveness and cost-effectiveness is not formally evaluated; it is difficult 
to justify taking something away if there is any perceived benefit, even if the gain is 
small. The broader benefits of the TB-STS are discussed further on page 201. 
8.5 Evaluating the Outputs 
Traditional evaluations measure the outputs of an intervention, as they are usually 
measurable indicators of a programme’s impact. The false positive TB isolation 
identified by the TB-STS is an example of where this is true – to measure the number 
of false positive isolates identified, data were collected from the reference 
laboratories on the number of incidents queried and source laboratories were 
surveyed to establish the outcome of the query and whether the incident had been 
previously identified. However, because the platform for cluster reporting and data 
synthesis was not available during the evaluation, collecting information on cluster 
investigations and their outcomes proved difficult. One way around this was to 
develop interim data collection strategies such as cluster outcome forms and a cluster 
monitoring database. However, there were no additional resources allocated to enter 
the data onto these platforms, so the data collected were sparse. Therefore, consistent 
with the MRC framework,
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 indirect Outputs of the TB-STS were investigated 
based on the hypothesised impact of the service: contact tracing yield, diagnostic 
delay, and rate of cluster growth were all analysed (Figure 11, page 31). There was 
no evidence to suggest that the TB-STS had an effect on the indirect Outputs of the 
TB-STS.  
The approach of this evaluation was pragmatic; using the best quality data available 
to find a different way of measuring the Outputs of the TB-STS. This is an example 
of how the evaluation design can be responsive and flexible to the system it is 
evaluating: by working with the intervention stakeholders to design and implement 
interim solutions, and find alternative indirect ways to measure the impact of the 
intervention. With this, however, come some considerable limitations.  
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There is uncertainty surrounding the conclusions drawn from these studies measuring 
the indirect Outputs of the TB-STS. The studies did not have the most rigorous 
control or comparison group, and were reliant on the limited amount of data 
collected since the initiation of the service in 2010 (which was further reduced to 
data from 2011 to 2012 because 2010 was considered the ‘roll out’ year and the 
evaluation period ended at the end of 2012). As a result, it cannot be concluded that 
the TB-STS did not have an impact on contact tracing yield, diagnostic delay or rate 
of cluster growth; rather, that there is no evidence to suggest an impact. The potential 
variability in the estimate of effect on contact tracing yield and diagnostic delay was 
explored using a deterministic sensitivity analysis in the mathematical and cost-
effectiveness models. 
The indirect methods adopted are useful indicators for assessing the quality of a TB 
control programme. Specifically, contact tracing yield is an indication of how 
effective active case finding is, and diagnostic delay is an indicator of the 
opportunity for onward transmission in the community. The rate of cluster growth is 
not widely used as so few countries have a universal typing service, but may be a 
useful indicator for rate of transmission. Though not direct Outputs of cluster 
investigations, if the TB-STS is helping to interrupt transmission, an increase in 
contact tracing yield, a decrease in diagnostic delay and a reduction in the rate of 
cluster growth should eventually be detectable. The studies presented here could 
provide a useful comparison for a future study after the TB-STS matures. 
As one of the drivers for setting up the TB-STS, it is surprising that the TB-STS did 
not identify much additional false positive TB. This suggests good quality practices 
throughout the laboratory service. If the TB-STS had been introduced to a laboratory 
service with less rigorous quality control procedures, or a service that had not 
previously conducted much strain typing, it may have had a greater impact. The 
experience of conducting strain typing in a UK laboratory since 2003 is likely to 
have resulted in improved systems across all three laboratories. Using strain typing to 
confirm or refute suspected false positive TB identified through another channel such 
as clinical suspicion, might be of more value as it would prevent clusters of false 
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positive patients from being investigated. However, this evaluation did not capture 
those incidents, as it was focussed on the false positive isolation suspected because 
of strain typing. A future evaluation might consider including this in their assessment 
of the TB-STS. 
8.6 Evaluating the Outcomes 
The inclusion of a transmission model and a cost-effectiveness model to this 
evaluation makes the results of the evaluation useful to the decision-makers at PHE 
as well as other countries within the UK and internationally, where the introduction 
of similar services is under consideration. It is also consistent with the MRC 
framework for evaluating complex interventions.
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 Using the effect of the TB-STS 
on TB transmission during the first three years of the service, the models have 
enabled us to estimate its impact over the next 20 years and to postulate whether it is 
a cost-effective use of public funds. 
A benefit of developing these models is that they have identified elements of the TB 
control strategy in England – the proportion of infections detected and the diagnostic 
delay, for example – that, if improved, will have a measurable impact on TB 
incidence over the next 20 years. This gives policy makers a clear objective for 
improving TB control in England, irrespective of the TB-STS. An additional strength 
of the models is their integration with each other and the rest of the evaluation 
(Figure 26, page 86).  
The transmission model and the cost-effectiveness model are limited by a general 
lack of available data (e.g. the proportion of LTBI currently detected, the annual risk 
of infection in different population groups, and the effectiveness of preventative 
therapy are unknown). Simple deterministic sensitivity analyses were used to explore 
the impact of the TB-STS over a 20 year period. It was not possible to conduct a 
probabilistic sensitivity analysis to characterise the overall impact of uncertainty over 
the parameters and assumptions over the transmission model and cost-effectiveness 
analysis due to the level of uncertainty already in the models.  
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More data are needed to determine whether an increase in the proportion of LTBI 
detected is possible. It will likely depend on the quality and completeness of the 
contact tracing that is conducted locally. However, when considering how to spend 
limited public funds for TB control, the screening of migrants from high incidence 
countries has been shown to be cost-effective
232
 and is likely to have a greater impact 
on the proportion of LTBI detected than the TB-STS.  
Assuming that about 15% of all culture positive cases are in a cluster that is 
investigated (~50% clustering over all (Table 19, page 137) and ~30% of clustered 
cases are in a cluster that is investigated (Table 29, page 151)), in theory, the average 
diagnostic delay of all TB cases could be reduced by reducing the diagnostic delay 
among cases that were detected as a result of cluster investigations. However, a large 
reduction would be necessary to have an impact on the overall average. One could 
argue that a reduction of up to six weeks may be plausible given that information 
from the TB-STS would not be available to the local team until about four weeks 
after diagnosis of the index case ( 
Table 13, page 108). By that time the initial examination of the domestic contacts is 
unlikely to have been completed so cluster information could be used to decide 
where else to look for contacts, which would take at least another two weeks. To 
date, there are no data on the proportion of cases that are detected through cluster 
investigations or passive presentation.  However, in the Netherlands, less than 10% 
of cases are detected through cluster investigations,
122
 which would suggest that a 
reduction in the diagnostic delay of more than 10% (i.e. one week) is unlikely to 
have been achieved in the UK.   
No other strain typing services in the world have been assessed for their cost-
effectiveness, making this the first of its kind. This might be because such a service 
is unlikely to be estimated cost-effective (because the impact is likely to be either 
very small and/or very difficult to measure), but the public health and research 
communities rely on such services for surveillance and data collection. There is also 
a competitive prestige associated with being at the forefront of typing across the 
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globe, and once the infrastructure has been developed in order to implement the 
service, it is unlikely to be removed. 
Based on the findings of the transmission and cost-effectiveness models, the TB-STS 
was neither effective nor cost-effective and therefore should not be continued. This is 
especially true where there is an opportunity cost to any public health strategy 
(money spent on the TB-STS cannot be spent on anything else), and where other TB 
control interventions have been shown to be cost-effective.
11,232
 However, it has been 
argued that cost-effectiveness alone should not be the determinant of a health 
investment.
233,234
 Consistent with this view and the evaluation framework used in this 
thesis, these findings are discussed in the following sections of this chapter alongside 
the broader benefits identified in the semi-structured interviews with service users, 
and the political and research contexts. 
8.7 Lack of impact or lack of evidence? 
The lack of observed impact of the TB-STS may be due to:  
1. A true lack of impact;  
2. The inability to observe the impact within the observation period; or  
3. The (limited) implementation of the service.  
Firstly, there may have been no impact, even if the TB-STS had been fully 
implemented. Strain typing information may not reach TB service staff early enough 
to inform contact screening decisions in a meaningful way. Possible reasons for this 
include the time needed to produce a typing result and/or the lack of sufficiently 
sophisticated reporting software. Furthermore, inadequate resources to act may be 
contributing – the generation of the strain typing information was well-resourced but 
no funds were allocated to local TB teams to embed the information in their decision 
processes.  
Secondly, we are evaluating the marginal impact of the TB-STS in a setting where a 
TB control programme already exists (which includes traditional TB control 
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strategies, such as stone in the pond contact tracing).
13,235
 Measuring the impact of 
the TB-STS in isolation may therefore not be feasible and, even if we could, the 
improvement we are trying to observe may be incremental. In addition, the three-
year evaluation period may have been too short for an impact to be observed given 
the delay between cause and effect in a complex system.
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Thirdly, there was limited implementation of the service due to delayed development 
of the STM as part of a well-integrated TB management system to capture linked 
cases, contacts and strains; and limited resources for local public health action. This 
also influenced the ability to evaluate the TB-STS, where suboptimal data collection 
systems meant that although some primary data collection was conducted, the 
evaluation was reliant on routine data sources to estimate model parameters. 
8.8 The broader benefits of the TB-STS 
There was no evidence to support the hypothesis that the current TB-STS would 
interrupt transmission – the TB-STS was not found to be effective or cost-effective in 
its current form – but the recommendations to PHE were not that the TB-STS should 
be discontinued, rather that it continues with substantial changes. This is because the 
qualitative data and the context of the service suggested that there were broader 
benefits to the service.  
The broader benefits of the TB-STS are three-fold. Firstly, benefits to the TB service, 
such as better engagement with TB nurses and improved contact tracing practices, as 
well as the sense that it would be “regressive” to take this new tool away from public 
health practitioners. Secondly, there is the value of a national dataset combining 
clinical, epidemiological and molecular information for each TB patient. This will 
lead to the possibility of multiple future analyses, TB programme evaluations and 
research projects. Thirdly, the outcomes of such projects will lead to the far-reaching 
benefits of increased understanding about TB epidemiology, lineage, transmission 
and control. These benefits, however, may not require prospective strain typing, but 
could be gained through retrospective strain typing. Reading beyond the results of an 
202 
 
economic evaluation is an approach argued for recently: that cost-effectiveness alone 
should not be the determinant of health investment.
233
  
Box 5 – Examples of the broader benefits of the TB-STS 
 
8.9 Recommendations  
This evaluation has resulted in recommendations for the TB-STS, for future 
molecular typing services and future evaluations. 
 Higher quality, more standardised information collection during initial contact tracing of cases 
(see section on “Information Gathering” under User experience: Results of the semi-structured 
interviews, page 111) 
 To understand the national and local epidemiology of TB: TB strain-typing in New York has 
enabled molecular epidemiological analyses to contribute to understanding of the TB 
epidemic and they have been able to tailor their public health response, especially amongst 
those with HIV or MDR-TB.
224
 National strain-typing in the Netherlands has contributed 
greatly to their understanding of TB epidemiology.
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 To understand the molecular epidemiology of TB, thereby contributing to the global 
knowledge of TB.
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 To monitor and evaluate TB programmes: an outreach screening service in the homeless and 
drug-using population in Rotterdam was evaluated using strain-typing;
84
 long-term trends are 
used to evaluate TB control strategies e.g. in San Francisco and the Netherlands.
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 To meet international obligations for molecular surveillance: ECDC Molecular surveillance of 
MDR-TB in Europe project.
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 To create a national repository of strain types: this can be used for national and local analyses, 
larger research projects, and provides the opportunity for national and international 
collaboration. 
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Recommendations for the TB-STS 
The recommendations for the TB-STS were discussed, debated and finalised by a 
multidisciplinary expert steering group. They are listed in Box 6.  Alternative designs 
for the public health arm of the TB-STS were considered:   
a) The status quo, whereby clusters are investigated at the local and national 
level with cluster investigators taking the lead and instructing local 
investigations;  
b) A locally run service where people at the local level decide whether to 
investigate clusters or not, so that there is no bottle neck created at the cluster 
investigator level; 
c) A service that does not initiate any cluster investigations (unless an outbreak 
is identified) but is used to monitor and evaluate TB control at the local and 
national level;  
d) A resource for informing policy and for further research at both the molecular 
and public health level, but no specific public health actions; or 
e) Given the available evidence, cease the TB-STS altogether. 
PHE have adopted many of the recommendations outlined in Box 6 to improve the 
TB-STS, making this evaluation an important contribution to the TB strain typing 
strategy in England. Table 41 shows how the recommendations have influenced the 
TB-STS to date (as of December 2014). This suggests that the recommendations 
were judged to be appropriate and implementable, which is an important feature of 
an evaluation. 
204 
 
1. The timely universal typing of all culture-confirmed TB cases should be continued. The resulting 
database of strain types linked to national surveillance data should be analysed nationally and 
locally, and be fully accessible across Public Health England (PHE), the NHS, UK universities 
and for international collaborations. The database could be used for the following: 
a. To access typing results in response to local or national incidents of suspected transmission, 
enabling the prospective, proactive, local-led application of strain typing for TB control and 
public health protection; 
b. To understand the national and local epidemiology of TB, including the identification of risk 
groups for TB attributable to recent transmission; 
c. To understand the molecular epidemiology of TB, including circulating strains, lineages and 
virulence; 
d. To monitor TB programmes by analysing the trends in estimates of recent transmission; 
e. To meet international obligations for molecular surveillance, Europe-wide and globally; 
f. To create a national repository of strain types. 
2. The epidemiological analysis of the data should be prioritised. Findings should be reported back 
to local HPUs and NHS partners.  
3. Cluster investigations should be reconsidered. The evaluation found no evidence to suggest that 
cluster investigations were effective or cost effective. However, as acknowledged in the 
limitations, this may be due to insufficient evidence.  
Local  It is recommended that cluster investigations are no longer led by CIs but are 
initiated from the local level in response to local demand. Under this scenario, the CIs and Field 
Epidemiologists should be available to assist Local HPTs when they choose to launch a cluster 
investigation.  
Regional It is recommended that regional cluster investigations are discontinued as they 
appear to add little value.  
National It is recommended that the routine investigations of national cluster investigations 
are discontinued and that national cluster investigations be limited to clusters that have been 
identified to be of public health importance, e.g. rapidly growing clusters and clusters of drug 
resistant TB. Under this scenario, CIs and Field Epidemiologists should be available to support 
these investigations. 
4. The STM should be released as a priority.  
5. Public health and laboratory quality assurance should continue.  
a. The actions and outcomes of all cluster investigations that are conducted should be routinely 
recorded and be accessible for future evaluations.  
b. A false positive TB isolation identification and reporting protocol should be agreed between 
the reference laboratories.  
c. The completeness of typing data (i.e. the proportion of all isolates typed and the availability 
of full 24-loci typing profiles) for meaningful analysis and interpretation should be improved.  
6. A review of the human resources and capacity across the TB-STS is recommended. This should 
include any potential impact the TB-STS has on the TB service more broadly. Moving forward, 
there is a need to recognise the potential capacity available to implement a complex intervention 
such as the TB-STS. 
7. The key driver for the effectiveness and cost-effectiveness of TB control identified in this 
evaluation was diagnostic delay. The TB service should focus on and invest in interventions and 
TB control strategies that will lead to the earlier diagnosis of TB. 
Box 6 – Recommendations made by the Evaluation Group for the TB-STS 
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Table 41 – PHE’s responses to the recommendations of this evaluation 
 Recommendation PHE response 
1. The timely universal typing of all culture-confirmed TB cases 
should be continued 
PHE continues to strain type all culture-confirmed TB cases 
2. The epidemiological analysis of the data should be prioritised The epidemiological analysis of the first three years of the TB-STS was presented in the PHE TB annual report in 
2014,3 other papers for publication are in the pipeline (personal correspondence with Maeve Lalor, PHE national CI)  
3. Cluster investigations should be reconsidered:  
a) Local investigations should be initiated from the local level 
b) Regional investigations should be discontinued 
c) National investigations should be limited to clusters that have 
been identified to be of public health importance 
 
a) Local investigations are now initiated at the local level 
b) Regional investigations have stopped 
c) National clusters are investigated where identified to be of particular public health importance 
4. The STM should be released as a priority The STM was released in November 2013 
5. Public health and laboratory quality assurance should continue: 
a) Cluster investigation activities and outcomes recorded 
b) False positive isolation recorded 
c) Completeness of typing reported 
 
 
a) Cluster investigation activities and outcomes are recorded on the STM 
b) Data on false positive TB incidents are collected from laboratories and clinics using a form. The data are 
stored on a database held at Colindale.  
c) Completeness of typing is reported in the PHE TB annual report3  
6. Review the human resources and capacity across the TB-STS Due to the recommendations from this evaluation, local cluster investigations are being led by HPUs who are 
responsible for reviewing their own resources. National cluster investigations have been de-prioritised, so far fewer 
clusters are being investigated. 
7. The TB service should focus on and invest in interventions and TB 
control strategies that will lead to the earlier diagnosis of TB 
An analysis of the diagnostic delay was presented in the PHE TB annual report for the first time in 2014, suggesting 
that it has become an important indicator for TB control. 
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This evaluation has made an important contribution to our understanding of the TB-
STS. It has already been helpful to other countries who are considering introducing 
or making changes to a strain typing service. Public Health Specialists from the 
Norwegian Institute of Public Health and the Robert Koch Institute in Germany have 
requested the results of this evaluation to inform the development of a strain typing 
service in their own countries, with Norwegian colleagues describing it as “so useful 
to us”. It has identified key areas for improved data collection and reporting in the 
TB service, which would benefit future evaluations of a comprehensive TB control 
strategy (described below). In addition, this evaluation provides a benchmark for 
future evaluations of a typing service for TB control.   
Recommendations for the design and implementation of a future service  
The findings of this evaluation are important given the current trend to introduce and 
upgrade national typing services.
69,199
 In the context of the rapid development of 
typing methodologies (e.g. WGS), political commitment to genomic analysis,
228
 and 
the development of PHE’s 2014-2019 National TB Strategy,237 this evaluation 
provides important evidence for policy makers. Based on the findings of this 
evaluation, unless current or new typing and diagnostic techniques accelerate 
diagnosis (including through analysis of primary specimens), reduce diagnostic 
delay, dramatically reduce the time it takes to type, and/or are embedded in a user-
friendly standardised TB management system, the adoption of such a method alone is 
unlikely to impact on TB control. Comprehensive TB control strategies that aim to 
reduce TB incidence over the next decades, need ongoing evaluation of proposed 
interventions. This includes evaluation of effective public health responses and 
appropriate use of strain typing, clinical and epidemiological information. 
In order to better evaluate the impact of the TB-STS, or any future molecular 
surveillance strategy for TB, the following data are required from both before and 
after its introduction: 
 The proportion of prevalent LTBI detected per year 
 The diagnostic delay 
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 The proportion of TB cases that are detected as a result of cluster 
investigations, contact tracing and through self-presentation 
 The proportion of contacts of TB cases that were identified and investigated 
through cluster investigations and traditional contact tracing 
 The additional number of contacts with TB and LTBI detected because of 
expanded contact tracing based on a cluster investigations 
Based on the learning from this evaluation, the following recommendations apply to 
the implementation of any future public health typing service for infectious diseases 
(e.g. a future TB molecular typing service such as WGS):  
1. The objectives of the service should be well-defined from the outset, making 
explicit the public health implications of such a service, and should be 
SMART (specific, measurable, attainable, relevant and time-bound); 
2. Service implementation should consider the evaluation design to enable the 
evaluation to capture the required data for a robust analysis (see next set of 
recommendations regarding evaluation); 
3. The service should be designed involving all stakeholders so that the role of 
each group is plausible given the resources (e.g. can you expect HPUs to 
manage cluster investigations?); 
4. Resources should be allocated for all elements of the service (e.g. if the NHS 
is required to contribute to the implementation of the service, this should be 
resourced); 
5. The molecular method used to type isolates should be able to discriminate 
between strains that have not been transmitted between patients recently, and 
the molecular clock of the biomarker should be slow enough to identify cases 
in the same chain of recent transmission and the genetic diversity of the 
organism (e.g. M.tuberculosis) in the population. In addition, it should be 
stable, rapid, reproducible across laboratories (e.g. could it be performed in a 
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single national laboratory to reduce cross-laboratory variation?), easy to 
perform and interpret, and applicable to clinical samples; 
6. The typing technique used must reduce diagnostic delay and/or dramatically 
reduce the time it takes to type in order for the intervention to impact on TB 
control. Alternatively, if a technology fulfills more than one purpose (for 
example case identification, typing and detection of drug resistance) it is more 
likely to be cost effective than if it is typing alone. For TB, this is especially 
true if you can identify resistance sooner, as MDR cases are expensive to 
treat;   
7. The service needs to be able to adapt to newer technologies and typing 
methods introduced in the future; 
8. Training should involve all those involved in delivering the service and 
expectations of each role in service delivery should be made clear; 
9. Software development/information management is often a particularly risky 
but important component of a complex intervention. It should be well-
resourced and managed, and would ideally be completed before the service is 
started; and 
10. Data collection for quality control, monitoring and evaluation should be 
implemented from the start of the service and be an integrated part of the 
service. 
 
Recommendations for the evaluation of a future service 
This evaluation could be used as a template for future evaluations of other services 
relating to alternative infections, especially considering the importance of increasing 
the evidence base on public health interventions and the compatible evaluation 
methods. Considering the rapid decline in the cost of sequencing,
238
 it will eventually 
be possible and affordable to sequence everything. It is worth learning from the 
experiences in TB how best to use this information to protect and improve public 
health.  
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This evaluation has led to the following recommendations for the evaluation of a 
future service: 
1. Evaluation is difficult but worthwhile, and is an essential component of any 
intervention; 
2. The evaluation should be conducted by an independent evaluation team and 
the dissemination of results should be timely, shared with stakeholders, and 
made available to the public; 
3. It is important to work with those designing and implementing the service to 
ensure that their objectives are appropriate and SMART (see above 
recommendations for the design/implementation of a service); 
4. Ideally, the evaluation will be able to influence the implementation of the 
service in order to design a robust, experimental evaluation study (e.g. 
ensuring time to collect baseline data, rolling out the service gradually by 
geographical area for a step-wedge design, or setting up a cluster randomised 
control trial); 
5. Evaluation frameworks are useful for structuring the evaluation and 
encompassing the whole service. The Donabedian Framework
161
 is 
particularly simple, flexible, and can be applied across any intervention. 
Alternative models may be appropriate depending on the nature of the 
intervention and its implementation (e.g. Theory of Change);
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6. Mixed-methods ensure that different data types can be collected and analysed 
appropriately. This is important for capturing the unexpected; 
7. Where possible, it is recommended to consider the long term outputs of a 
service; 
8. It is important to consider the impact of the evaluation on service delivery 
(e.g. data collection for the evaluation should not be a large burden on those 
delivering the service, unless additional resources are allocated for this 
purpose); and 
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9. To validate the quality, and to enable other countries, services and disciplines 
to learn from the results of future evaluations, findings should be available in 
the public domain, preferably published in peer-reviewed journals. 
 
8.10 Conclusion 
Evaluating a complex public health intervention requires a pragmatic approach, 
taking into account how the service has been implemented. The TB-STS was not 
found to be effective or cost-effective during its first three years; however, the 
broader benefits of such a service justify its continuation as a modified service. To 
reduce costs, improve efficiency and increase effectiveness, changes are 
recommended to the TB-STS, including discontinuing routine cluster investigations 
and focussing on reducing diagnostic delay across the TB programme. This 
evaluation of a complex intervention informs the future of strain typing in the era of 
rapidly-advancing technologies. Future evaluations of public health interventions 
should be established prior to the implementation of a national intervention. This 
would ensure that sufficient baseline data can be collected; enable the evaluation 
design to influence the roll-out of the intervention; and increase the evidence base on 
specific interventions and evaluation methods. 
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Appendix 1: Systematic review search strategy (Medline/Embase) 
1. (tubercle adj3 (bacillus or bacilli)).mp. [mp=title, original title, abstract, name 
of substance word, subject heading word, unique identifier]  
2. ((mycobacterium or mycobacteria) adj3 (bovis or africanum or microti or 
canetti)).mp.  
3. exp tuberculosis/ or mycobacterium tuberculosis/ or tuberculosis.mp. or 
tb.mp. or Mtb.mp. or "M tuberculosis complex".mp.  
4. or/1-3  
5. Minisatellite Repeats/ or Genotype/ or Interspersed Repetitive Sequences/ or 
DNA Fingerprinting/ or Bacterial Typing Techniques/  
6. "miru".mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
7. "vntr".mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
8. (miru adj3 vntr).mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]  
9. (mycobacterial adj3 interspersed adj3 repetitive adj3 units).mp. [mp=title, 
original title, abstract, name of substance word, subject heading word, unique 
identifier]  
10. (dna adj3 fingerprinting).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
11. ((strain adj3 type) or (strain adj3 typing) or (strain adj3 types)).mp. [mp=title, 
original title, abstract, name of substance word, subject heading word, unique 
identifier]  
12. ((molecular adj3 typing) or (molecular adj3 strain adj3 typ*)).mp. [mp=title, 
original title, abstract, name of substance word, subject heading word, unique 
identifier]  
13. (genotype or genotyping or genotypes).ti,ab.  
14. (minisatellite adj3 repeat*).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
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15. molecular epidemiology/mt or (molecular adj3 epidemiology).mp. [mp=title, 
original title, abstract, name of substance word, subject heading word, unique 
identifier]  
16. or/5-15  
17. exp disease outbreaks/ or (outbreak adj3 analysis).mp. or (outbreak adj3 
investigation).mp. or (outbreak adj3 management).mp. or (tuberculosis adj3 
outbreak).mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier]  
18. exp contact tracing/ or (contact adj3 tracing).mp. or (contact* adj3 
traced).mp. or (contact adj3 screen*).mp. [mp=title, original title, abstract, 
name of substance word, subject heading word, unique identifier]  
19. exp case management/ or (case adj3 management).mp. [mp=title, original 
title, abstract, name of substance word, subject heading word, unique 
identifier]  
20. exp Risk Factors/  
21. (risk adj3 factor*).mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]  
22. exp Epidemiologic Factors/  
23. infectious disease transmission.mp. or exp Disease Transmission, Infectious/  
24. exp case management/ or (case adj3 management).mp. [mp=title, original 
title, abstract, name of substance word, subject heading word, unique 
identifier]  
25. program evaluation/ or evaluation studies as topic/ or (program adj3 
evaluation).mp. or (programme adj3 evaluation).mp. [mp=title, original title, 
abstract, name of substance word, subject heading word, unique identifier]  
26. public health practice/ or (public adj3 health).mp. [mp=title, original title, 
abstract, name of substance word, subject heading word, unique identifier]  
27. ((tuberculosis adj3 control) or (tb adj3 control)).mp. [mp=title, original title, 
abstract, name of substance word, subject heading word, unique identifier]  
28. (molecular adj3 surveillance).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
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29. exp cluster analysis/ or (cluster* adj3 rate*).mp. or (cluster* adj3 
growth).mp. or (cluster* adj3 analysis).mp. or (cluster adj3 investigation).mp. 
or (proportion adj3 cluster*).mp. or (molecular adj3 cluster*).mp. [mp=title, 
original title, abstract, name of substance word, subject heading word, unique 
identifier]  
30. ((recent adj3 transmission) or (transmission adj3 event*) or (transmission 
adj3 rate*) or (chain adj3 transmission) or (transmission adj3 setting*)).mp. 
[mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier]  
31. or/17-30  
32. 4 and 16  
33. 32 and 31  
34. limit 33 to yr="1998-Current"  
35. limit 34 to english language  
36. animals/  
37. humans/  
38. 36 not 37  
39. 35 not 38 
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Appendix 2: Initial and follow-up survey questions 
Survey Questions 
Questions that are numbered without a letter were asked to all participants. Where a 
letter follows the question number the question was asked to that particular group 
(x=nurses, y=physicians, z=public health staff). The questions are divided by target 
group for Sections C and D. 
 
TB Control and Strain Typing: A Questionnaire for Nurses / Physicians / HPU staff 
The Health Protection Agency has commissioned an evaluation of the National TB 
Strain Typing Service (STS). We are interested in how much time nurses / physicians 
/ staff from HPUs spend on cluster investigations and their uptake and experience of 
using strain typing data. This is the second part of a two-part questionnaire (the first 
part was conducted in November 2010). All the information collected in this form 
will be anonymised and stored according to the Data Protection Act; we do ask for 
your name and contact details so we can link this to your response - oryour 
predecessor's response - to the first part of the questionnaire. 
THANK YOU FOR AGREEING TO TAKE PART IN THIS QUESTIONNAIRE 
You can save the questionnaire and return to it another time by clicking "save" at the 
bottom of any page and following the instructions. 
If you have any queries please do not hesitate to contact Jessica Mears, evaluation 
scientist - jessica.mears@hpa.org.uk, 0208 327 6265 
 
Section A -- This section asks basic information about where you work 
1. Name  
2. Email address 
3. Telephone number 
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4. Job title 
5.  
x. Which Health Protection Unit does your workplace fall under? 
(multiple selections available) List of 26 HPUs 
y. Which Health Protection Unit does your workplace fall under? 
(multiple selections available) List of 26 HPUs 
z. Do you work at the national level, regional level, or Health Protection 
Unit level (or other)? National / Regional / HPU / other 
 
Section B -- The following questions are about your current awareness and use of TB 
strain typing 
1. Have you heard of the National TB Strain Typing Service (aside from this 
questionnaire)? Y/N 
2. How do you access strain typing data? (multiple selections possible) Don’t 
get data / Send request for specific cases / Automatically receive for each 
case / Contact labs directly / Cluster reports from lab / Cluster report/phone 
call from HPU / Web-based ETS/LTBR / Contacted by a cluster investigator / 
Other 
*If you have answered “Don’t get data” in Section B Q2, skip to BQ7 
3.   
x. - How many weeks after a sample is sent to the lab do you receive the 
individual strain type? (weeks) 
y. - How many weeks after a sample is sent to the lab do you receive the 
individual strain type? (weeks) 
z. Do you usually access/get hold of strain typing data before or after 
you have finished contact tracing? Before / After 
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4. What do you use strain typing for? (multiple selections possible) Don’t know 
/ Identify clusters and links between cases / Disprove clusters and links 
between cases / Justify extended contact tracing / Justify stopping contact 
tracing / To provide more information / Other  (please specify) 
5. How often do you use strain typing data in your case management or 
outbreak investigation? Never / For few cases / For about half of cases / For 
many cases / For every case 
Any comments you have about how often you use the strain typing data would be 
helpful 
6. Do you find the strain typing information useful? Very useful / Quite useful / 
Not very useful / Useless 
Any comments you have about how useful you find the strain typing data would be 
helpful 
*Skip to BQ8 
7. If you had access to strain typing data, what would you use it for? (multiple 
selections possible) Don’t know / Identify clusters and links between cases / 
Disprove clusters and links between cases / Justify extended contact tracing / 
Justify stopping contact tracing / To provide more information / Other  
(please specify) 
8. Have you received any training on using strain typing data? Yes (please 
specify) / No 
9. Do you have access to any resources or tools to help interpret and use strain 
typing information? (multiple selections possible) No / Handbook / Training 
workshops / Colleagues / Webcast/online training / Other (please specify) 
10. How would you rate your knowledge of how to interpret MIRU-VNTR data? 
(no knowledge) 1 / 2 / 3 / 4 / 5 (Excellent knowledge) 
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Section C -- The following questions are about your current TB-related workload 
CX: Questions for Nurses 
1. What are your working hours? Full time / Part time / Other (please specify) 
2. Do you work on anything other than TB? Yes / No 
*If you have answered “No” in Section CX Q2, skip to CXQ4 
3. What proportion of your average week do you spend on TB-related work? % 
4. Are you involved in contact tracing? Yes / No 
*If you have answered “No” to CXQ4, skip to Section DX 
We are now going to ask a few questions about contact tracing and the contacts of TB 
patients. 
5. How do you do your contact tracing work? Dedicated time in clinic (% of 
contact tracing done in this way) / Telephone interviews (%) / Home visit (%) 
/ Other (please specify) 
6. In total, how many contacts have you screened in the last month? (using any of these 
methods: Mantoux, X-ray, IGRA, symptom check) (Number of people) 
7. How many hours did this take? (Hours) 
8. In the last month, what proportion (%) of your total working time have you spent on 
tracing and screening contacts in and out of clinic? (% of time) 
We are now going to ask you some questions about newly diagnosed TB patients. 
9. How many new active TB cases have you managed in the last full month? (cases) 
10. How many of these required contact tracing? (cases) 
This section asks you about 5 recent index cases for whom contact tracing has been 
completed. It might help to have your case management notes in front of you before 
starting this section. 
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11. Please fill in the following table based on 5 recent index cases whose contacts have been screened: 
 Case 1 Case 2 Case 3 Case 4 Case5 
ETS / LTBR No.      
Age / year of birth      
Site of disease Pulmonary / extra-pulm Pulmonary / extra-pulm Pulmonary / extra-pulm Pulmonary / extra-pulm Pulmonary / extra-pulm 
Smear test result Positive / Negative / 
Unknown 
Positive / Negative / 
Unknown 
Positive / Negative / 
Unknown 
Positive / Negative / 
Unknown 
Positive / Negative / 
Unknown 
Culture result Positive / Negative / 
Unknown 
Positive / Negative / 
Unknown 
Positive / Negative / 
Unknown 
Positive / Negative / 
Unknown 
Positive / Negative / 
Unknown 
When was the strain 
type available to you? 
Before contact 
investigation / During 
contact investigation / 
After contact 
investigation / Never 
Before contact 
investigation / During 
contact investigation / 
After contact 
investigation / Never 
Before contact 
investigation / During 
contact investigation / 
After contact 
investigation / Never 
Before contact 
investigation / During 
contact investigation / 
After contact 
investigation / Never 
Before contact 
investigation / During 
contact investigation / 
After contact 
investigation / Never 
No. contacts identified      
No. contacts screened      
No. contacts with active 
TB disease 
     
No. contacts with latent 
TB infection 
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CY: Questions for Physicians 
1. What are your working hours? Full time / Part time / Other (please specify) 
2. What kind of physician are you? 
3. What proportion of your average week do you spend on TB-related work? (%) 
4. On average throughout the year, how many new TB cases do you personally start on 
treatment per month? (cases) 
5. How often are you called to an incidence meeting to discuss contact 
tracing/screening? Once a month or more / Once every 1-3 months / Once 
every 3-6 months / Less than once every 6 months / Never 
6. Has the strain type of the case under discussion ever been relevant in an 
incident meeting? Yes / No 
If yes, please could you give some more details about the incident(s) 
CZ: Questions for Public Health Staff 
1. What are your working hours? Full time / Part time / Other (please specify) 
2. Do you work on anything other than TB? Yes / No 
*If you answered “No” to Section CZ Q2 skip to CZQ5 
3. What proportion of your average week do you spend on TB-related work? (%) 
4. On average, how many hours per week do you spend on TB-related work? (Hours) 
5. In the last 3 months, how many TB cases have been reported in your workplace 
(HPU, region or nationally)? (cases) 
 
6. In the last 3 months, how many extended contact investigations were initiated 
because the cases were known contacts (regardless of strain type)? (extended contact 
investigations) 
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7. In how many of these was strain typing used to provide more information? 
8. In how many of these investigations – investigations that were initially 
opened because cases were known contacts of each other – did strain typing 
influence your investigation? Number of investigations lengthened or 
reopened / Number of investigations stopped 
If possible, please provide more information about these incidents. 
 
9. In the last 3 months, how many cluster investigations were initiated because of strain 
typing data (i.e. where links between cases were not identified through initial contact 
tracing)? (cluster investigations) 
10. In how many of these investigations that were initiated because of the strain typing 
data were epidemiological links found between cases following the cluster 
investigation? 
If possible, please provide more information about these incidents. 
 
11. In the last month, what proportion (%) of your time have you spent on cluster 
investigation activities (investigating epidemiologically linked or strain type-linked 
cases)? (%) 
12. If you have any other comments about how you use (or don’t use) strain typing data 
and how useful you find it please write in the box below. 
 
Section D -- The following questions are about investigating transmission 
DX: Questions for Nurses 
In the last year have you investigated any clusters of 2 or more TB cases because… 
1. …they were contacts of each other (not because of strain type)? Yes / No 
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Comments welcome  
2. …they were linked by strain type along? Yes / No 
Comments welcome  
 
3. In the last year have you stopped investigating possible transmission because 
the cases involved had different strain types? Yes / No 
If yes, please could you give some more details about the incident. 
 
4. If you have any other comments about how you use (or don’t use) strain typing data 
and how useful you find it please write in the box below.  
 
DY: Questions for Physicians 
In the questions below, please estimate the number of TB investigations you have 
been involved in during the last 12 months. 
1. In the last year, have you investigated any clusters of 2 or more TB cases 
because they were contacts of each other (not because of strain type)? Yes / 
No 
If yes, approximately how many investigations were launched based on information 
gained through contact tracing only? 
2. In the last year have you investigated any clusters of 2 or more TB cases 
because they were linked by strain type along? Yes / No 
If yes, approximately how many investigations were launched based on strain type 
alone? 
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3. In the last year have you stopped investigating possible transmission because 
the cases involved had different strain types? Yes / No 
If yes, how many incidents does this apply to? Where possible, please provide more 
information about the incident(s) 
 
End 
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Appendix 3: False positive TB isolation follow-up surveys to source 
laboratories 
Below are email questionnaires that were sent to source laboratories regarding A) 
possible, B) unconfirmed, and C) unlikely cross contamination events. 
A) Possible cross contamination event 
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B) Unconfirmed cross contamination event 
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C) Unlikely cross contamination event 
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Appendix 4: Rate of cluster growth equations 
I prepared the data for analysis and the univariate and multivariate linear 
regression analyses were conducted by Ted Cohen and Leonid Chindelevitch.  
__ 
Data from the cluster monitoring database on the number of cases in a cluster, the 
date cases were added to a cluster and the date cluster investigations started were 
merged with the clinical and demographic data collected on ETS for the years 2010 
and 2011. After cleaning the data and excluding the first case in each of the 113 
clusters, there were a total of 949 cases. The final set of variables used in the 
multivariate linear regression were: sex, UK-born, age group (treated as an ordinal 
variable), site of disease, case order (the order in which cases were added to the 
cluster), after (our indicator of cases discovered after a cluster investigation was 
started), and cluster level (local, regional and national) and lineage, the latter being 
factor variables.  
It was assumed that each cluster had an intrinsic growth rate, which depends only on 
the scale of the cluster (either local, regional or national) and the lineage, and that it 
can only be altered by the opening of a cluster investigation. To fully specify the 
model, ƒ is defined as a function mapping   to the scale and lineage of the th 
cluster.  For the th case in the th cluster, the regression variables are: 
  the case is female 
  the case is not UK born 
  the case has extrapulmonary TB 
  the case was the th case added to the cluster  
 the case belongs to the th age group 
   and the case is diagnosed after the investigation starts 
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The following regression equation was performed: 
 ,
a
 
where    
 is the rate of cluster growth with a scale and lineage  
 is the effect of opening an investigation 
 is the effect of gender 
 is the effect of being UK born or not UK born 
 is the effect of the site of TB 
 is the effect of being in age group  
is the effect of being the th case in a cluster 
 
 
                                                 
a
 L. Forsberg White and M. Pagano, “A Likelihood-Based Method for Real-Time 
Estimation of the Serial Interval and Reproductive Number of an Epidemic,” 
Statistics in Medicine 27, no. 16 (2008): 2999–3016, doi:10.1002/sim.3136. 
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Appendix 5: Transmission model equations 
The transmission model was based on a model previously developed by Emilia 
Vynnycky.
1,2
 The model was adapted by Emilia for this evaluation.  
__ 
Overview 
Figure 24 in the thesis shows the general structure of the model.  The model is age 
structured, with the population stratified into single year age groups and 
deterministic, describing what happens on average over time, using weekly time 
steps (see below for further details, the difference equations and input parameters).  
The model includes immigration and emigration and considers the following three 
epidemiological scenarios: 
Scenario 1.  Low incidence, comparable to that in the white UK population. The 
predicted TB incidence increases with increasing age, reaching about seven per 
100,000 for those aged ≥55 years (figure 41A in the thesis), which is consistent with 
observed data (two to five and four to nine per 100,000 per year in 2011).
3
  Here the 
infection risk is assumed to have declined since 1950
4
 and has remained roughly 
constant since 1980, a small proportion (<10%) of those aged <55 years are assumed 
to have been infected, as compared with 50% on average of those aged ≥55 years 
(figure 41B in the thesis).   The proportion of disease that is attributable to recent 
transmission decreases steadily with increasing age, reaching <10% for those aged 
≥55 years (figure 41C in the thesis).   
Scenario 2. Medium incidence, comparable to that in the non-white UK-born. 
The disease incidence is about 20 per 100,000 per year, as compared with nine to 55 
per 100,000 in the observed 2009 data.
5
  The annual risk of infection (ARI) is 
assumed to have been constant over time at 0.1% per year, with a low proportion of 
individuals who have been infected (average of <20% for those aged ≥55 years).  
Scenario 3. High incidence, comparable to that in the non-UK born. The disease 
incidence is about 120 per 100,000 year, which is comparable to observed data 
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(notification rates of 59-273 per 100,000 in 2009, depending on the ethnic group).  
The ARI is assumed to have been constant over time at one percent per year, similar 
to that in some developing countries, with proportion of individuals who have been 
infected increasing with increasing age to reach an average of 20% for those aged 
≥55 years. 
For scenarios 2 and 3, the assumed in- and out- migration rates are eight and six per 
1000 per year respectively, based on data from the period 2000-2010.
6
   In-migrants 
are assumed to be aged 15-54 years; the assumed out-migration rate is identical for 
all ages.  The TB prevalence among in-migrants is assumed to be 0.02%, which is 
consistent with the predicted prevalence in the model for an ARI of one percent per 
year.  The TB incidence in these individuals in their native populations is similar to 
that shown in (figure 41A in the thesis) for an ARI of one percent per year, which is 
similar to that in the non-UK born population in the UK,
3
 but slightly lower than that 
estimated among immigrants, shortly after entering the UK (320-400 per 100,000 in 
1998).
7
  Based on recent data, we assume that no cases are detected when entering 
the UK.
8
 The model parameters are shown in Supplementary Table 1. 
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Supplementary Table 1 – Summary of assumed parameter values and their ranges.   
Definition Symbol Base case value Source/comment 
Transmission    
Number of people effectively contacted by 
each smear-positive case in 
a) Low incidence (similar to white UK 
population) 
b) Medium incidence (Non-white, UK-
born population) 
c) High incidence  (Non-white, non-UK-
born) 
ce  
 
 
 
Calculated to 
reproduce 
incidence 
consistent with 
observed 
notification rates 
Infectiousness of smear-negative TB 
cases, compared to that of smear-positives 
f 22% 
9
 
Force of infection at time t λ(t)  See text 
Disease onset    
Rate of disease onset following recent 
infection at time si since first infection 
among those not PT among of age a 
dp,z-,a(si) Cumulative risk 
over 5 years: 
4% (children) 
14% (adults), 
increases linearly 
between ages 10 
and 20 years 
10,1
 
Rate of disease onset following recent 
infection at time si since first infection 
among those on PT among of age a 
dp,z+,a(si) Calculated as 
dp,z-,a(si)πd,z+ 
 
Rate of disease onset at time sr following 
reinfection among those not on PT of age 
a 
dx,z-,a(sr) Cumulative risk 
over 5 years: 
8% 
10,1
 
Rate of disease onset at time sr following 
reinfection among those on PT of age a 
dx,z+,a(sr) Calculated as 
dx,z-,a(si)πd,z+ 
 
Annual rate of developing disease through 
reactivation (%/year) among those not on 
PT of age a 
dn,z-,a 0.03%/year 
10,1
 
Annual rate of developing disease through 
reactivation (%/year) among those on PT 
of age a 
dn,z+,a Calculated as 
dn,z-,aπd,z+ 
 
Percentage of respiratory TB disease that 
is smear-positive among those of age a 
os+,a 10% (children) Public Health 
England (PHE) 
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65% (adults) Enhanced 
Surveillance 
database and data 
in 
1
.  Follows the 
age-specific 
pattern in 
1
. 
Duration that people spend in the 
reinfected compartment (experiencing the 
risk of disease given reinfection before 
being transferred to the latent 
compartment 
RT  
5 years -- 
Duration that people spend in the infected 
compartment (experiencing the high risk 
of disease given infection before being 
transferred to the latent compartment 
ET  
5 years -- 
Demography    
Annual birth rate per 1000 per year  13.1 Office for 
National 
Statistics
6
 
Annual general population mortality rates  mtb-,a Age-dependent Office for 
National 
Statistics
6
 
Inmigration rate   0.8%/year Office for 
National 
Statistics
6
 
Outmigration rate for those of age a µa 0.6%/year Office for 
National 
Statistics
6
 
TB prevalence among immigrants  0.02% Consistent with 
model 
predictions based 
on an ARI of 
1%/year 
Case detection    
% of immigrant TB cases with smear 
status s that are detected on entry to the 
UK 
sfinp ,,
 
0% 
8
 
Average time from disease onset to 
detection (among non-immigrants) at time 
t 
Tdetect (t) 10 weeks (before 
the start of the 
TB-STS); 
varied thereafter 
PHE Enhanced 
Surveillance 
database 
Average rate at which cases are found rf (t) Calculated as 
1/Tdetect 
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Maximum duration of that people spend in 
the detected (found) compartment before 
being distributed to the undetected 
compartment, if they have not started TB 
treatment in the meantime. 
maxf
T
 
6 months -- 
Preventive treatment    
Proportion of infections that are detected 
at time t 
pi,det(t) Varied between 
3% and 13% per 
year 
No data 
available. 
Assumed to 
differs before and 
after the start of 
the strain-typing 
service 
Percentage of eligible contacts 
(TST/IGRA+ and aged <35 years) that 
start PT 
pz+,start 95% Plausible value, 
based on national 
policy
11
 
Proportion of infected people that start PT 
at time t 
iz+(t) Calculated as: 
pi,det pz+,start 
-- 
Protection provided by PT against disease 
whilst taking PT 
zdπ ,
 
65% 
12,13
 
Proportion of those taking PT who 
complete PT 
pz+,stop 85% 
11
 
Rate at which those taking PT stop taking 
PT  
iz- 1.3%/week Based on pz+,stop 
= 0.85 
Maximum duration of PT 
maxZ
T
 
3 months -- 
Treatment    
Average time from detection to start of TB 
treatment 
Ttreat, start 2 weeks -- 
Rate at which cases start TB treatment at 
time sf following detection 
τ(sf) sf< 4 weeks: 
35%/week 
sf≥ 4 weeks: 
0%/week 
Calculated so that 
82% of detected 
cases complete 
treatment (see 
text) 
Percentage of detected cases that complete 
TB treatment 
 82% PHE Enhanced 
Surveillance 
database 
Percentage of detected cases who default 
from treatment 
 5.5% PHE Enhanced 
Surveillance 
database 
Mortality rate among TB cases (before 
and during TB treatment) 
mtb+,a 7% PHE Enhanced 
Surveillance 
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database 
Percentage of detected cases that are lost 
to follow-up 
 5.5% PHE Enhanced 
Surveillance 
database 
Duration of TB treatment 
maxτ
T
 
26 weeks -- 
The subscript z- and z+ refer to those not on PT and on PT respectively, a refers to the age group.  The 
abbreviations sm- and sm+ refer to those who are smear-negative and smear-positive respectively.   
 
Model assumptions 
Individuals are assumed to be born uninfected and are infected at a rate λ(t) (the force 
or risk of infection). The force of infection depends on the prevalence of infectious 
individuals and is calculated as the product of the prevalence of infectious 
individuals and the effective contact rate, ce, defined as the average number of 
individuals effectively contacted by each infectious person per unit time.  An 
effective contact is defined as one that is sufficient to lead to transmission if it occurs 
between an uninfected (“susceptible”) person and an infectious person.14  The 
effective contact rate is calculated so it leads to given values for the annual risk of 
infection (see below).  
Following infection, individuals are assumed to face an increased rate of developing 
disease during the first five years after infection (“primary” disease), which 
decreases with time since infection, after which they can either experience disease 
through reactivation or following reinfection.  The rates at which they develop 
disease through the various mechanisms are age-dependent and are identical to those 
estimated in previous work.
1
  The rate of disease onset following reinfection is less 
than that following new “primary” infection, due to some immunity resulting from 
previous infection.
10,1
 
As in previous versions of the model, the proportion of disease that is sputum smear 
or culture-positive (infectious) is assumed to increase with age, based on observed 
data.
1
  For simplicity, females are not modelled explicitly in the model.  For 
simplicity, the effects of HIV are also not modelled, given the low prevalence of HIV 
(2.4 per 1000) in England and Wales by 2008.
15
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Following disease onset, cases are assumed to be detected at a constant rate, with an 
average time to detection of 10 weeks.  Given this relatively short time to detection, 
progression from smear negative to smear positive TB is not modelled explicitly.   
Following detection, cases are assumed to start TB treatment after an average period 
of two weeks, so that the average time from disease onset to detection is 12 weeks, as 
observed in the strain typing data.  82% of those who start treatment are assumed to 
complete it, with the remainder dying (7%), defaulting from treatment (5.5%) or 
being lost to follow-up (5.5%).
16
 Those who default from treatment are assumed to 
return to the undetected category and remain infectious. TB treatment is assumed to 
last a fixed period of six months.  TB treatment is assumed to clear infection and 
individuals can develop disease subsequently only following reinfection. The rate at 
which they develop disease following reinfection is assumed to be identical to the 
rate at which those who have been infected for at least five years (described as those 
in the “latent” category in figure 24 in the thesis) develop disease following 
reinfection.  
Based on observed data, 95% of those aged <35 years who are identified as having 
been infected, according to TST/IGRA, are assumed to start preventive treatment 
(PT) for three or six months, with 85% of these completing the full course.
8
 National 
policy dictates that PT is not given to those under 35 years.
11
 PT is assumed to 
provide 65% protection against disease whilst individuals are taking it.
12,13
  Given 
complete compliance, the full course of PT is assumed to fully cure the infection, so 
that individuals can only develop disease subsequently following reinfection.  It is 
also assumed that individuals who have either previously had TB treatment or PT 
would not be provided PT again. 
In the absence of the TB-STS, a small percentage (3%) of all infected individuals is 
assumed to have been detected and treated each year.  This proportion is unknown, 
but was probably very low, as implied by the number of tuberculin-positive contacts 
of tuberculosis cases that were identified for each tuberculosis cases that was 
investigated .  For example, data on contact tracing activity suggested that after the 
introduction of the TB-STS, on average, about four contacts of each identified 
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tuberculosis case who was not in a cluster, was traced, with one of the contacts being 
tuberculin positive.  Since approximately 9000 cases were reported in England in 
2009,
5
 this suggests that about 9000 tuberculin-positive people were identified.  If 
the average prevalence of tuberculous infection in England is less than 10% and 
given a population of 55 million in England and Wales,
17
 then the proportion of 
prevalent infections that is detected each year is likely to be less than 1%.  An 
analogous calculation suggests that if the average prevalence of tuberculous infection 
in England was less than one percent, then the proportion of prevalent infections that 
is detected each year is likely to be less than two percent.   
The amount by which the proportion of infections that were detected after the 
introduction of the TB-STS increased is also poorly understood.  However, it is 
unlikely to have increased substantially, given that the number of contacts that were 
screened per TB case for cases who were in a cluster was similar to that for cases 
who were not in a cluster.  We here assume that it increases by a factor of three, i.e. 
to 13% per year, which is likely to be close to or exceed the upper limit on the likely 
value.  
The proportion of those eligible who take up preventive treatment, once detected, is 
also unknown, as is the proportion of those who start taking preventive treatment 
who complete it.  We have assumed values of 95% (minimum and maximum values 
of 30% and 95% respectively) for the former and values of 85% (minimum and 
maximum values of 50% and 100% respectively) for the proportion of those starting 
preventive treatment who complete it.  These values are plausible, and are consistent 
with those used in previous decision analyses,
18
 although their accuracy is unclear.  
Studies of contact tracing activities in the USA from the period 1996-7 found that 
about 74% of tuberculin-positive positive contacts of tuberculosis cases started 
preventive treatment, with 56% completing it.
19
  Similar data from the UK are 
limited.  For example, studies have sometimes reported the numbers or proportions 
of contacts who started preventive treatment, without providing the numbers who 
were eligible or who completed preventive treatment.
20
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Model equations 
The model was set up using weekly time steps using the difference equations below.  
The model was written using the C programming language.  Supplementary Table 1 
provides the main parameters and variables; Supplementary Table 2 summarizes the 
definitions of the compartments and variables in the model; any additional 
parameters are defined below. 
Supplementary Table 2 – Definitions of the compartments and variables in the model. 
Symbol Definition 
Ua(t) Number of people of age a at time t  who have never been infected. 
Ez-,a(t,si) Number of people of age a who have been infected for duration si at time t, who 
have never had PT. 
Ez+,a(t,si,sz) Number of people of age a who have been infected for duration si and have been 
on PT for duration sz at time t. 
),(, iaz stE p
 
Number of people of age a who have been infected for duration si at time t, who 
have previously had PT. 
Lz-,a(t) Number of people of age a in the latent category at time t, who have never had 
PT. 
Lz+,a(t,sz) Number of people of age a in the latent category at time t, who have been on PT 
for duration sz. 
Pe+,a(t) Number of people of age a who have previously had PT, cleared their infection 
and have not been reinfected since clearing their infection. 
Pe-,a(t) Number of people of age a who have had PT, have not cleared their infection and 
have not been reinfected during the previous five years 
Rz-,a,(t,sr) Number of people of age a who have been reinfected for duration sr at time t, who 
have never had PT. 
Rz+,a(t,sr,sz) Number of people of age a who have been reinfected for duration sr and have 
been on PT for duration sz at time t. 
),(, raz stR p
 
Number of people of age a who have been reinfected for duration sr at time t, who 
have previously had PT. 
Dp,s,a(t,so) Number of undetected cases of age a and smear status s who have had disease 
because of recent (primary) infection for duration so at time t, if max
oo Ts  . If 
maxoo
Ts 
, Dp,s,a(t,so) represents the number of cases of age a, smear status s 
who have had disease because of recent (primary) infection for at least time 
maxo
T
at time t 
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Dn,s,a(t,so) Number of undetected cases of age a and smear status s who have had disease 
through (endogenous) reactivation for duration so at time t, if max
oo Ts  . If 
maxoo
Ts 
, Dn,s,a(t,so) represents the number of cases of age a, smear status s 
who have had disease through (endogenous) reactivation for at least time maxo
T
. 
Dx,s,a(t,so) Number of undetected cases of age a and smear status s who have had disease 
because of (exogenous) reinfection for duration so at time t, if max
oo Ts  . If 
maxoo
Ts 
, Dx,s,a(t,so) represents the number of cases of age a, smear status s 
who have had disease because of (exogenous) reinfection for at least time maxo
T
at 
time t 
Fs,a(t,sf) Number of cases of smear status s, age a, who have been detected (“found”) for 
duration sf at time t and have not yet started TB treatment. 
Ca(t,sτ) Number of cases of age a, who have been on TB treatment for duration sτ at time 
t. 
Vz-,a(t) Number of people of age a who are in the recovered category at time t who are 
not on PT. 
Vz+,a(t,sz) Number of people of age a, who are in the recovered category at time t who have 
been taking PT for duration sz. 
)(,, tM aUin
 
Number of new immigrants at time t, who are of age a, and not infected 
)(,, tM aLin
 
Number of new immigrants at time t, who are of age a, and in the latent category. 
),(,, iaEin stM
 
Number of new immigrants at time t who are of age a, and who have been newly 
infected for duration si 
),(,, raRin stM
 
Number of new immigrants at time t who are of age a, and who have been 
reinfected for duration sr 
),(,,, oasDin stM p
 
Number of new immigrants at time t who are of age a, who have been 
experiencing disease because of endogenous reactivation for duration so, and have 
smear status s.  
),(,,, oasDin stM n
 
Number of new immigrants at time t who are of age a, who have been 
experiencing disease because of recent (primary) infection for duration so, and 
have smear status s.  
),(,,, oasDin stM x
 
Number of new immigrants at time t of age a, who have been experiencing 
disease through exogenous reinfection for duration so, and have smear status s. 
)(,, tM aVin
 
Number of new immigrants at time t of age a, who have previously had TB, been 
treated and have not been reinfected since then. 
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People were allowed to experience the benefits of PT (i.e. reduced rates of disease 
onset) or lack of benefit in the same week as they started or stopped PT respectively.  
To simplify the equations whilst allowing this to occur, the population in the PT-
related compartments was transferred into subsequent strata at the end of each time 
step, once other transitions had been accounted for. 
Uninfected compartment 
))(1)(()( ,atbaaa mμtλtUtδtU   
Equation 1 
 
Recently (primary) infected compartment 
Recently (primary) infected people who are not on PT 
))0(1)(()())(1()0,( ,,, azpazaz dtUtλtitδtE  
 
Equation 2a 
),(
))(1)(,())(1(),(
,,
,,,,,
iaEin
atbaiazpiazziiaz
stM
mμsdstEtisδstδtE

 
 
Equation 2b 
Recently (primary) infected people who are on PT 
))(1)((),()0,,( ,,,,,, atbaiazpaziaziiaz mμsdtistEsδstδtE  
 
Equation 3a 
)()()(),0,( ,, tUtλtistδtE aazzaz  
 
Equation 3b 
))()(,,(
),,(),,(
,,,,
,,
aatbiazpziaz
ziazzziiaz
μmsdsstE
sstEsδssδstδtE




 
Equation 3c 
Recently (primary) infected people who have previously been on PT 
))()(,(),(),( ,,,,,, aatbiazpiaziaziiaz μmsdstEstEsδstδtE ppp  
 
Equation 4 
 
Latent and Reinfected compartments 
To ensure that no one in the population could start PT multiple times, the latent and 
reinfected compartments are subdivided according to whether or not they have been 
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on PT previously.  For simplicity, this detail is omitted from the model diagram 
(figure 24 in the thesis).  However, the disease-related compartments have not been 
stratified according to previous PT – this simplification is unlikely to affect 
conclusions since a negligible proportion of the model population is likely to 
experience PT twice and treatment for tuberculosis disease.   
People with Latent infection 
),(),()(
))(1))((1)(()(
,,,,
,,,,,,
EazRazaLin
aatbaznazazaz
TtETtRtM
μmtλdtitLtδtL




 
Equation 5a 
 
))(1)(()()0,( ,,,,,, aatbaznazazaz μmtλdtitLtδtL  
 
Equation 5b 
),,(),,(
))()(,(),(),(
,,
,,,,,,
zRazzEaz
aatbaznzazzazzzaz
sTtRsTtE
μmtλdstLstLsδstδtL




 
Equation 5c 
People who have completed PT but have not been reinfected in the previous 5 years 
),(),()())(()()(
maxmax ,,,,,,, zazzazaeaatbaeae
TtLTtVtPμmtλtPtδtP  
 
Equation 6a 
),(),())()(()()( ,,,,,, EzRzaatbaznaeaeae TtETtRμmtλdtPtPtδtP pp    
Equation 6b 
Reinfected people who are not on PT 
))0(1))(()()(())(1()0,( ,,,,, azxazazzaz dtVtLtλtitδtR  
 
Equation 7a 
),(
))(1)(,())(1(),(
,,
,,,,,
raRin
aatbrazxrazzrraz
stM
μmsdstRtisδstδtR

 
 
Equation 7b 
Reinfected people who are on PT 
))(1)((),()0,,( ,,,,,, aatbrazxazrazrraz μmsdtistRsδstδtR  
 
Equation 8a 
 
))0(1))(,(),()((),0,( ,,,,, azxzazzazzaz dstVstLtλstδtR  
 
Equation 8b 
))()(,,(
),,(),,(
,,,,
,,
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zrazzzrraz
μmsdsstR
sstRsδssδstδtR

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
 
Equation 8c 
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Reinfected people who have previously been on PT 
))0(1))(()()(()0,( ,,,,, azxaeaeaz dtPtPtλtδtR p  
 
Equation 9a 
))()(,(),(),( ,,,,,, aatbrazxrazrazrraz μmsdstRstRsδstδtR ppp  
 
Equation 9b 
 
Cases who have not yet been detected 
To allow calculation of the proportion of tuberculosis cases that have been reinfected 
recently, cases which have not yet been detected are further stratified according to 
the mechanism by which they are experiencing disease (i.e. (exogenous) reinfection 
or (endogenous) reactivation).  Once detected (“found”), cases remain in the detected 
compartments for a maximum period of 6 months (denoted by maxf
T
), unless they 
start treatment in the meantime, after which they are redistributed into the undetected 
compartments, according to their relative size. Considering cases experiencing 
disease through endogenous reactivation, this redistribution is calculated using the 
equation 
),(),(),(
),(
maxmaxmax
max
,,,,,,
,,
,,
oasxoasnoasp
oasn
asDn
TtDTtDTtD
TtD
p


   
The equation considering cases of primary or exogenous disease is analogous. 
Cases experiencing disease because of primary infection, who have not yet been 
detected 
 

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Equation 10a 
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Equation 10b 
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Ts 
 
 
Equation 10c 
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maxoo
Ts 
 
Equation 10d 
Cases experiencing disease because of reactivation, who have not yet been detected 
))()()(1()0,( ,,,,,,,,, aznazaznazasasn dtLdtLotδtD  
 
Equation 11a 
))()(()0,( ,,,,,,,,, aznazaznazasasn dtLdtLotδtD  
 
Equation 11b 
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Equation 11c 
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Equation 11d 
Cases experiencing disease because of reinfection, who have not yet been detected 
 
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Equation 12a 
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Equation 12b 
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Equation 12c 
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Equation 12d 
Detected cases 
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Equation 13a 
 
),())((),(),( ,,,, fasfaatbtbfasffas stFsτμmmstFsδstδtF  
 
Equation 13b 
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Equation 13c 
))()(,(),(),( ,,,, faatbtbfasfasffas sτμmmstFstFsδstδtF  
max
0 ff Ts   
Equation 13d 
Cases undergoing TB treatment 
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Equation 14a 
))(,(),(),( , aatbtbτaτaττa μmmstCstCsδstδtC        
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0 ττ Ts   
Equation 14b 
People who have recovered from TB disease 
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Equation 15a 
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Equation 15b 
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Equation 15c 
 
Transitions at the end of each time step 
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Equation 16 
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Equation 17 
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Equation 18 
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Equation 19a 
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Equation 19b 
))(1)(,,(),,( ,, zzziazzziiaz sisstEsδssδstE              
       maxzz
Ts 
 
 
Equation 20 
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Equation 21a 
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Equation 21b 
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Equation 22 
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Equation 23a 
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Equation 23b 
The force or risk of infection 
The force of infection at time t is given in Equation 24 in terms of the effective 
contact rate (ce) (defined as the average number of individuals effectively contacted 
by each infectious case), the total number of smear-negative and smear-positive 
cases (Is-(t) and Is+(t) respectively), the population size (N(t)) and the relative 
infectiousness of smear-negative, compared to smear-positive cases (f).  The latter 
equals 22%, consistent with molecular epidemiological data(2).   
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Equation 24 
Extending the definition used for acute infections, an effective contact is defined as 
one that is sufficient to lead to transmission if it occurs between an infectious 
individual and someone with either a “latent” infection or who has never been 
infected.14   
 
The total number of smear-positive individuals is given by the following equation 
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Equation 25 
 
The equation for smear-negative cases is analogous.  
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The rate at which detected cases start TB treatment 
The rate at which cases start treatment in the model was calculated so that the 
average time until cases had started treatment equalled 2 weeks and 82% of cases did 
not eventually start treatment. Cases who had not started treatment within 6 months 
were returned to the undetected categories (see above).  These rates were calculated 
as the values for τ(sf) satisfying the following equations:  
)()()()1( ffff susτsusu 
 
Equation 26 
18.0)4( u  
where: )( fsτ is the rate at which cases start TB treatment in week sf after detection 
(assumed to be constant in each month); )( fsu  is the estimated proportion of those 
detected who are still untreated sf weeks after detection. 
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Appendix 6: Cost-effectiveness model 
The cost-effectiveness model was developed by Jo Lord. 
__ 
Objective 
To estimate the cost-effectiveness of the TB-STS as an addition to the current system 
for TB control in England. 
Methods 
The analysis followed the methods recommended by the National Institute for Health 
and Clinical Excellence (NICE) for evaluation of public health interventions.1 
Perspective – A public sector perspective was used for costing, and included costs 
and savings attributable to the TB-STS for the NHS, Local Authorities, Department 
of Health and other public bodies.  The majority of costs and savings from the TB-
STS fall on the Public Health England (PHE) centre, regions, Health Protection Units 
(HPU), laboratories and NHS TB services.   
Measure of health effects – Health benefits attributable to the TB-STS were 
estimated in the form of Quality Adjusted Life Years (QALYs) gained for index 
cases, their contacts, and for people benefiting from prevention of onward 
transmission of TB (as estimated from the transmission model).  QALY estimates 
included TB-related mortality and morbidity. 
Time horizon – Costs and health effects resulting from operating the TB-STS were 
estimated over a period of 20 years.     
Incremental analysis – The results are presented in the form of an Incremental Cost 
Effectiveness Ratio (ICER), which is the additional cost per additional QALY gained 
with the TB-STS.  Thus we estimated the expected difference in costs and in health 
effects with/without the TB-STS.  Any costs or health effects incurred under both 
systems were ignored.  The resulting ICER was compared with the NICE-
recommended upper threshold of £30,000 per QALY gained.2  
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Uncertainty – Deterministic sensitivity analysis was used to test the impact of 
uncertainty over input parameters on the cost-effectiveness results.     
Discounting – Costs and QALYs were both discounted at the NICE recommended 
rate of 3.5% per year.  The impact of using the Department of Health recommended 
discount rates of 3.5% for costs and 1.5% discount rates for QALYs were tested in 
sensitivity analysis. 
The conceptual model underlying the economic analysis is illustrated in figure 25 in 
the thesis.  It was hypothesised that the introduction of the TB-STS might influence 
outcomes or health care expenditure through the following mechanisms: 
TB-STS infrastructure – The TB-STS has imposed capital and revenue costs for the 
reference laboratories and national, regional and local Health Protection Services 
(HPS).  These include direct costs of the tests, but also costs of establishing the 
infrastructure to request tests, report results and perform quality assurance.     
Detection of false positives – One potential benefit of strain typing is earlier 
identification of the false positive TB cases that can be caused by laboratory 
contamination.  In addition to the avoidance of anxiety for patients and their families, 
earlier identification of such cases has health and financial implications if treatment 
is avoided or reduced.  There might also be benefits in earlier detection of alternative 
diagnoses (e.g. lung cancer), but these are difficult to quantify, and have not been 
included in our analysis.   
Case finding activity – Introduction of the TB-STS might in theory have increased or 
decreased case finding activity and related costs.  As contact tracing is usually 
completed before the strain type result is available (Figure 39, page 145 in the main 
thesis), one would not expect it to impact on the initial number of contacts traced by 
TB clinics.  However, it is possible that it could have affected decisions by health 
protection staff to initiate or extend investigations of potential outbreaks.  If strain 
typing identifies otherwise unsuspected clusters of cases, the number of contacts 
followed up could increase, increasing costs.  But strain typing might also have the 
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effect of disproving links between epidemiologically linked cases, thus reducing case 
finding activity and costs.   
Case finding yield –  Regardless of the impact on the volume of case finding activity, 
we hypothesised that strain typing would improve the yield of case finding; 
increasing the number of cases of active disease and latent infection identified per 
case of TB.  If true, this would have a number of benefits: 
Earlier detection of active disease – It seems plausible that cases detected through 
the TB-STS-enhanced cluster investigations might benefit from earlier diagnosis and 
initiation of treatment, and that earlier treatment might be associated with a reduction 
in QALY loss from TB.   
Increased detection of latent infection – One might also expect an increase in the 
detection of latent infection resulting from strain typing.  Individuals diagnosed with 
Latent TB Infection (LTBI) who are suitable for and accept prophylactic treatment 
should then have a reduced risk of developing active disease themselves, avoiding 
QALY loss and NHS costs.  However, there are costs and side effects of prophylaxis, 
which will offset its benefits to some extent.   
Prevention of onward transmission – Both earlier detection of active disease and 
increased prophylactic treatment should help to prevent transmission.  If so, this 
would lead to further QALY gains and cost savings. 
In addition to the above direct effects, the TB-STS may well provide more indirect 
benefits.  For example, the availability of a national information resource on the 
distribution and growth of clusters might benefit future tuberculosis research and 
service development (see Box 5 in the thesis).  Such effects are hard to quantify or 
value, and so were not been included in the economic analysis, but they were 
discussed and taken into consider by the evaluation expert group. 
Estimated impact on false positive identification 
The survey of reference laboratories identified 70 possible false positive TB tests, of 
which 59 (84%) had a known outcome.  30 of the incidents with a known outcome 
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(51%) were confirmed as false positive results attributed to cross contamination.  Of 
these, 17 (57%) were not known about by the source laboratory before they were 
contacted by the reference lab.  For eight of the 30 confirmed cross-contamination 
incidents (27%), the patient commenced treatment.  For the economic analysis, it was 
assumed that five cases of unnecessary treatment would be avoided per year due to 
the TB-STS (ten cases per year was tested in sensitivity analysis).     
Estimated impact on case finding activity and yield 
Evidence on the impact of the TB-STS on the volume and yield of case finding 
activity was sparse.  There was some evidence of an increase in time spent on cluster 
investigations reported in the survey of health protection staff: from a mean of 2.7% 
before to 7.1% after implementation.
3
  However, TB specialist nurses did not report 
any significant increase in time spent on contact tracing.  In the economic analysis, 
an opportunity cost for additional time spent by HPU staff on cluster investigations 
was assumed: 4.4% Whole Time Equivalent (WTE) for each of 26 Consultants in 
Communicable Disease Control (CCDC) at £99,000pa, costing a total of £113,256 
per year (total annual cost of £50,000 per year and £500,000 per year tested in 
sensitivity analysis). 
There was no clear evidence of whether introduction of the TB-STS resulted in an 
increase in the number of contacts screened, or in the yield of contacts with active 
disease or latent infection found.  Analysis of the contact tracing database, national 
dataset and cluster monitoring dataset showed that a greater number of contacts were 
screened and more contacts with latent infection were identified in cases that were 
clustered and investigated compared with unique cases.  However, there were no 
significant differences in the numbers of contacts screened or cases of latent 
infection identified for clustered cases that were investigated compared with 
clustered cases that were not investigated.  Similarly, evidence for a change in the 
rate of cluster growth after the initiation of an investigation or for a change in the 
duration of diagnostic delay was equivocal.   
It is unclear whether these negative results reflect the absence of an effect of the TB-
STS, or the difficulties in obtaining evidence.  We therefore conducted a scenario 
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analysis, in which we estimated the cost-effectiveness of the TB-STS under a series 
of assumptions about its possible effects.   
Population assumptions 
Results were estimated across the population of England (53m) and took account of 
the age distribution of the population (age groups <15, 15-34, 35-54, 55+).4  The 
results were based on an epidemiological scenario with a medium TB incidence 
(similar to that in the non-white UK-born population in which the average infection 
risk was constant over time at 0.1%.) This was chosen to reflect an average risk level 
across the community.   
Scenarios investigated 
The transmission model was used to estimate the number of cases prevented under a 
range of assumptions about the effect of the TB-STS on: a) the proportion of 
previously infected individuals detected; and b) the mean length of time between 
onset of symptoms and treatment initiation.   
The base case scenario (S0) was intended to reflect the expected costs and outcomes 
of the TB control system in the absence of the TB-STS.  This was modelled 
assuming that three percent of previously infected individuals are detected per year 
and that the mean time from onset of symptoms to the start of treatment is 12 weeks.  
The transmission model results for this base case scenario are summarised in 
Supplementary Table 1 for the population of England over 20 years, and assuming a 
constant risk of infection of 0.1%  per annum.  The estimated number of cases 
diagnosed exceeds the number of new cases in each year, as there is a pool of cases 
who have previously not been diagnosed or who have defaulted from treatment. 
The cost-effectiveness of the TB-STS was then estimated under a range of 
assumptions about its effect on identification of cases of LTBI found and the 
diagnostic delay for active cases.  The results of the transmission model under these 
scenarios are summarised in table 37 in the thesis. They suggest that increases in the 
proportion of people with latent infection identified and treated have a relatively 
modest impact on TB incidence: if an additional 10% of prevalent infections were 
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detected each year, the number of new TB cases would fall by an estimated 736 
cases per year (11%).  In contrast, reductions in diagnostic delay for active cases 
were estimated to have a much bigger impact on TB incidence: a one week reduction 
in the time from onset of symptoms to treatment was associated with an estimated 
reduction of 1,650 TB cases (25%).  Furthermore, if such a reduction in diagnostic 
delay could be achieved, it would also be accompanied by a reduction in the number 
of people requiring prophylactic treatment. 
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Supplementary Table 1 – Summary of transmission model results for the base case 
scenario (S0)  
Scenario Year LTBI 
diagnosed 
LTBI starting 
treatment 
New TB cases TB cases 
diagnosed 
TB cases 
starting 
treatment 
S0 Year 1 9,069 8,616 6,730 7,568 6,698 
 Year 2 9,060 8,607 6,723 7,561 6,691 
 Year 3 9,051 8,599 6,717 7,554 6,685 
 Year 4 9,043 8,590 6,711 7,547 6,679 
 Year 5 9,034 8,582 6,705 7,540 6,673 
 Year 6 9,025 8,574 6,698 7,532 6,666 
 Year 7 9,016 8,566 6,692 7,526 6,660 
 Year 8 9,008 8,557 6,686 7,519 6,654 
 Year 9 8,999 8,549 6,680 7,512 6,648 
 Year 10 8,991 8,541 6,674 7,505 6,642 
 Year 11 8,982 8,533 6,668 7,498 6,636 
 Year 12 8,974 8,525 6,662 7,491 6,630 
 Year 13 8,966 8,517 6,656 7,485 6,624 
 Year 14 8,957 8,509 6,650 7,478 6,618 
 Year 15 8,949 8,502 6,644 7,472 6,612 
 Year 16 8,941 8,494 6,638 7,465 6,607 
 Year 17 8,933 8,486 6,633 7,458 6,601 
 Year 18 8,925 8,478 6,627 7,452 6,595 
 Year 19 8,916 8,471 6,621 7,446 6,589 
 Year 20 8,908 8,463 6,615 7,439 6,584 
       
 Total 179,747 170,760 133,431 150,046 132,794 
 Mean pa 8,987 8,538 6,672 7,502 6,640 
Estimated number of cases by year for population of England (53m) over 20 years, assuming constant 
ARI of 0.1%. 
 
Cost estimates 
The estimated costs of establishing and running the national strain typing programme 
were estimated from financial information obtained from Public Health England and 
TB Reference Laboratories.  Capital expenditure was converted to an equivalent 
annual cost assuming a 10 year lifetime of the investment and 3.5% annual discount 
rate.  Total costs were estimated at just under £1m per year (Table 9 in the thesis, 
page 96).   
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The estimated costs of screening, diagnosis and treatment are shown in 
Supplementary Table 2.  The average quantities of resource items per patient were 
based on standard treatment protocols, informed by expert judgement.  Unit costs per 
resource item were taken from standard national sources: Department of Health 
Reference Costs 2010-11 for Tuberculosis Specialist Nurse visits, outpatient 
consultations (respiratory clinic), and inpatient admissions; British National 
Formulary, Sept 2012 for medications; and published sources for tests.
5,6
 
The costs of treatment for latent and active disease were estimated at £743 and 
£1,114 respectively for a full course, or £669 and £1,002 respectively allowing for 
drop out from treatment: assuming that 15% of patients drop out, after a mean of one 
month for latent infection and 2 months for active disease. Patients with TB who 
drop out are likely to be identified and offered treatment again at a later time.  Such 
repeat cases are included in the transmission model estimates of the number of 
people diagnosed per year, and incur additional costs for diagnosis and treatment in 
the cost effectiveness analysis.  For simplicity, it is assumed that the cost of 
diagnosis and treatment is the same for new and repeat cases. 
The cost per contact screened was estimated at £234 (including contact tracing, TST 
and IGRA testing, and initial rule-out of active disease).  The total cost of contact 
screening was estimated as a function of the number of people diagnosed with LTBI, 
as estimated by the transmission model.  The study of the yield of cluster 
investigations above (Table 28 in the thesis, page 150) found that on average (across 
unique and clustered cases) 2.6 contacts were screened and 0.7 cases of LTBI were 
identified per TB case.  Therefore, it was assumed that to diagnose one case of LTBI, 
3.97 contacts would need to be screened, on average, at a cost of £963.  The cost of 
further follow-up and investigations for each contact suspected of having active 
disease was estimated at £434.  It was assumed that 20% of individuals investigated 
for active TB would receive a positive diagnosis (based on estimates of contact 
tracing yield reported here and expert opinion) so the estimated cost to diagnose one 
case of TB was £2,170 (5 x £434). The costs of treatment for latent and active 
disease were estimated at £743 and £1,114 respectively for a full course, or £669 and 
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£1,002 respectively allowing for drop out from treatment: assuming that 15% of 
patients drop out,
7
 after a mean of one month for LTBI and 2 months for active 
disease.  
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Supplementary Table 2 – Estimated costs of screening, diagnosis and treatment 
 Quantity Unit cost Cost Source 
Contact screening and follow up     
TB specialist nurse - non face to face 1 £27 £27 Ref cost 20118 
TB specialist nurse - face to face 2 £62 £124 Ref cost 2011 
Mantoux test 1 £1.22 £1.22 NICE 20119 
IGRA test 0.5 £56 £28 Pareek 201110 
Outpatient appointment for IGRA + 0.25 £187 £47 Ref cost 2011 
Chest X-ray (to rule out active disease) 0.25 £28 £7 NICE 201011 
Per contact screened   £234  
Per person diagnosed with LTBI a   £963  
     
Diagnosis of active disease     
TB specialist nurse - face to face 3 £62 £186 Ref cost 2011 
Outpatient appointment for diagnosis 1 £187 £187 Ref cost 2011 
Chest X-ray 1 £28 £28 NICE 2010 
Sputum smear microscopy 1 £1.56 £1.56 Dowdy 200812 
Culture & MDR identification 1 £30 £30 Dinnes 200713 
Liver function test 1 £1 £1 Ref cost 2011 
Per contact with suspected TB   £434  
Per person diagnosed with TB b   £2,170  
     
Management of LTBI     
Follow-up appointments nurse only 3 £62 £186 Ref cost 2011 
Follow-up appointments nurse & consultant 2 £185 £370 Ref cost 2011 
Isoniazid 300 mg daily (per month) 3 £41 £124 BNF 201214 
Rifampicin 600 mg daily (per month) 3 £21 £63 BNF 2012 
B6 pyridoxine 10mg tablets (per month) 3 £0.5 £1 BNF 2012 
Per person completing treatment   £743  
Per person starting treatment c   £669  
     
Management of active disease     
Admission 5% £2,949 £147 Ref cost 2011 
Follow-up appointments nurse only 5 £62 £310 Ref cost 2011 
Follow-up appointments nurse & consultant 2 £185 £370 Ref cost 2011 
Rifater (R,I ,P) 6 tablets daily for 2 months 2 £37 £74 BNF 2012 
Ethambutol 15 mg/kg for 2 months 2 £63 £126 BNF 2012 
Rifanah (R,I) 300/150 2 tab daily for 4 months 4 £21 £84 BNF 2012 
B6 pyridoxine (per month) 6 £0.5 £3 BNF 2012 
Per person completing treatment   £1,114  
Per person starting treatment d   £1,002  
a 
Assumes 4.11 contacts screened per person diagnosed with LTBI (Table 28, page 150 in the thesis); 
b 
Assumes 5 people investigated per person diagnosed with TB (expert opinion); 
c 
Assumes that 15% 
do not complete chemoprophylaxis, after an average 1 month of treatment (expert opnion); 
d 
Assumes 
that 15% do not complete treatment,
7
 after an average 2 months of treatment (expert opinion); BNF 
British National Formulary 
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QALY estimates 
Estimates of the QALY loss per case of TB are shown in Supplementary Table 3. At 
ages of 15 and older, TB-related mortality contributed more to estimated QALY loss 
than TB-related morbidity.  On average across all ages, a loss of 0.5 QALYs was 
attributable to case fatality out of a total estimated 0.62 QALYs lost. Estimates of 
QALY loss due to morbidity are based on simple assumptions about the duration and 
quality of life reduction in three periods of time: 
a. Pre-treatment period: from onset of symptoms to initiation of treatment, 
which is assumed to last for 12 weeks in scenarios S0 to S10, and is reduced 
according to the diagnostic delay in scenarios S11 to S14.  During this time, 
patients are assumed to have a utility equal to 90% of that of the general 
population of the same age. 
b. Acute period: assumed to last for 2 months from diagnosis, during which 
patients have a utility value of 0.675.
15
  
c. Post-acute period: from after the acute period to the end of treatment (4 
months), during which patients have a utility value of 0.813.
15
 
Overall QALY losses per case of TB are estimated to be 0.19, 0.40, 0.59 and 1.18, 
respectively, for patients in age group 0-14, 15-34, 35-54, and 55 plus. It is assumed 
that after treatment completion there is no lasting effect of TB on quality of life or 
mortality risk, although within the transmission model, individuals can be re-
infected, potentially incurring another QALY loss associated with a new TB 
incidence.  
The QALY impacts of adverse effects of treatment are assumed to be incorporated in 
the above utility multipliers for active disease.  Patients with a false positive TB 
diagnosis who start treatment, are assumed to be treated for four months on average, 
and during this time they are assumed to experience a utility loss of 0.1 due to the 
inconvenience and adverse side effects of TB treatment.  Thus, the avoidance of 
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treatment for a false positive is associated with a mean QALY gain of 0.03.  The 
QALY loss associated with the adverse effects of prophylactic treatment is estimated 
based on the assumption that 10% of patients experience some side effects, and that 
these last for one month on average, incurring a mean utility loss of 0.1.  Thus the 
mean QALY loss per person treated with prophylaxis is 0.0008.  It is assumed that 
there are no lasting consequences from adverse reactions to treatment for active 
disease or LTBI. 
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Age Male Female Male Female Male Female Male Female Male Female Pre-treat Acute Post acute Mortality Morbidity Total
0-4 62        78        0.3% 78.0   82.1     0.94     0.84    0.63    0.76    26.62   26.88   24.98   25.22   0.07     0.08     0.023  0.051  0.058  11        19       29
5-9 47        46        0.2% 73.5   77.5     0.94     0.84    0.63    0.76    26.29   26.59   24.67   24.94   0.05     0.05     0.023  0.051  0.058  5          12       17
10-14 77        103      0.2% 68.5   72.5     0.94     0.84    0.63    0.76    25.86   26.21   24.27   24.60   0.05     0.05     0.023  0.051  0.058  9          24       33
15-19 192      173      1.2% 63.5   67.6     0.94     0.84    0.63    0.76    25.36   25.78   23.80   24.19   0.29     0.29     0.023  0.051  0.058  105      48       153
20-24 582      406      1.2% 58.7   62.6     0.94     0.84    0.63    0.76    24.77   25.26   23.25   23.70   0.28     0.28     0.023  0.051  0.058  278      130     408
25-29 717      547      1.2% 53.9   57.7     0.94     0.84    0.63    0.76    24.09   24.65   22.60   23.13   0.27     0.28     0.023  0.051  0.058  346      167     513
30-34 686      500      1.2% 49.0   52.8     0.91     0.82    0.62    0.74    23.28   23.93   21.29   21.88   0.26     0.26     0.023  0.050  0.057  307      153     459
35-39 531      365      1.2% 44.3   47.9     0.91     0.82    0.61    0.74    22.34   23.08   20.26   20.93   0.24     0.25     0.023  0.049  0.057  221      114     335
40-44 416      294      1.2% 39.6   43.1     0.88     0.79    0.60    0.72    21.24   22.08   18.74   19.48   0.22     0.23     0.022  0.048  0.055  162      88       250
45-49 343      227      4.8% 34.9   38.3     0.86     0.78    0.58    0.70    19.97   20.92   17.25   18.07   0.83     0.87     0.022  0.047  0.054  481      68       549
50-54 290      223      4.8% 30.3   33.6     0.83     0.75    0.56    0.68    18.50   19.58   15.44   16.34   0.74     0.78     0.021  0.045  0.052  390      59       449
55-59 245      180      4.8% 25.9   29.1     0.82     0.74    0.55    0.67    16.85   18.05   13.86   14.84   0.67     0.71     0.021  0.045  0.051  291      48       340
60-64 200      163      4.8% 21.7   24.6     0.81     0.73    0.54    0.66    15.03   16.33   12.13   13.18   0.58     0.63     0.020  0.044  0.050  220      41       260
65-69 164      126      17.6% 17.7   20.4     0.80     0.72    0.54    0.65    13.05   14.40   10.49   11.58   1.85     2.04     0.020  0.044  0.050  560      30       590
70-74 168      133      17.6% 14.1   16.4     0.78     0.70    0.53    0.63    10.98   12.29   8.55     9.57     1.50     1.69     0.019  0.042  0.049  477      31       508
75-79 167      109      17.6% 10.8   12.6     0.75     0.68    0.51    0.61    8.86     10.08   6.67     7.59     1.17     1.34     0.019  0.041  0.047  342      27       369
80-84 127      82        17.6% 8.0      9.4        0.70     0.63    0.47    0.57    6.86     7.87     4.79     5.49     0.84     0.97     0.017  0.038  0.044  186      19       205
85-89 77        35        17.6% 5.8      6.7        0.65     0.58    0.44    0.53    5.16     5.87     3.35     3.81     0.59     0.67     0.016  0.035  0.040  69        9          78
90+ 21        21        17.6% 4.2      4.6        0.65     0.58    0.44    0.53    3.80     4.17     2.47     2.71     0.43     0.48     0.016  0.035  0.040  19        4          23
5,112  3,811  4,477  1,092 5,569     
Utility multipliers 0.9 0.675 0.813
Duration of health states (months) 3 2 4 0-14 0.06 0.13 0.19
15-34 0.27 0.13 0.40
35-54 0.47 0.12 0.59
55+ 1.07 0.10 1.18
All ages 0.50 0.12 0.62
Total QALYs lost
UtilityIncidence
Case 
fatality Life expectancy
Discounted to age of incidence
QALYs lost per fatality *LYL per fatality
 TB mortality
Pre- treatNo TB Acute Post acute
QALYs lost per case QALYs lost per case
TB morbidity
Supplementary Table 3 – Calculation of QALY loss per case of TB 
 
 
 
 
 
 
 
 
Approximation - assumes current quality of life persists for life 
Utility values from Kruijshaar et al 2010,
15
 reported in NICE guidance 2011
16
 
LYL years of life lost
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ABSTRACT
Objectives: To systematically review the evidence for
the impact of study design and setting on the
interpretation of tuberculosis (TB) transmission using
clustering derived from Mycobacterial Interspersed
Repetitive Units-Variable Number Tandem Repeats
(MIRU-VNTR) strain typing.
Data sources: MEDLINE, EMBASE, CINHAL, Web of
Science and Scopus were searched for articles
published before 21st October 2014.
Review methods: Studies in humans that reported the
proportion of clustering of TB isolates by MIRU-VNTR
were included in the analysis. Univariable meta-regression
analyses were conducted to assess the influence of study
design and setting on the proportion of clustering.
Results: The search identified 27 eligible articles
reporting clustering between 0% and 63%. The number of
MIRU-VNTR loci typed, requiring consent to type patient
isolates (as a proxy for sampling fraction), the TB
incidence and the maximum cluster size explained 14%,
14%, 27% and 48% of between-study variation,
respectively, and had a significant association with the
proportion of clustering.
Conclusions: Although MIRU-VNTR typing is being
adopted worldwide there is a paucity of data on how study
design and setting may influence estimates of clustering.
We have highlighted study design variables for
consideration in the design and interpretation of future
studies.
INTRODUCTION
The introduction of molecular typing
methods has improved our understanding of
Mycobacterium tuberculosis (TB) transmission
and has changed local and national control
policies.1–5 The proportion of cases that are
clustered is often used to estimate the
amount of ongoing transmission within the
population, based on the assumption that
cases with indistinguishable strain types are
part of a chain of transmission. TB molecular
typing methodology is changing rapidly and
it is important that we better understand
how to interpret the outputs and thus act.
TB molecular typing methods include
Spoligotyping,6 insertion sequence 6110
(IS6110) restriction fragment length poly-
morphism (RFLP) analysis (the recent gold
standard),7 Mycobacterial Interspersed
Repetitive Units-Variable Number Tandem
Repeats (MIRU-VNTR) typing,8 and whole
genome sequencing.9–11 Published reviews
have identiﬁed factors that might inﬂuence
or bias clustering by IS6110 RFLP.12 13 No
study has repeated this analysis using more
up-to-date typing methods, which is import-
ant for understanding of the epidemiology
of TB and to shape the application of
molecular typing to improve TB control.
Strengths and limitations of this study
▪ This is a timely evaluation of the impact of study
design on estimates of tuberculosis clustering
using Mycobacterial Interspersed Repetitive
Units-Variable Number Tandem Repeats strain
typing because it has been incorporated into
national typing services globally.
▪ The strength of this meta-analysis was limited by
the lack of detail reported by the included studies,
highlighting the need for better quality reporting in
primary studies.
▪ We have shown that the proportion of clustering
derived from MIRU-VTNR typing is influenced by
the number of loci typed, whether consent is
required to type isolates, TB incidence in the
study setting, and the maximum cluster size,
highlighting these as important considerations in
the design and interpretation of future studies.
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Published meta-analyses and modelling studies using
IS6110 RFLP data show that the proportion of clustering
observed can be affected by (1) study design (affecting the
proportion of eligible cases that are included in the study);
(2) features of the typing method (such as the ability to
type isolates with low copy numbers); and (3) study setting
(such as characteristics of the study population). For
example, the proportion of clustering increases when the
fraction of the total data sampled increases13–15 and when
study duration increases.16
MIRU-VNTR is currently the preferred method of
molecular typing,17–21 and can be used together with
Spoligotyping.8 Relative to IS6110 RFLP, MIRU-VNTR
does not have to exclude isolates with a low IS6110 copy
number, has a faster turnaround time, is high throughput
and the numeric strain types are more easily compared.
MIRU-VNTR strain typing is increasingly being adopted
worldwide,1 22–27 yet unlike IS6110 RFLP, the evidence for
the interpretation of the ﬁndings such as the impact of
study design and setting on clustering have not been
reviewed. Although the two typing methods have been
shown to have a similar discriminatory value, the markers
evolve independently and at different rates, resulting in a
difference in clustering between the two methods.28 This
suggests that there could be differences in the way study
design, typing method and setting affects clustering by
the two methods. We conducted a systematic review to
assess the evidence for the impact of study design and
setting on the interpretation of TB transmission using
clustering derived from MIRU-VNTR strain typing—as
has been shown using IS6110 RFLP typing.
METHODS
Five electronic databases were searched (EMBASE, ISI
Web of Science, CINHAL, Scopus and Medline (Ovid))
up to 20 October 2014. The search strategy combined the
following terms with Boolean operators: Tuberculosis,
strain typing, and transmission (see online supplementary
appendix 1). The search was limited to studies using the
standard MIRU-VNTR method,8 in humans only, and in
English.
All titles and abstracts from each of the searches were
examined. The full text of each paper was obtained and
reviewed if the study reported MIRU-VNTR strain typing
of M. tuberculosis complex isolates with at least 15 of the
standardised 24 loci (Exact Tandem Repeat A, B, C, D,
E; MIRU 2, 10, 16, 20, 23, 24, 26, 27, 39, 40; VNTR 424,
1955, 2163b, 2347, 2401, 3171, 3690, 4052, 4156).8 29 30
Studies using fewer than 15 loci were not included
because the level of discrimination is inadequate for epi-
demiological use (n=121).8 Studies that used loci different
to the standardised 15 and 24 set were not included in the
analysis in order to reduce the heterogeneity between
studies (n=19). All publication types were included in this
ﬁrst screen to ensure that no relevant data were missed.
Reviews, letters, editorials, outbreaks or case reports
(n=103) were excluded in the second screen. Studies that
used incomplete sampling (eg, random samples, studies
using subsets of populations such as multidrug-resistant
patients; n=47) and studies that had a sample size of less
than 50 (n=4) were also excluded.
A reviewer ( JM) extracted the following data items
from all included studies using a form developed in Excel
(Microsoft 2010): publication details (year, authors, study
country), study details (study duration, loci typed, second-
ary typing method, study population, whether participant
consent was required (a characteristic of the study design
that was used as proxy for sampling fraction, assuming
that where consent was required the sampling fraction
was low)), the number of clustered and unique isolates
and the covariates of interest: the maximum size of clus-
ters; the proportion of clusters containing two cases; the
proportion of the population that was culture positive;
the proportion of culture positive isolates typed; risk
factors for clustering; and the Hunter Gaston
Discriminatory Index (HGDI)31). IA extracted data from
10% of the papers for external validity, disagreements
were discussed and a consensus agreed on.
The main outcome measure—the proportion of TB
isolates clustered by MIRU-VNTR strain typing—was cal-
culated as the number of clustered isolates/number of
clustered+unique isolates. Where there were uncertain-
ties JM consulted with IA.
Authors were contacted if TB incidence rate was not
reported. Where no response was received WHO
country estimates of TB incidence for the study year
were used.32 As so few studies reported the proportion
coinfected with TB/HIV, these estimates for the study
country were taken from an European Union-wide
survey and WHO country proﬁles.33 34 Owing to poor
recording of the sampling fraction (the number of iso-
lates typed/the total number of culture positive TB cases
diagnosed during the study period (n=19)), whether the
Figure 1 Results of systematic search, screening and data
extraction.
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Table 1 The study setting and design characteristics of the included articles
Reference
Study setting Study design
Risk
of bias*
Clustering
(%)†
Study area
and country
TB incidence
(per 100 000)
TB/HIV
(per 100 000)‡
Previous TB
treatment (%)
Pulmonary
TB (%)
Maximum
cluster size
Clusters of
size 2 (%)
Study
duration
(months)
Study size
(clustered
+unique
isolates)
Culture
positive
in study
population
(%)
Culture
positive
isolates
typed
(%)
Typing
method§
Loci
typed¶
Consent
required
51 New South Wales,
Australia
6.7 0.2 0.0 63.7 36 1128 m24 N no low 20.1
40 Tabriz and Orumieh,
Azarbaijan
26.0 5.2 87.0 5 81.8 12 156 94.5 m15 O no low 32.7
52 Brussels-Capital
Region, Belgium
35.2 5.1 10.8 23 64.2 24 530 86.1 87.9 m24 N no low 29.6
53 Brussels-Capital
Region, Belgium
35.2 5.1 100 39 802 81.8 84.7 m24s N no low 28.8
54 Ontario, Canada 4.8 0.4 18 58.8 65 2016 m24s N no low 23.1
37 Changping District,
Beijing, China
0.3 100 0 30 318 31.5 94.6 m24 N no high 0.0
38 Croatia 19.0 0.1 45 48.3 36 1587 m15 N no high 62.8
55 Amhara region,
Northwest Ethiopia
24.0 17.6 100 13 5 244 m24 N yes low 45.1
56 Finland 5.0 0.0 20 48 1048 75.4 99.4 m15s no low 33.9
57 Hamburg, Germany 12.7 45.5 12 154 78.2 91.1 m24s N no low 22.1
45 Schleswig-Holstein,
Germany
3.2 0.1 22 44.4 48 277 m24s N no high 27.1
58 South West Ireland 15.3 3.3 82.7 12 36 171 79.5 96.1 m24s N no low 27.5
59 South Tawara,
Kiribati
370.0 4.1 100 25 55.6 24 73 45.4 98.6 m24s N yes low 75.3
60 Netherlands 6.5 0.2 57.2 60 3978 100.1 m24 N no low 46.7
41 Kharkiv, Russia 94.0 3.8 63.3 100 10 50.0 3 98 100 m15 O yes high 31.6
61 Eastern province,
Saudi Arabia
4.0 73.1 24 19.0 24 522 m24s N no low 40.2
62 Singapore 40.5 1.2 21 48.0 24 1128 82.0 34.5 m24s N no low 30.8
63 Slovenia 10.6 0.0 6 12 196 94.4 97.5 m24s N no low 36.2
47 Almeria, Spain 26.0 6.0 8 27 281 81.9 m15 N no high 43.1
64 Sweden 4.8 0.1 10 36 406 m24s N no low 21.2
65 Mubende, Uganda 86.0 31.1 87.8 11 70.0 6 67 21.5 90.5 m15s N yes low 35.8
42 East Lancashire, UK 18.3 8.2 13 58.3 102 332 48.5 69.9 m15 O no low 42.8
39 UK 8.2 42.3 12 50.0 48 102 90.7 87.2 m15 O no low 30.4
66 London, UK 44.9 8.2 9 964 36.0 100 m24 N no 37.0
43 Midlands, UK 15.0 8.2 48 4207 58.3 100 m15 O no 61.2
44 Odessa and
Nikolaev, Ukraine
80.4 3.9 34.2 100 4 225 m15 O yes** low 60.4
67 Hanoi, Vietnam 146.0 10.0 0.0 100 20 465 92.7 91.9 m15s N yes low 55.3
*Risk of bias was assessed using the STROME-ID checklist. Studies scoring <20 were categorised as have a high risk of bias. See online supplementary appendix 2 for STROME-ID scores.
†The proportion of clustering was calculated as the number of clustered isolates/number of clustered+unique isolates.
‡Estimates from of the prevalence of TB/HIV coinfection in the study country.33 34
§15=15 MIRU-VNTR loci (made up of the ‘old 12’ or ‘new 12’ defined in the footnote below), 24=24 MIRU-VNTR loci (ETR A, B, C, D, E; MIRU 2, 10, 16, 20, 23, 24, 26, 27, 39, 40; VNTR 424, 1955, 2163b, 2347, 2401,
3171, 3690, 4052, 4156), S=with Spoligotyping.
¶O=old 12 MIRU loci (MIRU 2, 4, 10, 16, 20, 23, 24, 26, 27,30, 31, 39, 40), N=new 12 MIRU loci (MIRU 10, 16, 26, 31, 40 +Mtub 04, 21, 39+ETR A C+QUB 11b, 26).
**11.3% did not consent to being part of the study. The other studies that required consent for isolates to be typed did not report the refusal rate.
ETR, Exact Tandem Repeat; TB, tuberculosis.
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study required the consent of participants (yes/no) was
included as a proxy for (low/high) sampling fraction.
The risk of bias within each study was assessed using the
STROME-ID checklist.35
Data were analysed in Stata V.12. Where studies
reported data from more than one set of loci, the
method with the highest discriminatory value was
included (ie, MIRU-VNTR 24 would be chosen over
MIRU-VNTR 15, and MIRU-VNTR 15 plus Spoligotyping
would be chosen over MIRU-VNTR 15 alone; n=8). This
review was not concerned with summary measures of clus-
tering, but factors that inﬂuenced clustering; therefore
articles must have included at least one of the covariates.
Continuous variables were transformed where the distri-
bution was skewed. The proportion clustered was trans-
formed using the Freeman Tukey transformation.36 Study
heterogeneity was assessed using a forest plot and the χ2
test of heterogeneity. Univariable meta-regression ana-
lyses were carried out to determine the effect of the study
design covariates on the proportion of clustered isolates.
All covariates in the analysis were hypothesised to inﬂu-
ence the proportion clustered a priori.
Sensitivity analyses were conducted to see the effect of
removing studies reporting 0% clustering, with only
extrapulmonary TB cases, only Mycobacterium bovis cases,
studies using the ‘old 12’ MIRU loci as part of their 15
loci, and studies assessed as having a high likelihood of
bias (STROME-ID score less than 20).
RESULTS
The search identiﬁed 7274 references resulting in 27
studies (25 journal articles and 2 conference abstracts)
included after deduplication and title/abstract/full text
screening (ﬁgure 1). The main characteristics of the
included studies are shown in table 1. Studies were pub-
lished between 2007 and 2014 and the clustering
reported varied from 0%37 to 62.8%.38 In all studies,
clustered isolates were deﬁned as having identical strain
types based on the MIRU-VNTR loci typed, with or
without Spoligotyping. Seventeen studies included iso-
lates from newly diagnosed TB cases, three studies
reported including isolates from new and chronic cases
of TB, and seven did not report this information. In add-
ition, 10 studies did not include repeat isolates from the
same patient, one study included a repeat isolate from
one patient and the remaining 17 did not report
whether repeat isolates were included or not.
Furthermore, four studies included isolates with missing
loci in the cluster analysis, whereas four excluded iso-
lates with missing loci and the remaining 20 did not
report how they dealt with missing loci. The number of
studies reporting each variable of interest is shown in
table 2. STROME-ID scores can be found in online sup-
plementary appendix 2.
A forest plot shows the spread of clustering reported
by number of loci and additional typing method
(ﬁgure 2). Signiﬁcant heterogeneity was identiﬁed
between the studies (p<0.001), suggesting that a metare-
gression would be an appropriate analysis.
The univariable metaregression shows evidence for the
proportion of clustering to decrease as the number of
MIRU-VNTR loci typed increased from 15 to 24 (p=0.04;
table 3), accounting for 14% of the between study vari-
ation, and to increase when the study participants con-
sented to being included in the study (p=0.03),
accounting for 14% of the between study variation. The
proportion of clustering increased as the TB incidence in
the population increased (p=0.007, adjusted R2=26.7).
There was also evidence for the proportion of clustering
Table 2 The number of studies that reported the variables of interest
Reported Missing
Study setting
TB incidence 8 15
TB/HIV coinfection 5 22
Previous TB treatment 9 18
Proportion pulmonary TB 14 13
Maximum cluster size 19 8
Percentage of clusters with 2 cases 14 13
Study design
Study duration 27 0
Study size 27 0
Percentage of population that is culture positive 15 12
Percentage of culture positive typed 19 8
24 loci (compared to 15) 27 0
Repeat isolates 12 15
Missing loci 8 19
Double alleles 1 26
Consent required 6* 21
Epidemiological information 6 21
*Only one study reported the consent rate.
TB, tuberculosis.
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to increase as the maximum cluster size increased
(p=0.001), accounting for 48% of between study vari-
ation. There was no evidence of the other study design or
study setting variables signiﬁcantly inﬂuencing the pro-
portion clustered. Though non-signiﬁcant (p>0.05), the
TB/HIV coinfection rate in the population explained 2%
of the between study variation. Too few studies included
information on the proportion of clusters containing two
cases, proportion of the study sample with previous TB or
with pulmonary TB, so these could not be included in
the analysis (table 2).
Sensitivity analyses to examine the effect of excluding
studies reporting 0% clustering,37 only M. bovis cases,39
studies using the ‘old 12’ MIRU loci,39–44 and studies
assessed as having a high risk of bias,37 38 45–47 did not
generally change the results. The proportion of culture-
positive TB in the population remained insigniﬁcant but
explained 2.6% of the between study variation when
excluding 0% clustering (p=0.278 and adjusted
R2=2.62). Similarly, the proportion of culture-positive TB
in the population remained insigniﬁcant but explained
2.6% of the between study variation when excluding
studies with the highest risk of bias (p=0.278 and
adjusted R2=2.62). The number of loci typed became
non-signiﬁcant, but explained 9.6% and 10.5% of the
between study variation when excluding studies using
the ‘old 12’ loci and the highest risk of bias, respectively
(p=0.106, adjusted R2=9.63; p=0.111, adjusted R2=10.51,
respectively).
DISCUSSION
This review identiﬁed 27 studies that met the inclusion
criteria. We illustrate that the interpretation of studies
Figure 2 Forest plot showing the proportion of clustering reported in each study by the number of MIRU-VNTR loci typed.
The number of loci typed is categorised into 15 loci (m15), 15 loci with Spoligotyping (m15 s), 24 loci (m24) and 24 loci with
Spoligotyping (m24 s). The study reference is shown in the right hand column.
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using MIRU-VNTR to estimate clustering is subject to
bias relating to study design and setting; however, there
were insufﬁcient data available to fully explore this
impact.
As expected, we found that the proportion of cluster-
ing decreased with a greater number of MIRU-VNTR
loci typed, with increasing TB incidence and with
increasing maximum cluster size. We found that requir-
ing consent to type patient isolates increased the propor-
tion of clustering, which is not expected, given that the
sampling fraction would be lower in these studies.
The other study design variables included in this ana-
lysis, such as study duration, did not signiﬁcantly inﬂu-
ence the proportion of isolates that were clustered,
contrary to previous ﬁndings.12 This is likely to be
because of a lack of good quality evidence: of the 27
studies that met the inclusion criteria for the review,
none reported all the variables of interest, reducing the
power of the analysis and precluding multivariable
metaregression (table 2). Importantly, key details of
cluster analyses were not reported consistently across the
studies, such as whether repeat isolates from the same
patients were included, or typing proﬁles with missing
loci were included, introducing new, unmeasured biases.
In addition, the range of the variables may have been
too limited to show any impact on clustering estimates.
For example, the proportion of culture-positive isolates
typed ranged from 34.5% to 100%, with 17 of the 19
studies reporting this variable from 81.9% to 100%.
Furthermore, most of the studies (17/27=63%) were
from low TB burden settings and therefore may be
reﬂecting the rate at which imported cases have match-
ing strain types by chance, rather than rates of recent
transmission.
The sensitivity analysis suggested that, when excluding
the studies with the greatest risk of bias, the culture-
positivity in the population might explain a small
amount of the between-study variation. This is consistent
with estimates of the inﬂuence of sampling on the
proportion of clustering using IS6110 RFLP typing.48 In
the sensitivity analysis excluding studies that used the
‘old 12’ loci, the effect of the number of loci typed
becomes non-signiﬁcant. This is likely because studies
using the ‘old 12’ accounted for six out of 10 studies
reporting 15 loci, reducing the number of studies and
the power of the model.
This study is a timely evaluation of the impact of study
design on estimates of TB clustering using MIRU-VNTR
strain typing because it has been incorporated into
national typing services globally.23 49 The ﬁndings are rele-
vant where strain typing is used to evaluate TB control
systems across different settings because the proportion of
clustering is inﬂuenced by the number of loci typed, the
TB incidence and the maximum cluster size. Given that
strain typing methods are advancing beyond MIRU-VNTR
typing and that the application of whole genome sequen-
cing to TB control and public health strategies has been
demonstrated,9–11 50 it is important that the biases in the
analysis of such methods are explored and compared.
Understanding how to design and compare research
studies for public health will greatly improve the beneﬁt
gained from newer technologies.
The strength of this meta-analysis was limited by the
(lack of) detail reported by the included studies. This
review has highlighted the need for better quality
reporting in primary studies to enable future reviews to
be more robust. Recently published standards for report-
ing of molecular epidemiology for infectious diseases
should improve the quality of reporting.35 This review is
further limited by our inability to access 58 of the title/
abstract screened articles for full text screening.
The use of TB strain typing as a public health tool in
TB control programmes is increasing globally. We have
identiﬁed a lack of good quality studies that can contrib-
ute to our understanding in interpreting the molecular
typing of TB. We have also shown that the proportion of
clustering derived from MIRU-VTNR typing is inﬂu-
enced by the number of loci typed, whether consent is
Table 3 Univariable metaregression showing the coefficients for change in the proportion of clustering and the percentage of
between-study variation explained by variables describing the study design and setting
n Coefficient* CI p Value Adjusted R2†
Study setting
TB incidence 23 0.14 0.04 to 0.24 0.007 26.74
TB/HIV coinfection 23 0.04 −0.03 to 0.11 0.246 2.00
Maximum cluster size 19 0.20 0.09 to 0.30 0.001 48.20
Study design
Study duration 27 −0.02 −0.09 to 0.06 0.677 −3.37
Percentage of population that is culture positive 15 0.34 −1.23 to 1.96 0.661 −5.92
Percentage of culture positive typed 19 0.22 −1.08 to 1.52 0.725 −5.41
Study size 27 0.03 −0.11 to 0.16 0.702 −3.31
24 loci (compared to 15) 27 −0.30 −0.59 to −0.01 0.04 13.58
Consent required 27 0.38 0.04 to 0.72 0.029 14.41
*Coefficients for the change in the proportion of clustering for each covariate. For example, for a one unit increase in maximum cluster size,
the proportion of clustering increases by 0.2.
†The proportion of between-study variation explained by the univariate metaregression.
TB, tuberculosis.
6 Mears J, et al. BMJ Open 2015;5:e005636. doi:10.1136/bmjopen-2014-005636
Open Access
group.bmj.com on January 26, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
required to type isolates, TB incidence in the study
setting and the maximum cluster size, highlighting these
as important considerations in the design and interpret-
ation of future studies.
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Abstract
Background: The national tuberculosis strain typing service (TB-STS) was introduced in England in 2010. The TB-STS
involves MIRU-VNTR typing of isolates from all TB patients for the prospective identification, reporting and investigation
of TB strain typing clusters. As part of a mixed-method evaluation, we report on a repeated cross-sectional survey to
illustrate the challenges surrounding the evaluation of a complex national public health intervention.
Methods: An online initial and follow-up questionnaire survey assessed the knowledge, attitudes and practices of
public health staff, physicians and nurses working in TB control in November 2010 and March 2012. It included
questions on the implementation, experience and uptake of the TB-STS. Participants that responded to both surveys
were included in the analysis.
Results: 248 participants responded to the initial survey and 137 of these responded to the follow-up survey
(56% retention).
Knowledge: A significant increase in knowledge was observed, including a rise in the proportion of respondents
who had received training (28.6% to 67.9%, p = 0.003), and the self-rated knowledge of how to use strain typing
had improved (‘no knowledge’ decreased from 43.2% to 27.4%).
Attitudes: The majority of respondents found strain typing useful; the proportion that reported strain typing to be
useful was similar across the two surveys (95.7% to 94.7%, p = 0.67).
Practices: There were significant increases between the initial and follow-up surveys in the number of respondents
who reported using strain typing (57.0% to 80.5%, p < 0.001) and the proportion of time health protection staff
spent on investigating TB (2.74% to 7.08%, p = 0.04).
Conclusions: Evaluation of a complex public health intervention is challenging. In this example, the immediate
national roll-out of the TB-STS meant that a controlled survey design was not possible. This study informs the future
development of the TB-STS by identifying the need for training to reach wider professional groups, and argues for its
continuation based on service users’ perception that it is useful. By highlighting the importance of a well-defined
sampling frame, collecting baseline information, and including all stakeholders, it provides lessons for the
implementation of similar services in other countries and future evaluations of public health interventions.
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Background
Complex public health interventions – interventions in-
volving multiple interacting components – when applied
at a national level, are often implemented in a way that
makes evaluating them with rigorously designed trials dif-
ficult [1]. Instead, they require a more pragmatic approach
using the available data [2].
Molecular typing of Mycobacterium tuberculosis is a tool
for TB surveillance and control. It has been used in combin-
ation with epidemiological information to identify outbreaks
[3], identify new routes of transmission [4], refute suspected
transmission [5,6], evaluate TB control programmes [7,8]
and detect laboratory cross contamination [9,10].
The National Tuberculosis Strain Typing Service (TB-
STS) is a complex public health intervention involving
laboratory, public health and clinical services across
England and was introduced in January 2010 [11]. A
mixed-method prospective evaluation of the acceptabil-
ity, implementation, effectiveness and cost-effectiveness
of the service was undertaken [12]. Here we report in
detail on one component of the evaluation: a cross-
sectional initial and follow-up survey of those delivering
and using the TB-STS to assess their knowledge, and to
understand the impact of the service on changes in atti-
tudes and practices associated with strain typing.
Methods
Intervention
A full description of the TB-STS, with laboratory guide-
lines for MIRU-VNTR strain typing and reporting [13]
and a handbook for public health actions relating to clus-
ter investigations (TB strain typing and cluster investiga-
tion handbook [14]) can be found on the Health
Protection Agency website [11]. Briefly, the TB-STS in-
volves prospectively typing the first M. tuberculosis isolate
from every culture-confirmed tuberculosis (TB) patient
using 24 locus Mycobacterial Interspersed Repetitive
Units-Variable Number Tandem Repeats (MIRU-VNTR),
a standardised molecular typing method [15]. Based on
the strain type result, patients are grouped into ‘clusters’
[13,14] which are reported to the Health Protection Units
(HPUs). If a cluster meets a certain threshold, as outlined
in the TB strain typing and cluster investigation hand-
book, [14] then a cluster investigation is launched to try to
establish epidemiological links between the clustered pa-
tients, thereby identifying the transmission setting and/or
an outbreak. As part of a cluster investigation the HPU
may decide to carry out enhanced contact tracing or
screening around the patients in the cluster or the identi-
fied transmission setting. By combining patients’ strain
type with epidemiological information the TB-STS aims to
inform public health decision-making at the local level.
The various components of the TB-STS were imple-
mented at different times (but always on a national
scale): prospective strain typing was introduced across
England in January 2010; one cluster investigator was
appointed in January 2010 and the remaining two were
appointed in January 2011; the training programme for
health protection staff working in HPUs was carried out be-
tween January 2011 and February 2012, consisting of a
seminar at the national Health Protection Conference, an
online seminar, a workshop conducted at each HPU, the
publication of the handbook [14] and a Q&A sheet [11] (in
December 2010); and the software linking patients’ elec-
tronic TB record and strain typing result with information
from clusters investigations was not developed during this
study period.
Study design
An initial survey was conducted in November 2010 and
a follow-up survey in March 2012 using a web-based
survey questionnaire (www.objectplanet.com/opinio).
The target population were all public health staff, chest/
respiratory physicians and TB nurses working in TB
control in England. Questions were asked about the
knowledge (awareness of the service, training, resources
and self-reported knowledge), attitudes (perceived use-
fulness of the service) and practice (if and how strain
typing is accessed and used, and its associated work-
load). All questions and possible responses are available
in the appendix (Additional file 1). The survey was
piloted with a nurse, a physician and a public health
specialist. The initial survey was emailed to all users of
the TB notification system [16] and to staff responsible
for TB control in HPUs who were asked to pass it on to
their local TB teams; the sampling frame could not be
enumerated. The follow-up survey was emailed to re-
spondents to the initial survey.
Analysis
Participants that responded to both surveys were included
in the statistical analysis. Responses from people working at
national, regional or PCT-level, including cluster investiga-
tors, and people working in Wales were excluded from this
analysis. We compared the knowledge, attitudes and prac-
tices of public health and clinical staff working on TB con-
trol in the initial and follow-up surveys by calculating and
comparing medians and inter-quartile ranges (IQR), and
means and standard deviations (SD), and using two-sample
t-tests, chi2 tests and logistic regression, where appropriate.
Calculations exclude item non-responses. Analyses were
conducted overall, by professional category and the TB in-
cidence of the HPU area in which respondents worked
(low, medium and high incidence defined as an annual no-
tification rate of <10/100,000 population, 10 to 19/100,000
and ≥20/100,000 respectively).
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Ethical considerations
The study was classified as a service evaluation by Univer-
sity College London Hospital Foundation Trust therefore
specific ethical approval was not required.
Results
Survey responses
There were 248 responses to the initial survey, 137 re-
sponses to the follow-up survey (55% retention), and for
124 we have responses to both the initial and follow-up
surveys (Figure 1). Respondents to the initial survey who
did not respond to the follow-up survey were not signifi-
cantly different to those that responded to both: no par-
ticular profession, full-time/part-time position or those
working in areas with different TB incidences was more
(or less) likely to respond to the follow-up survey, and
there was no significant difference between the proportion
of people who had heard of the TB-STS or had access to
strain typing at the time of the initial survey (Table 1). Re-
spondents were from all nine regions of England and cov-
ered 24 (of 26) HPUs.
Knowledge
Between the initial and follow-up surveys there were in-
creases in the proportion of respondents who had heard
of the TB-STS, had access to strain typing results, had
received training, and had access to training resources
(Table 2). The self-rated knowledge of how to use strain
typing also increased over time (Figure 2). Nurses re-
ported lower average knowledge in both surveys com-
pared to physicians and health protection staff.
Attitudes
69 people (69/124 = 56%) from the initial survey and 95
people (95/124 = 77%) from the follow-up survey reported
that they used strain typing. Opinions of the usefulness of
TB strain typing was high amongst all respondents and did
not change between the surveys (95.7% to 94.7%, p = 0.667;
Table 3). A greater proportion of respondents from low TB
incidence areas found strain typing useful, compared to
those working in high TB incidence areas (97.4% compared
to 89.3% in the follow-up survey, respectively), though this
result was not statistically significant (OR = 0.13, 95% CI
0.014-1.128, p = 0.075).
Non-responders to follow-
up survey (n=121)
Inial survey emails sent 
(n=736a) and cascadedb
Total responses (n=248)
Health protecon (n=54)
Physician (n=59)
Nurse (n=135)
Excluded (n=3f)
Total responses linked to 
inial survey (n=127)
Response rate 
(284/736=38%c)
Retenon rate 
(137/248=55%)
Excluded (n=36d)
Responses to inial survey 
(n=284)
Responses to follow-up 
survey (n=137)
Excluded (n=2e)
Total responses not linked to 
inial survey (n=10)
Responses included in 
analysis (n=124)
-
Health protecon (n=28)
Physician (n=30)
Nurse (n=66)
Figure 1 Responses to the initial and follow-up surveys.aThe email was sent to all users of the Enhanced TB Surveillance database. This
included all administrative staff as well as well as staff working at national, regional and Primary Care Trust level, for whom the survey may not be
relevant. bIt is not known how many people received the email via through the HPU cascade. cThis response rate is an underestimation because
of the denominator used. dRespondents working at national, regional or PCT-level (n = 27) and those from Wales (n = 9) were excluded from this
analysis. eEmail addresses not available from the initial survey (n = 2). fIn some cases it was not possible to link the follow-up response to the initial
response (n = 10). Respondents working at national, regional or PCT-level and those from Wales (n = 4) were excluded from this analysis.
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Practices
Figure 3 shows a significant increase in the number of
respondents that reported using strain typing between
the initial and follow-up surveys. There was an increase
in the number of respondents who reported using strain
typing to identify links between cases (65.3% to 78.2%,
p = 0.02; the most common use), disprove links between
cases (46.8% to 58.9%, p = 0.06) and to justify stopping
contact tracing (20.2% to 30.7%, p = 0.06) (Table 4).
Table 5 shows workload reported by nurses and health
protection staff. For the nurses, no significant changes in
contact tracing workload were reported.
Health protection staff reported a significant increase in
the mean number of investigations initiated because of
Table 1 Characteristics of responders and non-responders to the follow-up survey
Initial and follow-up responsesa Non-responders to the follow-up survey
N % n %
Total 124 121
Profession HPU 28 22.6 23 19.0
Physician 30 24.2 29 24.0
Nurse 66 53.2 69 57.0
TB incidenceb Low 56 45.2 50 42.0
Medium 33 26.6 32 26.9
High 35 28.2 37 31.1
Work time Full-time 95 79.2 87 77.0
Part-time 25 20.2 26 21.5
Heard of the TB-STS 105 85.4 100 84.7
Access to strain typing 90 72.6 99 81.8
aUsing the information reported in the initial survey.
bArea where respondents worked is defined as low, medium and high TB incidence: <10/100,000, 10-19/100,000, ≥20/100,000 population, respectively.
There were no significant differences between characteristics of non-responders and responders, including access to strain typing (81.8 % vs. 72.6 %, chi2
test p = 0.085).
Table 2 Knowledge: Awareness to the TB-STS and access to strain typing data and resources
Initial survey Follow-up survey
n % n % p-valued
Heard of the TB-STSa Total 105 85.4 123 99.2 <0.001
Profession Health protection 28 100 28 100 .
Physician 20 66.7 30 100 0.001
Nurse 57 86.4 65 98.5 0.015
TB incidence Low 49 87.5 56 100 0.006
Medium 24 72.7 32 97.0 0.010
High 32 91.4 35 100 0.077
Access to strain typing datab Total 90 72.6 108 87.1 0.004
Profession Health protection 26 92.9 27 96.4 0.553
Physician 21 70.0 23 76.7 0.559
Nurse 43 65.2 58 87.9 0.002
TB incidencec Low 38 67.9 47 83.9 0.047
Medium 24 72.7 28 84.9 0.228
High 28 80.0 33 94.3 0.074
Access to training (health protection staff) 8 28.6 19 67.9 0.003
Access to resources (health protection staff) 16 57.1 23 82.1 0.042
aHave you heard of the TB-STS (apart from in this survey)? (Yes / No).
bDo you have access to strain typing data? (Yes / No).
cArea where respondents worked is defined as low, medium and high TB incidence: <10/100,000, 10-19/100,000, ≥20/100,000 population, respectively.
dchi2 test of significance comparing responses from the initial and follow-up surveys.
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Figure 2 Self-reported knowledge of strain typing. Self-reported knowledge about how to use strain typing was scored on a scale of 1 to 5,
where 1 represented ‘no knowledge’ and 5 represented ‘excellent knowledge’. Dark bars represent responses to the initial survey and light bars
represent responses to the follow-up survey.
Table 3 Attitudes: Number and proportion of respondents that reported strain typing to be usefula
Initial survey Follow-up surveyb
Useful Not useful Useful Not useful
n % n % n % n % Pd
Total respondents that reported using strain typing 66 95.7 3 4.3 89 94.7 5 5.3 0.667
Profession Health protection 22 95.7 1 4.3 24 96.0 1 4.0 0.952
Physician 16 100 0 0.0 20 95.2 1 4.8 0.464
Nurse 28 93.3 2 6.7 45 93.8 3 6.3 0.942
TB incidencec Low 31 100 0 0.0 38 97.4 1 2.6 0.450
Medium 16 94.1 1 5.9 26 96.3 1 3.7 0.736
High 19 90.5 2 9.5 25 89.3 3 10.7 0.892
aThe following question was asked to respondents who reported that they used strain typing data for TB control (Figure 3): Do you find the strain typing
information useful? (Very useful / Quite useful / Not very useful / Useless) ‘Very useful’ and ‘Quite useful’ are grouped into ‘useful’, and ‘Not very useful’ is presented
as ‘Not useful’. No one reported finding the strain typing ‘useless’ in either survey.
bOne response was missing from the follow-up survey.
cArea where respondents worked is defined as low, medium and high TB incidence: <10/100,000, 10-19/100,000, ≥20/100,000 population, respectively.
dchi2 test for significance comparing responses from the initial and follow-up surveys, missing items were excluded.
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epidemiological links between patients over a three month
period (mean 0.5 to 2.8, p = 0.04) and the mean number of
these investigations for which strain typing was used to
provide more information (0.6 to 1.8, p = 0.03), but there
was no change in the number that were influenced by the
strain typing (1.2 to 0.4, p = 0.17). There was no reported
difference in the number of clusters investigated because of
their strain type (in high incidence areas a large, but non-
significant, decrease was reported) and the number of strain
typing investigations that identified epidemiological links
between cases remained low (Table 5). Overall, the propor-
tion of time health protection staff spent on cluster investi-
gations increased significantly (from 2.7% to 7.2%, p = 0.04).
There was no reported change over time in the fre-
quency at which physicians were called to incident meet-
ings (a meeting, often multi-disciplinary, held to discuss
a TB patient, group or cluster of cases that are of par-
ticular concern) (p = 0.503; most reported once every
three months or less (65.5% at in the initial survey and
67.9% at follow-up)) and there was no change in the
number of physicians who reported strain typing as
being relevant to an incident meeting (57.8% to 55.6%,
p = 0.875).
Discussion
Main findings
We present results from an initial and follow-up survey
assessing the knowledge, attitudes and practices of those
implementing and using the TB-STS. There were 124 re-
sponses to both the surveys, representing health protec-
tion staff and clinic-based physicians and nurses from 24
(of 26) HPUs across England. Strain typing was used by
more people, and an increase in knowledge of the TB-
STS was reported at the follow-up survey. A change in
attitude was not measured as the majority of respon-
dents found strain typing useful to them at both time
points. With respect to workload associated with the
TB-STS, there was no change over time in the contact
tracing activities of nurses or the frequency of incident
meetings attended by physicians; however the propor-
tion of time health protection staff spent on investigating
TB transmission increased significantly. Despite strain
typing being used to provide more information to public
health staff at follow-up, there was no increase in epi-
demiological links identified.
How this relates to previous studies
National TB strain typing services have been introduced
in other countries [17-20], but the knowledge, attitudes
and practices of users have not been evaluated. However,
the impact of strain typing on contact tracing activities
in the Netherlands has been assessed [5]. Consistent
with this study, we found no change in the workload as-
sociated with strain typing for nurses and physicians,
even though strain typing was used by more people at
the follow-up survey (indicating the successful roll-out
57
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26
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62
81
93
76
77
76
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88
0 20 40 60 80 100
Total
Health protecon
Physician
Nurse
Low
Medium
High
% of respondents that reported using strain typing
inial follow-up
<0.0001
0.245
0.097
<0.0001
0.036
0.013
0.017
Profession
TB incidence
p value
Figure 3 Practices: Respondents that use strain typing for TB controla. The proportion respondents that reported using strain typing for TB
control. Dark bars represent responses to the initial survey and light bars represent responses to the follow-up survey. P-values from chi2 tests for
significance comparing initial and follow-up proportions are shown. aHow often do you use strain typing data in your case management of outbreak
investigation? Never / For few cases / For about half of cases / For many cases / For every case. ‘For few cases’, ‘for about half of cases’, ‘for many cases’
and ‘for every case’ were grouped to show the proportion of respondents that use strain typing.
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of the service). This may be because it is difficult to
measure marginal changes in workload associated with a
particular service where the workforce is already work-
ing at full capacity. Health protection staff, however,
spent a greater proportion of time on cluster investiga-
tions. Given that the Handbook had not been published
and all the cluster investigation coordinators were not in
position at the time of the initial survey, this is not sur-
prising and suggests that the TB-STS had been inte-
grated into the TB control activities of the HPUs.
Based on evidence from the USA one would expect
more possible transmission links to be identified when
Table 4 Practices: How respondents use strain typing dataa
Initial survey Follow-up survey
n % n % Pc
Identify clusters and links between cases 81 65.3 97 78.2 0.024
Profession Health protection 22 78.6 25 89.3 0.275
Physician 18 60.0 21 70.0 0.417
Nurse 41 62.1 51 77.3 0.058
TB incidenceb Low 34 60.7 41 73.2 0.160
Medium 20 60.6 28 84.8 0.027
High 27 81.8 28 84.8 0.771
Disprove clusters and links between cases 58 46.8 73 58.9 0.056
Profession Health protection 21 75.0 24 85.7 0.313
Physician 13 43.3 15 50.0 0.605
Nurse 24 36.4 34 51.5 0.079
TB incidenceb Low 27 48.2 33 58.9 0.256
Medium 15 45.5 22 66.7 0.083
High 16 48.5 18 54.5 0.632
Justify extended contact tracing 51 41.1 60 48.4 0.250
Profession Health protection 16 57.1 19 67.9 0.408
Physician 11 36.7 10 33.3 0.787
Nurse 24 36.4 31 47.0 0.217
TB incidenceb Low 20 35.7 25 44.6 0.335
Medium 13 39.4 19 57.6 0.139
High 18 54.5 16 48.5 0.632
Justify stopping contact tracing 25 20.2 38 30.6 0.058
Profession Health protection 13 46.4 13 46.4 1
Physician 3 10.0 5 16.7 0.448
Nurse 9 13.6 20 30.3 0.021
TB incidenceb Low 9 16.1 18 32.1 0.047
Medium 8 24.2 13 39.4 0.186
High 8 24.2 7 21.2 0.771
To provide more information 34 27.4 44 35.5 0.171
Profession Health protection 13 46.4 10 35.7 0.415
Physician 5 16.7 6 20.0 0.739
Nurse 16 24.2 28 42.4 0.027
TB incidenceb Low 15 26.8 19 33.9 0.411
Medium 8 24.2 12 36.4 0.284
High 11 33.3 13 39.4 0.615
aWhat do you use strain typing for? (multiple selections possible) (Don’t know / Identify clusters and links between cases / Disprove clusters and links between cases /
Justify extended contact tracing / Justify stopping contact tracing / To provide more information / Other (please specify)).
bArea where respondents worked is defined as low, medium and high TB incidence: <10/100,000, 10-19/100,000, ≥20/100,000 population, respectively.
cchi2 test for significance comparing responses from the initial and follow-up surveys.
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Table 5 Practices: the workload associated with the TB-STS for nurses and health protection staff
TB incidencea Survey nb median (IQR) mean (SD) p-valuec
Nurses No. contacts screened in the last month Total Initial 57 21 (11–36) 37.1 (53.5)
Follow-up 55 20 (8–40) 33.9 (45.1) 0.37
Low Initial 26 16 (6–35) 23.8 (24.8)
Follow-up 23 15 (6–25) 17.2 (13.8) 0.13
Medium Initial 17 25 (14–30) 30.2 (26.2)
Follow-up 18 23 (15–42) 43.7 (43.7) 0.18
High Initial 14 32.5 (14–100) 70.2 (93.3)
Follow-up 14 16.5 (10–80) 48.6 (58.9) 0.24
No. hours spent on contact tracing in the last month Total Initial 55 8 (4–16) 12.0 (10.8)
Follow-up 52 7.5 (3.5-15.5) 16.1 (41.7) 0.24
Low Initial 25 8 (3–14) 10.1 (10.5)
Follow-up 21 6 (3–15) 11.5 (14.7) 0.35
Medium Initial 16 12 (4–23) 14.4 (11.4)
Follow-up 18 7.5 (4–12) 10.2 (7.8) 0.10
High Initial 14 9 (6–15) 12.5 (10.8)
Follow-up 13 8 (3–16) 31.9 (81.1) 0.19
% time spent on contact tracing Total Initial 57 20 (10–30) 24.2 (16.5)
Follow-up 54 20 (10–25) 21.7 (17.6) 0.22
Low Initial 26 20 (10–25) 21.2 (16.1)
Follow-up 23 20 (6–25) 21.8 (19.5) 0.45
Medium Initial 17 20 (20–30) 24.1 (13.8)
Follow-up 17 20 (10–25) 19.4 (10.4) 0.14
High Initial 14 30 (15–40) 30.0 (19.7)
Follow-up 14 20 (10–40) 24.4 (21.7) 0.24
Health protection staff Investigations initiated because of epidemiological links Total Initial 23 0 (0–1) 0.5 (0.8)
Follow-up 21 1 (0–2) 2.8 (6.1) 0.04
Low Initial 15 0 (0–1) 0.3 (0.62)
Follow-up 14 0.5 (0–1) 1.5 (2.3) 0.04
Medium Initial 3 1 (0–1) 0.7 (0.7)
Follow-up 3 1 (1–4) 2.0 (1.7) 0.14
High Initial 5 0 (0–1) 0.8 (1.3)
Follow-up 4 1.5 (0.5-15) 7.8 (13.5) 0.14
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Table 5 Practices: the workload associated with the TB-STS for nurses and health protection staff (Continued)
Strain typing used to provide more information in epidemiological investigation Total Initial 22 0 (0–1) 0.6 (1)
Follow-up 22 1 (0–2) 1.8 (2.5) 0.03
Low Initial 14 0 (0–1) 0.4 (0.8)
Follow-up 14 0.5 (0–2) 1.4 (2) 0.05
Medium Initial 4 0.5 (0–2) 1.0 (1.4)
Follow-up 3 1 (0–2) 1.0 (1) 0.50
High Initial 4 0.5 (0–2) 1.0 (1.4)
Follow-up 5 2 (1–3) 3.2 (4) 0.17
Strain typing influences an epidemiological investigation Total Initial 23 0 (0–1) 0.8 (1.1)
Follow-up 14 0.5 (0–2) 1.2 (1.6) 0.17
Low Initial 14 0 (0–1) 0.4 (0.8)
Follow-up 8 0 (0–0.5) 0.6 (1.4) 0.34
Medium Initial 4 0.5 (0–2) 1.0 (1.4)
Follow-up 2 1 (0–2) 1.0 (1.4) 0.50
High Initial 5 1 (1–3) 1.6 (1.3)
Follow-up 4 2 (1.5-3.5) 2.5 (1.7) 0.20
Investigation initiated because of strain typing Total Initial 23 0 (0–2) 2.2 (6.3)
Follow-up 22 0 (0–1) 1.1 (2.3) 0.79
Low Initial 14 0 (0–1) 0.4 (0.8)
Follow-up 14 0 (0–0) 0.5 (1.3) 0.43
Medium Initial 4 0.5 (0–1) 0.5 (0.6)
Follow-up 4 0.5 (0–1.5) 0.8 (1) 0.34
High Initial 5 4 (3–6) 8.6 (12.2)
Follow-up 4 1 (1–5.5) 3.3 (4.5) 0.78
Epidemiological links identified in strain typing cluster Total Initial 22 0 (0–0) 0.4 (0.8)
Follow-up 20 0 (0–0) 0.4 (0.8) 0.52
Low Initial 13 0 (0–0) 0.2 (0.6)
Follow-up 13 0 (0–0) 0.3 (0.9) 0.30
Medium Initial 3 0 (0–1) 0.3 (0.6)
Follow-up 3 0 (0–0) 0.0 (0) 0.81
High Initial 6 0.5 (0–1) 0.8 (1.2)
Follow-up 4 0.5 (0–1.5) 0.8 (1) 0.55
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Table 5 Practices: the workload associated with the TB-STS for nurses and health protection staff (Continued)
% time spent on investigations Total Initial 23 1 (0–5) 2.7 (3.2)
Follow-up 25 5 (0–5) 7.2 (11.1) 0.04
Low Initial 15 0 (0–5) 2.1 (3.1)
Follow-up 15 5 (0–12) 8.3 (13.1) 0.04
Medium Initial 3 5 (0–5) 3.3 (2.9)
Follow-up 4 5 (2.5-5) 3.8 (2.5) 0.42
High Initial 5 5 (1–5) 4.4 (3.7)
Follow-up 6 3.5 (0–5) 6.2 (9.5) 0.35
aArea where respondents worked is defined as low, medium and high TB incidence: <10/100,000, 10-19/100,000, ≥20/100,000 population, respectively.
bn is number of people who answered the question.
cPaired t-test comparing initial and follow-up responses.
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strain typing informs contact tracing activities [6,8]. How-
ever, in this study we found the proportion of time health
protection staff spent on cluster investigations increased
and the number of investigations that used strain typing
increased, but there was no increase in the reported num-
ber of possible transmission links found between clustered
cases. This discordance between the findings on subjective
report of utility and the public health outcomes reported
could be because the current methods used by public
health staff to identify epidemiological links may be in-
appropriate or ineffective, or there may have been an in-
crease in suspected (but not established) transmission
because of the strain typing information. For the TB-STS
to have a public health impact and reduce TB transmis-
sion, cluster investigations would have to lead to the de-
tection of previously unidentified latently infected and
active TB cases.
Limitations
The way the TB-STS was implemented and the survey
design have resulted in a number of limitations that pro-
vide important lessons for the TB-STS, the evaluation of
future services and other complex interventions.
Firstly, the survey was developed after the initiation of
the TB-STS so baseline information could not be col-
lected and we are likely to have underestimated the dif-
ference between the surveys. However, the initial survey
was conducted before the roll-out of any training for the
TB-STS and prior to the employment of all national staff
to coordinate cluster investigations. An alternative study
design, which would have had a control group, would
have been possible if the TB-STS was rolled out in a
step-wise process across the country, rather than
nationally.
Secondly, the target population for the survey was all
public health staff, physicians and nurses working in TB
control in England. It was not possible to enumerate the
sampling frame because no formal or informal register
of clinical and health protection staff working in TB
could be identified. As a result, we could not calculate a
response rate.
Finally, the 50% retention rate between the surveys
is quite low and we may have lost the opinions and ex-
periences of a particular group of people. However,
non-responders to the follow-up survey did not differ
significantly to those that responded to both surveys
based profession or burden of TB in their geographical
area. Because the study was conducted as part of a
programmatic service implementation, results must be
interpreted accordingly.
Recommendations
The findings of this survey inform the development of
the TB-STS and the design of future evaluations. Despite
a significant increase in the number of health protection
staff who had received training, there remained some
that had not received any, suggesting the need for an on-
going training programme that also takes into account
turnover of staff. Self-reported knowledge of how to use
the strain typing information was lower for nurses com-
pared with physicians and health protection staff, pos-
sibly representing a gap in the training strategy, which
did not include nurses. The finding that physicians had
the highest self-reported knowledge across the two sur-
veys, even though they were not included in the training
strategy, might be because they have had access to infor-
mation on strain typing from other sources and, relative
to nurses and public health staff, might self-rate their
knowledge higher.
The perception of usefulness did not change over time
as most people found strain typing to be useful in both
surveys. This suggests that any changes in practice are
due to increasing knowledge and access to strain typing,
rather than attitudes towards strain typing. Therefore, to
improve use and impact of the TB-STS, there should be
a focus on improving training and making strain typing
data easily accessible so that it can become better inte-
grated into the TB service.
The findings of this survey argue for the continuation
of the TB-STS. A majority of people reported the TB-
STS to be useful and health protection staff reported an
increase in the number of investigations for which strain
typing was used to provide more information, although
there was no increase in the number of investigations
that were influenced by strain typing. This discordance
between the findings on subjective report of utility and
the investigation outcomes reported may signify the high
value placed on information.
When implementing a public health intervention and
planning an evaluation it is essential to have a well-
defined sampling frame and a baseline that can be mea-
sured before the start of the service implementation.
Where possible, the evaluation of a service should start
prior to its implementation in order to capture the base-
line and to design the evaluation based on the planned
service implementation. This survey is an example of
where this was not possible and highlights the import-
ance of acknowledging the context in which the service
was implemented, both for assessing its success and un-
derstanding the limitations of the evaluation design.
The variation in knowledge, attitudes and practices
across the professions illustrates the importance of in-
cluding all the service stakeholders in the evaluation. For
example, in the TB-STS, nurse respondents reported
lower knowledge, suggesting that they could benefit
from being included in the training strategy.
This survey is the first component of the evaluation of
the TB-STS. To better understand the public health utility
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and evaluate the impact of such a service, a comprehensive
mixed-methods evaluation is underway [12]. This includes
modelling of the effectiveness and cost-effectiveness and
qualitative studies.
Conclusions
Evaluating a complex public health intervention requires a
pragmatic approach, taking into account how the service
has been implemented. In these initial and follow-up sur-
veys, public health staff, physicians and TB nurses found
the TB-STS useful and increased the amount they used it
in the first two years of the service, arguing for the con-
tinuation of the service. Despite this, the impact of the
TB-STS on cluster investigations remained unclear. We
recommend continuing the service but with ongoing and
more thorough training of service users and focussing on
improving knowledge and making data more accessible.
Future evaluations of complex interventions should be ini-
tiated prior to the implementation of the service, and
would benefit from an enumerable sampling frame and a
measurable baseline.
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Evaluation of the Tuberculosis Strain Typing Service  
in England  
J Mears1,2, E Vynnycky1,3, J Lord4, M Borgdorff5, T Cohen6, I Abubakar1,2, P Sonnenberg4  
 on behalf of the National TB strain-typing evaluation group 
1. Public Health England, UK; 2. University College London, UK 3. London School of Hygiene & Tropical Medicine, UK;  
4. Brunel University, UK ; 5. Public Health Service (GGD), The Netherlands; 6. Harvard School of Public Health, USA 
The national TB Strain-Typing Service (TB-STS), introduced in England in 2010, aims to type the 
first Mycobacterium tuberculosis isolate from all TB cases using 24-locus MIRU-VNTR.  
A TB-STS with better-targeted cluster investigations could reduce the TB burden by increasing the 
detection of latent infections and accelerating diagnosis of active cases. 
We describe the first service-wide evaluation of a national TB-STS to estimate effects on TB 
incidence and cost-effectiveness. 
Background 
Data analysis 
We estimated the: 
Proportion of M. tuberculosis false-
positive isolates in 2010-12, which 
were  identified only after strain-
typing results were known.  
Effect of cluster investigations on 
diagnostic delay (symptom onset to 
diagnosis) for TB cases diagnosed in 
2010-2011.  
Contact tracing yield (mean no. of 
infections or active cases identified 
per case) in NC London and Leicester 
in 2011, according to membership of 
investigated clusters. 
Methods 
Results 
Conclusions 
Fig 1: Components of the mixed methods 
evaluation of the outputs and 
effectiveness of the TB-STS. 
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Modelling & cost-effectiveness 
Using an age-structured 
deterministic transmission model 
we estimated the effect of the 
TB-STS in high, medium, low 
incidence groups, with plausible 
assumptions for in/out-migration, 
the proportion of infections 
detected, treatment delay & 
preventive treatment. 
Cost-effectiveness used model & 
service evaluation output, 
establishment & running costs & 
QALY (Quality Adjusted Life Year) 
impacts of infection & disease. 
17/30 (57%) incidents of false-positive 
isolation escaped identification before 
strain-typing results were known.  
Cluster investigations had no 
significant impact on diagnostic delay 
or contact tracing yield(Fig 2). 
According to mathematical modelling: 
• The TB-STS had the greatest impact 
in high incidence groups (Fig. 3) 
• Larger impacts were predicted with 
plausible  in treatment delay than 
with  in detection of infections 
• The impact depended on assumed 
TB prevalence among immigrants, 
in and out-migration, uptake and 
retention of PT 
 [JL1]LTBI Abbreviation not used elsewhere. 
Fig 3: Predicted impact of the TB-STS using 
mathematical modelling (see 3B for legend) 
Fig 2: A. Diagnostic delay (& IQ range) and 
B. Contact tracing yield (& 95% CI) in cases 
diagnosed before or after launching a 
cluster investigation 
However, the TB-STS provides an invaluable 
resource for epidemiological and microbiological 
research & surveillance, informing national & 
local TB control efforts & targeting interventions. 
Insufficient baseline and post-implementation 
data limit direct estimation of public health 
outcomes and interpretation of the model. 
Current models suggest TB-STS is not cost-
effective. 
For base case assumptions, the 
TB-STS was not estimated to be 
cost effective over 20-years 
(£97,311/QALY). 
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Evaluation of the National TB Strain Typing Service: Results from a Baseline 
Survey 
J Mears, on behalf of the TB Strain Typing Evaluation Group 
Abstract 
This survey is part of the National Tuberculosis Strain Typing Service (TBSTS) 
Evaluation. It aimed to establish the utilisation and perception of the STS by those 
working in TB control, before the TBSTS is fully implemented.   
An online self-completion questionnaire was developed by a multi-disciplinary team. 
The survey-link was emailed to nurses, physicians and health protection (HP) staff in 
England using the Enhanced Tuberculosis Surveillance user-list, and cascaded 
through Local and Regional Services. It assessed current awareness and knowledge 
of TB strain typing (STing), current use and perceived usefulness of the TBSTS. 
284 clinic and HP staff within all 26 Health Protection Units (HPUs) in England 
responded.  85% had heard of the TBSTS. 15% used STing in at least half of cases, 
62% for a few cases, and 23% had never used it. 96% found the ST quite or very 
useful when utilised. 8% of all respondents had received training. STing was most 
commonly used to identify clusters and/or links between cases. HPUs reported an 
average of 1.3 (range0-30) cluster investigations initiated during a 3-month period 
because of the ST, compared to 0.8 (0-4) because of known epidemiological links. 
The TBSTS is not utilised by the entire TB control service; however, when used it is 
perceived to be useful. The number of cluster investigations initiated by HPUs may 
be small due to a lack of training. They are likely to increase as the TBSTS is 
implemented and training delivered. A repeat survey in 2011 will measure changes in 
service use. 
Evaluation of the National TB Strain Typing 
Service: Results from a Baseline Survey 
Jessica Mears on behalf on the TB Strain Typing Evaluation Group1 
1The TB Strain Typing Evaluation Group consists of Ibrahim Abubakar, Martien Borgdorff, Ted Cohen, Debbie Crisp, Chris Griffiths, John Hayward, John Innes, 
Michelle Kruijshaar, Mike Lilley, Jo Lord, Helen Maguire, Tim McHugh, Pam Sonnenberg (Chair) and Emilia Vynnycky. 
Health Protection 2011 
Background 
 
This survey is part of the National Tuberculosis Strain Typing Service (TB STS) 
Evaluation. It aimed to address elements of the processes of the TB STS at baseline 
and provide inputs for transmission and cost effectiveness models. 
Objectives 
 
This poster reports on three of the objectives of the first survey, carried out in 
December 2010. These three objectives of the baseline survey were to establish, 
within the HPA and TB Services in England and Wales, baseline: 
1. Awareness and knowledge of the STS 
2. Use of the STS 
3. Perceived usefulness of the STS 
Methods  
 
Design  
• Two cross-sectional surveys: at baseline and once the STS has been implemented 
• A link to a web-based self-completion questionnaire was cascaded through local 
and regional services and through the Enhanced TB Surveillance user list 
Target Population  
• Nurses and physicians working in clinics in England and Wales 
• Health protection staff working in HPUs in England and Wales 
Results 
Results 1: Awareness of the STS 
Results 2: Use of the STS 
Results 3: Perceived usefulness of the STS 
Limitations 
 
• This was a convenience sample as a sampling frame was not available. However, 
there were a large number of responses from across the target area so the survey 
can be used to measure changes over time 
• We aimed to capture the baseline situation, before the implementation of the STS. 
However, because there was a large variation in ad hoc use of strain typing across 
the country (including universal strain typing in the West Midlands) and the STS 
was implemented at different rates around the country, the definition of ‘baseline’ 
varied across geographical area 
Conclusions 
 
• The survey was answered by 257 clinical and health protection professionals 
working in areas covered by all 26 HPUs across England and in Wales, but we 
cannot be sure of the representativeness of the respondents 
• Although many respondents had heard of the TB STS, very few had received any 
training on using the data 
• Most respondents had accessed strain typing data but only used it for a few cases; 
however, when strain typing was used it was perceived to be useful 
• A repeat survey in 2012 will measure changes in use of the TB STS  
Figure 3: Usefulness of the strain typing service as reported by clinical and health protection staff 
working in areas of low (n=56), medium (n=38) and high incidence (n=51) 
• There were 296 
respondents  
• 42 were excluded 
• A total of 254 
respondents from 
within all 26 HPUs 
were included in the 
analyses 
Figure 1: The TB 
Strain Typing 
Evaluation is using a 
structures, 
processes, outputs 
and outcomes 
framework. The 
components of this 
framework that are 
addressed in this 
survey are outlined 
in blue and orange; 
those in orange are 
presented here. 
Figure 2: The frequency with which strain typing data is used at baseline 
Table 1: Survey 
respondents’ workplace by 
setting and incidence 
Table 2: 
Numbers and 
proportions 
of 
respondents 
who had 
heard of the 
STS and 
received 
training 
Table 3: How the strain typing data is used once it is accessed. *Participants could select >1 option 
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Usefulness of the strain typing data by TB incidence (n=145)
low incidence
medium incidence
high incidence
 N % 
Heard of the Strain Typing Service 
Yes 211 84.4 
No 39 15.6 
missing 4  
Received any training on using strain typing data 
Yes 21 8.5 
No 225 91.5 
missing 8  
 
  N % 
Workplace setting    
Clinical  198 79.2 
 Nurse 139 55.6 
 Physician 59 23.6 
Health Protection  52 20.8 
 Nurse 18 7.2 
 Scientist/admin 7 2.8 
 Consultant 27 10.8 
missing  4  
TB Incidence/100,000  
Low <10 115 45.63 
Medium  10-20 62 24.60 
High >20 75 29.76 
missing  2  
 
 N % 
Do you access strain typing data? (n=254) 
Yes 197 77.6 
No 57 22.4 
If yes, how do you use strain typing data?* (n=197) 
Don't know 5 2.5 
Identify clusters and links between cases 173 87.8 
Disprove clusters and links between cases 105 53.3 
Justify extended contact tracing 95 48.2 
Justify stopping contact tracing 43 21.8 
To provide more information 78 39.6 
Other 12 6.1 
 
